
<html lang="en"     class="pb-page"  data-request-id="7b298168-0094-4642-9040-bdd275b5959c"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2017.60.issue-13;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.7b00426"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Hepatitis C Virus NS3/4A Protease Inhibitors Incorporating Flexible P2 Quinoxalines Target Drug Resistant Viral Variants" /></meta><meta name="dc.Creator" content="Ashley N.  Matthew" /></meta><meta name="dc.Creator" content="Jacqueto  Zephyr" /></meta><meta name="dc.Creator" content="Caitlin. J.  Hill" /></meta><meta name="dc.Creator" content="Muhammad  Jahangir" /></meta><meta name="dc.Creator" content="Alicia  Newton" /></meta><meta name="dc.Creator" content="Christos J.  Petropoulos" /></meta><meta name="dc.Creator" content="Wei  Huang" /></meta><meta name="dc.Creator" content="Nese  Kurt-Yilmaz" /></meta><meta name="dc.Creator" content="Celia A.  Schiffer" /></meta><meta name="dc.Creator" content="Akbar  Ali" /></meta><meta name="dc.Description" content="A substrate envelope-guided design strategy is reported for improving the resistance profile of HCV NS3/4A protease inhibitors. Analogues of 5172-mcP1P3 were designed by incorporating diverse quino..." /></meta><meta name="Description" content="A substrate envelope-guided design strategy is reported for improving the resistance profile of HCV NS3/4A protease inhibitors. Analogues of 5172-mcP1P3 were designed by incorporating diverse quino..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 19, 2017" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b00426" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2017 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00426" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b00426" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00426" /></link>
        
    
    

<title>Hepatitis C Virus NS3/4A Protease Inhibitors Incorporating Flexible P2 Quinoxalines Target Drug Resistant Viral Variants | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b00426" /></meta><meta property="og:title" content="Hepatitis C Virus NS3/4A Protease Inhibitors Incorporating Flexible P2 Quinoxalines Target Drug Resistant Viral Variants" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/large/jm-2017-004268_0011.jpeg" /></meta><meta property="og:description" content="A substrate envelope-guided design strategy is reported for improving the resistance profile of HCV NS3/4A protease inhibitors. Analogues of 5172-mcP1P3 were designed by incorporating diverse quinoxalines at the P2 position that predominantly interact with the invariant catalytic triad of the protease. Exploration of structure–activity relationships showed that inhibitors with small hydrophobic substituents at the 3-position of P2 quinoxaline maintain better potency against drug resistant variants, likely due to reduced interactions with residues in the S2 subsite. In contrast, inhibitors with larger groups at this position were highly susceptible to mutations at Arg155, Ala156, and Asp168. Excitingly, several inhibitors exhibited exceptional potency profiles with EC50 values ≤5 nM against major drug resistant HCV variants. These findings support that inhibitors designed to interact with evolutionarily constrained regions of the protease, while avoiding interactions with residues not essential for substrate recognition, are less likely to be susceptible to drug resistance." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b00426"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b00426">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b00426&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b00426&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b00426&amp;href=/doi/10.1021/acs.jmedchem.7b00426" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 13</span><span class="cit-fg-pageRange">, 5699-5716</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/13" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b00397" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.7b00425" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Hepatitis C Virus NS3/4A Protease Inhibitors Incorporating Flexible P2 Quinoxalines Target Drug Resistant Viral Variants</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ashley+N.++Matthew">Ashley N. Matthew</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jacqueto++Zephyr">Jacqueto Zephyr</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Caitlin.+J.++Hill">Caitlin. J. Hill</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol "><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Muhammad++Jahangir">Muhammad Jahangir</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol "><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Alicia++Newton">Alicia Newton</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Christos+J.++Petropoulos">Christos J. Petropoulos</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wei++Huang">Wei Huang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nese++Kurt-Yilmaz">Nese Kurt-Yilmaz</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Celia+A.++Schiffer">Celia A. Schiffer</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0003-2270-6613" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Akbar++Ali">Akbar Ali</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0003-3491-791X" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts 01605, United States</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Monogram Biosciences, South San Francisco, California 94080, United States</span></div><div class="corresp-info"><strong>*</strong>For A.A.: phone, +1 508 856 8873; fax, +1 508 856 6464; E-mail, <a href="/cdn-cgi/l/email-protection#ecad878e8d9ec2ad8085ac99818d9f9f818988c2898899"><span class="__cf_email__" data-cfemail="c687ada4a7b4e887aaaf86b3aba7b5b5aba3a2e8a3a2b3">[email protected]</span></a></div><div class="corresp-info"><strong>*</strong>For C.A.S.: phone, +1 508 856 8008; fax, +1 508 856 6464; E-mail, <a href="/cdn-cgi/l/email-protection#cc8fa9a0a5ade29fafa4a5aaaaa9be8cb9a1adbfbfa1a9a8e2a9a8b9"><span class="__cf_email__" data-cfemail="a2e1c7cecbc38cf1c1cacbc4c4c7d0e2d7cfc3d1d1cfc7c68cc7c6d7">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00426&amp;href=/doi/10.1021%2Facs.jmedchem.7b00426" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 13</span><span class="cit-pageRange">, 5699–5716</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 8, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>16 March 2017</li><li><span class="item_label"><b>Published</b> online</span>19 June 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 13 July 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b00426" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00426</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D5699%26pageCount%3D18%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DAshley%2BN.%2BMatthew%252C%2BJacqueto%2BZephyr%252C%2BCaitlin.%2BJ.%2BHill%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D60%26issueNum%3D13%26contentID%3Dacs.jmedchem.7b00426%26title%3DHepatitis%2BC%2BVirus%2BNS3%252F4A%2BProtease%2BInhibitors%2BIncorporating%2BFlexible%2BP2%2BQuinoxalines%2BTarget%2BDrug%2BResistant%2BViral%2BVariants%26numPages%3D18%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D5716%26publicationDate%3DJuly%2B2017">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b00426"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1294</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">21</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b00426" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Hepatitis C Virus NS3/4A Protease Inhibitors Incorporating Flexible P2 Quinoxalines Target Drug Resistant Viral Variants&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Ashley&quot;,&quot;last_name&quot;:&quot;N. Matthew&quot;},{&quot;first_name&quot;:&quot;Jacqueto&quot;,&quot;last_name&quot;:&quot;Zephyr&quot;},{&quot;first_name&quot;:&quot;Caitlin.&quot;,&quot;last_name&quot;:&quot;J. Hill&quot;},{&quot;first_name&quot;:&quot;Muhammad&quot;,&quot;last_name&quot;:&quot;Jahangir&quot;},{&quot;first_name&quot;:&quot;Alicia&quot;,&quot;last_name&quot;:&quot;Newton&quot;},{&quot;first_name&quot;:&quot;Christos&quot;,&quot;last_name&quot;:&quot;J. Petropoulos&quot;},{&quot;first_name&quot;:&quot;Wei&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Nese&quot;,&quot;last_name&quot;:&quot;Kurt-Yilmaz&quot;},{&quot;first_name&quot;:&quot;Celia&quot;,&quot;last_name&quot;:&quot;A. Schiffer&quot;},{&quot;first_name&quot;:&quot;Akbar&quot;,&quot;last_name&quot;:&quot;Ali&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;19&quot;,&quot;issue&quot;:&quot;13&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;5699-5716&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b00426&quot;},&quot;abstract&quot;:&quot;A substrate envelope-guided design strategy is reported for improving the resistance profile of HCV NS3/4A protease inhibitors. Analogues of 5172-mcP1P3 were designed by incorporating diverse quinoxalines at the P2 position that predominantly interact with the invariant catalytic triad of the protease. Exploration of structure–activity relationships showed that inhibitors with small hydrophobic substituents at the 3-position of P2 quinoxaline maintain better potency against drug resistant variants, likely due to reduced interactions with residues in the S2 subsite. In contrast, inhibitors with larger groups at this position were highly susceptible to mutations at Arg155, Ala156, and Asp168. Excitingly, several inhibitors exhibited exceptional potency profiles with EC50 values ≤5 nM against major drug resistant HCV variants. These findings support that inhibitors designed to interact with evolutionarily constrained regions of the protease, while avoiding interactions with residues not essential for substrate r&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00426&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00426" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00426&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00426" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00426&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00426" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00426&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00426&amp;href=/doi/10.1021/acs.jmedchem.7b00426" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b00426" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b00426" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (7 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00426&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b00426%26sid%3Dliteratum%253Aachs%26pmid%3D28594175%26genre%3Darticle%26aulast%3DMatthew%26date%3D2017%26atitle%3DHepatitis%2BC%2BVirus%2BNS3%252F4A%2BProtease%2BInhibitors%2BIncorporating%2BFlexible%2BP2%2BQuinoxalines%2BTarget%2BDrug%2BResistant%2BViral%2BVariants%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D13%26spage%3D5699%26epage%3D5716%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (4)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292227" title="Drug resistance">Drug resistance</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/13" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/jmcmar.2017.60.issue-13/20170713/jmcmar.2017.60.issue-13.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/medium/jm-2017-004268_0011.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/large/jm-2017-004268_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00426&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">A substrate envelope-guided design strategy is reported for improving the resistance profile of HCV NS3/4A protease inhibitors. Analogues of 5172-mcP1P3 were designed by incorporating diverse quinoxalines at the P2 position that predominantly interact with the invariant catalytic triad of the protease. Exploration of structure–activity relationships showed that inhibitors with small hydrophobic substituents at the 3-position of P2 quinoxaline maintain better potency against drug resistant variants, likely due to reduced interactions with residues in the S2 subsite. In contrast, inhibitors with larger groups at this position were highly susceptible to mutations at Arg155, Ala156, and Asp168. Excitingly, several inhibitors exhibited exceptional potency profiles with EC<sub>50</sub> values ≤5 nM against major drug resistant HCV variants. These findings support that inhibitors designed to interact with evolutionarily constrained regions of the protease, while avoiding interactions with residues not essential for substrate recognition, are less likely to be susceptible to drug resistance.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32536" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32536" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Hepatitis C virus (HCV) infects over 130 million people globally and is the leading cause of chronic liver disease, cirrhosis, and hepatocellular carcinoma.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> HCV is known as a “silent killer” as a majority of affected patients remain unaware of their infection, and over time the acute infection progresses to chronic liver disease.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> The rate of cirrhosis is estimated to increase from 16% to 32% by the year 2020 due to the high number of untreated patients.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Thus, there is an urgent need to ensure that patients infected with HCV receive proper treatment. However, HCV infection is difficult to treat, as the virus is genetically diverse with six known genotypes (genotype 1–6), each of which is further subdivided into numerous subtypes.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Genotype 1 (GT1) and genotype 3 (GT3) are the most prevalent, accounting for 46% and 30% of global infections, respectively.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4, 5)</a> Therapeutic regimen and viral response are largely genotype dependent, with most treatments being efficacious only against GT1.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a></div><div class="NLM_p">The recent advent of direct-acting antivirals (DAAs) targeting essential viral proteins NS3/4A, NS5A, and NS5B has remarkably improved therapeutic options and treatment outcomes for HCV infected patients.<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6, 7)</a> Four new all-oral combination therapies have been approved by the U.S. FDA: (1) sofosbuvir/ledipasvir,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> (2) ombitasvir/paritaprevir/ritonavir/dasabuvir,<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> (3) elbasvir/grazoprevir,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> and (4) sofosbuvir/velpatasvir.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> The DAA-based therapies are highly effective against GT1 with sustained virological response (SVR) rates greater than 90%.<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6, 7)</a> However, most of the FDA approved treatments and those in clinical development are not efficacious against other genotypes, especially GT3.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Moreover, except for sofosbuvir, all current DAAs are susceptible to drug resistance.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Therefore, more robust DAAs need to be developed with higher barriers to drug resistance and a broad spectrum of activity against different HCV genotypes.</div><div class="NLM_p">The HCV NS3/4A protease is a major therapeutic target for the development of pan-genotypic HCV inhibitors.<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13, 14)</a> The NS3/4A protease inhibitors (PIs) telaprevir<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> and boceprevir<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> were the first DAAs approved for the treatment of HCV GT1 infection in combination therapy with pegylated-interferon and ribavirin.<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17, 18)</a> Three recently approved PIs, simeprevir,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> paritaprevir,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> and grazoprevir,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) are integral components of various combination therapies currently used as the standard of care for HCV infected patients.<a onclick="showRef(event, 'ref6 ref7 ref14'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref14">(6, 7, 14)</a> Two other NS3/4A PIs, asunaprevir<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> and vaniprevir,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> have been approved in Japan. In addition, a number of next generation NS3/4A PIs are in clinical development, including glecaprevir<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> and voxilaprevir<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/medium/jm-2017-004268_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/large/jm-2017-004268_0001.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of HCV NS3/4A protease inhibitors. Simeprevir, paritaprevir, and grazoprevir are approved by the FDA; voxilaprevir and glecaprevir are in clinical development.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/large/jm-2017-004268_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00426&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">All NS3/4A PIs share a common peptidomimetic scaffold and are either linear or macrocyclic; the macrocycle is located either between P1–P3 or P2–P4 moieties.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> In addition, these inhibitors contain a large heterocyclic moiety attached to the P2 proline, which significantly improves inhibitor potency against wild-type (WT) NS3/4A protease.<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26, 27)</a> However, all NS3/4A PIs are susceptible to drug resistance, especially due to single site mutations at protease residues Arg155, Ala156, and Asp168.<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28, 29)</a> Notably, D168A/V mutations are present in nearly all patients who fail treatment with PIs.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Moreover, natural polymorphisms at this position are responsible for significantly reduced inhibitor potency against GT3.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> We previously determined the molecular mechanisms of drug resistance due to single site mutations by solving high-resolution crystal structures of PIs bound to WT and mutant proteases.<a onclick="showRef(event, 'ref31 ref32 ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref31 ref32 ref33 ref34">(31-34)</a> These crystal structures revealed that the large heterocyclic P2 moieties of PIs bind outside the substrate binding region, defined as the substrate envelope, and make extensive interactions with residues Arg155, Ala156, and Asp168.<a onclick="showRef(event, 'ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref32 ref33">(32, 33)</a> The inhibitor P2 moiety induces an extended S2 subsite by forcing the Arg155 side chain to rotate nearly 180° relative to its conformation in substrate complexes.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> This altered Arg155 conformation is stabilized by electrostatic interactions with Asp168, providing additional hydrophobic surface that is critical for efficient inhibitor binding. Disruption of electrostatic interactions between Arg155 and Asp168 due to mutations underlies drug resistance against NS3/4A PIs.<a onclick="showRef(event, 'ref31 ref32 ref33 ref35'); return false;" href="javascript:void(0);" class="ref ref31 ref32 ref33 ref35">(31-33, 35)</a> Moreover, we have shown that structural differences at the P2 moiety largely determine the resistance profile of these inhibitors.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></div><div class="NLM_p">Grazoprevir (MK-5172, <b>1</b>), one of the most potent HCV NS3/4A PIs, has a unique binding mode where the P2 quinoxaline moiety interacts with residues of the catalytic triad, avoiding direct interactions with Arg155 and Asp168 (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>).<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> As a result, <b>1</b> has an excellent potency profile across different genotypes and relatively low susceptibility to drug resistance due to mutations at Arg155 and Asp168.<a onclick="showRef(event, 'ref21 ref37'); return false;" href="javascript:void(0);" class="ref ref21 ref37">(21, 37)</a> However, <b>1</b> is highly susceptible to mutations at Ala156, mainly due to steric clashes of larger side chains with the P2–P4 macrocycle. We have shown that the P1–P3 macrocyclic analogue 5172-mcP1P3 (<b>2</b>) avoids this steric clash while still maintaining the unique binding mode of <b>1</b> (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>).<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Compound <b>2</b>, though slightly less potent than <b>1</b> against WT HCV, has an excellent potency profile with EC<sub>50</sub> values in the single-digit nanomolar range against drug resistant variants including A156T. Similar to <b>1</b>, the P2 quinoxaline moiety in <b>2</b> stacks against the catalytic residues His57 and Asp81 and largely avoids direct interactions with residues around the S2 subsite.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> But unlike <b>1</b>, the flexible P2 quinoxaline moiety in <b>2</b> better accommodates mutations at Ala156, resulting in an overall improved resistance profile.<a onclick="showRef(event, 'ref36 ref38'); return false;" href="javascript:void(0);" class="ref ref36 ref38">(36, 38)</a> Thus, the P1–P3 macrocyclic analogue <b>2</b> is a promising lead compound for structure–activity relationship (SAR) studies to further improve potency against drug resistant variants and other genotypes.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/medium/jm-2017-004268_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/large/jm-2017-004268_0002.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Chemical structures and binding modes of grazoprevir (<b>1</b>) and analogue <b>2</b>. (a) Compound <b>2</b> was designed by replacing the P2–P4 macrocycle in <b>1</b> with a P1–P3 macrocycle. (b) Binding conformation of <b>1</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3SUD">3SUD</a>) and <b>2</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EPN">5EPN</a>) in the active site of wild-type NS3/4A protease. Compound <b>2</b> maintains the unique binding mode of <b>1</b> whereby the P2 quinoxaline makes strong interactions with the catalytic residues, avoiding contacts with known drug resistance residues. The catalytic triad is highlighted in yellow, and drug resistance residues Arg155, Ala156, and Asp168 are shown in blue, red, and green, respectively. The canonical nomenclature for drug moiety positioning is indicated using grazoprevir.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/large/jm-2017-004268_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00426&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The substrate envelope model provides a rational approach to design NS3/4A PIs with improved resistance profiles by exploiting interactions with the protease residues essential for function and avoiding direct contacts with residues that can mutate to confer drug resistance.<a onclick="showRef(event, 'ref39 ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref39 ref40 ref41">(39-41)</a> Another approach applied to design PIs with improved resistant profiles involves incorporation of conformational flexibility that can allow the inhibitor to adapt to structural changes in the protease active site due to mutations.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Here, we describe a structure-guided strategy that combines these two approaches and, together with our understanding of the mechanisms of drug resistance, led to the design of NS3/4A PIs with exceptional potency profiles against major drug resistant HCV variants. Based on the lead compound <b>2</b>, a series of analogues were designed and synthesized with diverse substituents at the 3-position of P2 quinoxaline moiety. Investigation of SARs identified P2 quinoxaline derivatives that predominantly interact with the invariant catalytic triad and avoid contacts with the S2 subsite residues. The results indicate that combining the substrate envelope model with optimal conformational flexibility provides a general strategy for the rational design of NS3/4A PIs with improved resistance profiles.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44480" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44480" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The NS3/4A PIs with diverse P2 quinoxaline moieties were synthesized using the reaction sequence outlined in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. A Cs<sub>2</sub>CO<sub>3</sub>-mediated S<sub>N</sub>2 reaction of 3-substituted quinoxalin-2-ones <b>8a</b>–<b>g</b> with the activated proline derivative <b>3</b> provided the key P2 intermediates <b>9a</b>–<b>g</b> in 75–90% yield. The alternate S<sub>N</sub>Ar reaction between activated quinoxaline derivatives and Boc-protected hydroxy-proline resulted in lower yields, and purification of the resulting P2 acid products was significantly more challenging. The 3-substituted 7-methoxy-quinoxalin-2-ones <b>8a</b>–<b>b</b> and <b>8d</b>–<b>e</b> were prepared by condensation reactions of 4-methoxybenzene-1,2-diamine with the corresponding ethyl glyoxylates (see <a href="/doi/suppl/10.1021/acs.jmedchem.7b00426/suppl_file/jm7b00426_si_001.pdf" class="ext-link">Supporting Information</a> for details). The 3-chloro-7-methoxyquinoxalin-2-one <b>8c</b> was prepared according to a reported method.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/medium/jm-2017-004268_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/large/jm-2017-004268_0007.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of HCV NS3/4A Protease Inhibitors<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/large/jm-2017-004268_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00426&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Cs<sub>2</sub>CO<sub>3</sub>, NMP, 55 °C, 6 h; (b) 4 N HCl in dioxane, CH<sub>2</sub>Cl<sub>2</sub>, RT, 3 h; (c) HATU, DIEA, DMF, RT, 4 h; (d) LiOH·H<sub>2</sub>O, THF, H<sub>2</sub>O, RT, 24 h; (e) HATU, DIEA, DMF, RT, 2 h; (f) Zhan 1B catalyst, 1,2-DCE, 70 °C, 6 h; (g) 4 N HCl, dioxane, RT, 3 h; (h) <i>N</i>-(cyclopentyloxycarbonyloxy)-succinimide, DIEA, CH<sub>3</sub>CN, RT, 36 h.</p></p></figure><div class="NLM_p">The P1–P3 macrocyclic PIs were assembled from the P2 intermediates <b>9a</b>–<b>g</b> using a sequence of deprotection and peptide coupling steps followed by the ring-closing metathesis (RCM) reaction (method A). Removal of the Boc group in <b>9a</b>–<b>g</b> using 4 N HCl provided the amine salts <b>10a</b>–<b>g</b>, which were coupled with the amino acid <b>11</b> in the presence of HATU and DIEA to yield the P2–P3 ester intermediates <b>12a</b>–<b>g</b>. Hydrolysis of these esters with LiOH and reaction of the resulting carboxylic acids <b>13a</b>–<b>g</b> with the P1–P1′ fragments <b>14</b><a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> and <b>15</b><a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> under HATU/DIEA coupling conditions provided the bis-olefin intermediates <b>16a</b>–<b>g</b> and <b>17a</b>–<b>e</b>. Finally, cyclization of the bis-olefin intermediates was accomplished by using a highly efficient RCM catalyst Zhan 1B, and provided the inhibitors <b>18b</b>–<b>g</b> and <b>19a</b>–<b>e</b> in 45–80% yield. Interestingly, RCM reactions of bis-olefins <b>17a</b>–<b>e</b> bearing the 1-methylcyclopropylsulfonamide provided higher yield than the corresponding cyclopropylsulfonamide analogues <b>16a</b>–<b>g</b>. Finally, removal of the Boc group and reaction of the resulting amine salts <b>20a</b>–<b>g</b> and <b>21a</b>–<b>e</b> with the <i>N</i>-(cyclopentyloxycarbonyloxy)-succinimide in the presence of DIEA afforded the inhibitors <b>22a</b>–<b>g</b> and <b>23a</b>–<b>e</b> with the N-terminal cyclopentyl P4 moiety.</div><div class="NLM_p">A subset of inhibitors was synthesized using an alternate reaction sequence that allowed late-stage modification at both the P1′ and P4 positions as illustrated in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a> (method B). The P2–P3 acid intermediates <b>13a</b>–<b>d</b> were reacted with the commercially available amine salt <b>24</b> under HATU/DIEA coupling conditions to afford the bis-olefin intermediates <b>25a</b>–<b>d</b>. RCM reaction in the presence of Zhan 1B catalyst provided the macrocyclic intermediates <b>26a</b>–<b>d</b> in 75–90% yield, which was better than that obtained in the presence of the P1′ acylsulfonamide. The P1–P3 macrocyclic core intermediates <b>26a</b>–<b>d</b> can be modified in either direction after removing the C- or N-terminal protecting groups. Thus, hydrolysis of the C-terminal ethyl ester with LiOH provided the acids <b>27a</b>–<b>d</b>, which were then reacted with either cyclopropylsulfonamide <b>28</b> or 1-methylcyclopropylsulfonamide <b>29</b> in the presence of CDI and DBU to afford the final inhibitors <b>18b</b>–<b>d</b> and <b>19a</b>–<b>d</b>. The N-terminal <i>tert</i>-butyl capping group was replaced with the cyclopentyl moiety as described earlier to provide the target inhibitors <b>22a</b>–<b>d</b> and <b>23a</b>–<b>d</b>.</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/medium/jm-2017-004268_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/large/jm-2017-004268_0008.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Alternate Synthesis of HCV NS3/4A Protease Inhibitors<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/large/jm-2017-004268_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00426&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) HATU, DIEA, DMF, RT, 2 h; (b) Zhan 1B catalyst, 1,2-DCE, 70 °C, 5 h; (c) LiOH·H<sub>2</sub>O, THF, MeOH, H<sub>2</sub>O, RT, 24 h; (d) CDI, THF, DBU, reflux, 1.5 h, RT, 36 h.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73083" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73083" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Our goal was to develop a structure-guided design strategy to improve the resistance profile of HCV NS3/4A PIs based on the substrate envelope model.<a onclick="showRef(event, 'ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref39 ref40">(39, 40)</a> Compound <b>2</b> is an attractive scaffold for exploring this strategy due to the unique structural features: (1) the P2 quinoxaline moiety that predominantly interacts with the highly conserved catalytic residues Asp81 and His57 and (2) the conformational flexibility that allows the inhibitor to efficiently accommodate structural changes in the S2 subsite due to resistance mutations. Despite these promising features, optimization of substituents at the P2 quinoxaline and the N-terminal capping may be key to discovering analogues with improved potency and resistance profiles. Therefore, efforts were focused on exploration of SARs at the P2 quinoxaline moiety in <b>2</b>, specifically substituting the ethyl group at the 3-position that directly interacts with protease S2 subsite residues Arg155 and Ala156. The SAR strategy was based on insights from detailed structural analysis of <b>1</b> and <b>2</b> bound to wild-type NS3/4A protease and drug resistant variants.<a onclick="showRef(event, 'ref32 ref38'); return false;" href="javascript:void(0);" class="ref ref32 ref38">(32, 38)</a> Based on these insights, we hypothesized that small hydrophobic groups at the 3-position of the quinoxaline would be preferred for retaining inhibitor potency against drug resistant variants, but larger groups that make extensive interactions with Arg155, Ala156, and Asp168 would result in inhibitors highly susceptible to mutations at these positions. To test this hypothesis, a series of inhibitors with diverse substituents at the 3-position of P2 quinoxaline were designed and synthesized.</div><div class="NLM_p">The potency and resistance profiles of NS3/4A PIs were assessed using biochemical and replicon assays. The enzyme inhibition constants (<i>K</i><sub>i</sub>) were determined against wild-type GT1a NS3/4A protease, drug-resistant variant D168A, and GT3a NS3/4A protease (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). The cellular antiviral potencies (EC<sub>50</sub>) were determined using replicon-based antiviral assays against wild-type HCV and drug-resistant variants R155K, A156T, D168A, and D168V (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). Grazoprevir (GZR, <b>1</b>) was used as a control in all assays. The observed antiviral potencies are generally higher than protease inhibitory potencies, likely because biochemical assays were performed using the protease domain alone rather than the full-length NS3/4A.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Inhibitory Activity against Wild-Type NS3/4A Protease and Drug Resistant Variants</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/medium/jm-2017-004268_0009.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char="±"><i>K</i><sub>i</sub> (nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">inhibitor</th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">R<sup>2</sup></th><th class="colsep0 rowsep0" align="center">R<sup>3</sup></th><th class="colsep0 rowsep0" align="center" char="±">GT1a WT NS3/4A protease</th><th class="colsep0 rowsep0" align="center" char="±">GT1a D168A NS3/4A protease</th><th class="colsep0 rowsep0" align="center">GT3a NS3/4A protease</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char="±">3.29 ± 0.52</td><td class="colsep0 rowsep0" align="char" char="±">82.4 ± 4.4</td><td class="colsep0 rowsep0" align="center">204 ± 19</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19a</b></td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char="±">1.82 ± 0.38</td><td class="colsep0 rowsep0" align="char" char="±">55.2 ± 5.3</td><td class="colsep0 rowsep0" align="center">171 ± 23</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22a</b></td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char="±">1.24 ± 0.14</td><td class="colsep0 rowsep0" align="char" char="±">52.3 ± 3.2</td><td class="colsep0 rowsep0" align="center">211 ± 18</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23a</b></td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char="±">1.37 ± 0.34</td><td class="colsep0 rowsep0" align="char" char="±">55.2 ± 5.3</td><td class="colsep0 rowsep0" align="center">186 ± 30</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="7" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18b</b></td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char="±">3.40 ± 0.47</td><td class="colsep0 rowsep0" align="char" char="±">50.9 ± 3.7</td><td class="colsep0 rowsep0" align="center">152 ± 18</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19b</b></td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char="±">3.60 ± 0.44</td><td class="colsep0 rowsep0" align="char" char="±">52.0 ± 2.4</td><td class="colsep0 rowsep0" align="center">119 ± 18</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22b</b></td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char="±">0.93 ± 0.15</td><td class="colsep0 rowsep0" align="char" char="±">31.9 ± 2.5</td><td class="colsep0 rowsep0" align="center">147 ± 20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23b</b></td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char="±">1.13 ± 0.22</td><td class="colsep0 rowsep0" align="char" char="±">36.3 ± 1.8</td><td class="colsep0 rowsep0" align="center">121 ± 16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="7" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18c</b></td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char="±">1.07 ± 0.17</td><td class="colsep0 rowsep0" align="char" char="±">39.8 ± 3.4</td><td class="colsep0 rowsep0" align="center">67.5 ± 8.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19c</b></td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char="±">1.11 ± 0.38</td><td class="colsep0 rowsep0" align="char" char="±">77.7 ± 6.1</td><td class="colsep0 rowsep0" align="center">53.6 ± 5.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22c</b></td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char="±">0.49 ± 0.15</td><td class="colsep0 rowsep0" align="char" char="±">30.6 ± 2.6</td><td class="colsep0 rowsep0" align="center">85.6 ± 11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23c</b></td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char="±">0.44 ± 0.15</td><td class="colsep0 rowsep0" align="char" char="±">25.7 ± 1.8</td><td class="colsep0 rowsep0" align="center">61.0 ± 12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="7" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18d</b></td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char="±">13.3 ± 3.9</td><td class="colsep0 rowsep0" align="char" char="±">157 ± 12</td><td class="colsep0 rowsep0" align="center">344 ± 141</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19d</b></td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char="±">5.77 ± 1.78</td><td class="colsep0 rowsep0" align="char" char="±">118 ± 13</td><td class="colsep0 rowsep0" align="center">231 ± 74</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22d</b></td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char="±">7.55 ± 2.39</td><td class="colsep0 rowsep0" align="char" char="±">115 ± 12</td><td class="colsep0 rowsep0" align="center">757 ± 334</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23d</b></td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char="±">8.14 ± 2.37</td><td class="colsep0 rowsep0" align="char" char="±">110 ± 14</td><td class="colsep0 rowsep0" align="center">433 ± 206</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="7" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18e</b></td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left"><i>i</i>-Pr</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char="±">4.27 ± 1.34</td><td class="colsep0 rowsep0" align="char" char="±">239 ± 20</td><td class="colsep0 rowsep0" align="center">NT<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19e</b></td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left"><i>i</i>-Pr</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char="±">0.58 ± 0.08</td><td class="colsep0 rowsep0" align="char" char="±">211 ± 19</td><td class="colsep0 rowsep0" align="center">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22e</b></td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left"><i>i</i>-Pr</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char="±">1.44 ± 0.46</td><td class="colsep0 rowsep0" align="char" char="±">161 ± 11</td><td class="colsep0 rowsep0" align="center">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23e</b></td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left"><i>i</i>-Pr</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char="±">1.34 ± 0.48</td><td class="colsep0 rowsep0" align="char" char="±">156 ± 17</td><td class="colsep0 rowsep0" align="center">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="7" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18f</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">2-thiophene</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char="±">1.03 ± 0.13</td><td class="colsep0 rowsep0" align="char" char="±">1823 ± 347</td><td class="colsep0 rowsep0" align="center">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22f</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">2-thiophene</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char="±">1.59 ± 0.56</td><td class="colsep0 rowsep0" align="char" char="±">900 ± 81</td><td class="colsep0 rowsep0" align="center">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="7" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18g</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char="±">7.18 ± 1.02</td><td class="colsep0 rowsep0" align="char" char="±">190 ± 13</td><td class="colsep0 rowsep0" align="center">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22g</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char="±">1.99 ± 0.48</td><td class="colsep0 rowsep0" align="char" char="±">107 ± 7.0</td><td class="colsep0 rowsep0" align="center">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="7" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GZR (<b>1</b>)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="±">0.21 ± 0.03</td><td class="colsep0 rowsep0" align="char" char="±">49.1 ± 1.6</td><td class="colsep0 rowsep0" align="center">30.3 ± 1.9</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">NT: not tested.</p></div></div></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Antiviral Activity against Wild-Type HCV and Drug Resistant Variants</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/medium/jm-2017-004268_0010.gif" alt="" id="fx2" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="5" align="center" char=".">replicon EC<sub>50</sub> (nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">inhibitor</th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">R<sup>2</sup></th><th class="colsep0 rowsep0" align="center">R<sup>3</sup></th><th class="colsep0 rowsep0" align="center" char=".">WT</th><th class="colsep0 rowsep0" align="center" char=".">R155K</th><th class="colsep0 rowsep0" align="center" char=".">A156T</th><th class="colsep0 rowsep0" align="center" char=".">D168A</th><th class="colsep0 rowsep0" align="center" char=".">D168V</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">0.33</td><td class="colsep0 rowsep0" align="char" char=".">1.75</td><td class="colsep0 rowsep0" align="char" char=".">9.65</td><td class="colsep0 rowsep0" align="char" char=".">6.31</td><td class="colsep0 rowsep0" align="char" char=".">9.10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19a</b></td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char=".">0.43</td><td class="colsep0 rowsep0" align="char" char=".">1.80</td><td class="colsep0 rowsep0" align="char" char=".">4.52</td><td class="colsep0 rowsep0" align="char" char=".">4.97</td><td class="colsep0 rowsep0" align="char" char=".">6.42</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22a</b></td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">0.14</td><td class="colsep0 rowsep0" align="char" char=".">2.08</td><td class="colsep0 rowsep0" align="char" char=".">11.8</td><td class="colsep0 rowsep0" align="char" char=".">3.60</td><td class="colsep0 rowsep0" align="char" char=".">11.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23a</b></td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char=".">0.16</td><td class="colsep0 rowsep0" align="char" char=".">2.07</td><td class="colsep0 rowsep0" align="char" char=".">10.6</td><td class="colsep0 rowsep0" align="char" char=".">3.45</td><td class="colsep0 rowsep0" align="char" char=".">7.08</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="9" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18b</b></td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">0.39</td><td class="colsep0 rowsep0" align="char" char=".">1.17</td><td class="colsep0 rowsep0" align="char" char=".">5.95</td><td class="colsep0 rowsep0" align="char" char=".">4.24</td><td class="colsep0 rowsep0" align="char" char=".">3.17</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19b</b></td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char=".">0.30</td><td class="colsep0 rowsep0" align="char" char=".">0.80</td><td class="colsep0 rowsep0" align="char" char=".">1.57</td><td class="colsep0 rowsep0" align="char" char=".">2.37</td><td class="colsep0 rowsep0" align="char" char=".">1.60</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22b</b></td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">0.11</td><td class="colsep0 rowsep0" align="char" char=".">0.89</td><td class="colsep0 rowsep0" align="char" char=".">2.88</td><td class="colsep0 rowsep0" align="char" char=".">2.63</td><td class="colsep0 rowsep0" align="char" char=".">4.32</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23b</b></td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char=".">0.13</td><td class="colsep0 rowsep0" align="char" char=".">1.09</td><td class="colsep0 rowsep0" align="char" char=".">3.99</td><td class="colsep0 rowsep0" align="char" char=".">2.16</td><td class="colsep0 rowsep0" align="char" char=".">2.85</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="9" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18c</b></td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">0.16</td><td class="colsep0 rowsep0" align="char" char=".">0.44</td><td class="colsep0 rowsep0" align="char" char=".">16.2</td><td class="colsep0 rowsep0" align="char" char=".">1.42</td><td class="colsep0 rowsep0" align="char" char=".">0.73</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19c</b></td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char=".">0.18</td><td class="colsep0 rowsep0" align="char" char=".">0.40</td><td class="colsep0 rowsep0" align="char" char=".">8.86</td><td class="colsep0 rowsep0" align="char" char=".">1.07</td><td class="colsep0 rowsep0" align="char" char=".">0.49</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22c</b></td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">0.15</td><td class="colsep0 rowsep0" align="char" char=".">0.59</td><td class="colsep0 rowsep0" align="char" char=".">3.55</td><td class="colsep0 rowsep0" align="char" char=".">1.32</td><td class="colsep0 rowsep0" align="char" char=".">1.55</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23c</b></td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char=".">0.15</td><td class="colsep0 rowsep0" align="char" char=".">0.56</td><td class="colsep0 rowsep0" align="char" char=".">4.32</td><td class="colsep0 rowsep0" align="char" char=".">0.97</td><td class="colsep0 rowsep0" align="char" char=".">1.09</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="9" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18d</b></td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">1.98</td><td class="colsep0 rowsep0" align="char" char=".">3.45</td><td class="colsep0 rowsep0" align="char" char=".">36.2</td><td class="colsep0 rowsep0" align="char" char=".">16.8</td><td class="colsep0 rowsep0" align="char" char=".">17.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19d</b></td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char=".">1.52</td><td class="colsep0 rowsep0" align="char" char=".">2.30</td><td class="colsep0 rowsep0" align="char" char=".">20.5</td><td class="colsep0 rowsep0" align="char" char=".">8.64</td><td class="colsep0 rowsep0" align="char" char=".">8.31</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22d</b></td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">4.86</td><td class="colsep0 rowsep0" align="char" char=".">7.97</td><td class="colsep0 rowsep0" align="char" char=".">117</td><td class="colsep0 rowsep0" align="char" char=".">15.1</td><td class="colsep0 rowsep0" align="char" char=".">24.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23d</b></td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char=".">4.04</td><td class="colsep0 rowsep0" align="char" char=".">6.90</td><td class="colsep0 rowsep0" align="char" char=".">75.9</td><td class="colsep0 rowsep0" align="char" char=".">8.46</td><td class="colsep0 rowsep0" align="char" char=".">11.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="9" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18e</b></td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left"><i>i</i>-Pr</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">1.43</td><td class="colsep0 rowsep0" align="char" char=".">5.02</td><td class="colsep0 rowsep0" align="char" char=".">25.7</td><td class="colsep0 rowsep0" align="char" char=".">15.3</td><td class="colsep0 rowsep0" align="char" char=".">23.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19e</b></td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left"><i>i</i>-Pr</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char=".">1.86</td><td class="colsep0 rowsep0" align="char" char=".">4.14</td><td class="colsep0 rowsep0" align="char" char=".">21.2</td><td class="colsep0 rowsep0" align="char" char=".">11.9</td><td class="colsep0 rowsep0" align="char" char=".">18.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22e</b></td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left"><i>i</i>-Pr</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">0.48</td><td class="colsep0 rowsep0" align="char" char=".">7.63</td><td class="colsep0 rowsep0" align="char" char=".">32.1</td><td class="colsep0 rowsep0" align="char" char=".">7.96</td><td class="colsep0 rowsep0" align="char" char=".">30.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23e</b></td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left"><i>i</i>-Pr</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char=".">0.59</td><td class="colsep0 rowsep0" align="char" char=".">6.83</td><td class="colsep0 rowsep0" align="char" char=".">27.6</td><td class="colsep0 rowsep0" align="char" char=".">7.91</td><td class="colsep0 rowsep0" align="char" char=".">18.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="9" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18f</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">2-thiophene</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">0.98</td><td class="colsep0 rowsep0" align="char" char=".">21.7</td><td class="colsep0 rowsep0" align="char" char=".">256</td><td class="colsep0 rowsep0" align="char" char=".">111</td><td class="colsep0 rowsep0" align="char" char=".">193</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22f</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">2-thiophene</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">0.40</td><td class="colsep0 rowsep0" align="char" char=".">19.2</td><td class="colsep0 rowsep0" align="char" char=".">183</td><td class="colsep0 rowsep0" align="char" char=".">42.2</td><td class="colsep0 rowsep0" align="char" char=".">70.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="9" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18g</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">0.46</td><td class="colsep0 rowsep0" align="char" char=".">1.81</td><td class="colsep0 rowsep0" align="char" char=".">10.6</td><td class="colsep0 rowsep0" align="char" char=".">8.55</td><td class="colsep0 rowsep0" align="char" char=".">14.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22g</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">0.24</td><td class="colsep0 rowsep0" align="char" char=".">4.28</td><td class="colsep0 rowsep0" align="char" char=".">24.6</td><td class="colsep0 rowsep0" align="char" char=".">7.50</td><td class="colsep0 rowsep0" align="char" char=".">19.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="9" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GZR (<b>1</b>)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">0.14</td><td class="colsep0 rowsep0" align="char" char=".">1.89</td><td class="colsep0 rowsep0" align="char" char=".">238</td><td class="colsep0 rowsep0" align="char" char=".">9.69</td><td class="colsep0 rowsep0" align="char" char=".">5.41</td></tr></tbody></table></div></div><div class="NLM_p">Compound <b>1</b> showed subnanomolar inhibitory potency against WT NS3/4A protease and maintained nanomolar activity against drug resistant variant D168A and GT3a protease. Similarly, in replicon assays, <b>1</b> exhibited an excellent potency profile with subnanomolar activity against WT HCV (EC<sub>50</sub> = 0.14 nM) and low nanomolar activity against drug resistant variants R155K, D168A, and D168V. However, in line with previous reports,<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a><b>1</b> was highly susceptible to the A156T mutation (EC<sub>50</sub> = 238 nM), losing over 1000-fold potency against this variant. Compared to <b>1</b>, the P1–P3 macrocyclic analogue <b>2</b> exhibited lower inhibitory potency against WT protease and the D168A variant. Also, the inhibitory activity of <b>2</b> against the GT3a protease was considerably lower than that of <b>1</b>. However, as we have previously shown,<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a><b>2</b> displayed a superior potency profile in replicon assays with subnanomolar activity against WT HCV (EC<sub>50</sub> = 0.33 nM) and maintained single-digit nanomolar potency against all drug-resistant variants tested. Notably, unlike <b>1</b>, compound <b>2</b> maintained low nanomolar potency against the A156T variant (EC<sub>50</sub> = 9.65 nM). Thus, with an improved resistance profile compared to <b>1</b>, the P1–P3 macrocyclic analogue <b>2</b> is an attractive lead compound for further optimization.</div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Modifications of P1′ and P4 Capping Groups</h3><div class="NLM_p">Initial SAR efforts to optimize lead compound <b>2</b> focused on exploring changes at the P1′ position and N-terminal capping group. Recent SAR studies of diverse NS3/4A PIs indicate that replacement of the cyclopropylsulfonamide moiety at the P1′ position with a slightly more hydrophobic 1-methylcyclopropylsulfonamide improves inhibitor potency in replicon assays.<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43, 44)</a> Moreover, changes at the P4 position have been shown to significantly affect inhibitor potency against drug resistant variants, as these groups bind in close proximity to the pivotal drug resistance site Asp168.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> For carbamate-linked P4 capping groups, generally bulky hydrophobic moieties are preferred, but the size of the group appears to be dependent on the heterocyclic moiety present at the P2 position.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a></div><div class="NLM_p last">First, replacing the cyclopropylsulfonamide at the P1′ position in <b>2</b> with 1-methylcyclopropylsulfonamide provided the analogue <b>19a</b>. Compared to the parent compound <b>2</b>, <b>19a</b> showed slightly better <i>K</i><sub>i</sub> values against WT, D168A, and GT3a proteases and exhibited similar or slightly better antiviral potency against WT and drug resistant variants. Next, the <i>tert</i>-butyl P4 capping group in both <b>2</b> and <b>19a</b> was replaced with a larger cyclopentyl moiety, resulting in analogues <b>22a</b> and <b>23a</b>. Unlike the change at the P1′ position, the P4 cyclopentyl modification provided mixed results. Compound <b>22a</b> afforded a 2-fold increase in potency than <b>2</b> in biochemical assays against WT protease and a slight improvement against the D168A variant but was equipotent to <b>2</b> against GT3a protease. Similarly, in replicon assays, <b>22a</b> exhibited 2-fold enhanced potency against WT HCV and D168A variant but showed similar potency as <b>2</b> against the R155K and D168V variants. Compound <b>23a</b>, with a 1-methylcyclopropylsulfonamide moiety at the P1′ position and a cyclopentyl group at the P4 position, exhibited potency profile largely similar to <b>22a</b>. Surprisingly, a slight loss in potency was observed against the A156T variant for compounds with a cyclopentyl versus <i>tert</i>-butyl capping group. Overall, these minor modifications at the P1′ and N-terminal capping regions of inhibitor <b>2</b> were tolerated and provided analogues with improved potency profiles.</div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> SAR Exploration of P2 Quinoxaline</h3><div class="NLM_p">Next, SARs at the P2 quinoxaline in compound <b>2</b> were explored. Efforts mainly focused on replacing the 3-position ethyl group with diverse functional groups with respect to size and electronic properties. Replacement of the ethyl group in <b>2</b> with a smaller methyl group provided analogue <b>18b</b>. As expected, reducing the size of the hydrophobic group at this position resulted in improved potency profile. Compound <b>18b</b> showed slightly enhanced potency against drug resistant variants in biochemical and antiviral assays, with a notable ∼2-fold improvement against the D168V variant (EC<sub>50</sub> = 3.17 nM). The introduction of 1-methylcyclopropylsulfonamide moiety at the P1′ position afforded inhibitor <b>19b</b> with protease inhibitory activity comparable to the parent compound <b>18b</b>. However, similar to the 3-ethylquinoxaline analogue (<b>19a</b>), compound <b>19b</b> demonstrated significant gain in potency in replicon assays. In fact, compared to <b>2</b>, <b>19b</b> exhibited 2–6-fold enhancement in potency against drug resistant variants R155K (EC<sub>50</sub> = 0.80 nM), A156T (EC<sub>50</sub> = 1.57 nM), D168A (EC<sub>50</sub> = 2.37 nM), and D168V (EC<sub>50</sub> = 1.60 nM). Replacement of the <i>tert</i>-butyl P4 capping in <b>18b</b> and <b>19b</b> with a cyclopentyl group, providing <b>22b</b> and <b>23b</b>, resulted in an increase in WT and D168A inhibitory activity as well as 2–3-fold increase in WT replicon potency. Unlike the corresponding 3-ethylquinoxaline analogues (<b>22a</b> and <b>23a</b>), the 3-methyquinoxaline compounds <b>22b</b> and <b>23b</b> maintained the excellent potency profile observed for the corresponding <i>tert</i>-butyl analogues. Remarkably, with the exception of <b>18b</b> (A156T EC<sub>50</sub> = 5.95 nM), all compounds in the 3-methylquinoxaline series display exceptional potency profiles with EC<sub>50</sub> values below 5 nM against WT and clinically relevant drug resistant variants.</div><div class="NLM_p">To gain insights into the excellent potency profile observed for the 3-methyquinoxaline series, we determined the X-ray crystal structure of inhibitor <b>19b</b> in complex with the WT NS3/4A protease at a resolution of 1.8 Å (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>, Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00426/suppl_file/jm7b00426_si_001.pdf" class="ext-link">Table S3</a>, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5VOJ">5VOJ</a>). The WT-<b>19b</b> complex structure was compared with the previously reported structures of compound <b>2</b> in complex with WT protease and the A156T variant (PDBs <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EPN">5EPN</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EPY">5EPY</a>).<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> The two WT structures overlap very well, with only minor differences in the S1 and S2 subsites because of modifications in the inhibitor structure. In the WT-<b>2</b> crystal structure, the 3-ethyl group at the P2 quinoxaline makes hydrophobic interactions with the hydrocarbon portion of the Arg155 side chain, while the methylene portion of this group interacts with the side chain of Ala156. The smaller methyl group at this position in the WT-<b>19b</b> structure maintains hydrophobic interactions with Ala156 while minimizing chances of steric clash with a larger side chain such as in A156T.</div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/medium/jm-2017-004268_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/large/jm-2017-004268_0003.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (a) X-ray crystal structure of WT1a HCV NS3/4A protease in complex with inhibitor <b>19b</b> and (b) superposition of WT-<b>2</b> and WT-<b>19a</b> complexes. The protease active site is shown as a surface with inhibitor <b>19b</b> shown in orange and <b>2</b> shown in blue. The catalytic triad is highlighted in yellow, and drug resistance residues Arg155, Ala156, and Asp168 are shown as sticks.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/large/jm-2017-004268_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00426&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Unlike inhibitor <b>1</b>, the P1–P3 macrocyclic analogues retain potency against the A156T variant. Comparison of the WT-<b>2</b> and A156T-<b>2</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EPY">5EPY</a>) structures shows subtle changes in inhibitor interactions with the mutant protease.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> In the A156T-<b>2</b> structure, the P2 quinoxaline largely maintains interactions with the catalytic residues, but the ethyl group is shifted away from Arg155 side chain toward A156T. Moreover, to accommodate a larger Thr side chain, the Asp168 side chain adopts another conformation, moving away from Arg155. These changes underlie reduced inhibitor potency against the A156T variant, but unlike <b>1</b>, inhibitor <b>2</b> is able to better accommodate these changes due to a flexible P2 moiety. The 3-methylquinoxaline analogues are more potent against the A156T variant than the corresponding 3-ethylquinoxaline compounds, likely due the reduced interactions of the smaller methyl group with the Thr side chain. Replacing the methyl group with hydrogen at the 3-position of quinoxaline would further reduce interactions with the S2 subsite residues but could result in a highly flexible P2 moiety, likely destabilizing interactions with the catalytic residues. Thus, a small hydrophobic group at the 3-position of P2 quinoxaline is preferred to maintain favorable interactions with Ala156 and avoid steric clashes with the Thr side chain in the A156T variant.</div><div class="NLM_p">The improved potency profile of 3-methyquinoxaline compounds led to exploration of bioisosteric replacements of the 3-methyl group with varied size and electronic properties. To that end, analogues <b>18c</b> and <b>19c</b> bearing the 3-chloro-7-methoxyquinoxaline at the P2 position were prepared. The protease inhibitory potency profiles of these compounds were excellent and showed improvement against WT, D168A, and GT3a over <b>2</b>. These potency gains were not only maintained in replicon assays but were more significant, with the only exception of the A156T variant. Both compounds <b>18c</b> and <b>19c</b> were more active than the corresponding 3-methylquinoxaline analogues (<b>18b</b> and <b>19b</b>), with EC<sub>50</sub> values less than 1 nM against WT, R155K, and D168V and less than 2 nM against the D168A variant, but experienced about 3–6-fold reduction in potency against the A156T variant. However, potency losses against the A156T variant were largely reversed when the P4 <i>tert</i>-butyl group in <b>18c</b> and <b>19c</b> was replaced with a larger cyclopentyl moiety to afford <b>22c</b> and <b>23c</b>. Similar to the 3-methylquinoxaline compounds, the 3-chloroquinoxaline analogues displayed exceptional potency profiles with EC<sub>50</sub> values of less than 5 nM against all drug resistant variants including A156T. These results clearly demonstrate that small hydrophobic groups with weak electron-donating properties at the 3-position of P2 quinoxaline can be replaced with weak electron-withdrawing groups without affecting the overall potency profile.</div><div class="NLM_p">Next, a larger and strongly electron-withdrawing trifluoromethyl moiety was explored at the 3-position of P2 quinoxaline, leading to inhibitors <b>18d</b> and <b>19d</b>. This modification, however, resulted in significant potency losses in both biochemical and replicon assays. Compound <b>18d</b> was about 2–4-fold less active than <b>2</b> against WT protease and variants. Analogue <b>19d</b>, with the 1-methylcyclopropylsulfonamide moiety at the P1′ position, showed similar trends when compared to the corresponding <b>19a</b>. In line with biochemical data, both <b>18d</b> and <b>19d</b> suffered 2–6-fold decrease in replicon potency against WT and drug resistant variants, although <b>19d</b> maintained relatively good potency profile. In contrast to the results in previous series, the introduction of the larger cyclopentyl P4 capping group, as in <b>22d</b> and <b>23d</b>, was detrimental to replicon potency, particularly against the A156T variant. Moreover, compounds in the 3-(trifluoromethyl)quinoxaline series were among the least active against the GT3a protease in biochemical assays. These results indicate that strong electron-withdrawing groups at the 3-position of the P2 quinoxaline may be detrimental to potency. However, a recent SAR study indicates that PIs incorporating the 3-(trifluoromethyl)quinoxaline can be optimized with modifications at the 7-position of quinoxaline in combination with changes at the P1–P3 macrocycle and P4 capping group.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a></div><div class="NLM_p">In the absence of a cocrystal structure, the lower inhibitory potencies of compounds in the 3-(trifluoromethyl)quinoxaline series against WT protease could not be explained by molecular modeling, which suggested a similar binding conformation of the P2 quinoxaline in <b>18d</b> as observed for <b>2</b> (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>A). Perhaps there are repulsive interactions between trifluoromethyl moiety and the side chain of Asp168, and/or the strong electron-withdrawing effect may weaken the overall interactions of the P2 quinoxaline with the catalytic residues. Potency losses against resistant variants may also result from the larger size of the trifluoromethyl moiety, which is comparable to that of an ethyl group, although both have different topographical shapes.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a></div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/medium/jm-2017-004268_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/large/jm-2017-004268_0004.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Comparison of lead compound <b>2</b> with analogues (a) <b>18d</b> and (b) <b>18e</b> modeled in the active site of WT HCV NS3/4A protease. Compound <b>2</b> is shown in salmon, and modified inhibitors are in green. The catalytic triad is highlighted in yellow, and drug resistance residues Arg155, Ala156, and Asp168 are in sticks.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/large/jm-2017-004268_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00426&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To isolate the effects of larger size versus electronic properties on potency, inhibitors <b>18e</b> and <b>19e</b> with the larger isopropyl group at the 3-position of the P2 quinoxaline were designed and evaluated. These compounds showed WT protease inhibitory activity similar to the corresponding 3-ethylquinoxaline analogues (<b>2</b> and <b>19a</b>) but experienced 2–4-fold reduced activity against the D168A variant. A broader reduction in potency was observed for both <b>18e</b> and <b>19e</b> in replicon assays against WT and drug resistant variants. The cyclopentyl P4 group in analogues <b>22e</b> and <b>23e</b> slightly improved biochemical and replicon potency against WT and D168A variants but was largely unfavorable to replicon potency against R155K and A156T variants. This trend is broadly similar to the results observed with the 3-(trifluoromethyl)quinoxaline series, indicating that both electronic properties and size of the group at the 3-position of P2 quinoxaline are important for maintaining potency against drug resistant variants. Modeling indicated that compared to <b>2</b> the P2 quinoxaline moiety in <b>18e</b> has to shift away from the catalytic triad in order to accommodate the larger isopropyl group, thereby weakening critical stacking interactions with His57 (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>B). Overall, SAR data from the 3-isopropyl- and 3-(trifluoromethyl)-quinoxaline series supports the hypothesis that large substituents at the 3-position of P2 quinoxaline have a detrimental effect on inhibitor potency against drug resistant variants.</div><div class="NLM_p">These findings were further reinforced by the results obtained for the 3-(thiophen-2-yl)quinoxaline analogues <b>18f</b> and <b>22f</b>. On the basis of molecular modeling, the large thiophene moiety in these compounds was expected to make extensive interactions with the residues Arg155 and Ala156, resulting in improved potency against WT protease. However, mutations at these positions as well as at Asp168 would cause significant potency losses, as these residues are crucial for efficient inhibitor binding. As expected, compound <b>18f</b> (a previously reported NS3/4A PI incorrectly labeled as ABT-450)<a onclick="showRef(event, 'ref19 ref48'); return false;" href="javascript:void(0);" class="ref ref19 ref48">(19, 48)</a> showed a 3-fold enhancement in WT biochemical potency but was dramatically less active against the D168A variant, losing over 1800-fold potency. Similarly, in replicon assays, analogue <b>18f</b> showed considerably reduced potency against all drug resistant variants with losses ranging from 20- to 250-fold compared to WT (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00426/suppl_file/jm7b00426_si_001.pdf" class="ext-link">Tables S1 and S2</a>). The cyclopentyl P4 analogue <b>22f</b> also experienced large potency losses against the variants, albeit to a lesser extent than <b>18f</b>. Thus, inhibitors with large groups at the 3-position of P2 quinoxaline are highly susceptible to mutations at residues Arg155, Ala156, and Asp168, leading to poor resistance profiles.</div><div class="NLM_p">The X-ray crystal structure of inhibitor <b>18f</b> in complex with WT NS3/4A protease was determined at a resolution of 1.9 Å, providing insights into the binding mode of P2 quinoxaline with a larger thiophene substituent at the 3-position (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a> and Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00426/suppl_file/jm7b00426_si_001.pdf" class="ext-link">Table S3</a>, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5VP9">5VP9</a>). Comparison of the WT-<b>18f</b> and WT-<b>2</b> crystal structures showed significant differences in the interactions of quinoxaline moieties with the catalytic triad and S2 subsite residues. As predicted, the quinoxaline moiety in WT-<b>18f</b> structure is shifted toward the active site to accommodate the larger thiophene substituent. The thiophene ring makes extensive interactions with residues in the S2 subsite, including cation−π interactions with Arg155, likely contributing to the improved potency against the WT protease. As this Arg155 conformation is stabilized by electrostatic interactions with Asp168, mutations at either residue would disrupt inhibitor binding by loss of direct interactions as well as indirect structural effects. In addition, the A156T mutation would result in a steric clash with the thiophene ring, as reflected in the antiviral data for this variant. These biochemical and structural findings are in line with previous studies that show inhibitors that are dependent on extensive interactions with the S2 subsite residues for potency are highly susceptible to mutations at residues Arg155, Ala156, and Asp168.</div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/medium/jm-2017-004268_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/large/jm-2017-004268_0005.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (a) X-ray crystal structure of WT1a HCV NS3/4A protease in complex with inhibitor <b>18f</b> and (b) superposition of WT-<b>2</b> and WT-<b>18f</b> complexes. The protease active site is shown as a surface with inhibitor <b>18f</b> shown in orange and <b>2</b> shown in blue. The catalytic triad is highlighted in yellow, and drug resistance residues Arg155, Ala156, and Asp168 are shown as sticks.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/large/jm-2017-004268_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00426&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">As compounds <b>18f</b> and <b>22f</b> lacked the C-7 substituent at the P2 quinoxaline, analogues <b>18g</b> and <b>22g</b> were prepared to investigate the effect of this group on inhibitor potency. Compared to <b>2</b>, analogue <b>18g</b> experienced about 2-fold decrease in biochemical potency and only minor loss in replicon potency against WT and drug resistant variants. The P4 cyclopentyl analogue <b>22g</b> resulted in about 2-fold reduced potency compared to the corresponding compound <b>22a</b>. Thus, removal of the C-7 methoxy group has minimal effect on inhibitor potency. The slightly reduced potency of <b>18g</b> and <b>22g</b> is likely due to the reduced hydrophobic interactions with the aromatic ring of Tyr56 and the methylene portion of His57 of the catalytic triad. In contrast, the observed potency losses against resistant variants for the 3-(thiophen-2-yl)quinoxaline compounds most likely result from loss of interactions of the 2-thiophene moiety with the S2 subsite residues of the protease.</div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Effects of P2 Substituent Size and Flexibility</h3><div class="NLM_p">Taken together, our SAR results indicate that resistance profiles of compound <b>2</b> and analogues are strongly influenced by the substituent at the 3-position of P2 quinoxaline and N-terminal capping group. While all PIs showed reduced potency against drug resistance variants in both enzyme inhibition and replicon assays, fold potency losses varied significantly depending on the substituents at the 3-position of P2 quinoxaline. To evaluate susceptibility to the clinically important D168A variant, to which all current NS3/4A PIs are susceptible, potencies were normalized to WT for PIs with the same P4 capping groups (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>). Fold changes in <i>K</i><sub>i</sub> against the D168A protease variant for PIs with the same P1′ and P4 capping groups largely trended with the size of the substituent at the 3-position of P2 quinoxaline, with the exception of trifluoromethyl compounds. Losses in potency were significantly higher for compounds with the larger 2-thiophene substituent at the P2 quinoxaline. These results strongly support using the substrate envelope model to reduce direct inhibitor interactions in the S2 subsite, thereby reducing inhibitor susceptibility to drug resistance.</div><figure id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/medium/jm-2017-004268_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/large/jm-2017-004268_0006.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Resistance profiles of protease inhibitors in enzyme inhibition and antiviral assays for PIs with (a) <i>tert</i>-butyl and (b) cyclopentyl P4 capping groups. Enzyme inhibitory (blue bars) and antiviral (orange bars) activities against the D168A variant were normalized with respect to the wild-type NS3/4A protease domain or wild-type HCV replicon. *Indicates value higher than 1000.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/large/jm-2017-004268_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00426&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">As we and others have shown,<a onclick="showRef(event, 'ref31 ref32 ref33 ref35'); return false;" href="javascript:void(0);" class="ref ref31 ref32 ref33 ref35">(31-33, 35)</a> the reduced potencies of NS3/4A PIs against drug resistant variants R155K, A156T, and D168A/V mainly result from disruption of the electrostatic interactions between Arg155 and Asp168. Compared to <b>1</b>, compound <b>2</b> and most analogues incorporating flexible P2 quinoxaline showed lower fold-changes in potency against these variants (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00426/suppl_file/jm7b00426_si_001.pdf" class="ext-link">Tables S1 and S2</a>). In these P1–P3 macrocyclic PIs, the conformational flexibility of the P2 allows this moiety to adapt to the structural changes caused by mutations at Arg155, Ala156, and Asp168, resulting in better resistance profiles. Potency losses were higher for compound <b>1</b> because constraint imposed by the macrocycle does not allow the P2 moiety to adapt to the structural changes resulting from these mutations. Compound <b>1</b> and similar P2–P4 macrocyclic PIs, such as voxilaprevir and glecaprevir, are likely to be more susceptible to mutations that cause significant structural changes in the protease active site. However, the P1–P3 macrocyclic compounds reported here, as well as those reported in patent literature that incorporate similar flexible P2 quinoxaline moieties,<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> are likely to be more effective against clinically relevant drug resistant variants. More broadly, combining the substrate envelope model with optimal conformational flexibility provides a rational approach to design NS3/4A PIs with improved resistance profiles.</div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76842" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76842" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Drug resistance is a major problem across all DAA classes targeting HCV. As new therapies are developed, the potential for drug resistance must be minimized at the outset of inhibitor design. The substrate envelope model provides a rational approach to design robust NS3/4A PIs with improved resistance profiles. Our SAR findings support the hypothesis that reducing PI interactions with residues in the S2 subsite leads to inhibitors with exceptional potency and resistance profiles. Specifically, the P1–P3 macrocyclic inhibitors incorporating flexible P2 quinoxaline moieties bearing small hydrophobic groups at the 3-position maintain excellent potency in both enzymatic and antiviral assays against drug resistant variants. While these inhibitors protrude from the substrate envelope, they leverage interactions with the essential catalytic triad residues and avoid direct contacts with residues that can mutate to confer resistance. Moreover, conformational flexibility at the P2 moiety is essential to efficiently accommodate structural changes due to mutations in the S2 pocket in order to avoid resistance. These insights provide strategies for iterative rounds of inhibitor design with the paradigm that designing inhibitors with flexible P2 quinoxalines, leveraging evolutionarily constrained areas in the protease active site and expanding into the substrate envelope, may provide inhibitors that are robust against drug resistant variants.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28424" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28424" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> General</h3><div class="NLM_p last">All reactions were performed in oven-dried round-bottomed or modified Schlenk flasks fitted with rubber septa under argon atmosphere unless otherwise noted. All reagents and solvents, including anhydrous solvents, were purchased from commercial sources and used as received. Flash column chromatography was performed using silica gel (230–400 mesh, EMD Millipore). Thin-layer chromatography (TLC) was performed using silica gel (60 F-254) coated aluminum plates (EMD Millipore), and spots were visualized by exposure to ultraviolet light (UV), exposure to iodine adsorbed on silica gel, and/or exposure to an acidic solution of <i>p</i>-anisaldehyde (anisaldehyde) followed by brief heating. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were acquired on Varian Mercury 400 MHz and Bruker Avance III HD 500 MHz NMR instruments. Chemical shifts are reported in ppm (δ scale) with the residual solvent signal used as reference, and coupling constant (<i>J</i>) values are reported in hertz (Hz). Data are presented as follows: chemical shift, multiplicity (s = singlet, d = doublet, dd = doublet of doublet, t = triplet, q = quartet, m = multiplet, br s = broad singlet), coupling constant in Hz, and integration. High-resolution mass spectra (HRMS) were recorded on a Thermo Scientific Orbitrap Velos Pro mass spectrometer coupled with a Thermo Scientific Accela 1250 UPLC and an autosampler using electrospray ionization (ESI) in the positive mode. The purity of final compounds was determined by analytical HPLC and was found to be ≥95% pure. HPLC was performed on a Waters Alliance 2690 system equipped with a Waters 2996 photodiode array detector and an autosampler under the following conditions: column, Phenomenex Luna-2 RP-C18 (5 μm, 4.6 mm × 250 mm, 120 Å, Torrance, CA); solvent A, H<sub>2</sub>O containing 0.1% formic acid (FA); solvent B, CH<sub>3</sub>CN containing 0.1% FA; gradient, 50% B to 100% B over 15 min followed by 100% B over 5 min; injection volume, 10 μL; flow rate, 1 mL/min. Retention times and purity data for each target compound are provided in the <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Typical Procedures for the Synthesis of Protease Inhibitors Using Method A</h3><div id="sec5_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15"> 1-(<i>tert</i>-Butyl) 2-Methyl (2<i>S</i>,4<i>R</i>)-4-((3-Ethyl-7-methoxyquinoxalin-2-yl)oxy)pyrrolidine-1,2-dicarboxylate (<b>9a</b>)</h4><div class="NLM_p last">A solution of 3-ethyl-7-methoxyquinoxalin-2-one <b>8a</b> (3.0 g, 14.7 mmol) in anhydrous NMP (45 mL) was treated with Cs<sub>2</sub>CO<sub>3</sub> (7.40 g, 22.7 mmol). After stirring the reaction mixture at room temperature for 15 min, proline derivative <b>3</b> (6.20 g, 13.3 mmol) was added in one portion. The reaction mixture was heated to 55 °C, stirred for 4 h, and then another portion of proline derivative <b>3</b> (0.48 g, 1.0 mmol) was added. The resulting reaction mixture was stirred at 55 °C for an additional 2 h, cooled to room temperature, quenched with aqueous 1 N HCl solution (150 mL), and extracted with EtOAc (300 mL). The organic fraction was washed successively with saturated aqueous NaHCO<sub>3</sub> and NaCl (150 mL each), dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and evaporated under reduced pressure. The residue was purified by flash column chromatography using 15–30% EtOAc/hexanes as the eluent to provide <b>9a</b> (5.50 g, 87%) as a white foamy solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) (mixture of rotamers, major rotamer) δ 7.85 (d, <i>J</i> = 9.0 Hz, 1 H), 7.18 (m, 1H), 7.11 (d, <i>J</i> = 2.8 Hz, 1 H), 5.73 (br s, 1 H), 4.47 (t, <i>J</i> = 8.0 Hz, 1 H), 3.98–3.86 (m, 5 H), 3.78 (s, 3 H), 2.92 (q, <i>J</i> = 7.2 Hz, 2 H), 2.68–2.60 (m, 1 H), 2.43–2.36 (m, 1 H), 1.43 (s, 9 H), 1.31 (t, <i>J</i> = 7.2 Hz, 3 H) ppm. <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 173.56, 160.59, 155.38, 154.02, 148.95, 141.26, 134.12, 129.07, 119.02, 106.11, 80.76, 73.81, 58.43, 55.93, 52.73, 52.40, 36.88, 28.47, 26.68, 11.97 ppm. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>22</sub>H<sub>30</sub>N<sub>3</sub>O<sub>6</sub>, 432.2129; found, 432.2135.</div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16"> 1-(<i>tert</i>-Butyl) 2-Methyl (2<i>S</i>,4<i>R</i>)-4-((7-Methoxy-3-(trifluoromethyl)quinoxalin-2-yl)oxy)pyrrolidine-1,2-dicarboxylate (<b>9d</b>)</h4><div class="NLM_p last">The same procedure was used as described above for compound <b>9a</b>. 7-Methoxy-3-(trifluoromethyl)quinoxalin-2(1<i>H</i>)-one <b>8d</b> (4.76 g, 19.5 mmol) in NMP (65 mL) was treated with Cs<sub>2</sub>CO<sub>3</sub> (9.80 g, 30.0 mmol) and proline derivative <b>3</b> (9.0 g, 19.3 mmol) to provide <b>9d</b> (6.50 g, 71%) as a pale-yellow foamy solid. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) (mixture of rotamers, major rotamer) δ 7.77 (d, <i>J</i> = 9.0 Hz, 1 H), 7.48–7.43 (m, 2 H), 5.76 (br s, 1 H), 4.50 (t, <i>J</i> = 8.0 Hz, 1 H), 3.97–3.91 (m, 5 H), 3.78 (s, 3 H), 2.69–2.64 (m, 1 H), 2.41–2.34 (m, 1 H), 1.42 (s, 9 H) ppm. <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 173.43, 159.58, 153.98, 152.11, 138.39, 137.22, 127.99, 125.73, 120.70 (q, <i>J</i> = 273.4 Hz), 107.64, 80.69, 74.62, 58.27, 56.02, 52.32, 52.11, 36.70, 28.34 ppm. <sup>19</sup>F NMR (470 MHz, CDCl<sub>3</sub>) −67.73 ppm. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>21</sub>H<sub>25</sub>F<sub>3</sub>N<sub>3</sub>O<sub>6</sub>, 472.1690; found, 472.1689.</div></div><div id="sec5_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> Methyl (2<i>S</i>,4<i>R</i>)-1-((<i>S</i>)-2-((<i>tert</i>-Butoxycarbonyl)amino)non-8-enoyl)-4-((3-ethyl-7-methoxyquinoxalin-2-yl)oxy)pyrrolidine-2-carboxylate (<b>12a</b>)</h4><div class="NLM_p">A solution of ester <b>9a</b> (4.80 g, 11.1 mmol) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (30 mL) was treated with a solution of 4 N HCl in 1,4-dioxane (30 mL). After stirring the reaction mixture at room temperature for 3 h, solvents were evaporated under reduced pressure, and the residue was dried under high vacuum. The pale-yellow solid was triturated with diethyl ether (3 × 30 mL) and dried under high vacuum to yield the amine salt <b>10a</b> (4.0 g, 98%) as an off-white powder.</div><div class="NLM_p last">A mixture of amine salt <b>10a</b> (4.0 g, 10.9 mmol) and (<i>S</i>)-2-((<i>tert</i>-butoxycarbonyl)amino)non-8-enoic acid <b>11</b> (3.0 g, 11.1 mmol) in anhydrous DMF (60 mL) was treated with DIEA (7.30 mL, 44.2 mmol) and HATU (6.35 g, 16.7 mmol). The resulting reaction mixture was stirred at room temperature for 4 h, then diluted with EtOAc (400 mL) and washed successively with aqueous 0.5 N HCl, saturated aqueous NaHCO<sub>3</sub>, and saturated aqueous NaCl (250 mL each). The organic portion was dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and evaporated under reduced pressure. The residue was purified by flash chromatography using 20–30% EtOAc/hexanes as the eluent to provide <b>12a</b> (5.50 g, 86%) as a white foamy solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) (mixture of rotamers, major rotamer) δ 7.86 (d, <i>J</i> = 8.8 Hz, 1 H), 7.20 (dd, <i>J</i> = 9.2, 2.8 Hz, 1 H), 7.12 (d, <i>J</i> = 2.8 Hz, 1 H), 5.87–5.75 (m, 2 H), 5.20 (d, <i>J</i> = 8.4 Hz, 1 H), 5.02–4.92 (m, 2 H), 4.73 (t, <i>J</i> = 8.4 Hz, 1 H), 4.38 (q, <i>J</i> = 7.2 Hz, 1 H), 4.17 (d, <i>J</i> = 12.0 Hz, 1 H), 4.06 (dd, <i>J</i> = 11.6, 4.4 Hz, 1 H), 3.94 (s, 3 H), 3.78 (s, 3 H), 2.90 (q, <i>J</i> = 7.6 Hz, 2 H), 2.69–2.64 (m, 1 H), 2.41–2.34 (m, 1 H), 2.05 (app q, <i>J</i> = 6.8 Hz, 2 H), 1.82–1.74 (m, 1 H), 1.63–1.56 (m, 1 H), 1.45–1.25 (m, 18 H) ppm. <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 172.34, 171.96, 160.61, 155.61, 155.13, 148.95, 141.08, 139.18, 129.22, 119.08, 114.58, 106.14, 79.84, 74.48, 58.19, 55.91, 52.88, 52.67, 52.05, 35.16, 33.88, 32.88, 29.14, 28.96, 28.46, 26.52, 24.92, 11.86 ppm. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>31</sub>H<sub>45</sub>N<sub>4</sub>O<sub>7</sub>, 585.3283; found, 585.3286.</div></div><div id="sec5_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> Methyl (2<i>S</i>,4<i>R</i>)-1-((<i>S</i>)-2-((<i>tert</i>-Butoxycarbonyl)amino)non-8-enoyl)-4-((7-methoxy-3-(trifluoromethyl)quinoxalin-2-yl)oxy)pyrrolidine-2-carboxylate (<b>12d</b>)</h4><div class="NLM_p last">The same procedure was used as described above for compound <b>12a</b>. Compound <b>9d</b> (6.0 g, 12.7 mmol) was treated with 4 N HCl (40 mL) to afford amine salt <b>10d</b> (5.10 g, 12.5 mmol), which was coupled with acid <b>11</b> (3.80 g, 14.0 mmol) using DIEA (9.25 mL, 56.0 mmol) and HATU (7.60 g, 20.0 mmol) to provide <b>12d</b> (6.40 g, 81%) as a pale-yellow foamy solid. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) (mixture of rotamers, major rotamer) δ 7.78 (d, <i>J</i> = 9.0 Hz, 1 H), 7.48 (dd, <i>J</i> = 9.0, 2.5 Hz, 1 H), 7.44 (d, <i>J</i> = 2.5 Hz, 1 H), 5.86 (br s, 1 H), 5.84–5.78 (m, 1 H), 5.18 (d, <i>J</i> = 9.0 Hz, 1 H), 5.01–4.92 (m, 2 H), 4.75 (t, <i>J</i> = 8.0 Hz, 1 H), 4.35 (q, <i>J</i> = 7.5 Hz, 1 H), 4.19 (d, <i>J</i> = 12.0 Hz, 1 H), 4.08 (dd, <i>J</i> = 11.5, 4.5 Hz, 1 H), 3.95 (s, 3 H), 3.78 (s, 3 H), 2.70–2.65 (m, 1 H), 2.41–2.35 (m, 1 H), 2.04 (app q, <i>J</i> = 7.0 Hz, 2 H), 1.80–1.75 (m, 1 H), 1.60–1.54 (m, 1 H), 1.45–1.28 (m, 15 H) ppm. <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 172.10, 171.60, 159.99, 155.37, 151.78, 138.98, 138.41, 136.93, 134.40 (q, <i>J</i> = 36.3 Hz), 127.85, 125.66, 120.53 (q, <i>J</i> = 273.4 Hz), 114.33, 107.54, 79.58, 75.05, 57.83, 55.91, 52.44, 52.33, 51.75, 34.77, 33.65, 32.70, 28.91, 28.73, 28.18, 24.70 ppm. <sup>19</sup>F NMR (470 MHz, CDCl<sub>3</sub>) −67.73 ppm. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>30</sub>H<sub>40</sub>F<sub>3</sub>N<sub>4</sub>O<sub>7</sub>, 625.2844; found, 625.2844.</div></div><div id="sec5_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> <i>tert</i>-Butyl ((<i>S</i>)-1-((2<i>S</i>,4<i>R</i>)-2-(((1<i>R</i>,2<i>S</i>)-1-((Cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)carbamoyl)-4-((3-ethyl-7-methoxyquinoxalin-2-yl)oxy)pyrrolidin-1-yl)-1-oxonon-8-en-2-yl)carbamate (<b>16a</b>)</h4><div class="NLM_p">A solution of ester <b>12a</b> (5.86 g, 10.0 mmol) in THF–H<sub>2</sub>O mixture (1:1, 140 mL) was treated with LiOH·H<sub>2</sub>O (1.40 g, 33.4 mmol). The resulting reaction mixture was stirred at room temperature for 24 h. The reaction mixture was cooled to ∼5 °C, acidified to a pH of 2.0 by slow addition of aqueous 0.25 N HCl (∼200 mL), and extracted with EtOAc (2 × 400 mL). The organic portions were washed separately with saturated aqueous NaCl (200 mL), dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and evaporated under reduced pressure. The gummy residue was dissolved in CHCl<sub>3</sub> (50 mL), concentrated under reduced pressure, and the residue was dried under high vacuum overnight to yield the acid <b>13a</b> (5.70 g, 100%) as a white foamy solid.</div><div class="NLM_p last">A mixture of acid <b>13a</b> (2.10 g, 3.7 mmol) and amine salt <b>14</b><a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> (1.20 g, 4.5 mmol) in anhydrous DMF (35 mL) was treated with DIEA (2.43 mL, 14.7 mmol) and HATU (2.1 g, 5.5 mmol). The resulting reaction mixture was stirred at room temperature for 2.5 h, then diluted with EtOAc (300 mL) and washed successively with aqueous 0.5 N HCl, saturated aqueous NaHCO<sub>3</sub>, and saturated aqueous NaCl (200 mL each). The organic portion was dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and evaporated under reduced pressure. The residue was purified by flash chromatography using 50–70% EtOAc/hexanes as the eluent to provide the bis-olefin compound <b>16a</b> (2.50 g, 86%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.24 (s, 1 H), 7.84 (d, <i>J</i> = 8.8 Hz, 1 H), 7.18 (dd, <i>J</i> = 8.8, 2.4 Hz, 1 H), 7.13 (d, <i>J</i> = 2.8 Hz, 1 H), 7.04 (s, 1 H), 5.91 (br s, 1 H), 5.85–5.73 (m, 2 H), 5.32 (d, <i>J</i> = 8.4 Hz, 1 H), 5.27 (d, <i>J</i> = 17.2 Hz, 1 H), 5.14 (d, <i>J</i> = 11.2 Hz, 1 H), 5.01–4.90 (m, 2 H), 4.47 (t, <i>J</i> = 7.6 Hz, 1 H), 4.38–4.33 (m, 1 H), 4.20 (d, <i>J</i> = 11.6 Hz, 1 H), 4.02 (dd, <i>J</i> = 11.2, 4.0 Hz, 1 H), 3.94 (s, 3 H), 2.96–2.84 (m, 3 H), 2.56–2.51 (m, 2 H), 2.11 (q, <i>J</i> = 8.8 Hz, 1 H), 2.05–1.99 (m, 3 H), 1.74–1.54 (m, 2 H), 1.47–1.10 (m, 21 H), 1.08–1.03 (m, 2 H) ppm. <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 174.09, 172.58, 168.69, 160.54, 155.89, 154.99, 148.88, 140.95, 139.07, 134.69, 132.71, 129.45, 119.02, 118.77, 114.67, 106.13, 80.0, 74.66, 60.61, 55.91, 53.42, 52.62, 41.83, 35.46, 34.47, 33.89, 32.40, 31.39, 28.98, 28.89, 28.47, 26.68, 25.47, 23.83, 11.85, 6.68, 6.26 ppm. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>39</sub>H<sub>55</sub>N<sub>6</sub>O<sub>9</sub>S, 783.3746; found, 783.3734.</div></div><div id="sec5_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> <i>tert</i>-Butyl ((<i>S</i>)-1-((2<i>S</i>,4<i>R</i>)-4-((3-Ethyl-7-methoxyquinoxalin-2-yl)oxy)-2-(((1<i>R</i>,2<i>S</i>)-1-(((1-methylcyclopropyl)sulfonyl)carbamoyl)-2-vinylcyclopropyl)carbamoyl)pyrrolidin-1-yl)-1-oxonon-8-en-2-yl)carbamate (<b>17a</b>)</h4><div class="NLM_p last">The same procedure was used as described above for compound <b>16a</b>. Acid <b>13a</b> (1.50 g, 2.6 mmol) was coupled with amine salt <b>15</b><a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> (0.90 g, 3.2 mmol) using DIEA (1.75 mL, 10.6 mmol) and HATU (1.50 g, 3.9 mmol) to provide the bis-olefin compound <b>17a</b> (1.75 g, 84%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.02 (s, 1 H), 7.84 (d, <i>J</i> = 9.2 Hz, 1 H), 7.19 (dd, <i>J</i> = 8.8, 2.8 Hz, 1 H), 7.13 (d, <i>J</i> = 2.8 Hz, 1 H), 7.06 (s, 1 H), 5.90 (br s, 1 H), 5.83–5.73 (m, 2 H), 5.37 (d, <i>J</i> = 9.2 Hz, 1 H), 5.27 (d, <i>J</i> = 17.2 Hz, 1 H), 5.14 (d, <i>J</i> = 10.8 Hz, 1 H), 5.98 (dd, <i>J</i> = 17.2, 1.6 Hz, 1 H), 4.92 (dd, <i>J</i> = 10.4, 1.2 Hz, 1 H), 4.48 (t, <i>J</i> = 8.0 Hz, 1 H), 4.39–4.33 (m, 1 H), 4.16 (d, <i>J</i> = 12.0 Hz, 1 H), 4.02 (dd, <i>J</i> = 11.6, 4.0 Hz, 1 H), 3.94 (s, 3 H), 2.89 (q, <i>J</i> = 7.6 Hz, 2 H), 2.57–2.50 (m, 2 H), 2.12 (q, <i>J</i> = 8.8 Hz, 1 H), 2.05–1.99 (m, 3 H), 1.75–1.58 (m, 4 H), 1.49 (s, 3 H), 1.45–1.18 (m, 19 H), 0.93–0.79 (m, 2 H) ppm. <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 173.79, 172.41, 167.51, 160.31, 155.71, 154.76, 148.63, 140.73, 138.85, 134.41, 132.60, 129.18, 118.80, 118.54, 114.41, 105.89, 79.74, 74.42, 60.36, 55.68, 53.17, 52.43, 41.71, 36.56, 35.23, 34.22, 33.64, 32.19, 28.70, 28.67, 28.25, 26.43, 25.35, 23.49, 18.37, 14.27, 13.29, 11.64 ppm. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>40</sub>H<sub>57</sub>N<sub>6</sub>O<sub>9</sub>S, 797.3902; found, 797.3887.</div></div><div id="sec5_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> <i>tert</i>-Butyl ((2<i>R</i>,6<i>S</i>,13a<i>S</i>,14a<i>R</i>,16a<i>S</i>,<i>Z</i>)-14a-((Cyclopropylsulfonyl)carbamoyl)-2-((3-ethyl-7-methoxyquinoxalin-2-yl)oxy)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[<i>e</i>]pyrrolo[1,2-<i>a</i>][1,4]diazacyclopentadecin-6-yl)carbamate (<b>2</b>)</h4><div class="NLM_p last">A degassed solution of bis-olefin <b>16a</b> (1.40 g, 1.8 mmol) in 1,2-DCE (300 mL) was heated to 50 °C under argon, then Zhan 1B catalyst (0.150 g, 0.20 mmol) was added in two portions over 10 min. The resulting reaction mixture was heated to 70 °C and stirred for 6 h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by flash chromatography using 50–80% EtOAc/hexanes as the eluent to yield the P1–P3 macrocyclic product <b>2</b> (0.72 g, 53%) as an off-white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.28 (s, 1 H), 7.84 (d, <i>J</i> = 9.6 Hz, 1 H), 7.20–7.15 (m, 2 H), 6.91 (s, 1 H), 5.90 (br s, 1 H), 5.69 (q, <i>J</i> = 8.8 Hz, 1 H), 5.14 (d, <i>J</i> = 7.6 Hz, 1 H), 4.96 (t, <i>J</i> = 9.2 Hz, 1 H), 4.59 (t, <i>J</i> = 7.6 Hz, 1 H), 4.49 (d, <i>J</i> = 11.6 Hz, 1 H), 4.30–4.24 (m, 1 H), 4.02 (dd, <i>J</i> = 10.8, 4.0 Hz, 1 H), 3.94 (s, 3 H), 2.94–2.85 (m, 3 H), 2.70–2.51 (m, 3 H), 2.31 (q, <i>J</i> = 8.8 Hz, 1 H), 1.93–1.64 (m, 2 H), 1.60–1.05 (m, 24 H), 0.95–0.89 (m, 1 H) ppm. <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 177.15, 173.28, 168.02, 160.29, 155.00, 154.90, 148.66, 140.88, 136.31, 134.28, 128.90, 124.47, 118.82, 105.91, 79.84, 74.68, 59.45, 55.72, 53.08, 51.92, 44.57, 34.65, 32.81, 31.01, 29.70, 28.14, 27.11, 27.16, 26.31, 26.06, 22.16, 20.92, 11.56, 6.67, 6.12 ppm. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>37</sub>H<sub>51</sub>N<sub>6</sub>O<sub>9</sub>S, 755.3433; found, 755.3410. Anal. HPLC: <i>t</i><sub>R</sub> 14.23 min, purity 97%.</div></div><div id="sec5_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> <i>tert</i>-Butyl ((2<i>R</i>,6<i>S</i>,13a<i>S</i>,14a<i>R</i>,16a<i>S</i>,<i>Z</i>)-2-((3-Ethyl-7-methoxyquinoxalin-2-yl)oxy)-14a-(((1-methylcyclopropyl)sulfonyl)carbamoyl)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[<i>e</i>]pyrrolo[1,2-<i>a</i>][1,4]diazacyclopentadecin-6-yl)carbamate (<b>19a</b>)</h4><div class="NLM_p last">The same procedure was used as described above for compound <b>2</b>. Bis-olefin <b>17a</b> (1.45 g, 1.8 mmol) was treated with Zhan 1B catalyst (0.150 g, 0.20 mmol) in 1,2-DCE (300 mL) to afford the P1–P3 macrocyclic product <b>19a</b> (1.0 g, 71%) as an off-white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.16 (s, 1 H), 7.82 (d, <i>J</i> = 10.0 Hz, 1 H), 7.18–7.15 (m, 2 H), 6.94 (s, 1 H), 5.90 (br s, 1 H), 5.69 (q, <i>J</i> = 9.2 Hz, 1 H), 5.16 (d, <i>J</i> = 8.0 Hz, 1 H), 4.99 (t, <i>J</i> = 9.2 Hz, 1 H), 4.59 (t, <i>J</i> = 8.0 Hz, 1 H), 4.49 (d, <i>J</i> = 11.6 Hz, 1 H), 4.30–4.25 (m, 1 H), 4.04 (dd, <i>J</i> = 11.6, 4.0 Hz, 1 H), 3.94 (s, 3 H), 2.87 (q, <i>J</i> = 7.6 Hz, 2 H), 2.70–2.51 (m, 3 H), 2.33 (q, <i>J</i> = 8.0 Hz, 1 H), 1.92–1.68 (m, 4 H), 1.60–1.15 (m, 24 H), 0.85–0.78 (m, 2 H) ppm. <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 177.19, 173.24, 167.0, 160.23, 154.99, 154.88, 148.73, 140.84, 136.26, 134.25, 129.03, 124.89, 118.72, 105.92, 79.84, 74.67, 59.48, 55.72, 53.11, 51.92, 44.71, 36.43, 34.68, 32.80, 29.62, 28.14, 27.09, 26.38, 26.12, 22.19, 20.93, 18.17, 14.51, 12.50, 11.54 ppm. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>38</sub>H<sub>53</sub>N<sub>6</sub>O<sub>9</sub>S, 769.3589; found, 769.3561. Anal. HPLC: <i>t</i><sub>R</sub> 15.01 min, purity 99%.</div></div><div id="sec5_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> Cyclopentyl ((2<i>R</i>,6<i>S</i>,13a<i>S</i>,14a<i>R</i>,16a<i>S</i>,<i>Z</i>)-14a-((Cyclopropylsulfonyl)carbamoyl)-2-((3-ethyl-7-methoxyquinoxalin-2-yl)oxy)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[<i>e</i>]pyrrolo[1,2-<i>a</i>][1,4]diazacyclopentadecin-6-yl)carbamate (<b>22a</b>)</h4><div class="NLM_p">Compound <b>2</b> (0.40 g, 0.53 mmol) was treated with a solution of 4 N HCl in 1,4-dioxane (10 mL). The reaction mixture was stirred at room temperature for 3 h, then concentrated under reduced pressure, and the residue was dried under high vacuum. The off-white solid was triturated with diethyl ether (3 × 10 mL) and dried under high vacuum to yield the amine salt <b>20a</b> (0.37 g, 100%) as a white powder.</div><div class="NLM_p last">A solution of the above amine salt <b>20a</b> (0.37 g, 0.53 mmol) in anhydrous CH<sub>3</sub>CN (15 mL) was treated with DIEA (0.35 mL, 2.1 mmol) and <i>N</i>-(cyclopentyloxycarbonyloxy)-succinimide (0.15 g, 0.66 mmol). The reaction mixture was stirred at room temperature for 36 h, then concentrated under reduced pressure and dried under high vacuum. The residue was purified by flash chromatography using 50–90% EtOAc/hexanes as the eluent to provide the target compound <b>22a</b> (0.32 g, 79%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.29 (s, 1 H), 7.83 (d, <i>J</i> = 9.6 Hz, 1 H), 7.21–7.16 (m, 2 H), 6.94 (s, 1 H), 5.93 (br s, 1 H), 5.70 (q, <i>J</i> = 8.8 Hz, 1 H), 5.26 (d, <i>J</i> = 8.0 Hz, 1 H), 4.96 (t, <i>J</i> = 8.4 Hz, 1 H), 4.86–4.82 (m, 1 H), 4.60 (t, <i>J</i> = 7.6 Hz, 1 H), 4.45 (d, <i>J</i> = 11.2 Hz, 1 H), 4.34–4.28 (m, 1 H), 4.03 (dd, <i>J</i> = 11.2, 4.0 Hz, 1 H), 3.94 (s, 3 H), 2.93–2.85 (m, 3 H), 2.70–2.48 (m, 3 H), 2.30 (q, <i>J</i> = 8.8 Hz, 1 H), 1.93–1.23 (m, 23 H), 1.15–1.06 (m, 2 H), 0.96–0.88 (m, 1 H) ppm. <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 177.18, 173.03, 168.04, 160.28, 155.65, 154.93, 148.78, 140.90, 136.27, 134.20, 128.92, 124.46, 118.80, 105.92, 77.87, 74.55, 59.47, 55.72, 53.01, 52.17, 44.54, 34.58, 32.72, 32.63, 32.59, 31.01, 29.70, 27.14, 27.05, 26.40, 26.05, 23.56, 22.16, 20.90, 11.61, 6.67, 6.12 ppm. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>38</sub>H<sub>51</sub>N<sub>6</sub>O<sub>9</sub>S, 767.3433; found, 767.3408. Anal. HPLC: <i>t</i><sub>R</sub> 14.50 min, purity 98%.</div></div><div id="sec5_2_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> Cyclopentyl ((2<i>R</i>,6<i>S</i>,13a<i>S</i>,14a<i>R</i>,16a<i>S</i>,<i>Z</i>)-2-((3-Ethyl-7-methoxyquinoxalin-2-yl)oxy)-14a-(((1-methylcyclopropyl)sulfonyl)carbamoyl)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[<i>e</i>]pyrrolo[1,2-<i>a</i>][1,4]diazacyclopentadecin-6-yl)carbamate (<b>23a</b>)</h4><div class="NLM_p last">The same procedure was used as described above for compound <b>22a</b>. Compound <b>19a</b> (0.40 g, 0.52 mmol) was treated with 4 N HCl in 1,4-dioxane (10 mL) to yield the amine salt <b>21a</b>, which was treated with DIEA (0.35 mL, 2.1 mmol) and <i>N</i>-(cyclopentyloxycarbonyloxy)-succinimide (0.15 g, 0.66 mmol) to provide the target compound <b>23a</b> (0.30 g, 74%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.17 (s, 1 H), 7.81 (d, <i>J</i> = 9.6 Hz, 1 H), 7.21–7.16 (m, 2 H), 6.93 (s, 1 H), 5.92 (br s, 1 H), 5.70 (q, <i>J</i> = 9.2 Hz, 1 H), 5.26 (d, <i>J</i> = 7.6 Hz, 1 H), 4.99 (t, <i>J</i> = 9.6 Hz, 1 H), 4.86–4.81 (m, 1 H), 4.59 (t, <i>J</i> = 7.6 Hz, 1 H), 4.45 (d, <i>J</i> = 11.2 Hz, 1 H), 4.34–4.28 (m, 1 H), 4.04 (dd, <i>J</i> = 11.6, 4.0 Hz, 1 H), 3.94 (s, 3 H), 2.87 (q, <i>J</i> = 7.2 Hz, 2 H), 2.70–2.48 (m, 3 H), 2.32 (q, <i>J</i> = 8.8 Hz, 1 H), 1.92–1.23 (m, 27 H), 0.85–0.78 (m, 2 H) ppm. <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 177.21, 172.99, 166.98, 160.22, 155.63, 154.90, 148.84, 140.85, 136.22, 134.36, 129.05, 124.88, 118.70, 105.93, 77.86, 74.54, 59.51, 55.71, 53.05, 52.16, 44.70, 36.43, 34.61, 32.72, 32.64, 32.58, 29.63, 27.13, 27.06, 26.47, 26.12, 23.56, 22.18, 20.94, 18.17, 14.49, 12.50, 11.59 ppm. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>39</sub>H<sub>53</sub>N<sub>6</sub>O<sub>9</sub>S, 781.3589; found, 781.3561. Anal. HPLC: <i>t</i><sub>R</sub> 15.25 min, purity 99%.</div></div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Typical Procedures for the Synthesis of Protease Inhibitors Using Method B</h3><div id="sec5_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> Ethyl (1<i>R</i>,2<i>S</i>)-1-((2<i>S</i>,4<i>R</i>)-1-((<i>S</i>)-2-((<i>tert</i>-Butoxycarbonyl)amino)non-8-enoyl)-4-((7-methoxy-3-(trifluoromethyl)quinoxalin-2-yl)oxy)pyrrolidine-2-carboxamido)-2-vinylcyclopropane-1-carboxylate (<b>25d</b>)</h4><div class="NLM_p">A solution of ester <b>12d</b> (6.40 g, 10.25 mmol) in THF–H<sub>2</sub>O (1:1 mixture, 140 mL) was treated with LiOH·H<sub>2</sub>O (1.38 g, 32.0 mmol). The resulting reaction mixture was stirred at room temperature for 24 h, then cooled to ∼5 °C, acidified to a pH of 2.0 by slow addition of aqueous 0.25 N HCl (∼200 mL), and extracted with EtOAc (2 × 500 mL). The organic portions were washed separately with saturated aqueous NaCl (250 mL), dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and evaporated under reduced pressure. The gummy residue was dissolved in CHCl<sub>3</sub> (50 mL), concentrated under reduced pressure, and the residue dried under high vacuum to yield the acid <b>13d</b> (6.12 g, 98%) as a pale-yellow foamy solid.</div><div class="NLM_p last">A solution of acid <b>13d</b> (6.12 g, 10.0 mmol) and amine salt <b>24</b> (2.50 g, 13.0 mmol) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (100 mL) was treated with DIEA (9.10 mL, 55.0 mmol), HATU (5.30 g, 14.0 mmol), and DMAP (0.60 g, 4.9 mmol). The resulting reaction mixture was stirred at room temperature for 14 h, then diluted with EtOAc (500 mL) and washed successively with aqueous 1.0 N HCl, saturated aqueous NaHCO<sub>3</sub>, and saturated aqueous NaCl (250 mL each). The organic portion was dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and evaporated under reduced pressure. The residue was purified by flash chromatography using 25–35% EtOAc/hexanes as the eluent to provide the bis-olefin compound <b>25d</b> (6.54 g, 87%) as a pale-yellow foamy solid. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) (mixture of rotamers, major rotamer) δ 7.78 (d, <i>J</i> = 9.2 Hz, 1 H), 7.53 (br s, 1 H), 7.47 (dd, <i>J</i> = 9.2, 2.8 Hz, 1 H), 7.43 (d, <i>J</i> = 2.4 Hz, 1 H), 5.88 (br s, 1 H), 5.81–5.70 (m, 2 H), 5.30 (dd, <i>J</i> = 16.8, 0.8 Hz, 1 H), 5.14–5.10 (m, 2 H), 5.01–4.89 (m, 2 H), 4.79 (dd, <i>J</i> = 14.0, 5.6 Hz, 1 H), 4.35–4.29 (m, 1 H), 4.21–4.08 (m, 3 H), 3.94 (s, 3 H), 2.90–2.82 (m, 1 H), 2.48–2.38 (m, 1 H), 2.16 (q, <i>J</i> = 9.0 Hz, 1 H), 2.04–1.98 (m, 2 H), 1.86 (dd, <i>J</i> = 8.0, 5.2 Hz, 1 H), 1.66–1.52 (m, 2 H), 1.46 (dd, <i>J</i> = 9.6, 5.6 Hz, 1 H), 1.43–1.21 (m, 19 H) ppm. <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 173.02, 171.00, 169.87, 159.62, 155.52, 152.03, 138.92, 138.48, 137.16, 133.66, 128.02, 125.73, 120.72 (q, <i>J</i> = 273.6 Hz), 118.08, 114.52, 107.66, 79.98, 75.26, 61.40, 58.41, 56.02, 52.58, 52.43, 40.14, 33.89, 33.77, 32.76, 32.62, 28.97, 28.78, 28.31, 25.18, 23.11, 14.48 ppm. <sup>19</sup>F NMR (470 MHz, CDCl<sub>3</sub>) −67.77 ppm. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>37</sub>H<sub>49</sub>F<sub>3</sub>N<sub>5</sub>O<sub>8</sub>, 748.3528; found 748.3514.</div></div><div id="sec5_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> Ethyl (2<i>R</i>,6<i>S</i>,13a<i>S</i>,14a<i>R</i>,16a<i>S</i>,<i>Z</i>)-6-((<i>tert</i>-Butoxycarbonyl)amino)-2-((7-methoxy-3-(trifluoromethyl)quinoxalin-2-yl)oxy)-5,16-dioxo-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[<i>e</i>]pyrrolo[1,2-<i>a</i>][1,4]diazacyclopentadecine-14a(5<i>H</i>)-carboxylate (<b>26d</b>)</h4><div class="NLM_p last">A degassed solution of bis-olefin <b>25d</b> (1.50 g, 2.0 mmol) in 1,2-DCE (300 mL) was heated to 50 °C under argon, then Zhan 1B catalyst (0.150 g, 0.20 mmol) was added in two portions over 10 min. The resulting mixture was heated to 70 °C and stirred for 5 h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by flash chromatography using 25–35% EtOAc/hexanes as the eluent to yield the P1–P3 macrocyclic product <b>26d</b> (1.0 g, 70%) as an off-white foamy solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.77 (d, <i>J</i> = 8.8 Hz, 1 H), 7.47 (dd, <i>J</i> = 8.8, 2.8 Hz, 1 H), 7.44 (d, <i>J</i> = 2.4 Hz, 1 H), 7.03 (br s, 1 H), 5.84–5.80 (m, 1 H), 5.56–5.49 (m, 1 H), 5.32–5.22 (m, 2 H), 4.92 (q, <i>J</i> = 4.4 Hz, 1 H), 4.49 (t, <i>J</i> = 7.6 Hz, 1 H), 4.24–4.05 (m, 4 H), 3.95 (s, 3 H), 3.05–2.99 (m, 1 H), 2.41–2.35 (m, 1 H), 2.24–2.14 (m, 3 H), 1.93–1.86 (m, 2 H), 1.66–1.60 (m, 1 H), 1.55 (dd, <i>J</i> = 96, 5.2 Hz, 1 H), 1.46–1.20 (m, 18 H) ppm. <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 172.81, 171.95, 169.74, 159.69, 155.21, 152.20, 138.56, 137.25, 134.50, 128.08, 125.91, 125.84, 120.80 (q, <i>J</i> = 276 Hz), 107.73, 80.04, 75.42, 61.50, 58.08, 56.13, 52.21, 51.39, 41.36, 32.16, 31.77, 28.45, 28.10, 28.02, 26.37, 25.74, 23.70, 22.57, 14.72 ppm. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>35</sub>H<sub>45</sub>F<sub>3</sub>N<sub>5</sub>O<sub>8</sub>, 720.3215; found, 720.3203.</div></div><div id="sec5_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> <i>tert</i>-Butyl ((2<i>R</i>,6<i>S</i>,13a<i>S</i>,14a<i>R</i>,16a<i>S</i>,<i>Z</i>)-14a-((Cyclopropylsulfonyl)carbamoyl)-2-((7-methoxy-3-(trifluoromethyl)quinoxalin-2-yl)oxy)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[<i>e</i>]pyrrolo[1,2-<i>a</i>][1,4]diazacyclopentadecin-6-yl)carbamate (<b>18d</b>)</h4><div class="NLM_p">A solution of ester <b>26d</b> (1.0 g, 1.4 mmol) in THF–MeOH–H<sub>2</sub>O (1:1:1 mixture, 20 mL) was treated with LiOH·H<sub>2</sub>O (0.18 g, 4.2 mmol). The resulting reaction mixture was stirred at room temperature for 24 h, then cooled to ∼5 °C, acidified to a pH of 2.0 by slow addition of aqueous 0.25 N HCl, and extracted with EtOAc (2 × 150 mL). The organic portions were washed separately with saturated aqueous NaCl (100 mL), dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and evaporated under reduced pressure. The gummy residue was dissolved in CHCl<sub>3</sub> (10 mL), concentrated under reduced pressure, and the residue dried under high vacuum to yield the acid <b>27d</b> (0.95 g, 98%) as a pale-yellow foamy solid.</div><div class="NLM_p last">A mixture of acid <b>27d</b> (0.40 g, 0.58 mmol) and CDI (0.131 g, 0.81 mmol) in anhydrous THF (8 mL) was heated at reflux for 1.5 h. The solution was cooled to room temperature and slowly added to a solution of cyclopropanesulfonamide <b>28</b> (0.10 g, 0.82 mmol) in anhydrous THF (4 mL) followed by DBU (0.12 mL, 0.81 mmol). The resulting reaction mixture was stirred at room temperature for 24 h, then quenched with aqueous 0.5 N HCl to pH ∼ 2. Solvents were partially evaporated under reduced pressure, and the residue was extracted with EtOAc (2 × 100 mL). The combined organic portions were washed with saturated aqueous NaCl (100 mL), dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and evaporated under reduced pressure. The residue was purified by flash chromatography using 40–70% EtOAc/hexanes as the eluent to afford the title compound <b>18d</b> (0.28 g, 60%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.28 (s, 1 H), 7.83 (d, <i>J</i> = 9.2 Hz, 1 H), 7.49 (dd, <i>J</i> = 8.8, 2.8 Hz, 1 H), 7.42 (d, <i>J</i> = 2.8 Hz, 1 H), 6.87 (s, 1 H), 5.92 (br s, 1 H), 5.70 (q, <i>J</i> = 8.8 Hz, 1 H), 5.13 (d, <i>J</i> = 7.6 Hz, 1 H), 4.97 (t, <i>J</i> = 8.4 Hz, 1 H), 4.62–4.56 (m, 2 H), 4.23–4.17 (m, 1 H), 4.01 (dd, <i>J</i> = 11.6, 3.2 Hz, 1 H), 3.94 (s, 3 H), 2.93–2.87 (m, 1 H), 2.68–2.50 (m, 3 H), 2.31 (q, <i>J</i> = 8.8 Hz, 1 H), 1.95–1.54 (m, 2 H), 1.53–1.02 (m, 21 H), 0.96–0.88 (m, 1 H) ppm. <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 176.99, 173.31, 167.91, 159.45, 154.93, 151.76, 138.27, 136.99, 136.32, 134.56 (q, <i>J</i> = 36.2 Hz), 127.99, 125.57, 124.53, 120.8 (q, <i>J</i> = 274.0 Hz), 107.40, 79.76, 75.54, 59.44, 55.89, 52.72, 51.86, 44.65, 34.61, 32.82, 31.02, 29.61, 28.02, 27.04, 25.99, 22.21, 20.93, 6.67, 6.12 ppm. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>36</sub>H<sub>46</sub>F<sub>3</sub>N<sub>6</sub>O<sub>9</sub>S, 795.2994; found, 795.2974. Anal. HPLC: <i>t</i><sub>R</sub> 14.59 min, purity 100%.</div></div><div id="sec5_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> <i>tert</i>-Butyl ((2<i>R</i>,6<i>S</i>,13a<i>S</i>,14a<i>R</i>,16a<i>S</i>,<i>Z</i>)-2-((7-Methoxy-3-(trifluoromethyl)quinoxalin-2-yl)oxy)-14a-(((1-methylcyclopropyl)sulfonyl)carbamoyl)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[<i>e</i>]pyrrolo[1,2-<i>a</i>][1,4]diazacyclopentadecin-6-yl)carbamate (<b>19d</b>)</h4><div class="NLM_p last">The same procedure was used as described above for compound <b>18d</b>. Acid <b>27d</b> (0.43 g, 0.62 mmol) was treated with CDI (0.141 g, 0.87 mmol), 1-methylcyclopropanesulfonamide <b>29</b> (0.118 g, 0.87 mmol), and DBU (0.13 mL, 0.87 mmol) to afford the title compound <b>19d</b> (0.34 g, 68%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.15 (s, 1 H), 7.83 (d, <i>J</i> = 9.2 Hz, 1 H), 7.48 (dd, <i>J</i> = 9.2, 2.8 Hz, 1 H), 7.42 (d, <i>J</i> = 2.8 Hz, 1 H), 6.90 (s, 1 H), 5.91 (s, 1 H), 5.70 (q, <i>J</i> = 9.2 Hz, 1 H), 5.14 (d, <i>J</i> = 7.6 Hz, 1 H), 5.00 (t, <i>J</i> = 9.2 Hz, 1 H), 4.62–4.55 (m, 2 H), 4.24–4.18 (m, 1 H), 4.02 (dd, <i>J</i> = 11.6, 3.6 Hz, 1 H), 3.94 (s, 3 H), 2.71–2.51 (m, 3 H), 2.33 (q, <i>J</i> = 8.4 Hz, 1 H), 1.93–1.75 (m, 4 H), 1.56–1.18 (m, 21 H), 0.85–0.78 (m, 2 H) ppm. <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 177.30, 173.46, 167.15, 159.68, 155.16, 152.01, 138.50, 137.23, 136.50, 134.60 (q, <i>J</i> = 36.0 Hz), 128.23, 125.79, 125.19, 120.83 (d, <i>J</i> = 274.0 Hz), 107.65, 80.01, 75.79, 59.70, 56.12, 52.97, 52.08, 45.03, 36.65, 34.86, 33.06, 29.81, 28.26, 27.31, 27.24, 26.32, 22.47, 21.21, 18.42, 14.73, 12.77 ppm. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>37</sub>H<sub>48</sub>F<sub>3</sub>N<sub>6</sub>O<sub>9</sub>S, 809.3150; found, 809.3129. Anal. HPLC: <i>t</i><sub>R</sub> 15.23 min, purity 99%.</div></div><div id="sec5_3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> Cyclopentyl ((2<i>R</i>,6<i>S</i>,13a<i>S</i>,14a<i>R</i>,16a<i>S</i>,<i>Z</i>)-14a-((Cyclopropylsulfonyl)carbamoyl)-2-((7-methoxy-3-(trifluoromethyl)quinoxalin-2-yl)oxy)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[<i>e</i>]pyrrolo[1,2-<i>a</i>][1,4]diazacyclopentadecin-6-yl)carbamate (<b>22d</b>)</h4><div class="NLM_p">Compound <b>18d</b> (0.40 g, 0.52 mmol) was treated with a solution of 4 N HCl in 1,4-dioxane (10 mL). The reaction mixture was stirred at room temperature for 3 h, concentrated under reduced pressure, and the residue dried under high vacuum. The pale-yellow solid was triturated with diethyl ether (3 × 10 mL) and dried under high vacuum to yield the amine salt <b>20d</b> (0.37 g, 100%) as a white powder.</div><div class="NLM_p last">A solution of the above amine salt <b>20d</b> (0.37 g, 0.52 mmol) in anhydrous CH<sub>3</sub>CN (15 mL) was treated with DIEA (0.35 mL, 2.1 mmol) and <i>N</i>-(cyclopentyloxycarbonyloxy)-succinimide (0.15 g, 0.66 mmol). The reaction mixture was stirred at room temperature for 24 h, then concentrated under reduced pressure and dried under high vacuum. The residue was purified by flash chromatography using 50–90% EtOAc/hexanes as the eluent to provide the target compound <b>22d</b> (0.30 g, 74%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.27 (s, 1 H), 7.82 (d, <i>J</i> = 9.2 Hz, 1 H), 7.48 (dd, <i>J</i> = 9.2, 2.8 Hz, 1 H), 7.42 (d, <i>J</i> = 2.8 Hz, 1 H), 6.78 (s, 1 H), 5.95 (s, 1 H), 5.70 (q, <i>J</i> = 9.6 Hz, 1 H), 5.23 (d, <i>J</i> = 8.0 Hz, 1 H), 4.98 (t, <i>J</i> = 8.8 Hz, 1 H), 4.74–4.69 (m, 1 H), 4.60 (t, <i>J</i> = 7.6, 1 H), 4.54 (d, <i>J</i> = 11.6, 1 H), 4.25–4.19 (m, 1 H), 3.99 (dd, <i>J</i> = 11.6, 4.0 Hz, 1 H), 3.94 (s, 3 H), 2.94–2.88 (m, 1 H), 2.68–2.50 (m, 3 H), 2.31 (q, <i>J</i> = 8.8 Hz, 1 H), 1.94–1.24 (m, 21 H), 1.20–1.07 (m, 2 H), 0.96–0.89 (m, 1 H) ppm. <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 177.33, 173.29, 168.27, 159.68, 155.87, 152.08, 138.56, 137.24, 136.47, 134.74 (q, <i>J</i> = 36.0 Hz), 128.24, 125.75, 124.79, 120.87 (d, <i>J</i> = 273.2 Hz), 107.62, 78.02, 75.70, 59.68, 56.11, 52.90, 52.35, 44.83, 34.71, 32.92, 32.81, 32.64, 31.26, 29.87, 27.27, 26.24, 23.81, 23.75, 22.49, 21.11, 6.89, 6.34 ppm. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]+ calcd for C<sub>37</sub>H<sub>46</sub>F<sub>3</sub>N<sub>6</sub>O<sub>9</sub>S, 807.2994; found, 807.2976. Anal. HPLC: <i>t</i><sub>R</sub> 14.98 min, purity 99%.</div></div><div id="sec5_3_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> Cyclopentyl ((2<i>R</i>,6<i>S</i>,13a<i>S</i>,14a<i>R</i>,16a<i>S</i>,<i>Z</i>)-2-((7-Methoxy-3-(trifluoromethyl)quinoxalin-2-yl)oxy)-14a-(((1-methylcyclopropyl)sulfonyl)carbamoyl)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[<i>e</i>]pyrrolo[1,2-<i>a</i>][1,4]diazacyclopentadecin-6-yl)carbamate (<b>23d</b>)</h4><div class="NLM_p last">The same procedure was used as described above for compound <b>22d</b>. Compound <b>19d</b> (0.40 g, 0.52 mmol) was treated with 4 N HCl in 1,4-dioxane (10 mL) to yield the amine salt <b>21d</b>, which was treated with DIEA (0.35 mL, 2.1 mmol) and <i>N</i>-(cyclopentyloxycarbonyloxy)-succinimide (0.15 g, 0.66 mmol) to provide the target compound <b>23d</b> (0.30 g, 74%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl3) δ 10.18 (s, 1 H), 7.83 (d, <i>J</i> = 9.6 Hz, 1 H), 7.48 (dd, <i>J</i> = 8.8, 2.8 Hz, 1 H), 7.41 (d, <i>J</i> = 2.8 Hz, 1 H), 6.94 (s, 1 H), 5.94 (s, 1 H), 5.70 (q, <i>J</i> = 8.8 Hz, 1 H), 5.28 (d, <i>J</i> = 7.6 Hz, 1 H), 5.00 (t, <i>J</i> = 8.8 Hz, 1 H), 4.74–4.69 (m, 1 H), 4.60 (t, <i>J</i> = 7.6, 1 H), 4.54 (d, <i>J</i> = 12.0, 1 H), 4.25–4.19 (m, 1 H), 4.00 (dd, <i>J</i> = 11.6, 3.6 Hz, 1 H), 3.94 (s, 3 H), 2.68–2.50 (m, 3 H), 2.31 (q, <i>J</i> = 8.4 Hz, 1 H), 1.92–1.20 (m, 24 H), 0.85–0.78 (m, 2 H) ppm. <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 177.33, 173.25, 167.13, 159.68, 155.84, 152.08, 138.56, 137.24, 136.44, 134.75 (q, <i>J</i> = 35.2 Hz), 128.25, 125.74, 125.21, 120.86 (d, <i>J</i> = 274.0 Hz), 107.62, 78.02, 75.71, 59.73, 56.12, 52.89, 52.34, 45.03, 36.65, 34.73, 32.93, 32.82, 32.64, 29.83, 27.26, 27.21, 26.29, 23.81, 23.75, 22.52, 21.23, 18.42, 14.73, 12.76 ppm. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>38</sub>H<sub>48</sub>F<sub>3</sub>N<sub>6</sub>O<sub>9</sub>S, 821.3150; found, 821.3133. Anal. HPLC: <i>t</i><sub>R</sub> 15.65 min, purity 97%.</div></div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Enzyme Inhibition Assays</h3><div class="NLM_p last">For each assay, 2 nM of NS3/4A protease (GT1a, D168A, and GT3a) was preincubated at room temperature for 1 h with increasing concentration of inhibitors in assay buffer [50 mM Tris, 5% glycerol, 10 mM DTT, 0.6 mM LDAO, and 4% dimethyl sulfoxide]. Inhibition assays were performed in nonbinding surface 96-well black half-area plates (Corning) in a reaction volume of 60 μL. The proteolytic reaction was initiated by the injection of 5 μL of HCV NS3/4A protease substrate (AnaSpec) to a final concentration of 200 nM and kinetically monitored using a PerkinElmer EnVision plate reader (excitation at 485 nm, emission at 530 nm). Three independent data sets were collected for each inhibitor with each protease construct. Each inhibitor titration included at least 12 inhibitor concentration points, which were globally fit to the Morrison equation to obtain the <i>K</i><sub>i</sub> value.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> Cell-Based Drug Susceptibility Assays</h3><div class="NLM_p last">Mutations (R155K, A516T, D168A, and D168V) were constructed by site-directed mutagenesis using a Con1 (genotype 1b) luciferase reporter replicon containing the H77 (genotype 1a) NS3 sequence.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Replicon RNA of each protease variant was introduced into Huh7 cells by electroporation. Replication was then assessed in the presence of increasing concentrations of protease inhibitors by measuring luciferase activity (relative light units) 96 h after electroporation. The drug concentrations required to inhibit replicon replication by 50% (EC<sub>50</sub>) were calculated directly from the drug inhibition curves.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> Crystallization and Structure Determination</h3><div class="NLM_p">Protein expression and purification were carried out as previously described (see <a href="/doi/suppl/10.1021/acs.jmedchem.7b00426/suppl_file/jm7b00426_si_001.pdf" class="ext-link">Supporting Information</a> for details).<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> The Ni-NTA purified WT1a protein was thawed, concentrated to 3 mg/mL, and loaded on a HiLoad Superdex75 16/60 column equilibrated with gel filtration buffer (25 mM MES, 500 mM NaCl, 10% glycerol, and 2 mM DTT, pH 6.5). The protease fractions were pooled and concentrated to 25 mg/mL with an Amicon Ultra-15 10 kDa filter unit (Millipore). The concentrated samples were incubated for 1 h with 3:1 molar excess of inhibitor. Diffraction quality crystals were obtained overnight by mixing equal volumes of concentrated protein solution with precipitant solution (20–26% PEG-3350, 0.1 M sodium MES buffer, 4% ammonium sulfate, pH 6.5) at RT or 15 °C in 24-well VDX hanging drop trays. Crystals were harvested and data were collected at 100 K. Cryogenic conditions contained the precipitant solution supplemented with 15% glycerol or ethylene glycol.</div><div class="NLM_p last">Diffraction data were collected using an in-house Rigaku X-ray system with a Saturn 944 detector. All data sets were processed using HKL-3000.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Structures were solved by molecular replacement using PHASER.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> The WT-<b>2</b> complex structure (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EPN">5EPN</a>)<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> was used as the starting structure for all structure solutions. Model building and refinement were performed using Coot<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> and PHENIX,<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> respectively. The final structures were evaluated with MolProbity<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> prior to deposition in the PDB. To limit the possibility of model bias throughout the refinement process, 5% of the data were reserved for the free <i>R</i>-value calculation.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> Structure analysis, superposition, and figure generation were done using PyMOL.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> X-ray data collection and crystallographic refinement statistics are presented in the Supporting Information (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00426/suppl_file/jm7b00426_si_001.pdf" class="ext-link">Table S3</a>).</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> Molecular Modeling</h3><div class="NLM_p last">Molecular modeling was carried out using MacroModel (Schrödinger, LLC, New York, NY).<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> Briefly, inhibitors were modeled into the active site of WT1a and A156T proteases using the WT-<b>2</b> and A156T-<b>2</b> complex structures (PDBs <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EPN">5EPN</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EPY">5EPY</a>).<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Structures were prepared using the Protein Preparation tool in Maestro 11. Two-dimensional chemical structures were modified with the appropriate changes using the Build tool in Maestro. Once modeled, molecular energy minimizations were performed for each inhibitor–protease complex using the PRCG method with 2500 maximum iterations and 0.05 gradient convergence threshold. PDB files of modeled complexes were generated in Maestro for structural analysis.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i36"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00426">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61203" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61203" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b00426" class="ext-link">10.1021/acs.jmedchem.7b00426</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Enzyme inhibitory and antiviral activity data with fold-change relative to wild-type; X-ray data collection and crystallographic refinement statistics; synthesis of intermediates and final compounds; protein expression, purification and <i>K</i><sub>m</sub> experiments (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00426/suppl_file/jm7b00426_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00426/suppl_file/jm7b00426_si_002.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Compound <b>18d</b> model (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00426/suppl_file/jm7b00426_si_003.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Compound <b>18e</b> model (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00426/suppl_file/jm7b00426_si_004.pdb" class="ext-link">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00426/suppl_file/jm7b00426_si_001.pdf">jm7b00426_si_001.pdf (718.44 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00426/suppl_file/jm7b00426_si_002.csv">jm7b00426_si_002.csv (4.74 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00426/suppl_file/jm7b00426_si_003.pdb">jm7b00426_si_003.pdb (286.3 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00426/suppl_file/jm7b00426_si_004.pdb">jm7b00426_si_004.pdb (286.9 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">The PDB accession codes for inhibitors <b>18f</b>- and <b>19b</b>-bound WT NS3/4A protease X-ray structures are <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5VP9">5VP9</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5VOJ">5VOJ</a>. Authors will release the atomic coordinates and experimental data upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.7b00426" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34661" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34661" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Celia A. Schiffer</span> - <span class="hlFld-Affiliation affiliation">Department
of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts 01605, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2270-6613" title="Orcid link">http://orcid.org/0000-0003-2270-6613</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#4e0d2b22272f601d2d262728282b3c0e3b232f3d3d232b2a602b2a3b"><span class="__cf_email__" data-cfemail="1b587e77727a35487873727d7d7e695b6e767a6868767e7f357e7f6e">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Akbar Ali</span> - <span class="hlFld-Affiliation affiliation">Department
of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts 01605, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3491-791X" title="Orcid link">http://orcid.org/0000-0003-3491-791X</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#3b7a50595a49157a57527b4e565a4848565e5f155e5f4e"><span class="__cf_email__" data-cfemail="0e4f656c6f7c204f62674e7b636f7d7d636b6a206b6a7b">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ashley N. Matthew</span> - <span class="hlFld-Affiliation affiliation">Department
of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts 01605, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jacqueto Zephyr</span> - <span class="hlFld-Affiliation affiliation">Department
of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts 01605, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Caitlin. J. Hill</span> - <span class="hlFld-Affiliation affiliation">Department
of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts 01605, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Muhammad Jahangir</span> - <span class="hlFld-Affiliation affiliation">Department
of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts 01605, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alicia Newton</span> - <span class="hlFld-Affiliation affiliation">Monogram
Biosciences, South
San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christos J. Petropoulos</span> - <span class="hlFld-Affiliation affiliation">Monogram
Biosciences, South
San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wei Huang</span> - <span class="hlFld-Affiliation affiliation">Monogram
Biosciences, South
San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nese Kurt-Yilmaz</span> - <span class="hlFld-Affiliation affiliation">Department
of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts 01605, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): AN, CJP and WH are employees of Monogram Biosciences.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e5212-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i40">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87618" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87618" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by a grant from the National Institute of Allergy and Infectious Diseases of the NIH (R01 AI085051). A.N.M was also supported by the National Institute of General Medical Sciences of the NIH (F31 GM119345). M.J. was supported by a Postdoctoral Fellowship from the Higher Education Commission of Pakistan (H.E.C.). We thank Dr. Kiran K. Reddy and members of the Schiffer and Miller laboratories for helpful discussions.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i41" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i41"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i42" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i42"> Abbreviations Used</h2><tr><td class="NLM_term">CDI</td><td class="NLM_def"><p class="first last">1,1′-carbonyldiimidazole</p></td></tr><tr><td class="NLM_term">DBU</td><td class="NLM_def"><p class="first last">1,8-diazabicyclo[5.4.0]undec-7-ene</p></td></tr><tr><td class="NLM_term">1,2-DCE</td><td class="NLM_def"><p class="first last">1,2-dichloroethane</p></td></tr><tr><td class="NLM_term">DIEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">GT</td><td class="NLM_def"><p class="first last">genotype</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">1-[bis(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo-[4,5-<i>b</i>]-pyridinium 3-oxide hexafluorophosphate</p></td></tr><tr><td class="NLM_term">NMP</td><td class="NLM_def"><p class="first last"><i>N</i>-methylpyrrolidinone</p></td></tr><tr><td class="NLM_term">PI</td><td class="NLM_def"><p class="first last">protease inhibitor</p></td></tr><tr><td class="NLM_term">RT</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">WT</td><td class="NLM_def"><p class="first last">wild-type</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i43">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62354" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62354" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 58 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span>Hepatitis C Fact Sheet; <span class="NLM_publisher-name">World Health Organization (WHO)</span>: <span class="NLM_publisher-loc">Geneva</span>, Updated July<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">; </span><a href="http://www.who.int/mediacentre/factsheets/fs164/en/" class="extLink">http://www.who.int/mediacentre/factsheets/fs164/en/</a> (accessed February 6, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Hepatitis+C+Fact+Sheet%3B+World+Health+Organization+%28WHO%29%3A+Geneva%2C+Updated+July+2016%3B+http%3A%2F%2Fwww.who.int%2Fmediacentre%2Ffactsheets%2Ffs164%2Fen%2F+%28accessed+February+6%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DHepatitis%2520C%2520Fact%2520Sheet%26pub%3DWorld%2520Health%2520Organization%2520%2528WHO%2529%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Hajarizadeh, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grebely, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dore, G. J.</span><span> </span><span class="NLM_article-title">Epidemiology and natural history of HCV infection</span> <span class="citation_source-journal">Nat. Rev. Gastroenterol. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">553</span><span class="NLM_x">–</span> <span class="NLM_lpage">562</span><span class="refDoi"> DOI: 10.1038/nrgastro.2013.107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1038%2Fnrgastro.2013.107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=23817321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVWru77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=553-562&author=B.+Hajarizadehauthor=J.+Grebelyauthor=G.+J.+Dore&title=Epidemiology+and+natural+history+of+HCV+infection&doi=10.1038%2Fnrgastro.2013.107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Epidemiology and natural history of HCV infection</span></div><div class="casAuthors">Hajarizadeh, Behzad; Grebely, Jason; Dore, Gregory J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Gastroenterology & Hepatology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">553-562</span>CODEN:
                <span class="NLM_cas:coden">NRGHA9</span>;
        ISSN:<span class="NLM_cas:issn">1759-5045</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Worldwide, an estd. 130-170 million people have HCV infection.  HCV prevalence is highest in Egypt at >10% of the general population and China has the most people with HCV (29.8 million).  Differences in past HCV incidence and current HCV prevalence, together with the generally protracted nature of HCV disease progression, has led to considerable diversity in the burden of advanced liver disease in different countries.  Countries with a high incidence of HCV or peak incidence in the recent past will have further escalations in HCV-related cirrhosis and hepatocellular carcinoma (HCC) over the next two decades.  Acute HCV infection is difficult to detect because of the generally asymptomatic nature of the disease and the marginalization of at-risk populations.  Around 25% of patients with acute HCV infection undergo spontaneous clearance, with increased rates among those with favorable IL28B genotypes, acute symptoms and in women.  The remaining 75% of patients progress to chronic HCV infection and are subsequently at risk of progression to hepatic fibrosis, cirrhosis and HCC.  Chronic hepatitis C generally progresses slowly in the initial two decades, but can be accelerated during this time as a result of advancing age and co-factors such as heavy alc. intake and HIV co-infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAGJrt4DO4BLVg90H21EOLACvtfcHk0lhaLOVwRyyJ7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVWru77F&md5=1542a3394c3bd84018527b88232950d4</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrgastro.2013.107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrgastro.2013.107%26sid%3Dliteratum%253Aachs%26aulast%3DHajarizadeh%26aufirst%3DB.%26aulast%3DGrebely%26aufirst%3DJ.%26aulast%3DDore%26aufirst%3DG.%2BJ.%26atitle%3DEpidemiology%2520and%2520natural%2520history%2520of%2520HCV%2520infection%26jtitle%3DNat.%2520Rev.%2520Gastroenterol.%2520Hepatol.%26date%3D2013%26volume%3D10%26spage%3D553%26epage%3D562%26doi%3D10.1038%2Fnrgastro.2013.107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Razavi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waked, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarrazin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myers, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Idilman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calinas, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogel, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendes Correa, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hezode, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lazaro, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akarca, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aleman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balik, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bihl, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bilodeau, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blasco, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandao Mello, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruggmann, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calleja, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheinquer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clausen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coelho, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cramp, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dore, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doss, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duberg, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Sayed, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ergor, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esmat, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falconer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felix, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferraz, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferreira, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frankova, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Samaniego, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerstoft, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giria, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goncales, F. L.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gower, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gschwantler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guimaraes Pessoa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hindman, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Husa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaberg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaita, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kautz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaymakoglu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krajden, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krarup, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laleman, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavanchy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marinho, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marotta, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mauss, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Negro, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nemecek, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ormeci, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ovrehus, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasini, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peltekian, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramji, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reis, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenberg, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roudot-Thoraval, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryder, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarmento-Castro, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Semela, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiha, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sievert, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sperl, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Starkel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stauber, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urbanek, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Damme, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Thiel, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Vlierberghe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandijck, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wedemeyer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weis, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiegand, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yosry, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zekry, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornberg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullhaupt, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estes, C.</span><span> </span><span class="NLM_article-title">The present and future disease burden of hepatitis C virus (HCV) infection with today’s treatment paradigm</span> <span class="citation_source-journal">J. Viral. Hepat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">34</span><span class="NLM_x">–</span> <span class="NLM_lpage">59</span><span class="refDoi"> DOI: 10.1111/jvh.12248</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1111%2Fjvh.12248" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=24713005" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A280%3ADC%252BC2cnhvFeltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=34-59&author=H.+Razaviauthor=I.+Wakedauthor=C.+Sarrazinauthor=R.+P.+Myersauthor=R.+Idilmanauthor=F.+Calinasauthor=W.+Vogelauthor=M.+C.+Mendes+Correaauthor=C.+Hezodeauthor=P.+Lazaroauthor=U.+Akarcaauthor=S.+Alemanauthor=I.+Balikauthor=T.+Bergauthor=F.+Bihlauthor=M.+Bilodeauauthor=A.+J.+Blascoauthor=C.+E.+Brandao+Melloauthor=P.+Bruggmannauthor=M.+Butiauthor=J.+L.+Callejaauthor=H.+Cheinquerauthor=P.+B.+Christensenauthor=M.+Clausenauthor=H.+S.+Coelhoauthor=M.+E.+Crampauthor=G.+J.+Doreauthor=W.+Dossauthor=A.+S.+Dubergauthor=M.+H.+El-Sayedauthor=G.+Ergorauthor=G.+Esmatauthor=K.+Falconerauthor=J.+Felixauthor=M.+L.+Ferrazauthor=P.+R.+Ferreiraauthor=S.+Frankovaauthor=J.+Garcia-Samaniegoauthor=J.+Gerstoftauthor=J.+A.+Giriaauthor=F.+L.+Goncalesauthor=E.+Gowerauthor=M.+Gschwantlerauthor=M.+Guimaraes+Pessoaauthor=S.+J.+Hindmanauthor=H.+Hoferauthor=P.+Husaauthor=M.+Kabergauthor=K.+D.+Kaitaauthor=A.+Kautzauthor=S.+Kaymakogluauthor=M.+Krajdenauthor=H.+Krarupauthor=W.+Lalemanauthor=D.+Lavanchyauthor=R.+T.+Marinhoauthor=P.+Marottaauthor=S.+Maussauthor=C.+Morenoauthor=K.+Murphyauthor=F.+Negroauthor=V.+Nemecekauthor=N.+Ormeciauthor=A.+L.+Ovrehusauthor=J.+Parkesauthor=K.+Pasiniauthor=K.+M.+Peltekianauthor=A.+Ramjiauthor=N.+Reisauthor=S.+K.+Robertsauthor=W.+M.+Rosenbergauthor=F.+Roudot-Thoravalauthor=S.+D.+Ryderauthor=R.+Sarmento-Castroauthor=D.+Semelaauthor=M.+Shermanauthor=G.+E.+Shihaauthor=W.+Sievertauthor=J.+Sperlauthor=P.+Starkelauthor=R.+E.+Stauberauthor=A.+J.+Thompsonauthor=P.+Urbanekauthor=P.+Van+Dammeauthor=I.+van+Thielauthor=H.+Van+Vlierbergheauthor=D.+Vandijckauthor=H.+Wedemeyerauthor=N.+Weisauthor=J.+Wiegandauthor=A.+Yosryauthor=A.+Zekryauthor=M.+Cornbergauthor=B.+Mullhauptauthor=C.+Estes&title=The+present+and+future+disease+burden+of+hepatitis+C+virus+%28HCV%29+infection+with+today%E2%80%99s+treatment+paradigm&doi=10.1111%2Fjvh.12248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm</span></div><div class="casAuthors">Razavi H; Waked I; Sarrazin C; Myers R P; Idilman R; Calinas F; Vogel W; Mendes Correa M C; Hezode C; Lazaro P; Akarca U; Aleman S; Balik I; Berg T; Bihl F; Bilodeau M; Blasco A J; Brandao Mello C E; Bruggmann P; Buti M; Calleja J L; Cheinquer H; Christensen P B; Clausen M; Coelho H S M; Cramp M E; Dore G J; Doss W; Duberg A S; El-Sayed M H; Ergor G; Esmat G; Falconer K; Felix J; Ferraz M L G; Ferreira P R; Frankova S; Garcia-Samaniego J; Gerstoft J; Giria J A; Goncales F L Jr; Gower E; Gschwantler M; Guimaraes Pessoa M; Hindman S J; Hofer H; Husa P; Kaberg M; Kaita K D E; Kautz A; Kaymakoglu S; Krajden M; Krarup H; Laleman W; Lavanchy D; Marinho R T; Marotta P; Mauss S; Moreno C; Murphy K; Negro F; Nemecek V; Ormeci N; Ovrehus A L H; Parkes J; Pasini K; Peltekian K M; Ramji A; Reis N; Roberts S K; Rosenberg W M; Roudot-Thoraval F; Ryder S D; Sarmento-Castro R; Semela D; Sherman M; Shiha G E; Sievert W; Sperl J; Starkel P; Stauber R E; Thompson A J; Urbanek P; Van Damme P; van Thiel I; Van Vlierberghe H; Vandijck D; Wedemeyer H; Weis N; Wiegand J; Yosry A; Zekry A; Cornberg M; Mullhaupt B; Estes C</div><div class="citationInfo"><span class="NLM_cas:title">Journal of viral hepatitis</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">21 Suppl 1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">34-59</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The disease burden of hepatitis C virus (HCV) is expected to increase as the infected population ages.  A modelling approach was used to estimate the total number of viremic infections, diagnosed, treated and new infections in 2013.  In addition, the model was used to estimate the change in the total number of HCV infections, the disease progression and mortality in 2013-2030.  Finally, expert panel consensus was used to capture current treatment practices in each country.  Using today's treatment paradigm, the total number of HCV infections is projected to decline or remain flat in all countries studied.  However, in the same time period, the number of individuals with late-stage liver disease is projected to increase.  This study concluded that the current treatment rate and efficacy are not sufficient to manage the disease burden of HCV.  Thus, alternative strategies are required to keep the number of HCV individuals with advanced liver disease and liver-related deaths from increasing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSSybyU3yDU0YhLSh9fo81bfW6udTcc2eZY_pkiQ_Ym77ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cnhvFeltw%253D%253D&md5=73a208b1f3b0e52c06578d5b36676102</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1111%2Fjvh.12248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjvh.12248%26sid%3Dliteratum%253Aachs%26aulast%3DRazavi%26aufirst%3DH.%26aulast%3DWaked%26aufirst%3DI.%26aulast%3DSarrazin%26aufirst%3DC.%26aulast%3DMyers%26aufirst%3DR.%2BP.%26aulast%3DIdilman%26aufirst%3DR.%26aulast%3DCalinas%26aufirst%3DF.%26aulast%3DVogel%26aufirst%3DW.%26aulast%3DMendes%2BCorrea%26aufirst%3DM.%2BC.%26aulast%3DHezode%26aufirst%3DC.%26aulast%3DLazaro%26aufirst%3DP.%26aulast%3DAkarca%26aufirst%3DU.%26aulast%3DAleman%26aufirst%3DS.%26aulast%3DBalik%26aufirst%3DI.%26aulast%3DBerg%26aufirst%3DT.%26aulast%3DBihl%26aufirst%3DF.%26aulast%3DBilodeau%26aufirst%3DM.%26aulast%3DBlasco%26aufirst%3DA.%2BJ.%26aulast%3DBrandao%2BMello%26aufirst%3DC.%2BE.%26aulast%3DBruggmann%26aufirst%3DP.%26aulast%3DButi%26aufirst%3DM.%26aulast%3DCalleja%26aufirst%3DJ.%2BL.%26aulast%3DCheinquer%26aufirst%3DH.%26aulast%3DChristensen%26aufirst%3DP.%2BB.%26aulast%3DClausen%26aufirst%3DM.%26aulast%3DCoelho%26aufirst%3DH.%2BS.%26aulast%3DCramp%26aufirst%3DM.%2BE.%26aulast%3DDore%26aufirst%3DG.%2BJ.%26aulast%3DDoss%26aufirst%3DW.%26aulast%3DDuberg%26aufirst%3DA.%2BS.%26aulast%3DEl-Sayed%26aufirst%3DM.%2BH.%26aulast%3DErgor%26aufirst%3DG.%26aulast%3DEsmat%26aufirst%3DG.%26aulast%3DFalconer%26aufirst%3DK.%26aulast%3DFelix%26aufirst%3DJ.%26aulast%3DFerraz%26aufirst%3DM.%2BL.%26aulast%3DFerreira%26aufirst%3DP.%2BR.%26aulast%3DFrankova%26aufirst%3DS.%26aulast%3DGarcia-Samaniego%26aufirst%3DJ.%26aulast%3DGerstoft%26aufirst%3DJ.%26aulast%3DGiria%26aufirst%3DJ.%2BA.%26aulast%3DGoncales%26aufirst%3DF.%2BL.%26aulast%3DGower%26aufirst%3DE.%26aulast%3DGschwantler%26aufirst%3DM.%26aulast%3DGuimaraes%2BPessoa%26aufirst%3DM.%26aulast%3DHindman%26aufirst%3DS.%2BJ.%26aulast%3DHofer%26aufirst%3DH.%26aulast%3DHusa%26aufirst%3DP.%26aulast%3DKaberg%26aufirst%3DM.%26aulast%3DKaita%26aufirst%3DK.%2BD.%26aulast%3DKautz%26aufirst%3DA.%26aulast%3DKaymakoglu%26aufirst%3DS.%26aulast%3DKrajden%26aufirst%3DM.%26aulast%3DKrarup%26aufirst%3DH.%26aulast%3DLaleman%26aufirst%3DW.%26aulast%3DLavanchy%26aufirst%3DD.%26aulast%3DMarinho%26aufirst%3DR.%2BT.%26aulast%3DMarotta%26aufirst%3DP.%26aulast%3DMauss%26aufirst%3DS.%26aulast%3DMoreno%26aufirst%3DC.%26aulast%3DMurphy%26aufirst%3DK.%26aulast%3DNegro%26aufirst%3DF.%26aulast%3DNemecek%26aufirst%3DV.%26aulast%3DOrmeci%26aufirst%3DN.%26aulast%3DOvrehus%26aufirst%3DA.%2BL.%26aulast%3DParkes%26aufirst%3DJ.%26aulast%3DPasini%26aufirst%3DK.%26aulast%3DPeltekian%26aufirst%3DK.%2BM.%26aulast%3DRamji%26aufirst%3DA.%26aulast%3DReis%26aufirst%3DN.%26aulast%3DRoberts%26aufirst%3DS.%2BK.%26aulast%3DRosenberg%26aufirst%3DW.%2BM.%26aulast%3DRoudot-Thoraval%26aufirst%3DF.%26aulast%3DRyder%26aufirst%3DS.%2BD.%26aulast%3DSarmento-Castro%26aufirst%3DR.%26aulast%3DSemela%26aufirst%3DD.%26aulast%3DSherman%26aufirst%3DM.%26aulast%3DShiha%26aufirst%3DG.%2BE.%26aulast%3DSievert%26aufirst%3DW.%26aulast%3DSperl%26aufirst%3DJ.%26aulast%3DStarkel%26aufirst%3DP.%26aulast%3DStauber%26aufirst%3DR.%2BE.%26aulast%3DThompson%26aufirst%3DA.%2BJ.%26aulast%3DUrbanek%26aufirst%3DP.%26aulast%3DVan%2BDamme%26aufirst%3DP.%26aulast%3Dvan%2BThiel%26aufirst%3DI.%26aulast%3DVan%2BVlierberghe%26aufirst%3DH.%26aulast%3DVandijck%26aufirst%3DD.%26aulast%3DWedemeyer%26aufirst%3DH.%26aulast%3DWeis%26aufirst%3DN.%26aulast%3DWiegand%26aufirst%3DJ.%26aulast%3DYosry%26aufirst%3DA.%26aulast%3DZekry%26aufirst%3DA.%26aulast%3DCornberg%26aufirst%3DM.%26aulast%3DMullhaupt%26aufirst%3DB.%26aulast%3DEstes%26aufirst%3DC.%26atitle%3DThe%2520present%2520and%2520future%2520disease%2520burden%2520of%2520hepatitis%2520C%2520virus%2520%2528HCV%2529%2520infection%2520with%2520today%25E2%2580%2599s%2520treatment%2520paradigm%26jtitle%3DJ.%2520Viral.%2520Hepat.%26date%3D2014%26volume%3D21%26spage%3D34%26epage%3D59%26doi%3D10.1111%2Fjvh.12248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Gower, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blach, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Razavi-Shearer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Razavi, H.</span><span> </span><span class="NLM_article-title">Global epidemiology and genotype distribution of the hepatitis C virus infection</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">S45</span><span class="NLM_x">–</span> <span class="NLM_lpage">S57</span><span class="refDoi"> DOI: 10.1016/j.jhep.2014.07.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1016%2Fj.jhep.2014.07.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=25086286" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2014&pages=S45-S57&author=E.+Gowerauthor=C.+Estesauthor=S.+Blachauthor=K.+Razavi-Shearerauthor=H.+Razavi&title=Global+epidemiology+and+genotype+distribution+of+the+hepatitis+C+virus+infection&doi=10.1016%2Fj.jhep.2014.07.027"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2014.07.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2014.07.027%26sid%3Dliteratum%253Aachs%26aulast%3DGower%26aufirst%3DE.%26aulast%3DEstes%26aufirst%3DC.%26aulast%3DBlach%26aufirst%3DS.%26aulast%3DRazavi-Shearer%26aufirst%3DK.%26aulast%3DRazavi%26aufirst%3DH.%26atitle%3DGlobal%2520epidemiology%2520and%2520genotype%2520distribution%2520of%2520the%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DJ.%2520Hepatol.%26date%3D2014%26volume%3D61%26spage%3DS45%26epage%3DS57%26doi%3D10.1016%2Fj.jhep.2014.07.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Messina, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humphreys, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaxman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooke, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pybus, O. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnes, E.</span><span> </span><span class="NLM_article-title">Global distribution and prevalence of hepatitis C virus genotypes</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">77</span><span class="NLM_x">–</span> <span class="NLM_lpage">87</span><span class="refDoi"> DOI: 10.1002/hep.27259</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1002%2Fhep.27259" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=25069599" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A280%3ADC%252BC2cbms1CgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2015&pages=77-87&author=J.+P.+Messinaauthor=I.+Humphreysauthor=A.+Flaxmanauthor=A.+Brownauthor=G.+S.+Cookeauthor=O.+G.+Pybusauthor=E.+Barnes&title=Global+distribution+and+prevalence+of+hepatitis+C+virus+genotypes&doi=10.1002%2Fhep.27259"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Global distribution and prevalence of hepatitis C virus genotypes</span></div><div class="casAuthors">Messina Jane P; Humphreys Isla; Flaxman Abraham; Brown Anthony; Cooke Graham S; Pybus Oliver G; Barnes Eleanor</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Baltimore, Md.)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">77-87</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">UNLABELLED:  Hepatitis C virus (HCV) exhibits high genetic diversity, characterized by regional variations in genotype prevalence.  This poses a challenge to the improved development of vaccines and pan-genotypic treatments, which require the consideration of global trends in HCV genotype prevalence.  Here we provide the first comprehensive survey of these trends.  To approximate national HCV genotype prevalence, studies published between 1989 and 2013 reporting HCV genotypes are reviewed and combined with overall HCV prevalence estimates from the Global Burden of Disease (GBD) project.  We also generate regional and global genotype prevalence estimates, inferring data for countries lacking genotype information.  We include 1,217 studies in our analysis, representing 117 countries and 90% of the global population.  We calculate that HCV genotype 1 is the most prevalent worldwide, comprising 83.4 million cases (46.2% of all HCV cases), approximately one-third of which are in East Asia.  Genotype 3 is the next most prevalent globally (54.3 million, 30.1%); genotypes 2, 4, and 6 are responsible for a total 22.8% of all cases; genotype 5 comprises the remaining <1%.  While genotypes 1 and 3 dominate in most countries irrespective of economic status, the largest proportions of genotypes 4 and 5 are in lower-income countries.  CONCLUSION:  Although genotype 1 is most common worldwide, nongenotype 1 HCV cases--which are less well served by advances in vaccine and drug development--still comprise over half of all HCV cases.  Relative genotype proportions are needed to inform healthcare models, which must be geographically tailored to specific countries or regions in order to improve access to new treatments.  Genotype surveillance data are needed from many countries to improve estimates of unmet need.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR2Xg9XEOxbiuQ4Pl9hzjQhfW6udTcc2ebVsHP8aZ0sAbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbms1CgtA%253D%253D&md5=4ad9cc1d6592acffdc485d0baccfe939</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1002%2Fhep.27259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.27259%26sid%3Dliteratum%253Aachs%26aulast%3DMessina%26aufirst%3DJ.%2BP.%26aulast%3DHumphreys%26aufirst%3DI.%26aulast%3DFlaxman%26aufirst%3DA.%26aulast%3DBrown%26aufirst%3DA.%26aulast%3DCooke%26aufirst%3DG.%2BS.%26aulast%3DPybus%26aufirst%3DO.%2BG.%26aulast%3DBarnes%26aufirst%3DE.%26atitle%3DGlobal%2520distribution%2520and%2520prevalence%2520of%2520hepatitis%2520C%2520virus%2520genotypes%26jtitle%3DHepatology%26date%3D2015%26volume%3D61%26spage%3D77%26epage%3D87%26doi%3D10.1002%2Fhep.27259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span>Guidelines for the Screening, Care and Treatment of Persons with Chronic Hepatitis C Infection; <span class="NLM_publisher-name">World Health Organization</span>: <span class="NLM_publisher-loc">Geneva</span>, updated version, April 2016; <a href="http://www.who.int/hepatitis/publications/hepatitis-c-guidelines-2016/en/" class="extLink">http://www.who.int/hepatitis/publications/hepatitis-c-guidelines-2016/en/</a> (Accessed February 6, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Guidelines+for+the+Screening%2C+Care+and+Treatment+of+Persons+with+Chronic+Hepatitis+C+Infection%3B+World+Health+Organization%3A+Geneva%2C+updated+version%2C+April+2016%3B+http%3A%2F%2Fwww.who.int%2Fhepatitis%2Fpublications%2Fhepatitis-c-guidelines-2016%2Fen%2F+%28Accessed+February+6%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DGuidelines%2520for%2520the%2520Screening%252C%2520Care%2520and%2520Treatment%2520of%2520Persons%2520with%2520Chronic%2520Hepatitis%2520C%2520Infection%26pub%3DWorld%2520Health%2520Organization" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Asselah, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyer, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saadoun, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinot-Peignoux, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcellin, P.</span><span> </span><span class="NLM_article-title">Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives</span> <span class="citation_source-journal">Liver Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">47</span><span class="NLM_x">–</span> <span class="NLM_lpage">57</span><span class="refDoi"> DOI: 10.1111/liv.13027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1111%2Fliv.13027" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2016&pages=47-57&author=T.+Asselahauthor=N.+Boyerauthor=D.+Saadounauthor=M.+Martinot-Peignouxauthor=P.+Marcellin&title=Direct-acting+antivirals+for+the+treatment+of+hepatitis+C+virus+infection%3A+optimizing+current+IFN-free+treatment+and+future+perspectives&doi=10.1111%2Fliv.13027"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1111%2Fliv.13027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fliv.13027%26sid%3Dliteratum%253Aachs%26aulast%3DAsselah%26aufirst%3DT.%26aulast%3DBoyer%26aufirst%3DN.%26aulast%3DSaadoun%26aufirst%3DD.%26aulast%3DMartinot-Peignoux%26aufirst%3DM.%26aulast%3DMarcellin%26aufirst%3DP.%26atitle%3DDirect-acting%2520antivirals%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%2520virus%2520infection%253A%2520optimizing%2520current%2520IFN-free%2520treatment%2520and%2520future%2520perspectives%26jtitle%3DLiver%2520Int.%26date%3D2016%26volume%3D36%26spage%3D47%26epage%3D57%26doi%3D10.1111%2Fliv.13027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Afdhal, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeuzem, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chojkier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gitlin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puoti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero-Gomez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarski, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agarwal, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buggisch, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foster, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bräu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanian, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Symonds, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHutchison, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muir, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mangia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcellin, P.</span><span> </span><span class="NLM_article-title">Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">1889</span><span class="NLM_x">–</span> <span class="NLM_lpage">1898</span><span class="refDoi"> DOI: 10.1056/NEJMoa1402454</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1056%2FNEJMoa1402454" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=24725239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGksbnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=1889-1898&author=N.+Afdhalauthor=S.+Zeuzemauthor=P.+Kwoauthor=M.+Chojkierauthor=N.+Gitlinauthor=M.+Puotiauthor=M.+Romero-Gomezauthor=J.-P.+Zarskiauthor=K.+Agarwalauthor=P.+Buggischauthor=G.+R.+Fosterauthor=N.+Br%C3%A4uauthor=M.+Butiauthor=I.+M.+Jacobsonauthor=G.+M.+Subramanianauthor=X.+Dingauthor=H.+Moauthor=J.+C.+Yangauthor=P.+S.+Pangauthor=W.+T.+Symondsauthor=J.+G.+McHutchisonauthor=A.+J.+Muirauthor=A.+Mangiaauthor=P.+Marcellin&title=Ledipasvir+and+sofosbuvir+for+untreated+HCV+genotype+1+infection&doi=10.1056%2FNEJMoa1402454"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection</span></div><div class="casAuthors">Afdhal, Nezam; Zeuzem, Stefan; Kwo, Paul; Chojkier, Mario; Gitlin, Norman; Puoti, Massimo; Romero-Gomez, Manuel; Zarski, Jean-Pierre; Agarwal, Kosh; Buggisch, Peter; Foster, Graham R.; Brau, Norbert; Buti, Maria; Jacobson, Ira M.; Subramanian, G. Mani; Ding, Xiao; Mo, Hongmei; Yang, Jenny C.; Pang, Phillip S.; Symonds, William T.; McHutchison, John G.; Muir, Andrew J.; Mangia, Alessandra; Marcellin, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1889-1898, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: In phase 2 studies, treatment with the all-oral combination of the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor ledipasvir resulted in high rates of sustained virol. response among previously untreated patients with hepatitis C virus (HCV) genotype 1 infection.  Methods: We conducted a phase 3, open-label study involving previously untreated patients with chronic HCV genotype 1 infection.  Patients were randomly assigned in a 1:1:1:1 ratio to receive ledipasvir and sofosbuvir in a fixed-dose combination tablet once daily for 12 wk, ledipasvir-sofosbuvir plus ribavirin for 12 wk, ledipasvir- sofosbuvir for 24 wk, or ledipasvir-sofosbuvir plus ribavirin for 24 wk.  The primary end point was a sustained virol. response at 12 wk after the end of therapy.  Results: Of the 865 patients who underwent randomization and were treated, 16% had cirrhosis, 12% were black, and 67% had HCV genotype 1a infection.  The rates of sustained virol. response were 99% (95% confidence interval [CI], 96 to 100) in the group that received 12 wk of ledipasvir-sofosbuvir; 97% (95% CI, 94 to 99) in the group that received 12 wk of ledipasvir-sofosbuvir plus ribavirin; 98% (95% CI, 95 to 99) in the group that received 24 wk of ledipasvir-sofosbuvir; and 99% (95% CI, 97 to 100) in the group that received 24 wk of ledipasvir-sofosbuvir plus ribavirin.  No patient in either 12-wk group discontinued ledipasvir-sofosbuvir owing to an adverse event.  The most common adverse events were fatigue, headache, insomnia, and nausea.  Conculsions: Once-daily ledipasvir-sofosbuvir with or without ribavirin for 12 or 24 wk was highly effective in previously untreated patients with HCV genotype 1 infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroadkxw2jRR7Vg90H21EOLACvtfcHk0lju2YymRIlOwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGksbnM&md5=e433fd7d493c1c0f9dfef37c1527388f</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1402454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1402454%26sid%3Dliteratum%253Aachs%26aulast%3DAfdhal%26aufirst%3DN.%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DKwo%26aufirst%3DP.%26aulast%3DChojkier%26aufirst%3DM.%26aulast%3DGitlin%26aufirst%3DN.%26aulast%3DPuoti%26aufirst%3DM.%26aulast%3DRomero-Gomez%26aufirst%3DM.%26aulast%3DZarski%26aufirst%3DJ.-P.%26aulast%3DAgarwal%26aufirst%3DK.%26aulast%3DBuggisch%26aufirst%3DP.%26aulast%3DFoster%26aufirst%3DG.%2BR.%26aulast%3DBr%25C3%25A4u%26aufirst%3DN.%26aulast%3DButi%26aufirst%3DM.%26aulast%3DJacobson%26aufirst%3DI.%2BM.%26aulast%3DSubramanian%26aufirst%3DG.%2BM.%26aulast%3DDing%26aufirst%3DX.%26aulast%3DMo%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26aulast%3DPang%26aufirst%3DP.%2BS.%26aulast%3DSymonds%26aufirst%3DW.%2BT.%26aulast%3DMcHutchison%26aufirst%3DJ.%2BG.%26aulast%3DMuir%26aufirst%3DA.%2BJ.%26aulast%3DMangia%26aufirst%3DA.%26aulast%3DMarcellin%26aufirst%3DP.%26atitle%3DLedipasvir%2520and%2520sofosbuvir%2520for%2520untreated%2520HCV%2520genotype%25201%2520infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26spage%3D1889%26epage%3D1898%26doi%3D10.1056%2FNEJMoa1402454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Ferenci, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernstein, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lalezari, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marinho, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nyberg, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Younes, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Enayati, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baruch, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhandari, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caruntu, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sepe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chulanov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janczewska, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizzardini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gervain, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Planas, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassanein, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Podsadecki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, K. R.</span><span> </span><span class="NLM_article-title">ABT-450/r–ombitasvir and dasabuvir with or without ribavirin for HCV</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">1983</span><span class="NLM_x">–</span> <span class="NLM_lpage">1992</span><span class="refDoi"> DOI: 10.1056/NEJMoa1402338</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1056%2FNEJMoa1402338" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=24795200" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGksbnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=1983-1992&author=P.+Ferenciauthor=D.+Bernsteinauthor=J.+Lalezariauthor=D.+Cohenauthor=Y.+Luoauthor=C.+Cooperauthor=E.+Tamauthor=R.+T.+Marinhoauthor=N.+Tsaiauthor=A.+Nybergauthor=T.+D.+Boxauthor=Z.+Younesauthor=P.+Enayatiauthor=S.+Greenauthor=Y.+Baruchauthor=B.+R.+Bhandariauthor=F.+A.+Caruntuauthor=T.+Sepeauthor=V.+Chulanovauthor=E.+Janczewskaauthor=G.+Rizzardiniauthor=J.+Gervainauthor=R.+Planasauthor=C.+Morenoauthor=T.+Hassaneinauthor=W.+Xieauthor=M.+Kingauthor=T.+Podsadeckiauthor=K.+R.+Reddy&title=ABT-450%2Fr%E2%80%93ombitasvir+and+dasabuvir+with+or+without+ribavirin+for+HCV&doi=10.1056%2FNEJMoa1402338"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">ABT-450/r-mbitasvir and dasabuvir with or without ribavirin for HCV</span></div><div class="casAuthors">Ferenci, Peter; Bernstein, David; Lalezari, Jacob; Cohen, Daniel; Luo, Yan; Cooper, Curtis; Tam, Edward; Marinho, Rui T.; Tsai, Naoky; Nyberg, Anders; Box, Terry D.; Younes, Ziad; Enayati, Pedram; Green, Sinikka; Baruch, Yaacov; Bhandari, Bal Raj; Caruntu, Florin Alexandru; Sepe, Thomas; Chulanov, Vladimir; Janczewska, Ewa; Rizzardini, Giuliano; Gervain, Judit; Planas, Ramon; Moreno, Christophe; Hassanein, Tarek; Xie, Wangang; King, Martin; Podsadecki, Thomas; Reddy, K. Rajender</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">1983-1992, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: The interferon-free regimen of ABT-450 with ritonavir (ABT-450/r), ombitasvir, and dasabuvir with or without ribavirin has shown efficacy in inducing a sustained virol. response in a phase 2 study involving patients with hepatitis C virus (HCV) genotype 1 infection.  We conducted two phase 3 trials to examine the efficacy and safety of this regimen in previously untreated patients with HCV genotype 1 infection and no cirrhosis.  Methods: We randomly assigned 419 patients with HCV genotype 1b infection (PEARL-III study) and 305 patients with genotype 1a infection (PEARL-IV study) to 12 wk of ABT-450/r-ombitasvir (at a once-daily dose of 150 mg of ABT-450, 100 mg of ritonavir, and 25 mg of ombitasvir), dasabuvir (250 mg twice daily), and ribavirin administered according to body wt. or to matching placebo for ribavirin.  The primary efficacy end point was a sustained virol. response (an HCV RNA level of <25 IU per mL) 12 wk after the end of treatment.  Results: The study regimen resulted in high rates of sustained virol. response among patients with HCV genotype 1b infection (99.5% with ribavirin and 99.0% without ribavirin) and among those with genotype 1a infection (97.0% and 90.2%, resp.).  Of patients with genotype 1b infection, 1 had virol. failure, and 2 did not have data available at post-treatment week 12.  Among patients with genotype 1a infection, the rate of virol. failure was higher in the ribavirin-free group than in the ribavirin group (7.8% vs. 2.0%).  In both studies, decreases in the Hb level were significantly more common in patients receiving ribavirin.  Two patients (0.3%) discontinued the study drugs owing to adverse events.  The most common adverse events were fatigue, headache, and nausea.  Conclusions: Twelve weeks of treatment with ABT-450/r-ombitasvir and dasabuvir without ribavirin was assocd. with high rates of sustained virol. response among previously untreated patients with HCV genotype 1 infection.  Rates of virol. failure were higher without ribavirin than with ribavirin among patients with genotype 1a infection but not among those with genotype 1b infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGru0b7jyqCe37Vg90H21EOLACvtfcHk0lju2YymRIlOwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGksbnN&md5=b08a13aba3156a82bdcdd71203269b28</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1402338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1402338%26sid%3Dliteratum%253Aachs%26aulast%3DFerenci%26aufirst%3DP.%26aulast%3DBernstein%26aufirst%3DD.%26aulast%3DLalezari%26aufirst%3DJ.%26aulast%3DCohen%26aufirst%3DD.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DCooper%26aufirst%3DC.%26aulast%3DTam%26aufirst%3DE.%26aulast%3DMarinho%26aufirst%3DR.%2BT.%26aulast%3DTsai%26aufirst%3DN.%26aulast%3DNyberg%26aufirst%3DA.%26aulast%3DBox%26aufirst%3DT.%2BD.%26aulast%3DYounes%26aufirst%3DZ.%26aulast%3DEnayati%26aufirst%3DP.%26aulast%3DGreen%26aufirst%3DS.%26aulast%3DBaruch%26aufirst%3DY.%26aulast%3DBhandari%26aufirst%3DB.%2BR.%26aulast%3DCaruntu%26aufirst%3DF.%2BA.%26aulast%3DSepe%26aufirst%3DT.%26aulast%3DChulanov%26aufirst%3DV.%26aulast%3DJanczewska%26aufirst%3DE.%26aulast%3DRizzardini%26aufirst%3DG.%26aulast%3DGervain%26aufirst%3DJ.%26aulast%3DPlanas%26aufirst%3DR.%26aulast%3DMoreno%26aufirst%3DC.%26aulast%3DHassanein%26aufirst%3DT.%26aulast%3DXie%26aufirst%3DW.%26aulast%3DKing%26aufirst%3DM.%26aulast%3DPodsadecki%26aufirst%3DT.%26aulast%3DReddy%26aufirst%3DK.%2BR.%26atitle%3DABT-450%252Fr%25E2%2580%2593ombitasvir%2520and%2520dasabuvir%2520with%2520or%2520without%2520ribavirin%2520for%2520HCV%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26spage%3D1983%26epage%3D1992%26doi%3D10.1056%2FNEJMoa1402338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Lawitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gane, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearlman, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghesquiere, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guyader, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alric, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bronowicki, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lester, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sievert, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghalib, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balart, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sund, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lagging, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutko, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaughnessy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howe, A. Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wahl, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barr, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, B.</span><span> </span><span class="NLM_article-title">Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">385</span><span class="NLM_x">, </span> <span class="NLM_fpage">1075</span><span class="NLM_x">–</span> <span class="NLM_lpage">1086</span><span class="refDoi"> DOI: 10.1016/S0140-6736(14)61795-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1016%2FS0140-6736%2814%2961795-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=25467591" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFSgtr3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=385&publication_year=2015&pages=1075-1086&author=E.+Lawitzauthor=E.+Ganeauthor=B.+Pearlmanauthor=E.+Tamauthor=W.+Ghesquiereauthor=D.+Guyaderauthor=L.+Alricauthor=J.-P.+Bronowickiauthor=L.+Lesterauthor=W.+Sievertauthor=R.+Ghalibauthor=L.+Balartauthor=F.+Sundauthor=M.+Laggingauthor=F.+Dutkoauthor=M.+Shaughnessyauthor=P.+Hwangauthor=A.+Y.+M.+Howeauthor=J.+Wahlauthor=M.+Robertsonauthor=E.+Barrauthor=B.+Haber&title=Efficacy+and+safety+of+12+weeks+versus+18+weeks+of+treatment+with+grazoprevir+%28MK-5172%29+and+elbasvir+%28MK-8742%29+with+or+without+ribavirin+for+hepatitis+C+virus+genotype+1+infection+in+previously+untreated+patients+with+cirrhosis+and+patients+with+previous+null+response+with+or+without+cirrhosis+%28C-WORTHY%29%3A+a+randomised%2C+open-label+phase+2+trial&doi=10.1016%2FS0140-6736%2814%2961795-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial</span></div><div class="casAuthors">Lawitz, Eric; Gane, Edward; Pearlman, Brian; Tam, Edward; Ghesquiere, Wayne; Guyader, Dominique; Alric, Laurent; Bronowicki, Jean-Pierre; Lester, Laura; Sievert, William; Ghalib, Reem; Balart, Luis; Sund, Fredrik; Lagging, Martin; Dutko, Frank; Shaughnessy, Melissa; Hwang, Peggy; Howe, Anita Y. M.; Wahl, Janice; Robertson, Michael; Barr, Eliav; Haber, Barbara</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">385</span>
        (<span class="NLM_cas:issue">9973</span>),
    <span class="NLM_cas:pages">1075-1086</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">There is a high medical need for an interferon-free, all-oral, short-duration therapy for hepatitis C virus (HCV) that is highly effective across diverse patient populations, including patients with cirrhosis or previous null response to pegylated interferon (peginterferon) plus ribavirin (PR-null responders).  We aimed to assess the efficacy, safety, and effective treatment duration of grazoprevir (an HCV NS3/4A protease inhibitor) combined with elbasvir (an HCV NS5A inhibitor) with or without ribavirin in patients with HCV genotype 1 infection with baseline characteristics of poor response.  The C-WORTHY trial is a randomised, open-label phase 2 trial of grazoprevir plus elbasvir with or without ribavirin; here we report findings for two cohorts of previously untreated patients with cirrhosis (cohort 1) and those with previous PR-null response with or without cirrhosis (cohort 2) enrolled in part B of the study.  Eligible patients were adults aged 18 years or older with chronic HCV genotype 1 infection and HCV RNA concns. of 10 000 IU/mL or higher in peripheral blood.  We randomly assigned patients to receive grazoprevir (100 mg daily) and elbasvir (50 mg daily) with or without ribavirin for 12 or 18 wk.  Randomisation was done centrally with an interactive voice response system; patients and study investigators were masked to treatment duration up to week 12 but not to treatment allocation.  The primary endpoint was the proportion of patients achieving HCV RNA less than 25 IU/mL at 12 wk after end of treatment (SVR12), assessed by COBAS TaqMan version 2.0.  This study is registered with ClinicalTrials.gov, no. NCT01717326.  We describe findings for 253 patients enrolled in cohort 1 (n=123) or cohort 2 (n=130).  In cohort 1, we randomly assigned 60 patients to the 12-wk regimen (31 with ribavirin and 29 with no ribavirin) and 63 to the 18-wk regimen (32 with ribavirin and 31 with no ribavirin); in cohort 2, we randomly assigned 65 patients to the 12-wk regimen (32 with ribavirin and 33 with no ribavirin) and 65 to the 18-wk regimen 33 with ribavirin and 32 with no ribavirin. High SVR12 rates were achieved irresp. of the use of ribavirin or extension of the treatment duration from 12 to 18 wk; SVR12 rates ranged from 90% (95% CI 74-98; 28/31; cohort 1, 12 wk, ribavirin-contg.) to 100% (95% CI 89-100; 33/33; cohort 2, 18 wk, ribavirin-contg.).  Among patients treated for 12 wk with grazoprevir plus elbasvir without ribavirin, 97% (95% CI 82-100, 28/29) of patients in cohort 1 and 91% (76-98, 30/33) of patients in cohort 2 achieved SVR12.  Adverse events reported in more than 10% of patients were fatigue (66 patients, 26% [95% CI 21-32]), headache (58 patients, 23% [95% CI 18-29]), and asthenia (35 patients, 14% [95% CI 10-19]).  Treatment with grazoprevir plus elbasvir, both with and without ribavirin and for both 12 and 18 wk' treatment duration, showed high rates of efficacy in previously untreated patients with cirrhosis and previous PR-null responders with and without cirrhosis.  These results support the phase 3 development of grazoprevir plus elbasvir.Merck & Co, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQI1vPRgvrsrVg90H21EOLACvtfcHk0lg8E6HhkixXoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFSgtr3I&md5=e10e9a1ec653df21f11c1e8c725731bf</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2814%2961795-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252814%252961795-5%26sid%3Dliteratum%253Aachs%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DGane%26aufirst%3DE.%26aulast%3DPearlman%26aufirst%3DB.%26aulast%3DTam%26aufirst%3DE.%26aulast%3DGhesquiere%26aufirst%3DW.%26aulast%3DGuyader%26aufirst%3DD.%26aulast%3DAlric%26aufirst%3DL.%26aulast%3DBronowicki%26aufirst%3DJ.-P.%26aulast%3DLester%26aufirst%3DL.%26aulast%3DSievert%26aufirst%3DW.%26aulast%3DGhalib%26aufirst%3DR.%26aulast%3DBalart%26aufirst%3DL.%26aulast%3DSund%26aufirst%3DF.%26aulast%3DLagging%26aufirst%3DM.%26aulast%3DDutko%26aufirst%3DF.%26aulast%3DShaughnessy%26aufirst%3DM.%26aulast%3DHwang%26aufirst%3DP.%26aulast%3DHowe%26aufirst%3DA.%2BY.%2BM.%26aulast%3DWahl%26aufirst%3DJ.%26aulast%3DRobertson%26aufirst%3DM.%26aulast%3DBarr%26aufirst%3DE.%26aulast%3DHaber%26aufirst%3DB.%26atitle%3DEfficacy%2520and%2520safety%2520of%252012%2520weeks%2520versus%252018%2520weeks%2520of%2520treatment%2520with%2520grazoprevir%2520%2528MK-5172%2529%2520and%2520elbasvir%2520%2528MK-8742%2529%2520with%2520or%2520without%2520ribavirin%2520for%2520hepatitis%2520C%2520virus%2520genotype%25201%2520infection%2520in%2520previously%2520untreated%2520patients%2520with%2520cirrhosis%2520and%2520patients%2520with%2520previous%2520null%2520response%2520with%2520or%2520without%2520cirrhosis%2520%2528C-WORTHY%2529%253A%2520a%2520randomised%252C%2520open-label%2520phase%25202%2520trial%26jtitle%3DLancet%26date%3D2015%26volume%3D385%26spage%3D1075%26epage%3D1086%26doi%3D10.1016%2FS0140-6736%2814%2961795-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Everson, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Towner, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyles, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nahass, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thuluvath, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etzkorn, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinestrosa, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabinovitz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNally, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brainard, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doehle, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHutchison, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, T. T.</span><span> </span><span class="NLM_article-title">Sofosbuvir with velpatasvir in treatment-naive noncirrhotic patients with genotype 1 to 6 hepatitis C virus infection: a randomized trial</span> <span class="citation_source-journal">Ann. Intern. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">163</span><span class="NLM_x">, </span> <span class="NLM_fpage">818</span><span class="NLM_x">–</span> <span class="NLM_lpage">826</span><span class="refDoi"> DOI: 10.7326/M15-1000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.7326%2FM15-1000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=26551051" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A280%3ADC%252BC28vgt1agtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2015&pages=818-826&author=G.+T.+Eversonauthor=W.+J.+Townerauthor=M.+N.+Davisauthor=D.+L.+Wylesauthor=R.+G.+Nahassauthor=P.+J.+Thuluvathauthor=K.+Etzkornauthor=F.+Hinestrosaauthor=M.+Tongauthor=M.+Rabinovitzauthor=J.+McNallyauthor=D.+M.+Brainardauthor=L.+Hanauthor=B.+Doehleauthor=J.+G.+McHutchisonauthor=T.+Morganauthor=R.+T.+Chungauthor=T.+T.+Tran&title=Sofosbuvir+with+velpatasvir+in+treatment-naive+noncirrhotic+patients+with+genotype+1+to+6+hepatitis+C+virus+infection%3A+a+randomized+trial&doi=10.7326%2FM15-1000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial</span></div><div class="casAuthors">Everson Gregory T; Towner William J; Davis Mitchell N; Wyles David L; Nahass Ronald G; Thuluvath Paul J; Etzkorn Kyle; Hinestrosa Federico; Tong Myron; Rabinovitz Mordechai; McNally John; Brainard Diana M; Han Lingling; Doehle Brian; McHutchison John G; Morgan Timothy; Chung Raymond T; Tran Tram T</div><div class="citationInfo"><span class="NLM_cas:title">Annals of internal medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">818-26</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Effective, pangenotypic treatments for hepatitis C virus (HCV) infection are needed.  OBJECTIVE:  To assess the safety and efficacy of sofosbuvir with velpatasvir in patients infected with HCV genotypes 1 to 6.  DESIGN:  Randomized, phase 2, open-label study. (ClinicalTrials.gov: NCT01858766).  SETTING:  48 U.S. sites.  PATIENTS:  377 treatment-naive noncirrhotic patients.  In part A, patients infected with HCV genotypes 1 to 6 were randomly assigned to sofosbuvir, 400 mg, with velpatasvir, 25 or 100 mg, for 12 weeks.  In part B, patients with genotype 1 or 2 HCV infection were randomly assigned to sofosbuvir, 400 mg, and velpatasvir, 25 or 100 mg, with or without ribavirin for 8 weeks.  MEASUREMENTS:  Sustained virologic response at 12 weeks (SVR12).  RESULTS:  In part A, SVR12 rates were 96% (26 of 27) with velpatasvir, 25 mg, and 100% (28 of 28) with velpatasvir, 100 mg, for genotype 1; 93% (25 of 27) in both groups for genotype 3; and 96% (22 of 23) with velpatasvir, 25 mg, and 95% (21 of 22) with velpatasvir, 100 mg, for genotypes 2, 4, 5, and 6.  In part B, for genotype 1, SVR12 rates were 87% (26 of 30) with velpatasvir, 25 mg; 83% (25 of 30) with velpatasvir, 25 mg, plus ribavirin; 90% (26 of 29) with velpatasvir, 100 mg; and 81% (25 of 31) with velpatasvir, 100 mg, plus ribavirin.  For genotype 2, SVR12 rates were 77% (20 of 26) with velpatasvir, 25 mg; 88% (22 of 25) with velpatasvir, 25 mg, plus ribavirin; 88% (23 of 26) with velpatasvir, 100 mg; and 88% (23 of 26) with velpatasvir, 100 mg, plus ribavirin.  Adverse events included fatigue (21%), headache (20%), and nausea (12%).  One patient committed suicide.  LIMITATION:  The study was open-label, no inferential statistics were planned, and sample sizes were small.  CONCLUSION:  Twelve weeks of sofosbuvir, 400 mg, and velpatasvir, 100 mg, was well-tolerated and resulted in high SVR in patients infected with HCV genotypes 1 to 6.  PRIMARY FUNDING SOURCE:  Gilead Sciences.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSe_4IC_iyrYa2q3xNe7a7QfW6udTcc2eaFmnNcoqGeELntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28vgt1agtg%253D%253D&md5=d849efe4192fca8ae7921dd1e2bebfcb</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.7326%2FM15-1000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7326%252FM15-1000%26sid%3Dliteratum%253Aachs%26aulast%3DEverson%26aufirst%3DG.%2BT.%26aulast%3DTowner%26aufirst%3DW.%2BJ.%26aulast%3DDavis%26aufirst%3DM.%2BN.%26aulast%3DWyles%26aufirst%3DD.%2BL.%26aulast%3DNahass%26aufirst%3DR.%2BG.%26aulast%3DThuluvath%26aufirst%3DP.%2BJ.%26aulast%3DEtzkorn%26aufirst%3DK.%26aulast%3DHinestrosa%26aufirst%3DF.%26aulast%3DTong%26aufirst%3DM.%26aulast%3DRabinovitz%26aufirst%3DM.%26aulast%3DMcNally%26aufirst%3DJ.%26aulast%3DBrainard%26aufirst%3DD.%2BM.%26aulast%3DHan%26aufirst%3DL.%26aulast%3DDoehle%26aufirst%3DB.%26aulast%3DMcHutchison%26aufirst%3DJ.%2BG.%26aulast%3DMorgan%26aufirst%3DT.%26aulast%3DChung%26aufirst%3DR.%2BT.%26aulast%3DTran%26aufirst%3DT.%2BT.%26atitle%3DSofosbuvir%2520with%2520velpatasvir%2520in%2520treatment-naive%2520noncirrhotic%2520patients%2520with%2520genotype%25201%2520to%25206%2520hepatitis%2520C%2520virus%2520infection%253A%2520a%2520randomized%2520trial%26jtitle%3DAnn.%2520Intern.%2520Med.%26date%3D2015%26volume%3D163%26spage%3D818%26epage%3D826%26doi%3D10.7326%2FM15-1000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Pawlotsky, J. M.</span><span> </span><span class="NLM_article-title">Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">151</span><span class="NLM_x">, </span> <span class="NLM_fpage">70</span><span class="NLM_x">–</span> <span class="NLM_lpage">86</span><span class="refDoi"> DOI: 10.1053/j.gastro.2016.04.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1053%2Fj.gastro.2016.04.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=27080301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVyhs7bE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2016&pages=70-86&author=J.+M.+Pawlotsky&title=Hepatitis+C+virus+resistance+to+direct-acting+antiviral+drugs+in+interferon-free+regimens&doi=10.1053%2Fj.gastro.2016.04.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens</span></div><div class="casAuthors">Pawlotsky, Jean-Michel</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">70-86</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Treatment of hepatitis C virus (HCV) infection has progressed considerably with the approval of interferon-free, direct-acting antiviral (DAA)-based combination therapies.  Although most treated patients achieve virol. cure, HCV resistance to DAAs has an important role in the failure of interferon-free treatment regimens.  The presence of viral variants resistant to NS5A inhibitors at baseline is assocd. with lower rates of virol. cure in certain groups of patients, such as those with genotype 1a or 3 HCV, those with cirrhosis, and/or prior nonresponders to pegylated interferon-based regimens.  DAA-resistant HCV is generally dominant at virol. failure (most often relapse).  Viruses resistant to NS3-4A protease inhibitors disappear from peripheral blood in a few weeks to months, whereas NS5A inhibitor-resistant viruses persist for years.  Re-treatment options are available, but first-line treatment strategies should be optimized to efficiently prevent treatment failure due to HCV resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqN3LhkXIk5e7Vg90H21EOLACvtfcHk0ljvB-9JwakLtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVyhs7bE&md5=b536a77a661808be47d80a62175b24f5</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2016.04.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2016.04.003%26sid%3Dliteratum%253Aachs%26aulast%3DPawlotsky%26aufirst%3DJ.%2BM.%26atitle%3DHepatitis%2520C%2520virus%2520resistance%2520to%2520direct-acting%2520antiviral%2520drugs%2520in%2520interferon-free%2520regimens%26jtitle%3DGastroenterology%26date%3D2016%26volume%3D151%26spage%3D70%26epage%3D86%26doi%3D10.1053%2Fj.gastro.2016.04.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Meanwell, N. A.</span><span> </span><span class="NLM_article-title">2015 Philip S. Portoghese Medicinal Chemistry Lectureship. Curing hepatitis C virus infection with direct-acting antiviral agents: the arc of a medicinal chemistry triumph</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">7311</span><span class="NLM_x">–</span> <span class="NLM_lpage">7351</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00915</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00915" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht12itr%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7311-7351&author=N.+A.+Meanwell&title=2015+Philip+S.+Portoghese+Medicinal+Chemistry+Lectureship.+Curing+hepatitis+C+virus+infection+with+direct-acting+antiviral+agents%3A+the+arc+of+a+medicinal+chemistry+triumph&doi=10.1021%2Facs.jmedchem.6b00915"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">2015 Philip S. Portoghese Medicinal Chemistry Lectureship. Curing Hepatitis C Virus Infection with Direct-Acting Antiviral Agents: The Arc of a Medicinal Chemistry Triumph</span></div><div class="casAuthors">Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7311-7351</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The development of direct-acting antiviral agents that can cure a chronic hepatitis C virus (HCV) infection after 8-12 wk of daily, well-tolerated therapy has revolutionized the treatment of this insidious disease.  In this article, three of Bristol-Myers Squibb's HCV programs are summarized, each of which produced a clin. candidate: the NS3 protease inhibitor asunaprevir (64), marketed as Sunvepra, the NS5A replication complex inhibitor daclatasvir (117), marketed as Daklinza, and the allosteric NS5B polymerase inhibitor beclabuvir (142), which is in late stage clin. studies.  A clin. study with 64 and 117 established for the first time that a chronic HCV infection could be cured by treatment with direct-acting antiviral agents alone in the absence of interferon.  The development of small mol. HCV therapeutics, designed by medicinal chemists, has been hailed as "the arc of a medical triumph" but may equally well be described as "the arc of a medicinal chem. triumph".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-IMg2ReRMArVg90H21EOLACvtfcHk0lgDvEuxPvir0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht12itr%252FO&md5=c8232aba85caf67bf38494bc5ddeb508</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00915%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3D2015%2520Philip%2520S.%2520Portoghese%2520Medicinal%2520Chemistry%2520Lectureship.%2520Curing%2520hepatitis%2520C%2520virus%2520infection%2520with%2520direct-acting%2520antiviral%2520agents%253A%2520the%2520arc%2520of%2520a%2520medicinal%2520chemistry%2520triumph%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7311%26epage%3D7351%26doi%3D10.1021%2Facs.jmedchem.6b00915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">McCauley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudd, M. T.</span><span> </span><span class="NLM_article-title">Hepatitis C virus NS3/4a protease inhibitors</span> <span class="citation_source-journal">Curr. Opin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">84</span><span class="NLM_x">–</span> <span class="NLM_lpage">92</span><span class="refDoi"> DOI: 10.1016/j.coph.2016.07.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1016%2Fj.coph.2016.07.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=27544488" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1ygurrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=84-92&author=J.+A.+McCauleyauthor=M.+T.+Rudd&title=Hepatitis+C+virus+NS3%2F4a+protease+inhibitors&doi=10.1016%2Fj.coph.2016.07.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis C virus NS3/4a protease inhibitors</span></div><div class="casAuthors">McCauley, John A.; Rudd, Michael T.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">84-92</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) infection is a major health issue around the world and HCV NS3/4a protease inhibitors have been the focus of intensive research for the past 20 years.  From the first identification of substrate-derived peptide inhibitors to the complex, macrocyclic compds., including paritaprevir and grazoprevir, that are currently available, the field has used structure-based design to confront the issues of potency, resistance and pharmacokinetics.  Numerous breakthrough structures from a multitude of companies have led to compds. that are now key components of combination therapies with cure rates of >90%.  Herein, we detail the compds. that have advanced to clin. trials including their design and their impact on the NS3/4a protease field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoecX2r0UguZLVg90H21EOLACvtfcHk0lgDvEuxPvir0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1ygurrJ&md5=1d7d626d8c10ab9d619e8caa14a3f9a5</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2016.07.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2016.07.015%26sid%3Dliteratum%253Aachs%26aulast%3DMcCauley%26aufirst%3DJ.%2BA.%26aulast%3DRudd%26aufirst%3DM.%2BT.%26atitle%3DHepatitis%2520C%2520virus%2520NS3%252F4a%2520protease%2520inhibitors%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2016%26volume%3D30%26spage%3D84%26epage%3D92%26doi%3D10.1016%2Fj.coph.2016.07.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Kwong, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kauffman, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurter, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mueller, P.</span><span> </span><span class="NLM_article-title">Discovery and development of telaprevir: an NS3–4A protease inhibitor for treating genotype 1 chronic hepatitis C virus</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">993</span><span class="NLM_x">–</span> <span class="NLM_lpage">1003</span><span class="refDoi"> DOI: 10.1038/nbt.2020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1038%2Fnbt.2020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=22068541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVCntLvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=993-1003&author=A.+D.+Kwongauthor=R.+S.+Kauffmanauthor=P.+Hurterauthor=P.+Mueller&title=Discovery+and+development+of+telaprevir%3A+an+NS3%E2%80%934A+protease+inhibitor+for+treating+genotype+1+chronic+hepatitis+C+virus&doi=10.1038%2Fnbt.2020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus</span></div><div class="casAuthors">Kwong, Ann D.; Kauffman, Robert S.; Hurter, Patricia; Mueller, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">993-1003</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Infection with hepatitis C virus (HCV) is a major medical problem with over 170 million people infected worldwide.  Substantial morbidity and mortality are assocd. with hepatic manifestations (cirrhosis and hepatocellular carcinoma), which develop with increasing frequency in people infected with HCV for more than 20 years.  Less well known is the burden of HCV disease assocd. with extrahepatic manifestations (diabetes, B-cell proliferative disorders, depression, cognitive disorders, arthritis and Sjoegren's syndrome).  For patients infected with genotype 1 HCV, treatment with polyethylene glycol decorated interferon (peginterferon) α and ribavirin (PR) is assocd. with a low (40-50%) success rate, substantial treatment-limiting side effects and a long (48-wk) duration of treatment.  In the past 15 years, major scientific advances have enabled the development of new classes of HCV therapy, the direct-acting antiviral agents, also known as specifically targeted antiviral therapy for hepatitis C (STAT-C).  In combination with PR, the HCV NS3-4A protease inhibitor telaprevir has recently been approved for treatment of genotype 1 chronic HCV in the United States, Canada, European Union and Japan.  Compared with PR, telaprevir combination therapy offers significantly improved viral cure rates and the possibility of shortened treatment duration for diverse patient populations.  Developers of innovative drugs have to blaze a new path with few validated sign posts to guide the way.  Indeed, telaprevir's development was once put on hold because of its performance in a std. IC50 assay.  Data from new hypotheses and novel expts. were required to justify further investment and reduce risk that the drug might fail in the clinic.  In addn., the poor drug-like properties of telaprevir were a formidable hurdle, which the manufg. and formulation teams had to overcome to make the drug.  Finally, novel clin. trial designs were developed to improve efficacy and shorten treatment in parallel instead of sequentially.  Lessons learned from the development of telaprevir suggest that makers of innovative medicines cannot rely solely on traditional drug discovery metrics, but must develop innovative, scientifically guided pathways for success.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodUEHshXTAvbVg90H21EOLACvtfcHk0lgY-LUw6mVqdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVCntLvJ&md5=952966419a2e72107550d0a63c337ae4</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2020%26sid%3Dliteratum%253Aachs%26aulast%3DKwong%26aufirst%3DA.%2BD.%26aulast%3DKauffman%26aufirst%3DR.%2BS.%26aulast%3DHurter%26aufirst%3DP.%26aulast%3DMueller%26aufirst%3DP.%26atitle%3DDiscovery%2520and%2520development%2520of%2520telaprevir%253A%2520an%2520NS3%25E2%2580%25934A%2520protease%2520inhibitor%2520for%2520treating%2520genotype%25201%2520chronic%2520hepatitis%2520C%2520virus%26jtitle%3DNat.%2520Biotechnol.%26date%3D2011%26volume%3D29%26spage%3D993%26epage%3D1003%26doi%3D10.1038%2Fnbt.2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Venkatraman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bogen, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arasappan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jao, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovey, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendrata, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parekh, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinto, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Popov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pike, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santhanam, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vibulbhan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butkiewicz, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chase, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agrawal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingravallo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pichardo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baroudy, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malcolm, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prongay, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madison, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broske, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, K.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brisson, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prelusky, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korfmacher, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bogdanowich-Knipp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavlovsky, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saksena, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ganguly, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piwinski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girijavallabhan, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Njoroge, F. G.</span><span> </span><span class="NLM_article-title">Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">6074</span><span class="NLM_x">–</span> <span class="NLM_lpage">6086</span><span class="refDoi"> DOI: 10.1021/jm060325b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060325b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BD28XptlOlsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6074-6086&author=S.+Venkatramanauthor=S.+L.+Bogenauthor=A.+Arasappanauthor=F.+Bennettauthor=K.+Chenauthor=E.+Jaoauthor=Y.-T.+Liuauthor=R.+Loveyauthor=S.+Hendrataauthor=Y.+Huangauthor=W.+Panauthor=T.+Parekhauthor=P.+Pintoauthor=V.+Popovauthor=R.+Pikeauthor=S.+Ruanauthor=B.+Santhanamauthor=B.+Vibulbhanauthor=W.+Wuauthor=W.+Yangauthor=J.+Kongauthor=X.+Liangauthor=J.+Wongauthor=R.+Liuauthor=N.+Butkiewiczauthor=R.+Chaseauthor=A.+Hartauthor=S.+Agrawalauthor=P.+Ingravalloauthor=J.+Pichardoauthor=R.+Kongauthor=B.+Baroudyauthor=B.+Malcolmauthor=Z.+Guoauthor=A.+Prongayauthor=V.+Madisonauthor=L.+Broskeauthor=X.+Cuiauthor=K.-C.+Chengauthor=Y.+Hsiehauthor=J.-M.+Brissonauthor=D.+Preluskyauthor=W.+Korfmacherauthor=R.+Whiteauthor=S.+Bogdanowich-Knippauthor=A.+Pavlovskyauthor=P.+Bradleyauthor=A.+K.+Saksenaauthor=A.+Gangulyauthor=J.+Piwinskiauthor=V.+Girijavallabhanauthor=F.+G.+Njoroge&title=Discovery+of+%281R%2C5S%29-N-%5B3-amino-1-%28cyclobutylmethyl%29-2%2C3-dioxopropyl%5D-+3-%5B2%28S%29-%5B%5B%5B%281%2C1-dimethylethyl%29amino%5Dcarbonyl%5Damino%5D-3%2C3-dimethyl-1-oxobutyl%5D-+6%2C6-dimethyl-3-azabicyclo%5B3.1.0%5Dhexan-2%28S%29-carboxamide+%28SCH+503034%29%2C+a+selective%2C+potent%2C+orally+bioavailable+hepatitis+C+virus+NS3+protease+inhibitor%3A+a+potential+therapeutic+agent+for+the+treatment+of+hepatitis+C+infection&doi=10.1021%2Fjm060325b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (1R,5S)-N-[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a Selective, Potent, Orally Bioavailable Hepatitis C Virus NS3 Protease Inhibitor: A Potential Therapeutic Agent for the Treatment of Hepatitis C Infection</span></div><div class="casAuthors">Venkatraman, Srikanth; Bogen, Stephane L.; Arasappan, Ashok; Bennett, Frank; Chen, Kevin; Jao, Edwin; Liu, Yi-Tsung; Lovey, Raymond; Hendrata, Siska; Huang, Yuhua; Pan, Weidong; Parekh, Tejal; Pinto, Patrick; Popov, Veljko; Pike, Russel; Ruan, Sumei; Santhanam, Bama; Vibulbhan, Bancha; Wu, Wanli; Yang, Weiying; Kong, Jianshe; Liang, Xiang; Wong, Jesse; Liu, Rong; Butkiewicz, Nancy; Chase, Robert; Hart, Andrea; Agrawal, Sony; Ingravallo, Paul; Pichardo, John; Kong, Rong; Baroudy, Bahige; Malcolm, Bruce; Guo, Zhuyan; Prongay, Andrew; Madison, Vincent; Broske, Lisa; Cui, Xiaoming; Cheng, Kuo-Chi; Hsieh, Tony Y.; Brisson, Jean-Marc; Prelusky, Danial; Korfmacher, Walter; White, Ronald; Bogdanowich-Knipp, Susan; Pavlovsky, Anastasia; Bradley, Prudence; Saksena, Anil K.; Ganguly, Ashit; Piwinski, John; Girijavallabhan, Viyyoor; Njoroge, F. George</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6074-6086</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) infection is the major cause of chronic liver disease, leading to cirrhosis and hepatocellular carcinoma, which affects more than 170 million people worldwide.  Currently the only therapeutic regimens are s.c. interferon-α or polyethylene glycol (PEG)-interferon-α alone or in combination with oral ribavirin.  Although combination therapy is reasonably successful with the majority of genotypes, its efficacy against the predominant genotype (genotype 1) is moderate at best, with only about 40% of the patients showing sustained virol. response.  Herein, the SAR leading to the discovery of SCH 503034 (I), a novel, potent, selective, orally bioavailable NS3 protease inhibitor that has been advanced to clin. trials in human beings for the treatment of hepatitis C viral infections is described.  X-ray structure of I complexed with the NS3 protease and biol. data are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjAR2KjtnJV7Vg90H21EOLACvtfcHk0ljYoOlSbEj23Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptlOlsLg%253D&md5=e48b2e2d3eb19f7f28aaa76f96d03414</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm060325b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060325b%26sid%3Dliteratum%253Aachs%26aulast%3DVenkatraman%26aufirst%3DS.%26aulast%3DBogen%26aufirst%3DS.%2BL.%26aulast%3DArasappan%26aufirst%3DA.%26aulast%3DBennett%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DJao%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DY.-T.%26aulast%3DLovey%26aufirst%3DR.%26aulast%3DHendrata%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DPan%26aufirst%3DW.%26aulast%3DParekh%26aufirst%3DT.%26aulast%3DPinto%26aufirst%3DP.%26aulast%3DPopov%26aufirst%3DV.%26aulast%3DPike%26aufirst%3DR.%26aulast%3DRuan%26aufirst%3DS.%26aulast%3DSanthanam%26aufirst%3DB.%26aulast%3DVibulbhan%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DKong%26aufirst%3DJ.%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DWong%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DButkiewicz%26aufirst%3DN.%26aulast%3DChase%26aufirst%3DR.%26aulast%3DHart%26aufirst%3DA.%26aulast%3DAgrawal%26aufirst%3DS.%26aulast%3DIngravallo%26aufirst%3DP.%26aulast%3DPichardo%26aufirst%3DJ.%26aulast%3DKong%26aufirst%3DR.%26aulast%3DBaroudy%26aufirst%3DB.%26aulast%3DMalcolm%26aufirst%3DB.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DProngay%26aufirst%3DA.%26aulast%3DMadison%26aufirst%3DV.%26aulast%3DBroske%26aufirst%3DL.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DCheng%26aufirst%3DK.-C.%26aulast%3DHsieh%26aufirst%3DY.%26aulast%3DBrisson%26aufirst%3DJ.-M.%26aulast%3DPrelusky%26aufirst%3DD.%26aulast%3DKorfmacher%26aufirst%3DW.%26aulast%3DWhite%26aufirst%3DR.%26aulast%3DBogdanowich-Knipp%26aufirst%3DS.%26aulast%3DPavlovsky%26aufirst%3DA.%26aulast%3DBradley%26aufirst%3DP.%26aulast%3DSaksena%26aufirst%3DA.%2BK.%26aulast%3DGanguly%26aufirst%3DA.%26aulast%3DPiwinski%26aufirst%3DJ.%26aulast%3DGirijavallabhan%26aufirst%3DV.%26aulast%3DNjoroge%26aufirst%3DF.%2BG.%26atitle%3DDiscovery%2520of%2520%25281R%252C5S%2529-N-%255B3-amino-1-%2528cyclobutylmethyl%2529-2%252C3-dioxopropyl%255D-%25203-%255B2%2528S%2529-%255B%255B%255B%25281%252C1-dimethylethyl%2529amino%255Dcarbonyl%255Damino%255D-3%252C3-dimethyl-1-oxobutyl%255D-%25206%252C6-dimethyl-3-azabicyclo%255B3.1.0%255Dhexan-2%2528S%2529-carboxamide%2520%2528SCH%2520503034%2529%252C%2520a%2520selective%252C%2520potent%252C%2520orally%2520bioavailable%2520hepatitis%2520C%2520virus%2520NS3%2520protease%2520inhibitor%253A%2520a%2520potential%2520therapeutic%2520agent%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%2520infection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6074%26epage%3D6086%26doi%3D10.1021%2Fjm060325b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Zeuzem, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreone, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pol, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diago, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Focaccia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Younossi, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foster, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horban, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferenci, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nevens, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullhaupt, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pockros, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terg, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shouval, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Hoek, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiland, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Heeswijk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Meyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boogaerts, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Picchio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beumont, M.</span><span> </span><span class="NLM_article-title">Telaprevir for retreatment of HCV infection</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">2417</span><span class="NLM_x">–</span> <span class="NLM_lpage">2428</span><span class="refDoi"> DOI: 10.1056/NEJMoa1013086</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1056%2FNEJMoa1013086" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=21696308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotVCrsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=2417-2428&author=S.+Zeuzemauthor=P.+Andreoneauthor=S.+Polauthor=E.+Lawitzauthor=M.+Diagoauthor=S.+Robertsauthor=R.+Focacciaauthor=Z.+Younossiauthor=G.+R.+Fosterauthor=A.+Horbanauthor=P.+Ferenciauthor=F.+Nevensauthor=B.+Mullhauptauthor=P.+Pockrosauthor=R.+Tergauthor=D.+Shouvalauthor=B.+van+Hoekauthor=O.+Weilandauthor=R.+Van+Heeswijkauthor=S.+De+Meyerauthor=D.+Luoauthor=G.+Boogaertsauthor=R.+Poloauthor=G.+Picchioauthor=M.+Beumont&title=Telaprevir+for+retreatment+of+HCV+infection&doi=10.1056%2FNEJMoa1013086"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Telaprevir for retreatment of HCV infection</span></div><div class="casAuthors">Zeuzem, Stefan; Andreone, Pietro; Pol, Stanislas; Lawitz, Eric; Diago, Moises; Roberts, Stuart; Focaccia, Roberto; Younossi, Zobair; Foster, Graham R.; Horban, Andrzej; Ferenci, Peter; Nevens, Frederik; Mullhaupt, Beat; Pockros, Paul; Terg, Ruben; Shouval, Daniel; van Hoek, Bart; Weiland, Ola; Van Heeswijk, Rolf; De Meyer, Sandra; Luo, Don; Boogaerts, Griet; Polo, Ramon; Picchio, Gaston; Beumont, Maria</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2417-2428</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Up to 60% of patients with hepatitis C virus (HCV) genotype 1 infection do not have a sustained virol. response to therapy with peginterferon alfa plus ribavirin.  METHODS: In this randomized, phase 3 trial, we evaluated the addn. of telaprevir to peginterferon alfa-2a plus ribavirin in patients with HCV genotype 1 infection who had no response or a partial response to previous therapy or who had a relapse after an initial response.  A total of 663 patients were assigned to one of three groups: the T12PR48 group, which received telaprevir for 12 wk and peginterferon plus ribavirin for a total of 48 wk; the lead-in T12PR48 group, which received 4 wk of peginterferon plus ribavirin followed by 12 wk of telaprevir and peginterferon plus ribavirin for a total of 48 wk; and the control group (PR48), which received peginterferon plus ribavirin for 48 wk.  The primary end point was the rate of sustained virol. response, which was defined as undetectable HCV RNA 24 wk after the last planned dose of a study drug.  RESULTS: Rates of sustained virol. response were significantly higher in the two telaprevir groups than in the control group among patients who had a previous relapse (83% in the T12PR48 group, 88% in the lead-in T12PR48 group, and 24% in the PR48 group), a partial response (59%, 54%, and 15%, resp.), and no response (29%, 33%, and 5%, resp.) (P < 0.001 for all comparisons).  Grade 3 adverse events (mainly anemia, neutropenia, and leukopenia) were more frequent in the telaprevir groups than in the control group (37% vs. 22%).  CONCLUSIONS: Telaprevir combined with peginterferon plus ribavirin significantly improved rates of sustained virol. response in patients with previously treated HCV infection, regardless of whether there was a lead-in phase. (Funded by Tibotec and Vertex Pharmaceuticals; REALIZE ClinicalTrials.gov no., NCT00703118.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzx61JZTi22bVg90H21EOLACvtfcHk0lgXv9HaA4hXaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotVCrsrg%253D&md5=de254ca59467daf5259a3dff8d2d831a</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1013086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1013086%26sid%3Dliteratum%253Aachs%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DAndreone%26aufirst%3DP.%26aulast%3DPol%26aufirst%3DS.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DDiago%26aufirst%3DM.%26aulast%3DRoberts%26aufirst%3DS.%26aulast%3DFocaccia%26aufirst%3DR.%26aulast%3DYounossi%26aufirst%3DZ.%26aulast%3DFoster%26aufirst%3DG.%2BR.%26aulast%3DHorban%26aufirst%3DA.%26aulast%3DFerenci%26aufirst%3DP.%26aulast%3DNevens%26aufirst%3DF.%26aulast%3DMullhaupt%26aufirst%3DB.%26aulast%3DPockros%26aufirst%3DP.%26aulast%3DTerg%26aufirst%3DR.%26aulast%3DShouval%26aufirst%3DD.%26aulast%3Dvan%2BHoek%26aufirst%3DB.%26aulast%3DWeiland%26aufirst%3DO.%26aulast%3DVan%2BHeeswijk%26aufirst%3DR.%26aulast%3DDe%2BMeyer%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DD.%26aulast%3DBoogaerts%26aufirst%3DG.%26aulast%3DPolo%26aufirst%3DR.%26aulast%3DPicchio%26aufirst%3DG.%26aulast%3DBeumont%26aufirst%3DM.%26atitle%3DTelaprevir%2520for%2520retreatment%2520of%2520HCV%2520infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D2417%26epage%3D2428%26doi%3D10.1056%2FNEJMoa1013086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Poordad, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCone, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bacon, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruno, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manns, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sulkowski, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodman, Z. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boparai, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiNubile, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sniukiene, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brass, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albrecht, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bronowicki, J.-P.</span><span> </span><span class="NLM_article-title">Boceprevir for untreated chronic HCV genotype 1 infection</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">1195</span><span class="NLM_x">–</span> <span class="NLM_lpage">1206</span><span class="refDoi"> DOI: 10.1056/NEJMoa1010494</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1056%2FNEJMoa1010494" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=21449783" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkt1Chtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=1195-1206&author=F.+Poordadauthor=J.+McConeauthor=B.+R.+Baconauthor=S.+Brunoauthor=M.+P.+Mannsauthor=M.+S.+Sulkowskiauthor=I.+M.+Jacobsonauthor=K.+R.+Reddyauthor=Z.+D.+Goodmanauthor=N.+Boparaiauthor=M.+J.+DiNubileauthor=V.+Sniukieneauthor=C.+A.+Brassauthor=J.+K.+Albrechtauthor=J.-P.+Bronowicki&title=Boceprevir+for+untreated+chronic+HCV+genotype+1+infection&doi=10.1056%2FNEJMoa1010494"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Boceprevir for untreated chronic HCV genotype 1 infection</span></div><div class="casAuthors">Poordad, Fred; McCone, Jonathan, Jr.; Bacon, Bruce; Bruno, Savino; Manns, Michael P.; Sulkowski, Mark S.; Jacobson, Ira M.; Rajender Reddy, K.; Goodman, Zachary D.; Boparai, Navdeep; DiNubile, Mark J.; Sniukiene, Vilma; Brass, Clifford A.; Albrecht, Janice K.; Bronowicki, Jean-Pierre</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1195-1206</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Peginterferon-ribavirin therapy is the current std. of care for chronic infection with hepatitis C virus (HCV).  The rate of sustained virol. response has been below 50% in cases of HCV genotype 1 infection.  Boceprevir, a potent oral HCV-protease inhibitor, has been evaluated as an addnl. treatment in phase 1 and phase 2 studies.  We conducted a double-blind study in which previously untreated adults with HCV genotype 1 infection were randomly assigned to one of three groups.  In all three groups, peginterferon alfa-2b and ribavirin were administered for 4 wk (the lead- in period).  Subsequently, group 1 (the control group) received placebo plus peginterferon-ribavirin for 44 wk; group 2 received boceprevir plus peginterferon-ribavirin for 24 wk, and those with a detectable HCV RNA level between weeks 8 and 24 received placebo plus peginterferon-ribavirin for an addnl. 20 wk; and group 3 received boceprevir plus peginterferon-ribavirin for 44 wk.  Non-black patients and black patients were enrolled and analyzed sep.  A total of 938 non-black and 159 black patients were treated.  In the non-black cohort, a sustained virol. response was achieved in 125 of the 311 patients (40%) in group 1, in 211 of the 316 patients (67%) in group 2 (P < 0.001), and in 213 of the 311 patients (68%) in group 3 (P < 0.001).  In the black cohort, a sustained virol. response was achieved in 12 of the 52 patients (23%) in group 1, in 22 of the 52 patients (42%) in group 2 (P = 0.04), and in 29 of the 55 patients (53%) in group 3 (P = 0.004).  In group 2, a total of 44% of patients received peginterferon-ribavirin for 28 wk.  Anemia led to dose redns. in 13% of controls and 21% of boceprevir recipients, with discontinuations in 1% and 2%, resp.  The addn. of boceprevir to std. therapy with peginterferon-ribavirin, as compared with std. therapy alone, significantly increased the rates of sustained virol. response in previously untreated adults with chronic HCV genotype 1 infection.  The rates were similar with 24 wk and 44 wk of boceprevir.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCdL0rY0lmGrVg90H21EOLACvtfcHk0lgXv9HaA4hXaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkt1Chtrc%253D&md5=47ea838a941fdf7f9a27350a403e794e</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1010494&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1010494%26sid%3Dliteratum%253Aachs%26aulast%3DPoordad%26aufirst%3DF.%26aulast%3DMcCone%26aufirst%3DJ.%26aulast%3DBacon%26aufirst%3DB.%2BR.%26aulast%3DBruno%26aufirst%3DS.%26aulast%3DManns%26aufirst%3DM.%2BP.%26aulast%3DSulkowski%26aufirst%3DM.%2BS.%26aulast%3DJacobson%26aufirst%3DI.%2BM.%26aulast%3DReddy%26aufirst%3DK.%2BR.%26aulast%3DGoodman%26aufirst%3DZ.%2BD.%26aulast%3DBoparai%26aufirst%3DN.%26aulast%3DDiNubile%26aufirst%3DM.%2BJ.%26aulast%3DSniukiene%26aufirst%3DV.%26aulast%3DBrass%26aufirst%3DC.%2BA.%26aulast%3DAlbrecht%26aufirst%3DJ.%2BK.%26aulast%3DBronowicki%26aufirst%3DJ.-P.%26atitle%3DBoceprevir%2520for%2520untreated%2520chronic%2520HCV%2520genotype%25201%2520infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D1195%26epage%3D1206%26doi%3D10.1056%2FNEJMoa1010494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Rosenquist, Å.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samuelsson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johansson, P.-O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenz, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raboisson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vendeville, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Kock, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilsson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horvath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalmeijer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de la Rosa, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beumont-Mauviel, M.</span><span> </span><span class="NLM_article-title">Discovery and development of simeprevir (TMC435), a HCV NS3/4A protease inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1673</span><span class="NLM_x">–</span> <span class="NLM_lpage">1693</span><span class="refDoi"> DOI: 10.1021/jm401507s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401507s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpslekuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1673-1693&author=%C3%85.+Rosenquistauthor=B.+Samuelssonauthor=P.-O.+Johanssonauthor=M.+D.+Cummingsauthor=O.+Lenzauthor=P.+Raboissonauthor=K.+Simmenauthor=S.+Vendevilleauthor=H.+de+Kockauthor=M.+Nilssonauthor=A.+Horvathauthor=R.+Kalmeijerauthor=G.+de+la+Rosaauthor=M.+Beumont-Mauviel&title=Discovery+and+development+of+simeprevir+%28TMC435%29%2C+a+HCV+NS3%2F4A+protease+inhibitor&doi=10.1021%2Fjm401507s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Simeprevir (TMC435), a HCV NS3/4A Protease Inhibitor</span></div><div class="casAuthors">Rosenquist, Aasa; Samuelsson, Bertil; Johansson, Per-Ola; Cummings, Maxwell D.; Lenz, Oliver; Raboisson, Pierre; Simmen, Kenny; Vendeville, Sandrine; de Kock, Herman; Nilsson, Magnus; Horvath, Andras; Kalmeijer, Ronald; de la Rosa, Guy; Beumont-Mauviel, Maria</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1673-1693</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Hepatitis C virus is a blood-borne infection and the leading cause of chronic liver disease (including cirrhosis and cancer) and liver transplantation.  Since the identification of HCV in 1989, there has been an extensive effort to identify and improve treatment options.  An important milestone was reached in 2011 with the approval of the first-generation HCV NS3/4A protease inhibitors.  However, new therapies are needed to improve cure rates, shorten treatment duration, and improve tolerability.  Here we summarize the extensive medicinal chem. effort to develop novel P2 cyclopentane macrocyclic inhibitors guided by HCV NS3 protease assays, the cellular replicon system, structure-based design, and a panel of DMPK assays.  The selection of compd. 29 (simeprevir, TMC435) as clin. candidate was based on its excellent biol., PK, and safety pharmacol. profile.  Compd. 29 has recently been approved for treatment of chronic HCV infection in combination with pegylated interferon-α and ribavirin in Japan, Canada, and USA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryCRg3NRRjzrVg90H21EOLACvtfcHk0li_gU3ZRPwxGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpslekuw%253D%253D&md5=fd9c1df095e47a111d9680af4c40ccc6</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm401507s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401507s%26sid%3Dliteratum%253Aachs%26aulast%3DRosenquist%26aufirst%3D%25C3%2585.%26aulast%3DSamuelsson%26aufirst%3DB.%26aulast%3DJohansson%26aufirst%3DP.-O.%26aulast%3DCummings%26aufirst%3DM.%2BD.%26aulast%3DLenz%26aufirst%3DO.%26aulast%3DRaboisson%26aufirst%3DP.%26aulast%3DSimmen%26aufirst%3DK.%26aulast%3DVendeville%26aufirst%3DS.%26aulast%3Dde%2BKock%26aufirst%3DH.%26aulast%3DNilsson%26aufirst%3DM.%26aulast%3DHorvath%26aufirst%3DA.%26aulast%3DKalmeijer%26aufirst%3DR.%26aulast%3Dde%2Bla%2BRosa%26aufirst%3DG.%26aulast%3DBeumont-Mauviel%26aufirst%3DM.%26atitle%3DDiscovery%2520and%2520development%2520of%2520simeprevir%2520%2528TMC435%2529%252C%2520a%2520HCV%2520NS3%252F4A%2520protease%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1673%26epage%3D1693%26doi%3D10.1021%2Fjm401507s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Pilot-Matias, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tripathi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaultier, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dekhtyar, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reisch, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopkins, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pithawalla, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middleton, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDaniel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Or, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menon, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kempf, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, C.</span><span> </span><span class="NLM_article-title">In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">988</span><span class="NLM_x">–</span> <span class="NLM_lpage">997</span><span class="refDoi"> DOI: 10.1128/AAC.04227-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1128%2FAAC.04227-14" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=988-997&author=T.+Pilot-Matiasauthor=R.+Tripathiauthor=D.+Cohenauthor=I.+Gaultierauthor=T.+Dekhtyarauthor=L.+Luauthor=T.+Reischauthor=M.+Irvinauthor=T.+Hopkinsauthor=R.+Pithawallaauthor=T.+Middletonauthor=T.+Ngauthor=K.+McDanielauthor=Y.+S.+Orauthor=R.+Menonauthor=D.+Kempfauthor=A.+Mollaauthor=C.+Collins&title=In+vitro+and+in+vivo+antiviral+activity+and+resistance+profile+of+the+hepatitis+C+virus+NS3%2F4A+protease+inhibitor+ABT-450&doi=10.1128%2FAAC.04227-14"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1128%2FAAC.04227-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.04227-14%26sid%3Dliteratum%253Aachs%26aulast%3DPilot-Matias%26aufirst%3DT.%26aulast%3DTripathi%26aufirst%3DR.%26aulast%3DCohen%26aufirst%3DD.%26aulast%3DGaultier%26aufirst%3DI.%26aulast%3DDekhtyar%26aufirst%3DT.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DReisch%26aufirst%3DT.%26aulast%3DIrvin%26aufirst%3DM.%26aulast%3DHopkins%26aufirst%3DT.%26aulast%3DPithawalla%26aufirst%3DR.%26aulast%3DMiddleton%26aufirst%3DT.%26aulast%3DNg%26aufirst%3DT.%26aulast%3DMcDaniel%26aufirst%3DK.%26aulast%3DOr%26aufirst%3DY.%2BS.%26aulast%3DMenon%26aufirst%3DR.%26aulast%3DKempf%26aufirst%3DD.%26aulast%3DMolla%26aufirst%3DA.%26aulast%3DCollins%26aufirst%3DC.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520antiviral%2520activity%2520and%2520resistance%2520profile%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS3%252F4A%2520protease%2520inhibitor%2520ABT-450%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26spage%3D988%26epage%3D997%26doi%3D10.1128%2FAAC.04227-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Harper, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCauley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudd, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiFilippo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crescenzi, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrocchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holloway, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butcher, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romano, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bush, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nizi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludmerer, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burlein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMuzio, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHale, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahlhut, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monteagudo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cianetti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giuliano, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pucci, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trainor, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fandozzi, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vacca, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Summa, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liverton, N. J.</span><span> </span><span class="NLM_article-title">Discovery of MK-5172, a macrocyclic hepatitis C virus NS3/4a protease inhibitor</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">332</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span><span class="refDoi"> DOI: 10.1021/ml300017p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300017p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtFyjurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=332-336&author=S.+Harperauthor=J.+A.+McCauleyauthor=M.+T.+Ruddauthor=M.+Ferraraauthor=M.+DiFilippoauthor=B.+Crescenziauthor=U.+Kochauthor=A.+Petrocchiauthor=M.+K.+Hollowayauthor=J.+W.+Butcherauthor=J.+J.+Romanoauthor=K.+J.+Bushauthor=K.+F.+Gilbertauthor=C.+J.+McIntyreauthor=K.+T.+Nguyenauthor=E.+Niziauthor=S.+S.+Carrollauthor=S.+W.+Ludmererauthor=C.+Burleinauthor=J.+M.+DiMuzioauthor=D.+J.+Grahamauthor=C.+M.+McHaleauthor=M.+W.+Stahlhutauthor=D.+B.+Olsenauthor=E.+Monteagudoauthor=S.+Cianettiauthor=C.+Giulianoauthor=V.+Pucciauthor=N.+Trainorauthor=C.+M.+Fandozziauthor=M.+Rowleyauthor=P.+J.+Colemanauthor=J.+P.+Vaccaauthor=V.+Summaauthor=N.+J.+Liverton&title=Discovery+of+MK-5172%2C+a+macrocyclic+hepatitis+C+virus+NS3%2F4a+protease+inhibitor&doi=10.1021%2Fml300017p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor</span></div><div class="casAuthors">Harper, Steven; McCauley, John A.; Rudd, Michael T.; Ferrara, Marco; DiFilippo, Marcello; Crescenzi, Benedetta; Koch, Uwe; Petrocchi, Alessia; Holloway, M. Katharine; Butcher, John W.; Romano, Joseph J.; Bush, Kimberly J.; Gilbert, Kevin F.; McIntyre, Charles J.; Nguyen, Kevin T.; Nizi, Emanuela; Carroll, Steven S.; Ludmerer, Steven W.; Burlein, Christine; DiMuzio, Jillian M.; Graham, Donald J.; McHale, Carolyn M.; Stahlhut, Mark W.; Olsen, David B.; Monteagudo, Edith; Cianetti, Simona; Giuliano, Claudio; Pucci, Vincenzo; Trainor, Nicole; Fandozzi, Christine M.; Rowley, Michael; Coleman, Paul J.; Vacca, Joseph P.; Summa, Vincenzo; Liverton, Nigel J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">332-336</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new class of HCV NS3/4a protease inhibitors contg. a P2 to P4 macrocyclic constraint was designed using a mol. modeling-derived strategy.  Building on the profile of previous clin. compds. and exploring the P2 and linker regions of the series allowed for optimization of broad genotype and mutant enzyme potency, cellular activity, and rat liver exposure following oral dosing.  These studies led to the identification of clin. candidate 15 (MK-5172), which is active against genotype 1-3 NS3/4a and clin. relevant mutant enzymes and has good plasma exposure and excellent liver exposure in multiple species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAzCaAN9VqJrVg90H21EOLACvtfcHk0lggaG_EmBW2IQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtFyjurg%253D&md5=efc04ad0ad47aef13b367fc38d6bbf63</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fml300017p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300017p%26sid%3Dliteratum%253Aachs%26aulast%3DHarper%26aufirst%3DS.%26aulast%3DMcCauley%26aufirst%3DJ.%2BA.%26aulast%3DRudd%26aufirst%3DM.%2BT.%26aulast%3DFerrara%26aufirst%3DM.%26aulast%3DDiFilippo%26aufirst%3DM.%26aulast%3DCrescenzi%26aufirst%3DB.%26aulast%3DKoch%26aufirst%3DU.%26aulast%3DPetrocchi%26aufirst%3DA.%26aulast%3DHolloway%26aufirst%3DM.%2BK.%26aulast%3DButcher%26aufirst%3DJ.%2BW.%26aulast%3DRomano%26aufirst%3DJ.%2BJ.%26aulast%3DBush%26aufirst%3DK.%2BJ.%26aulast%3DGilbert%26aufirst%3DK.%2BF.%26aulast%3DMcIntyre%26aufirst%3DC.%2BJ.%26aulast%3DNguyen%26aufirst%3DK.%2BT.%26aulast%3DNizi%26aufirst%3DE.%26aulast%3DCarroll%26aufirst%3DS.%2BS.%26aulast%3DLudmerer%26aufirst%3DS.%2BW.%26aulast%3DBurlein%26aufirst%3DC.%26aulast%3DDiMuzio%26aufirst%3DJ.%2BM.%26aulast%3DGraham%26aufirst%3DD.%2BJ.%26aulast%3DMcHale%26aufirst%3DC.%2BM.%26aulast%3DStahlhut%26aufirst%3DM.%2BW.%26aulast%3DOlsen%26aufirst%3DD.%2BB.%26aulast%3DMonteagudo%26aufirst%3DE.%26aulast%3DCianetti%26aufirst%3DS.%26aulast%3DGiuliano%26aufirst%3DC.%26aulast%3DPucci%26aufirst%3DV.%26aulast%3DTrainor%26aufirst%3DN.%26aulast%3DFandozzi%26aufirst%3DC.%2BM.%26aulast%3DRowley%26aufirst%3DM.%26aulast%3DColeman%26aufirst%3DP.%2BJ.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26aulast%3DSumma%26aufirst%3DV.%26aulast%3DLiverton%26aufirst%3DN.%2BJ.%26atitle%3DDiscovery%2520of%2520MK-5172%252C%2520a%2520macrocyclic%2520hepatitis%2520C%2520virus%2520NS3%252F4a%2520protease%2520inhibitor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D332%26epage%3D336%26doi%3D10.1021%2Fml300017p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Scola, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, A. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venables, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sit, S.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cocuzza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bilder, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Andrea, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewawasam, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friborg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falk, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levine, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheaffer, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barry, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, Y.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schartman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donoso, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosure, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinz, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zvyaga, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Good, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajamani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kish, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tredup, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klei, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mueller, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grasela, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levesque, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warner, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span> </span><span class="NLM_article-title">The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1730</span><span class="NLM_x">–</span> <span class="NLM_lpage">1752</span><span class="refDoi"> DOI: 10.1021/jm500297k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500297k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtVeqsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1730-1752&author=P.+M.+Scolaauthor=L.-Q.+Sunauthor=A.+X.+Wangauthor=J.+Chenauthor=N.+Sinauthor=B.+L.+Venablesauthor=S.-Y.+Sitauthor=Y.+Chenauthor=A.+Cocuzzaauthor=D.+M.+Bilderauthor=S.+V.+D%E2%80%99Andreaauthor=B.+Zhengauthor=P.+Hewawasamauthor=Y.+Tuauthor=J.+Friborgauthor=P.+Falkauthor=D.+Hernandezauthor=S.+Levineauthor=C.+Chenauthor=F.+Yuauthor=A.+K.+Sheafferauthor=G.+Zhaiauthor=D.+Barryauthor=J.+O.+Knipeauthor=Y.-H.+Hanauthor=R.+Schartmanauthor=M.+Donosoauthor=K.+Mosureauthor=M.+W.+Sinzauthor=T.+Zvyagaauthor=A.+C.+Goodauthor=R.+Rajamaniauthor=K.+Kishauthor=J.+Tredupauthor=H.+E.+Kleiauthor=Q.+Gaoauthor=L.+Muellerauthor=R.+J.+Colonnoauthor=D.+M.+Graselaauthor=S.+P.+Adamsauthor=J.+Loyauthor=P.+C.+Levesqueauthor=H.+Sunauthor=H.+Shiauthor=L.+Sunauthor=W.+Warnerauthor=D.+Liauthor=J.+Zhuauthor=N.+A.+Meanwellauthor=F.+McPhee&title=The+discovery+of+asunaprevir+%28BMS-650032%29%2C+an+orally+efficacious+NS3+protease+inhibitor+for+the+treatment+of+hepatitis+C+virus+infection&doi=10.1021%2Fjm500297k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The Discovery of Asunaprevir (BMS-650032), An Orally Efficacious NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection</span></div><div class="casAuthors">Scola, Paul M.; Sun, Li-Qiang; Wang, Alan Xiangdong; Chen, Jie; Sin, Ny; Venables, Brian L.; Sit, Sing-Yuen; Chen, Yan; Cocuzza, Anthony; Bilder, Donna M.; D'Andrea, Stanley V.; Zheng, Barbara; Hewawasam, Piyasena; Tu, Yong; Friborg, Jacques; Falk, Paul; Hernandez, Dennis; Levine, Steven; Chen, Chaoqun; Yu, Fei; Sheaffer, Amy K.; Zhai, Guangzhi; Barry, Diana; Knipe, Jay O.; Han, Yong-Hae; Schartman, Richard; Donoso, Maria; Mosure, Kathy; Sinz, Michael W.; Zvyaga, Tatyana; Good, Andrew C.; Rajamani, Ramkumar; Kish, Kevin; Tredup, Jeffrey; Klei, Herbert E.; Gao, Qi; Mueller, Luciano; Colonno, Richard J.; Grasela, Dennis M.; Adams, Stephen P.; Loy, James; Levesque, Paul C.; Sun, Huabin; Shi, Hong; Sun, Lucy; Warner, William; Li, Danshi; Zhu, Jialong; Meanwell, Nicholas A.; McPhee, Fiona</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1730-1752</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of asunaprevir (BMS-650032) is described.  This tripeptidic acylsulfonamide inhibitor of the NS3/4A enzyme is currently in phase III clin. trials for the treatment of hepatitis C virus infection.  The discovery of Asunaprevir was enabled by employing an isolated rabbit heart model to screen for the cardiovascular (CV) liabilities (changes to HR and SNRT) that were responsible for the discontinuation of an earlier lead from this chem. series, BMS-605339, from clin. trials.  The structure-activity relationships (SARs) developed with respect to CV effects established that small structural changes to the P2* subsite of the mol. had a significant impact on the CV profile of a given compd.  The antiviral activity, preclin. PK profile, and toxicol. studies in rat and dog supported clin. development of BMS-650032.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCzMFiXs8YO7Vg90H21EOLACvtfcHk0lhIz-fnMgr7kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtVeqsLc%253D&md5=e8015d3874b80be645a9b80b5bd05865</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm500297k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500297k%26sid%3Dliteratum%253Aachs%26aulast%3DScola%26aufirst%3DP.%2BM.%26aulast%3DSun%26aufirst%3DL.-Q.%26aulast%3DWang%26aufirst%3DA.%2BX.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DSin%26aufirst%3DN.%26aulast%3DVenables%26aufirst%3DB.%2BL.%26aulast%3DSit%26aufirst%3DS.-Y.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DCocuzza%26aufirst%3DA.%26aulast%3DBilder%26aufirst%3DD.%2BM.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DS.%2BV.%26aulast%3DZheng%26aufirst%3DB.%26aulast%3DHewawasam%26aufirst%3DP.%26aulast%3DTu%26aufirst%3DY.%26aulast%3DFriborg%26aufirst%3DJ.%26aulast%3DFalk%26aufirst%3DP.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DLevine%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DF.%26aulast%3DSheaffer%26aufirst%3DA.%2BK.%26aulast%3DZhai%26aufirst%3DG.%26aulast%3DBarry%26aufirst%3DD.%26aulast%3DKnipe%26aufirst%3DJ.%2BO.%26aulast%3DHan%26aufirst%3DY.-H.%26aulast%3DSchartman%26aufirst%3DR.%26aulast%3DDonoso%26aufirst%3DM.%26aulast%3DMosure%26aufirst%3DK.%26aulast%3DSinz%26aufirst%3DM.%2BW.%26aulast%3DZvyaga%26aufirst%3DT.%26aulast%3DGood%26aufirst%3DA.%2BC.%26aulast%3DRajamani%26aufirst%3DR.%26aulast%3DKish%26aufirst%3DK.%26aulast%3DTredup%26aufirst%3DJ.%26aulast%3DKlei%26aufirst%3DH.%2BE.%26aulast%3DGao%26aufirst%3DQ.%26aulast%3DMueller%26aufirst%3DL.%26aulast%3DColonno%26aufirst%3DR.%2BJ.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26aulast%3DAdams%26aufirst%3DS.%2BP.%26aulast%3DLoy%26aufirst%3DJ.%26aulast%3DLevesque%26aufirst%3DP.%2BC.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DWarner%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DMcPhee%26aufirst%3DF.%26atitle%3DThe%2520discovery%2520of%2520asunaprevir%2520%2528BMS-650032%2529%252C%2520an%2520orally%2520efficacious%2520NS3%2520protease%2520inhibitor%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1730%26epage%3D1752%26doi%3D10.1021%2Fjm500297k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">McCauley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudd, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romano, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butcher, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bush, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holloway, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swestock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMuzio, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludmerer, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahlhut, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fandozzi, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trainor, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vacca, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liverton, N. J.</span><span> </span><span class="NLM_article-title">Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2443</span><span class="NLM_x">–</span> <span class="NLM_lpage">2463</span><span class="refDoi"> DOI: 10.1021/jm9015526</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9015526" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitV2gsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2443-2463&author=J.+A.+McCauleyauthor=C.+J.+McIntyreauthor=M.+T.+Ruddauthor=K.+T.+Nguyenauthor=J.+J.+Romanoauthor=J.+W.+Butcherauthor=K.+F.+Gilbertauthor=K.+J.+Bushauthor=M.+K.+Hollowayauthor=J.+Swestockauthor=B.+L.+Wanauthor=S.+S.+Carrollauthor=J.+M.+DiMuzioauthor=D.+J.+Grahamauthor=S.+W.+Ludmererauthor=S.+S.+Maoauthor=M.+W.+Stahlhutauthor=C.+M.+Fandozziauthor=N.+Trainorauthor=D.+B.+Olsenauthor=J.+P.+Vaccaauthor=N.+J.+Liverton&title=Discovery+of+vaniprevir+%28MK-7009%29%2C+a+macrocyclic+hepatitis+C+virus+NS3%2F4a+protease+inhibitor&doi=10.1021%2Fjm9015526"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Vaniprevir (MK-7009), a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor</span></div><div class="casAuthors">McCauley, John A.; McIntyre, Charles J.; Rudd, Michael T.; Nguyen, Kevin T.; Romano, Joseph J.; Butcher, John W.; Gilbert, Kevin F.; Bush, Kimberly J.; Holloway, M. Katharine; Swestock, John; Wan, Bang-Lin; Carroll, Steven S.; DiMuzio, Jillian M.; Graham, Donald J.; Ludmerer, Steven W.; Mao, Shi-Shan; Stahlhut, Mark W.; Fandozzi, Christine M.; Trainor, Nicole; Olsen, David B.; Vacca, Joseph P.; Liverton, Nigel J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2443-2463</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new class of HCV NS3/4a protease inhibitors which contain a P2 to P4 macrocyclic constraint was designed using a mol.-modeling derived strategy.  Exploration of the P2 heterocyclic region, the P2 to P4 linker, and the P1 side chain of this class of compds. via a modular synthetic strategy allowed for the optimization of enzyme potency, cellular activity, and rat liver exposure following oral dosing.  These studies led to the identification of clin. candidate vaniprevir, MK-7009, which is active against both the genotype 1 and genotype 2 NS3/4a protease enzymes and has good plasma exposure and excellent liver exposure in multiple species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_2CVs9I1H_7Vg90H21EOLACvtfcHk0lhIz-fnMgr7kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitV2gsr8%253D&md5=dc820c588d5482f6913091a87eaf9af1</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm9015526&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9015526%26sid%3Dliteratum%253Aachs%26aulast%3DMcCauley%26aufirst%3DJ.%2BA.%26aulast%3DMcIntyre%26aufirst%3DC.%2BJ.%26aulast%3DRudd%26aufirst%3DM.%2BT.%26aulast%3DNguyen%26aufirst%3DK.%2BT.%26aulast%3DRomano%26aufirst%3DJ.%2BJ.%26aulast%3DButcher%26aufirst%3DJ.%2BW.%26aulast%3DGilbert%26aufirst%3DK.%2BF.%26aulast%3DBush%26aufirst%3DK.%2BJ.%26aulast%3DHolloway%26aufirst%3DM.%2BK.%26aulast%3DSwestock%26aufirst%3DJ.%26aulast%3DWan%26aufirst%3DB.%2BL.%26aulast%3DCarroll%26aufirst%3DS.%2BS.%26aulast%3DDiMuzio%26aufirst%3DJ.%2BM.%26aulast%3DGraham%26aufirst%3DD.%2BJ.%26aulast%3DLudmerer%26aufirst%3DS.%2BW.%26aulast%3DMao%26aufirst%3DS.%2BS.%26aulast%3DStahlhut%26aufirst%3DM.%2BW.%26aulast%3DFandozzi%26aufirst%3DC.%2BM.%26aulast%3DTrainor%26aufirst%3DN.%26aulast%3DOlsen%26aufirst%3DD.%2BB.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26aulast%3DLiverton%26aufirst%3DN.%2BJ.%26atitle%3DDiscovery%2520of%2520vaniprevir%2520%2528MK-7009%2529%252C%2520a%2520macrocyclic%2520hepatitis%2520C%2520virus%2520NS3%252F4a%2520protease%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2443%26epage%3D2463%26doi%3D10.1021%2Fjm9015526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Lawitz, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Riordan, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asatryan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freilich, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overcash, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, T. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kort, J.</span><span> </span><span class="NLM_article-title">Potent antiviral activities of the direct-acting antivirals ABT-493 and ABT-530 with three-day monotherapy for hepatitis C virus genotype 1 infection</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">1546</span><span class="NLM_x">–</span> <span class="NLM_lpage">1555</span><span class="refDoi"> DOI: 10.1128/AAC.02264-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1128%2FAAC.02264-15" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2016&pages=1546-1555&author=E.+J.+Lawitzauthor=W.+D.+O%E2%80%99Riordanauthor=A.+Asatryanauthor=B.+L.+Freilichauthor=T.+D.+Boxauthor=J.+S.+Overcashauthor=S.+Lovellauthor=T.+I.+Ngauthor=W.+Liuauthor=A.+Campbellauthor=C.+W.+Linauthor=B.+Yaoauthor=J.+Kort&title=Potent+antiviral+activities+of+the+direct-acting+antivirals+ABT-493+and+ABT-530+with+three-day+monotherapy+for+hepatitis+C+virus+genotype+1+infection&doi=10.1128%2FAAC.02264-15"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1128%2FAAC.02264-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.02264-15%26sid%3Dliteratum%253Aachs%26aulast%3DLawitz%26aufirst%3DE.%2BJ.%26aulast%3DO%25E2%2580%2599Riordan%26aufirst%3DW.%2BD.%26aulast%3DAsatryan%26aufirst%3DA.%26aulast%3DFreilich%26aufirst%3DB.%2BL.%26aulast%3DBox%26aufirst%3DT.%2BD.%26aulast%3DOvercash%26aufirst%3DJ.%2BS.%26aulast%3DLovell%26aufirst%3DS.%26aulast%3DNg%26aufirst%3DT.%2BI.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DCampbell%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DC.%2BW.%26aulast%3DYao%26aufirst%3DB.%26aulast%3DKort%26aufirst%3DJ.%26atitle%3DPotent%2520antiviral%2520activities%2520of%2520the%2520direct-acting%2520antivirals%2520ABT-493%2520and%2520ABT-530%2520with%2520three-day%2520monotherapy%2520for%2520hepatitis%2520C%2520virus%2520genotype%25201%2520infection%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2016%26volume%3D60%26spage%3D1546%26epage%3D1555%26doi%3D10.1128%2FAAC.02264-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Rodriguez-Torres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glass, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freilich, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Bisceglie, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirby, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dvory-Sobol, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">An, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stamm, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brainard, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krefetz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marbury, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E.</span><span> </span><span class="NLM_article-title">GS-9857 in patients with chronic hepatitis C virus genotype 1–4 infection: a randomized, double-blind, dose-ranging phase 1 study</span> <span class="citation_source-journal">J. Viral. Hepat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">614</span><span class="NLM_x">–</span> <span class="NLM_lpage">622</span><span class="refDoi"> DOI: 10.1111/jvh.12527</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1111%2Fjvh.12527" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=26957110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFOkurbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2016&pages=614-622&author=M.+Rodriguez-Torresauthor=S.+Glassauthor=J.+Hillauthor=B.+Freilichauthor=D.+Hassmanauthor=A.+M.+Di+Bisceglieauthor=J.+G.+Taylorauthor=B.+J.+Kirbyauthor=H.+Dvory-Sobolauthor=J.+C.+Yangauthor=D.+Anauthor=L.+M.+Stammauthor=D.+M.+Brainardauthor=S.+Kimauthor=D.+Krefetzauthor=W.+Smithauthor=T.+Marburyauthor=E.+Lawitz&title=GS-9857+in+patients+with+chronic+hepatitis+C+virus+genotype+1%E2%80%934+infection%3A+a+randomized%2C+double-blind%2C+dose-ranging+phase+1+study&doi=10.1111%2Fjvh.12527"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 study</span></div><div class="casAuthors">Rodriguez-Torres, M.; Glass, S.; Hill, J.; Freilich, B.; Hassman, D.; Di Bisceglie, A. M.; Taylor, J. G.; Kirby, B. J.; Dvory-Sobol, H.; Yang, J. C.; An, D.; Stamm, L. M.; Brainard, D. M.; Kim, S.; Krefetz, D.; Smith, W.; Marbury, T.; Lawitz, E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Viral Hepatitis</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">614-622</span>CODEN:
                <span class="NLM_cas:coden">JVHEER</span>;
        ISSN:<span class="NLM_cas:issn">1365-2893</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Summary : GS-9857, an inhibitor of the hepatitis C virus (HCV) nonstructural protein (NS) 3/4A, demonstrates potent activity against HCV genotypes 1-6 and improved coverage against commonly encountered NS3 resistance-assocd. variants (RAVs).  In this study, the safety, tolerability, antiviral activity and pharmacokinetics (PK) of GS-9857 were evaluated in patients with chronic HCV genotype 1-4 infection.  Patients with genotype 1-4 infection received placebo or once-daily GS-9857 at doses ranging from 50 to 300 mg for 3 days under fasting conditions.  GS-9857 was well tolerated; all reported adverse events (AEs) were mild or moderate in severity.  Diarrhoea and headache were the most commonly reported AEs.  Grade 3 or 4 lab. abnormalities were obsd. in 17% of patients receiving GS-9857; there were no Grade 3 or 4 abnormalities in alanine aminotransferase, aspartate aminotransferase or alk. phosphatase levels.  GS-9857 demonstrated potent antiviral activity in patients with chronic HCV infection, achieving mean and median max. redns. in HCV RNA of ≥3 log10 IU/mL following administration of a 100-mg dose in patients with HCV genotype 1a, 1b, 2, 3 or 4 infection.  The antiviral activity of GS-9857 was unaffected by the presence of pretreatment NS3 RAVs.  In patients with genotype 1-4 infection, GS-9857 exhibited linear PK and was assocd. with a median half-life of 29-42 h, supporting once-daily dosing.  Thus, the tolerability, efficacy and pharmacokinetic profile of GS-9857 support its further evaluation for treatment of patients with chronic HCV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8oJDwl-bOdbVg90H21EOLACvtfcHk0liMjKgYNq6SFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFOkurbK&md5=257769b545cb4289b8f9fc5298454f91</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1111%2Fjvh.12527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjvh.12527%26sid%3Dliteratum%253Aachs%26aulast%3DRodriguez-Torres%26aufirst%3DM.%26aulast%3DGlass%26aufirst%3DS.%26aulast%3DHill%26aufirst%3DJ.%26aulast%3DFreilich%26aufirst%3DB.%26aulast%3DHassman%26aufirst%3DD.%26aulast%3DDi%2BBisceglie%26aufirst%3DA.%2BM.%26aulast%3DTaylor%26aufirst%3DJ.%2BG.%26aulast%3DKirby%26aufirst%3DB.%2BJ.%26aulast%3DDvory-Sobol%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26aulast%3DAn%26aufirst%3DD.%26aulast%3DStamm%26aufirst%3DL.%2BM.%26aulast%3DBrainard%26aufirst%3DD.%2BM.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DKrefetz%26aufirst%3DD.%26aulast%3DSmith%26aufirst%3DW.%26aulast%3DMarbury%26aufirst%3DT.%26aulast%3DLawitz%26aufirst%3DE.%26atitle%3DGS-9857%2520in%2520patients%2520with%2520chronic%2520hepatitis%2520C%2520virus%2520genotype%25201%25E2%2580%25934%2520infection%253A%2520a%2520randomized%252C%2520double-blind%252C%2520dose-ranging%2520phase%25201%2520study%26jtitle%3DJ.%2520Viral.%2520Hepat.%26date%3D2016%26volume%3D23%26spage%3D614%26epage%3D622%26doi%3D10.1111%2Fjvh.12527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Tsantrizos, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonneau, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goudreau, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukolj, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaPlante, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Llinas-Brunet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nar, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamarre, D.</span><span> </span><span class="NLM_article-title">Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">1356</span><span class="NLM_x">–</span> <span class="NLM_lpage">1360</span><span class="refDoi"> DOI: 10.1002/anie.200390347</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1002%2Fanie.200390347" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjtlygsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2003&pages=1356-1360&author=Y.+S.+Tsantrizosauthor=G.+Bolgerauthor=P.+Bonneauauthor=D.+R.+Cameronauthor=N.+Goudreauauthor=G.+Kukoljauthor=S.+R.+LaPlanteauthor=M.+Llinas-Brunetauthor=H.+Narauthor=D.+Lamarre&title=Macrocyclic+inhibitors+of+the+NS3+protease+as+potential+therapeutic+agents+of+hepatitis+C+virus+infection&doi=10.1002%2Fanie.200390347"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection</span></div><div class="casAuthors">Tsantrizos, Youla S.; Bolger, Gordon; Bonneau, Pierre; Cameron, Dale R.; Goudreau, Nathalie; Kukolj, George; LaPlante, Steven R.; Llinas-Brunet, Montse; Nar, Herbert; Lamarre, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1356-1360</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A novel class of selective inhibitors of the hepatitis C virus NS3 protease, an enzyme which is essential for viral replication in vivo, was developed.  The inhibitors are based on the structure-activity relationship between a substrate-based peptidomimetic ligand and the HCV NS3 serine protease.  The designed HCV inhibitor and its satd. analogs are the first inhibitors of the NS3 protease which inhibit HCV RNA replication in the cell-based replicon assay.  In addn., they are orally absorbed and stable to metabolic breakdown.  Thus, these compds. show many of the desirable properties of a druglike archetype and could lead t a clin. useful antiviral agent for the treatment of hepatitis C viral infections in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCij3shP5tmLVg90H21EOLACvtfcHk0liYmqxXEq2YMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjtlygsrc%253D&md5=e0a3c98ee0096bfc3d058bf0b92b81c3</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1002%2Fanie.200390347&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200390347%26sid%3Dliteratum%253Aachs%26aulast%3DTsantrizos%26aufirst%3DY.%2BS.%26aulast%3DBolger%26aufirst%3DG.%26aulast%3DBonneau%26aufirst%3DP.%26aulast%3DCameron%26aufirst%3DD.%2BR.%26aulast%3DGoudreau%26aufirst%3DN.%26aulast%3DKukolj%26aufirst%3DG.%26aulast%3DLaPlante%26aufirst%3DS.%2BR.%26aulast%3DLlinas-Brunet%26aufirst%3DM.%26aulast%3DNar%26aufirst%3DH.%26aulast%3DLamarre%26aufirst%3DD.%26atitle%3DMacrocyclic%2520inhibitors%2520of%2520the%2520NS3%2520protease%2520as%2520potential%2520therapeutic%2520agents%2520of%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2003%26volume%3D42%26spage%3D1356%26epage%3D1360%26doi%3D10.1002%2Fanie.200390347" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">LaPlante, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nar, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemke, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakalian, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aubry, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawai, S. H.</span><span> </span><span class="NLM_article-title">Ligand bioactive conformation plays a critical role in the design of drugs that target the hepatitis C virus NS3 protease</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1777</span><span class="NLM_x">–</span> <span class="NLM_lpage">1789</span><span class="refDoi"> DOI: 10.1021/jm401338c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401338c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1Cktb7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1777-1789&author=S.+R.+LaPlanteauthor=H.+Narauthor=C.+T.+Lemkeauthor=A.+Jakalianauthor=N.+Aubryauthor=S.+H.+Kawai&title=Ligand+bioactive+conformation+plays+a+critical+role+in+the+design+of+drugs+that+target+the+hepatitis+C+virus+NS3+protease&doi=10.1021%2Fjm401338c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand Bioactive Conformation Plays a Critical Role in the Design of Drugs That Target the Hepatitis C Virus NS3 Protease</span></div><div class="casAuthors">LaPlante, Steven R.; Nar, Herbert; Lemke, Christopher T.; Jakalian, Araz; Aubry, Norman; Kawai, Stephen H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1777-1789</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A ligand-focused strategy employed NMR, X-ray, modeling, and medicinal chem. to expose the crit. role that bioactive conformation played in the design of a variety of drugs that target the HCV protease.  The bioactive conformation (bound states) were detd. for key inhibitors identified along our drug discovery pathway from the hit to clin. compds.  All adopt similar bioactive conformations for the common core derived from the hit peptide DDIVPC.  A carefully designed SAR anal., based on the advanced inhibitor 1 in which the P1 to P3 side chains and the N-terminal Boc were sequentially truncated, revealed a correlation between affinity and the relative predominance of the bioactive conformation in the free state.  Interestingly, synergistic conformation effects on potency were also noted.  Comparisons with clin. and recently marketed drugs from the pharmaceutical industry showed that all have the same core and similar bioactive conformations.  This suggested that the variety of appendages discovered for these compds. also properly satisfy the bioactive conformation requirements and allowed for a large variety of HCV protease drug candidates to be designed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFi-4R4F9wwbVg90H21EOLACvtfcHk0liYmqxXEq2YMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1Cktb7P&md5=2ccb36504903255ba012223529318a69</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm401338c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401338c%26sid%3Dliteratum%253Aachs%26aulast%3DLaPlante%26aufirst%3DS.%2BR.%26aulast%3DNar%26aufirst%3DH.%26aulast%3DLemke%26aufirst%3DC.%2BT.%26aulast%3DJakalian%26aufirst%3DA.%26aulast%3DAubry%26aufirst%3DN.%26aulast%3DKawai%26aufirst%3DS.%2BH.%26atitle%3DLigand%2520bioactive%2520conformation%2520plays%2520a%2520critical%2520role%2520in%2520the%2520design%2520of%2520drugs%2520that%2520target%2520the%2520hepatitis%2520C%2520virus%2520NS3%2520protease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1777%26epage%3D1789%26doi%3D10.1021%2Fjm401338c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Lontok, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrington, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howe, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kieffer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lennerstrand, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenz, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pilot-Matias, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V.</span><span> </span><span class="NLM_article-title">Hepatitis C virus drug resistance-associated substitutions: state of the art summary</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">1623</span><span class="NLM_x">–</span> <span class="NLM_lpage">1632</span><span class="refDoi"> DOI: 10.1002/hep.27934</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1002%2Fhep.27934" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=26095927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A280%3ADC%252BC2MblsFaluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2015&pages=1623-1632&author=E.+Lontokauthor=P.+Harringtonauthor=A.+Howeauthor=T.+Kiefferauthor=J.+Lennerstrandauthor=O.+Lenzauthor=F.+McPheeauthor=H.+Moauthor=N.+Parkinauthor=T.+Pilot-Matiasauthor=V.+Miller&title=Hepatitis+C+virus+drug+resistance-associated+substitutions%3A+state+of+the+art+summary&doi=10.1002%2Fhep.27934"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis C virus drug resistance-associated substitutions: State of the art summary</span></div><div class="casAuthors">Lontok Erik; Miller Veronica; Harrington Patrick; Howe Anita; Kieffer Tara; Lennerstrand Johan; Lenz Oliver; McPhee Fiona; Mo Hongmei; Parkin Neil; Pilot-Matias Tami</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Baltimore, Md.)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1623-32</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">UNLABELLED:  Hepatitis C virus (HCV) drug development has resulted in treatment regimens composed of interferon-free, all-oral combinations of direct-acting antivirals.  While the new regimens are potent and highly efficacious, the full clinical impact of HCV drug resistance, its implications for retreatment, and the potential role of baseline resistance testing remain critical research and clinical questions.  In this report, we discuss the viral proteins targeted by HCV direct-acting antivirals and summarize clinically relevant resistance data for compounds that have been approved or are currently in phase 3 clinical trials.  CONCLUSION:  This report provides a comprehensive, systematic review of all resistance information available from sponsors' trials as a tool to inform the HCV drug development field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSWdgOjMha0H1WTCLT8lX9SfW6udTcc2ebvhAXFXzasArntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MblsFaluw%253D%253D&md5=7d87bedfe7e1e825117a9f9a325da452</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fhep.27934&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.27934%26sid%3Dliteratum%253Aachs%26aulast%3DLontok%26aufirst%3DE.%26aulast%3DHarrington%26aufirst%3DP.%26aulast%3DHowe%26aufirst%3DA.%26aulast%3DKieffer%26aufirst%3DT.%26aulast%3DLennerstrand%26aufirst%3DJ.%26aulast%3DLenz%26aufirst%3DO.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DMo%26aufirst%3DH.%26aulast%3DParkin%26aufirst%3DN.%26aulast%3DPilot-Matias%26aufirst%3DT.%26aulast%3DMiller%26aufirst%3DV.%26atitle%3DHepatitis%2520C%2520virus%2520drug%2520resistance-associated%2520substitutions%253A%2520state%2520of%2520the%2520art%2520summary%26jtitle%3DHepatology%26date%3D2015%26volume%3D62%26spage%3D1623%26epage%3D1632%26doi%3D10.1002%2Fhep.27934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Kieffer, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, S.</span><span> </span><span class="NLM_article-title">Resistance to hepatitis C virus protease inhibitors</span> <span class="citation_source-journal">Curr. Opin. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">16</span><span class="NLM_x">–</span> <span class="NLM_lpage">21</span><span class="refDoi"> DOI: 10.1016/j.coviro.2014.04.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1016%2Fj.coviro.2014.04.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=24852142" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslGjsbbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2014&pages=16-21&author=T.+L.+Kiefferauthor=S.+George&title=Resistance+to+hepatitis+C+virus+protease+inhibitors&doi=10.1016%2Fj.coviro.2014.04.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Resistance to hepatitis C virus protease inhibitors</span></div><div class="casAuthors">Kieffer, Tara L.; George, Shelley</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Virology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">16-21</span>CODEN:
                <span class="NLM_cas:coden">COVUAF</span>;
        ISSN:<span class="NLM_cas:issn">1879-6257</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">Significant scientific advances have enabled the development of new classes of antivirals for the treatment of HCV.  Protease inhibitors were the first approved, achieving substantially higher response rates, with shorter treatment durations, in the majority of genotype 1 infected patients.  However, in patients who fail treatment, drug resistant variants frequently emerge.  The pattern of resistant variants obsd. is a result of the specific inhibitor, viral subtype, and level of drug selective pressure.  Data suggest the replacement of these variants over time; however, retreatment of these patients is an area of needed investigation.  As multiple drug classes progress in development, combinations of agents improve treatment success, increase the genetic barrier to resistance, and provide shorter treatment durations for diverse patient populations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5RruOLoAqxLVg90H21EOLACvtfcHk0lhT7drG3RPCUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslGjsbbF&md5=6603e69f789b515ec49c0eaee2ada46e</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.coviro.2014.04.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coviro.2014.04.008%26sid%3Dliteratum%253Aachs%26aulast%3DKieffer%26aufirst%3DT.%2BL.%26aulast%3DGeorge%26aufirst%3DS.%26atitle%3DResistance%2520to%2520hepatitis%2520C%2520virus%2520protease%2520inhibitors%26jtitle%3DCurr.%2520Opin.%2520Virol.%26date%3D2014%26volume%3D8%26spage%3D16%26epage%3D21%26doi%3D10.1016%2Fj.coviro.2014.04.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Chan, K.; Yu, M.; Peng, B.; Corsa, A.; Worth, A.; Gong, R.; Xu, S.; Chen, X.; Appleby, T. C.; Taylor, J.; Delaney, W. E.; Cheng, G.</span><span> </span><span class="NLM_article-title">In vitro efficacy and resistance profiling of protease inhibitors against a novel HCV genotype 3a replicon</span>. In International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies, Toronto, ON, Canada, 2013;<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=K.+Chan&author=M.+Yu&author=B.+Peng&author=A.+Corsa&author=A.+Worth&author=R.+Gong&author=S.+Xu&author=X.+Chen&author=T.+C.+Appleby&author=J.+Taylor&author=W.+E.+Delaney&author=G.+Cheng&title=In+vitro+efficacy+and+resistance+profiling+of+protease+inhibitors+against+a+novel+HCV+genotype+3a+replicon"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DK.%26atitle%3DIn%2520vitro%2520efficacy%2520and%2520resistance%2520profiling%2520of%2520protease%2520inhibitors%2520against%2520a%2520novel%2520HCV%2520genotype%25203a%2520replicon%26jtitle%3DInternational%2520Workshop%2520on%2520HIV%2520%2526%2520Hepatitis%2520Virus%2520Drug%2520Resistance%2520and%2520Curative%2520Strategies%252C%2520Toronto%252C%2520ON%252C%2520Canada%252C%25202013%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Romano, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Royer, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiffer, C. A.</span><span> </span><span class="NLM_article-title">Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">20986</span><span class="NLM_x">–</span> <span class="NLM_lpage">20991</span><span class="refDoi"> DOI: 10.1073/pnas.1006370107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1073%2Fpnas.1006370107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=21084633" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFyrsbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=20986-20991&author=K.+P.+Romanoauthor=A.+Aliauthor=W.+E.+Royerauthor=C.+A.+Schiffer&title=Drug+resistance+against+HCV+NS3%2F4A+inhibitors+is+defined+by+the+balance+of+substrate+recognition+versus+inhibitor+binding&doi=10.1073%2Fpnas.1006370107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Drug resistance against: HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding</span></div><div class="casAuthors">Romano, Keith P.; Ali, Akbar; Royer, William E.; Schiffer, Celia A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">20986-20991, S20986/1-S20986/5</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Hepatitis C virus infects an estd. 180 million people worldwide, prompting enormous efforts to develop inhibitors targeting the essential NS3/4A protease.  Resistance against the most promising protease inhibitors, telaprevir, boceprevir, and ITMN-191, has emerged in clin. trials.  In this study, crystal structures of the NS3/4A protease domain reveal that viral substrates bind to the protease active site in a conserved manner defining a consensus vol., or substrate envelope.  Mutations that confer the most severe resistance in the clinic occur where the inhibitors protrude from the substrate envelope, as these changes selectively weaken inhibitor binding without compromising the binding of substrates.  These findings suggest a general model for predicting the susceptibility of protease inhibitors to resistance: drugs designed to fit within the substrate envelope will be less susceptible to resistance, as mutations affecting inhibitor binding would simultaneously interfere with the recognition of viral substrates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6Sz81F04YRrVg90H21EOLACvtfcHk0ljq6XUikVm0AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFyrsbbM&md5=db72884b6a45110805bcdf70fbaea6a4</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1006370107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1006370107%26sid%3Dliteratum%253Aachs%26aulast%3DRomano%26aufirst%3DK.%2BP.%26aulast%3DAli%26aufirst%3DA.%26aulast%3DRoyer%26aufirst%3DW.%2BE.%26aulast%3DSchiffer%26aufirst%3DC.%2BA.%26atitle%3DDrug%2520resistance%2520against%2520HCV%2520NS3%252F4A%2520inhibitors%2520is%2520defined%2520by%2520the%2520balance%2520of%2520substrate%2520recognition%2520versus%2520inhibitor%2520binding%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26spage%3D20986%26epage%3D20991%26doi%3D10.1073%2Fpnas.1006370107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Romano, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aydin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soumana, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Özen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deveau, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silver, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petropoulos, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiffer, C. A.</span><span> </span><span class="NLM_article-title">The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors</span> <span class="citation_source-journal">PLoS Pathog.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">e1002832</span><span class="refDoi"> DOI: 10.1371/journal.ppat.1002832</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1371%2Fjournal.ppat.1002832" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=22910833" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFeisrbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=e1002832&author=K.+P.+Romanoauthor=A.+Aliauthor=C.+Aydinauthor=D.+Soumanaauthor=A.+%C3%96zenauthor=L.+M.+Deveauauthor=C.+Silverauthor=H.+Caoauthor=A.+Newtonauthor=C.+J.+Petropoulosauthor=W.+Huangauthor=C.+A.+Schiffer&title=The+molecular+basis+of+drug+resistance+against+hepatitis+C+virus+NS3%2F4A+protease+inhibitors&doi=10.1371%2Fjournal.ppat.1002832"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors</span></div><div class="casAuthors">Romano, Keith P.; Ali, Akbar; Aydin, Cihan; Soumana, Djade; Ozen, Aysegul; Deveau, Laura M.; Silver, Casey; Cao, Hong; Newton, Alicia; Petropoulos, Christos J.; Huang, Wei; Schiffer, Celia A.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Pathogens</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">e1002832</span>CODEN:
                <span class="NLM_cas:coden">PPLACN</span>;
        ISSN:<span class="NLM_cas:issn">1553-7374</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) infects over 170 million people worldwide and is the leading cause of chronic liver diseases, including cirrhosis, liver failure and liver cancer.  Available antiviral therapies cause severe side effects and are effective only for a subset of patients, though treatment outcomes have recently been improved by the combination therapy now including boceprevir and telaprevir, which inhibit the viral NS3/4A protease.  Despite extensive efforts to develop more potent next-generation protease inhibitors, however, the long-term efficacy of this drug class is challenged by the rapid emergence of resistance.  Single-site mutations at protease residues R155, A156 and D168 confer resistance to nearly all inhibitors in clin. development.  Thus, developing the next-generation of drugs that retain activity against a broader spectrum of resistant viral variants requires a comprehensive understanding of the mol. basis of drug resistance.  In this study, 16 high-resoln. crystal structures of four representative protease inhibitors - telaprevir, danoprevir, vaniprevir and MK-5172 - in complex with the wild-type protease and three major drug-resistant variants R155K, A156T and D168A, reveal unique mol. underpinnings of resistance to each drug.  The drugs exhibit differential susceptibilities to these protease variants in both enzymic and antiviral assays.  Telaprevir, danoprevir and vaniprevir interact directly with sites that confer resistance upon mutation, while MK-5172 interacts in a unique conformation with the catalytic triad.  This novel mode of MK-5172 binding explains its retained potency against two multi-drug-resistant variants, R155K and D168A.  These findings define the mol. basis of HCV N3/4A protease inhibitor resistance and provide potential strategies for designing robust therapies against this rapidly evolving virus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprECYOGWNgj7Vg90H21EOLACvtfcHk0ljq6XUikVm0AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFeisrbK&md5=15ca5b9d370793cd3fa814755ddf99c6</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1002832&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1002832%26sid%3Dliteratum%253Aachs%26aulast%3DRomano%26aufirst%3DK.%2BP.%26aulast%3DAli%26aufirst%3DA.%26aulast%3DAydin%26aufirst%3DC.%26aulast%3DSoumana%26aufirst%3DD.%26aulast%3D%25C3%2596zen%26aufirst%3DA.%26aulast%3DDeveau%26aufirst%3DL.%2BM.%26aulast%3DSilver%26aufirst%3DC.%26aulast%3DCao%26aufirst%3DH.%26aulast%3DNewton%26aufirst%3DA.%26aulast%3DPetropoulos%26aufirst%3DC.%2BJ.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DSchiffer%26aufirst%3DC.%2BA.%26atitle%3DThe%2520molecular%2520basis%2520of%2520drug%2520resistance%2520against%2520hepatitis%2520C%2520virus%2520NS3%252F4A%2520protease%2520inhibitors%26jtitle%3DPLoS%2520Pathog.%26date%3D2012%26volume%3D8%26spage%3De1002832%26doi%3D10.1371%2Fjournal.ppat.1002832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Soumana, D. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiffer, C. A.</span><span> </span><span class="NLM_article-title">Structural analysis of asunaprevir resistance in HCV NS3/4A protease</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">2485</span><span class="NLM_x">–</span> <span class="NLM_lpage">2490</span><span class="refDoi"> DOI: 10.1021/cb5006118</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb5006118" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFygtb%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=2485-2490&author=D.+I.+Soumanaauthor=A.+Aliauthor=C.+A.+Schiffer&title=Structural+analysis+of+asunaprevir+resistance+in+HCV+NS3%2F4A+protease&doi=10.1021%2Fcb5006118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Analysis of Asunaprevir Resistance in HCV NS3/4A Protease</span></div><div class="casAuthors">Soumana, Djade I.; Ali, Akbar; Schiffer, Celia A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2485-2490</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Asunaprevir (ASV), an isoquinoline-based competitive inhibitor targeting the hepatitis C virus (HCV) NS3/4A protease, is very potent in vivo.  However, the potency is significantly compromised by the drug resistance mutations R155K and D168A.  In this study three crystal structures of ASV and an analog were detd. to analyze the structural basis of drug resistance susceptibility.  These structures revealed that ASV makes extensive contacts with Arg155 outside the substrate envelope.  Arg155 in turn is stabilized by Asp168, and thus when either residue is mutated, the enzyme's interaction with ASV's P2* isoquinoline is disrupted.  Adding a P1-P3 macrocycle to ASV enhances the inhibitor's resistance barrier, likely due to poising the inhibitor to its bound conformation.  Macrocyclic inhibitors with P2* extension moieties avoiding interaction with the protease S2 residues including Arg155 must be chosen for future design of more robust protease inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIGE9O_qeabbVg90H21EOLACvtfcHk0ljNfULuSKukZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFygtb%252FM&md5=ee215d143e48b8305d1272c4e9192def</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fcb5006118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb5006118%26sid%3Dliteratum%253Aachs%26aulast%3DSoumana%26aufirst%3DD.%2BI.%26aulast%3DAli%26aufirst%3DA.%26aulast%3DSchiffer%26aufirst%3DC.%2BA.%26atitle%3DStructural%2520analysis%2520of%2520asunaprevir%2520resistance%2520in%2520HCV%2520NS3%252F4A%2520protease%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D2485%26epage%3D2490%26doi%3D10.1021%2Fcb5006118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Soumana, D. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurt Yilmaz, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prachanronarong, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiffer, C. A.</span><span> </span><span class="NLM_article-title">Molecular and dynamic mechanism underlying drug resistance in genotype 3 hepatitis C NS3/4A protease</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">138</span><span class="NLM_x">, </span> <span class="NLM_fpage">11850</span><span class="NLM_x">–</span> <span class="NLM_lpage">11859</span><span class="refDoi"> DOI: 10.1021/jacs.6b06454</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.6b06454" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlamt7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2016&pages=11850-11859&author=D.+I.+Soumanaauthor=N.+Kurt+Yilmazauthor=A.+Aliauthor=K.+L.+Prachanronarongauthor=C.+A.+Schiffer&title=Molecular+and+dynamic+mechanism+underlying+drug+resistance+in+genotype+3+hepatitis+C+NS3%2F4A+protease&doi=10.1021%2Fjacs.6b06454"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular and Dynamic Mechanism Underlying Drug Resistance in Genotype 3 Hepatitis C NS3/4A Protease</span></div><div class="casAuthors">Soumana, Djade I.; Kurt Yilmaz, Nese; Ali, Akbar; Prachanronarong, Kristina L.; Schiffer, Celia A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">11850-11859</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV), affecting an estd. 150 million people worldwide, is the leading cause of viral hepatitis, cirrhosis and hepatocellular carcinoma.  HCV is genetically diverse with six genotypes (GTs) and multiple subtypes of different global distribution and prevalence.  Recent development of direct-acting antivirals against HCV including NS3/4A protease inhibitors (PIs) has greatly improved treatment outcomes for GT-1.  However, all current PIs exhibit significantly lower potency against GT-3.  Lack of structural data on GT-3 protease has limited the ability to understand PI failure in GT-3.  In this study the mol. basis for reduced potency of current inhibitors to GT-3 NS3/4A protease is elucidated with structure detn., mol. dynamics simulations and inhibition assays.  A chimeric GT-1a3a NS3/4A protease amenable to crystn. was engineered to fully recapitulate decreased sensitivity of GT-3 protease to PIs.  High-resoln. crystal structures of this GT-1a3a bound to 3 PIs, asunaprevir, danoprevir and vaniprevir, had only subtle differences relative to GT-1 despite orders of magnitude loss in affinity.  In contrast, hydrogen-bonding interactions within and with the protease active site, and dynamic fluctuations of the PIs were drastically altered.  The correlation between loss of intermol. dynamics and inhibitor potency suggest a drug resistance mechanism where polymorphisms (or mutations) at the drug target confer resistance through altering the intermol. dynamics of the protein-inhibitor complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_Ljasdqx_-7Vg90H21EOLACvtfcHk0ljNfULuSKukZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlamt7vE&md5=318231c49ad4eff7ec424112c1d56273</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjacs.6b06454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.6b06454%26sid%3Dliteratum%253Aachs%26aulast%3DSoumana%26aufirst%3DD.%2BI.%26aulast%3DKurt%2BYilmaz%26aufirst%3DN.%26aulast%3DAli%26aufirst%3DA.%26aulast%3DPrachanronarong%26aufirst%3DK.%2BL.%26aulast%3DSchiffer%26aufirst%3DC.%2BA.%26atitle%3DMolecular%2520and%2520dynamic%2520mechanism%2520underlying%2520drug%2520resistance%2520in%2520genotype%25203%2520hepatitis%2520C%2520NS3%252F4A%2520protease%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2016%26volume%3D138%26spage%3D11850%26epage%3D11859%26doi%3D10.1021%2Fjacs.6b06454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">O’Meara, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemke, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godbout, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukolj, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lagacé, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreau, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thibeault, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Llinàs-Brunet, M.</span><span> </span><span class="NLM_article-title">Molecular mechanism by which a potent hepatitis C virus NS3-NS4A protease inhibitor overcomes emergence of resistance</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">288</span><span class="NLM_x">, </span> <span class="NLM_fpage">5673</span><span class="NLM_x">–</span> <span class="NLM_lpage">5681</span><span class="refDoi"> DOI: 10.1074/jbc.M112.439455</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1074%2Fjbc.M112.439455" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=23271737" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtVGhu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=5673-5681&author=J.+A.+O%E2%80%99Mearaauthor=C.+T.+Lemkeauthor=C.+Godboutauthor=G.+Kukoljauthor=L.+Lagac%C3%A9author=B.+Moreauauthor=D.+Thibeaultauthor=P.+W.+Whiteauthor=M.+Llin%C3%A0s-Brunet&title=Molecular+mechanism+by+which+a+potent+hepatitis+C+virus+NS3-NS4A+protease+inhibitor+overcomes+emergence+of+resistance&doi=10.1074%2Fjbc.M112.439455"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Mechanism by Which a Potent Hepatitis C Virus NS3-NS4A Protease Inhibitor Overcomes Emergence of Resistance</span></div><div class="casAuthors">O'Meara, Jeff A.; Lemke, Christopher T.; Godbout, Cedrickx; Kukolj, George; Lagace, Lisette; Moreau, Benoit; Thibeault, Diane; White, Peter W.; Llinas-Brunet, Montse</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">5673-5681</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Although optimizing the resistance profile of an inhibitor can be challenging, it is potentially important for improving the long term effectiveness of antiviral therapy.  This work describes our rational approach toward the identification of a macrocyclic acylsulfonamide that is a potent inhibitor of the NS3-NS4A proteases of all hepatitis C virus genotypes and of a panel of genotype 1-resistant variants.  The enhanced potency of this compd. vs. variants D168V and R155K facilitated x-ray detn. of the inhibitor-variant complexes.  In turn, these structural studies revealed a complex mol. basis of resistance and rationalized how such compds. are able to circumvent these mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUYkmfd-pz4rVg90H21EOLACvtfcHk0lhhfl4xLbFcfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtVGhu7k%253D&md5=f595fad59b9278f76873eab3bd29897c</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M112.439455&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M112.439455%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Meara%26aufirst%3DJ.%2BA.%26aulast%3DLemke%26aufirst%3DC.%2BT.%26aulast%3DGodbout%26aufirst%3DC.%26aulast%3DKukolj%26aufirst%3DG.%26aulast%3DLagac%25C3%25A9%26aufirst%3DL.%26aulast%3DMoreau%26aufirst%3DB.%26aulast%3DThibeault%26aufirst%3DD.%26aulast%3DWhite%26aufirst%3DP.%2BW.%26aulast%3DLlin%25C3%25A0s-Brunet%26aufirst%3DM.%26atitle%3DMolecular%2520mechanism%2520by%2520which%2520a%2520potent%2520hepatitis%2520C%2520virus%2520NS3-NS4A%2520protease%2520inhibitor%2520overcomes%2520emergence%2520of%2520resistance%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26spage%3D5673%26epage%3D5681%26doi%3D10.1074%2Fjbc.M112.439455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Ali, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aydin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gildemeister, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romano, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Özen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soumana, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petropoulos, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiffer, C. A.</span><span> </span><span class="NLM_article-title">Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3/4A protease inhibitors to drug resistance</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1469</span><span class="NLM_x">–</span> <span class="NLM_lpage">1478</span><span class="refDoi"> DOI: 10.1021/cb400100g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb400100g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtVWksr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=1469-1478&author=A.+Aliauthor=C.+Aydinauthor=R.+Gildemeisterauthor=K.+P.+Romanoauthor=H.+Caoauthor=A.+%C3%96zenauthor=D.+Soumanaauthor=A.+Newtonauthor=C.+J.+Petropoulosauthor=W.+Huangauthor=C.+A.+Schiffer&title=Evaluating+the+role+of+macrocycles+in+the+susceptibility+of+hepatitis+C+virus+NS3%2F4A+protease+inhibitors+to+drug+resistance&doi=10.1021%2Fcb400100g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluating the Role of Macrocycles in the Susceptibility of Hepatitis C Virus NS3/4A Protease Inhibitors to Drug Resistance</span></div><div class="casAuthors">Ali, Akbar; Aydin, Cihan; Gildemeister, Reinhold; Romano, Keith P.; Cao, Hong; Ozen, Aysegul; Soumana, Djade; Newton, Alicia; Petropoulos, Christos J.; Huang, Wei; Schiffer, Celia A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1469-1478</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The hepatitis C virus (HCV) infects an estd. 150 million people worldwide and is the major cause of viral hepatitis, cirrhosis, and liver cancer.  The available antiviral therapies, which include PEGylated interferon, ribavirin, and one of the HCV NS3/4A protease inhibitors telaprevir or boceprevir, are ineffective for some patients and cause severe side effects.  More potent NS3/4A protease inhibitors are in clin. development, but the long-term effectiveness of these drugs is challenged by the development of drug resistance.  Here, the authors investigated the role of macrocycles in the susceptibility of NS3/4A protease inhibitors to drug resistance in asunaprevir, danoprevir, vaniprevir, and MK-5172, with similar core structures but varied P2 moieties and macrocyclizations.  Linear and macrocyclic analogs of these drugs were designed, synthesized, and tested against wild-type and drug-resistant variants R155K, V36M/R155K, A156T, and D168A in enzymic and antiviral assays.  Macrocyclic inhibitors were generally more potent, but the location of the macrocycle was crit. for retaining activity against drug-resistant variants: the P1-P3 macrocyclic inhibitors were less susceptible to drug resistance than the linear and P2-P4 macrocyclic analogs.  In addn., the heterocyclic moiety at P2 largely detd. the inhibitor resistance profile, susceptibility to drug resistance, and the extent of modulation by the helicase domain.  Our findings suggest that to design robust inhibitors that retain potency to drug-resistant NS3/4A protease variants, inhibitors should combine P1-P3 macrocycles with flexible P2 moieties that optimally contact with the invariable catalytic triad of this enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSMqHEQz0LDLVg90H21EOLACvtfcHk0lhhfl4xLbFcfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtVWksr0%253D&md5=141011162bbb591eb06990071fca3d84</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fcb400100g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb400100g%26sid%3Dliteratum%253Aachs%26aulast%3DAli%26aufirst%3DA.%26aulast%3DAydin%26aufirst%3DC.%26aulast%3DGildemeister%26aufirst%3DR.%26aulast%3DRomano%26aufirst%3DK.%2BP.%26aulast%3DCao%26aufirst%3DH.%26aulast%3D%25C3%2596zen%26aufirst%3DA.%26aulast%3DSoumana%26aufirst%3DD.%26aulast%3DNewton%26aufirst%3DA.%26aulast%3DPetropoulos%26aufirst%3DC.%2BJ.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DSchiffer%26aufirst%3DC.%2BA.%26atitle%3DEvaluating%2520the%2520role%2520of%2520macrocycles%2520in%2520the%2520susceptibility%2520of%2520hepatitis%2520C%2520virus%2520NS3%252F4A%2520protease%2520inhibitors%2520to%2520drug%2520resistance%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2013%26volume%3D8%26spage%3D1469%26epage%3D1478%26doi%3D10.1021%2Fcb400100g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Summa, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludmerer, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCauley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fandozzi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burlein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Claudio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMuzio, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Filippo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gates, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harper, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hazuda, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHale, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monteagudo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pucci, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudd, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soriano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahlhut, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vacca, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liverton, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, S. S.</span><span> </span><span class="NLM_article-title">MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">4161</span><span class="NLM_x">–</span> <span class="NLM_lpage">4167</span><span class="refDoi"> DOI: 10.1128/AAC.00324-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1128%2FAAC.00324-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=22615282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFajs7zF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=4161-4167&author=V.+Summaauthor=S.+W.+Ludmererauthor=J.+A.+McCauleyauthor=C.+Fandozziauthor=C.+Burleinauthor=G.+Claudioauthor=P.+J.+Colemanauthor=J.+M.+DiMuzioauthor=M.+Ferraraauthor=M.+Di+Filippoauthor=A.+T.+Gatesauthor=D.+J.+Grahamauthor=S.+Harperauthor=D.+J.+Hazudaauthor=C.+McHaleauthor=E.+Monteagudoauthor=V.+Pucciauthor=M.+Rowleyauthor=M.+T.+Ruddauthor=A.+Sorianoauthor=M.+W.+Stahlhutauthor=J.+P.+Vaccaauthor=D.+B.+Olsenauthor=N.+J.+Livertonauthor=S.+S.+Carroll&title=MK-5172%2C+a+selective+inhibitor+of+hepatitis+C+virus+NS3%2F4a+protease+with+broad+activity+across+genotypes+and+resistant+variants&doi=10.1128%2FAAC.00324-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants</span></div><div class="casAuthors">Summa, Vincenzo; Ludmerer, Steven W.; McCauley, John A.; Fandozzi, Christine; Burlein, Christine; Claudio, Giuliano; Coleman, Paul J.; DiMuzio, Jillian M.; Ferrara, Marco; Di Filippo, Marcello; Gates, Adam T.; Graham, Donald J.; Harper, Steven; Hazuda, Daria J.; McHale, Carolyn; Monteagudo, Edith; Pucci, Vincenzo; Rowley, Michael; Rudd, Michael T.; Soriano, Aileen; Stahlhut, Mark W.; Vacca, Joseph P.; Olsen, David B.; Liverton, Nigel J.; Carroll, Steven S.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4161-4167</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">HCV NS3/4a protease inhibitors are proven therapeutic agents against chronic hepatitis C virus infection, with boceprevir and telaprevir having recently received regulatory approval as add-on therapy to pegylated interferon/ribavirin for patients harboring genotype 1 infections.  Overcoming antiviral resistance, broad genotype coverage, and a convenient dosing regimen are important attributes for future agents to be used in combinations without interferon.  In this communication, we report the preclin. profile of MK-5172, a novel P2-P4 quinoxaline macrocyclic NS3/4a protease inhibitor currently in clin. development.  The compd. demonstrates subnanomolar activity against a broad enzyme panel encompassing major hepatitis C virus (HCV) genotypes as well as variants resistant to earlier protease inhibitors.  In replicon selections, MK-5172 exerted high selective pressure, which yielded few resistant colonies.  In both rat and dog, MK-5172 demonstrates good plasma and liver exposures, with 24-h liver levels suggestive of once-daily dosing.  When administered to HCV-infected chimpanzees harboring chronic gt1a or gt1b infections, MK-5172 suppressed viral load between 4 to 5 logs at a dose of 1 mg/kg of body wt. twice daily (b.i.d.) for 7 days.  Based on its preclin. profile, MK-5172 is anticipated to be broadly active against multiple HCV genotypes and clin. important resistance variants and highly suited for incorporation into newer all-oral regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomXxLJMTmWqrVg90H21EOLACvtfcHk0lhv416EZLMqoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFajs7zF&md5=8874f9279917137113e429cda31c1bba</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1128%2FAAC.00324-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00324-12%26sid%3Dliteratum%253Aachs%26aulast%3DSumma%26aufirst%3DV.%26aulast%3DLudmerer%26aufirst%3DS.%2BW.%26aulast%3DMcCauley%26aufirst%3DJ.%2BA.%26aulast%3DFandozzi%26aufirst%3DC.%26aulast%3DBurlein%26aufirst%3DC.%26aulast%3DClaudio%26aufirst%3DG.%26aulast%3DColeman%26aufirst%3DP.%2BJ.%26aulast%3DDiMuzio%26aufirst%3DJ.%2BM.%26aulast%3DFerrara%26aufirst%3DM.%26aulast%3DDi%2BFilippo%26aufirst%3DM.%26aulast%3DGates%26aufirst%3DA.%2BT.%26aulast%3DGraham%26aufirst%3DD.%2BJ.%26aulast%3DHarper%26aufirst%3DS.%26aulast%3DHazuda%26aufirst%3DD.%2BJ.%26aulast%3DMcHale%26aufirst%3DC.%26aulast%3DMonteagudo%26aufirst%3DE.%26aulast%3DPucci%26aufirst%3DV.%26aulast%3DRowley%26aufirst%3DM.%26aulast%3DRudd%26aufirst%3DM.%2BT.%26aulast%3DSoriano%26aufirst%3DA.%26aulast%3DStahlhut%26aufirst%3DM.%2BW.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26aulast%3DOlsen%26aufirst%3DD.%2BB.%26aulast%3DLiverton%26aufirst%3DN.%2BJ.%26aulast%3DCarroll%26aufirst%3DS.%2BS.%26atitle%3DMK-5172%252C%2520a%2520selective%2520inhibitor%2520of%2520hepatitis%2520C%2520virus%2520NS3%252F4a%2520protease%2520with%2520broad%2520activity%2520across%2520genotypes%2520and%2520resistant%2520variants%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D4161%26epage%3D4167%26doi%3D10.1128%2FAAC.00324-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Soumana, D. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurt Yilmaz, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prachanronarong, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aydin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiffer, C. A.</span><span> </span><span class="NLM_article-title">Structural and thermodynamic effects of macrocyclization in HCV NS3/4A inhibitor MK-5172</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">900</span><span class="NLM_x">–</span> <span class="NLM_lpage">909</span><span class="refDoi"> DOI: 10.1021/acschembio.5b00647</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.5b00647" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVGitb3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=900-909&author=D.+I.+Soumanaauthor=N.+Kurt+Yilmazauthor=K.+L.+Prachanronarongauthor=C.+Aydinauthor=A.+Aliauthor=C.+A.+Schiffer&title=Structural+and+thermodynamic+effects+of+macrocyclization+in+HCV+NS3%2F4A+inhibitor+MK-5172&doi=10.1021%2Facschembio.5b00647"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Thermodynamic Effects of Macrocyclization in HCV NS3/4A Inhibitor MK-5172</span></div><div class="casAuthors">Soumana, Djade I.; Kurt Yilmaz, Nese; Prachanronarong, Kristina L.; Aydin, Cihan; Ali, Akbar; Schiffer, Celia A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">900-909</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Recent advances in direct-acting antivirals against Hepatitis C Virus (HCV) have led to the development of potent inhibitors, including MK-5172, that target the viral NS3/4A protease with relatively low susceptibility to resistance.  MK-5172 has a P2-P4 macrocycle and a unique binding mode among current protease inhibitors where the P2 quinoxaline packs against the catalytic residues H57 and D81.  However, the effect of macrocyclization on this binding mode is not clear, as is the relation between macrocyclization, thermodn. stabilization, and susceptibility to the resistance mutation A156T.  We have detd. high-resoln. crystal structures of linear and P1-P3 macrocyclic analogs of MK-5172 bound to WT and A156T protease and compared these structures, their mol. dynamics, and exptl. binding thermodn. to the parent compd.  We find that the "unique" binding mode of MK-5172 is conserved even when the P2-P4 macrocycle is removed or replaced with a P1-P3 macrocycle.  While beneficial to decreasing the entropic penalty assocd. with binding, the constraint exerted by the P2-P4 macrocycle prevents efficient rearrangement to accommodate the A156T mutation, a deficit alleviated in the linear and P1-P3 analogs.  Design of macrocyclic inhibitors against NS3/4A needs to achieve the best balance between exerting optimal conformational constraint for enhancing potency, fitting within the substrate envelope and allowing adaptability to be robust against resistance mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVaszg0NfWS7Vg90H21EOLACvtfcHk0lhv416EZLMqoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVGitb3F&md5=4f3cadfdedbb5af22d0ef55c088d3687</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Facschembio.5b00647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.5b00647%26sid%3Dliteratum%253Aachs%26aulast%3DSoumana%26aufirst%3DD.%2BI.%26aulast%3DKurt%2BYilmaz%26aufirst%3DN.%26aulast%3DPrachanronarong%26aufirst%3DK.%2BL.%26aulast%3DAydin%26aufirst%3DC.%26aulast%3DAli%26aufirst%3DA.%26aulast%3DSchiffer%26aufirst%3DC.%2BA.%26atitle%3DStructural%2520and%2520thermodynamic%2520effects%2520of%2520macrocyclization%2520in%2520HCV%2520NS3%252F4A%2520inhibitor%2520MK-5172%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2016%26volume%3D11%26spage%3D900%26epage%3D909%26doi%3D10.1021%2Facschembio.5b00647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">King, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prabu-Jeyabalan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nalivaika, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiffer, C. A.</span><span> </span><span class="NLM_article-title">Combating susceptibility to drug resistance: lessons from HIV-1 protease</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1333</span><span class="NLM_x">–</span> <span class="NLM_lpage">1338</span><span class="refDoi"> DOI: 10.1016/j.chembiol.2004.08.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1016%2Fj.chembiol.2004.08.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=15489160" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BD2cXos1Ciu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2004&pages=1333-1338&author=N.+M.+Kingauthor=M.+Prabu-Jeyabalanauthor=E.+A.+Nalivaikaauthor=C.+A.+Schiffer&title=Combating+susceptibility+to+drug+resistance%3A+lessons+from+HIV-1+protease&doi=10.1016%2Fj.chembiol.2004.08.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Combating Susceptibility to Drug Resistance Lessons from HIV-1 Protease</span></div><div class="casAuthors">King, Nancy M.; Prabu-Jeyabalan, Moses; Nalivaika, Ellen A.; Schiffer, Celia A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1333-1338</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Drug resistance is a major obstacle in modern medicine.  However, resistance is rarely considered in drug development and may inadvertently be facilitated, as many designed inhibitors contact residues that can mutate to confer resistance, without significantly impairing function.  Contemporary drug design often ignores the detailed at. basis for function and primarily focuses on disrupting the target's activity, which is necessary but not sufficient for developing a robust drug.  In this study, we examine the impact of drug-resistant mutations in HIV-1 protease on substrate recognition and demonstrate that most primary active site mutations do not extensively contact substrates, but are crit. to inhibitor binding.  We propose a general, structure-based strategy to reduce the probability of drug resistance by designing inhibitors that interact only with those residues that are essential for function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbsk2AyTcCmbVg90H21EOLACvtfcHk0lgB-h7723dcMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXos1Ciu78%253D&md5=701599b15cf9ecc2c026ad4eac650a90</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2004.08.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2004.08.010%26sid%3Dliteratum%253Aachs%26aulast%3DKing%26aufirst%3DN.%2BM.%26aulast%3DPrabu-Jeyabalan%26aufirst%3DM.%26aulast%3DNalivaika%26aufirst%3DE.%2BA.%26aulast%3DSchiffer%26aufirst%3DC.%2BA.%26atitle%3DCombating%2520susceptibility%2520to%2520drug%2520resistance%253A%2520lessons%2520from%2520HIV-1%2520protease%26jtitle%3DChem.%2520Biol.%26date%3D2004%26volume%3D11%26spage%3D1333%26epage%3D1338%26doi%3D10.1016%2Fj.chembiol.2004.08.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Özen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherman, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiffer, C. A.</span><span> </span><span class="NLM_article-title">Improving the resistance profile of hepatitis C NS3/4A inhibitors: dynamic substrate envelope guided design</span> <span class="citation_source-journal">J. Chem. Theory Comput.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">5693</span><span class="NLM_x">–</span> <span class="NLM_lpage">5705</span><span class="refDoi"> DOI: 10.1021/ct400603p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ct400603p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1amt7%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=5693-5705&author=A.+%C3%96zenauthor=W.+Shermanauthor=C.+A.+Schiffer&title=Improving+the+resistance+profile+of+hepatitis+C+NS3%2F4A+inhibitors%3A+dynamic+substrate+envelope+guided+design&doi=10.1021%2Fct400603p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Improving the Resistance Profile of Hepatitis C NS3/4A Inhibitors: Dynamic Substrate Envelope Guided Design</span></div><div class="casAuthors">Ozen, Aysegul; Sherman, Woody; Schiffer, Celia A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Theory and Computation</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5693-5705</span>CODEN:
                <span class="NLM_cas:coden">JCTCCE</span>;
        ISSN:<span class="NLM_cas:issn">1549-9618</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Drug resistance is a principal concern in the treatment of quickly evolving diseases.  The viral protease NS3/4A is a primary drug target for the hepatitis C virus (HCV) and is known to evolve resistance mutations in response to drug therapy.  At the mol. level, drug resistance reflects a subtle change in the balance of mol. recognition by NS3/4A; the drug resistant protease variants are no longer effectively inhibited by the competitive active site inhibitors but can still process the natural substrates with enough efficiency for viral survival.  In previous works, the authors have developed the "substrate envelope" hypothesis, which posits that inhibitors should be less susceptible to drug resistance if they better mimic the natural substrate mol. recognition features.  The authors perform mol. dynamics simulations on four native substrates bound to NS3/4A and discover a clearly conserved dynamic substrate envelope.  The authors show that the most severe drug resistance mutations in NS3/4A occur at residues that are outside the substrate envelope.  Comparative anal. of three NS3/4A inhibitors reveals structural and dynamic characteristics of inhibitors that could lead to resistance.  The authors also suggest inhibitor modifications to improve resistance profiles based on the dynamic substrate envelope.  This study provides a general framework for guiding the development of novel inhibitors that will be more robust against resistance by mimicking the static and dynamic binding characteristics of natural substrates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk2uHtoexId7Vg90H21EOLACvtfcHk0lgB-h7723dcMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1amt7%252FF&md5=91c75667e5fc91c1c07d59c71e995283</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fct400603p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fct400603p%26sid%3Dliteratum%253Aachs%26aulast%3D%25C3%2596zen%26aufirst%3DA.%26aulast%3DSherman%26aufirst%3DW.%26aulast%3DSchiffer%26aufirst%3DC.%2BA.%26atitle%3DImproving%2520the%2520resistance%2520profile%2520of%2520hepatitis%2520C%2520NS3%252F4A%2520inhibitors%253A%2520dynamic%2520substrate%2520envelope%2520guided%2520design%26jtitle%3DJ.%2520Chem.%2520Theory%2520Comput.%26date%3D2013%26volume%3D9%26spage%3D5693%26epage%3D5705%26doi%3D10.1021%2Fct400603p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Kurt Yilmaz, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swanstrom, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiffer, C. A.</span><span> </span><span class="NLM_article-title">Improving viral protease inhibitors to counter drug resistance</span> <span class="citation_source-journal">Trends Microbiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">547</span><span class="NLM_x">–</span> <span class="NLM_lpage">557</span><span class="refDoi"> DOI: 10.1016/j.tim.2016.03.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1016%2Fj.tim.2016.03.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=27090931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC28XlslCjtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=547-557&author=N.+Kurt+Yilmazauthor=R.+Swanstromauthor=C.+A.+Schiffer&title=Improving+viral+protease+inhibitors+to+counter+drug+resistance&doi=10.1016%2Fj.tim.2016.03.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Improving Viral Protease Inhibitors to Counter Drug Resistance</span></div><div class="casAuthors">Kurt Yilmaz, Nese; Swanstrom, Ronald; Schiffer, Celia A.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Microbiology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">547-557</span>CODEN:
                <span class="NLM_cas:coden">TRMIEA</span>;
        ISSN:<span class="NLM_cas:issn">0966-842X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Drug resistance is a major problem in health care, undermining therapy outcomes and necessitating novel approaches to drug design.  Extensive studies on resistance to viral protease inhibitors, particularly those of HIV-1 and hepatitis C virus (HCV) protease, revealed a plethora of information on the structural and mol. mechanisms underlying resistance.  These insights led to several strategies to improve viral protease inhibitors to counter resistance, such as exploiting the essential biol. function and leveraging evolutionary constraints.  Incorporation of these strategies into structure-based drug design can minimize vulnerability to resistance, not only for viral proteases but for other quickly evolving drug targets as well, toward designing inhibitors one step ahead of evolution to counter resistance with more intelligent and rational design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrl6bKzn4Yf4rVg90H21EOLACvtfcHk0lgqd7BwiYB3RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlslCjtL4%253D&md5=a14170ffc3d71a9770e3d1f7a3146d6c</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.tim.2016.03.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tim.2016.03.010%26sid%3Dliteratum%253Aachs%26aulast%3DKurt%2BYilmaz%26aufirst%3DN.%26aulast%3DSwanstrom%26aufirst%3DR.%26aulast%3DSchiffer%26aufirst%3DC.%2BA.%26atitle%3DImproving%2520viral%2520protease%2520inhibitors%2520to%2520counter%2520drug%2520resistance%26jtitle%3DTrends%2520Microbiol.%26date%3D2016%26volume%3D24%26spage%3D547%26epage%3D557%26doi%3D10.1016%2Fj.tim.2016.03.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Wang, X. A.; Sun, L.-Q.; Sit, S.-Y.; Sin, N.; Scola, P. M.; Hewawasam, P.; Good, A. C.; Chen, Y.; Campbell, J. A.</span><span> </span><span class="NLM_article-title">Hepatitis C Virus Inhibitors</span>. US Patent 6995174,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=X.+A.+Wang&author=L.-Q.+Sun&author=S.-Y.+Sit&author=N.+Sin&author=P.+M.+Scola&author=P.+Hewawasam&author=A.+C.+Good&author=Y.+Chen&author=J.+A.+Campbell&title=Hepatitis+C+Virus+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%2BA.%26atitle%3DHepatitis%2520C%2520Virus%2520Inhibitors%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Rudd, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butcher, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romano, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bush, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liverton, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holloway, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harper, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiFilippo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Summa, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swestock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritzen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burlein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMuzio, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gates, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McClain, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHale, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahlhut, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chase, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soriano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fandozzi, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trainor, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludmerer, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCauley, J. A.</span><span> </span><span class="NLM_article-title">P2-quinazolinones and bis-macrocycles as new templates for next-generation hepatitis C virus NS3/4a protease inhibitors: discovery of MK-2748 and MK-6325</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">727</span><span class="NLM_x">–</span> <span class="NLM_lpage">735</span><span class="refDoi"> DOI: 10.1002/cmdc.201402558</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1002%2Fcmdc.201402558" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=25759009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvVShurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=727-735&author=M.+T.+Ruddauthor=J.+W.+Butcherauthor=K.+T.+Nguyenauthor=C.+J.+McIntyreauthor=J.+J.+Romanoauthor=K.+F.+Gilbertauthor=K.+J.+Bushauthor=N.+J.+Livertonauthor=M.+K.+Hollowayauthor=S.+Harperauthor=M.+Ferraraauthor=M.+DiFilippoauthor=V.+Summaauthor=J.+Swestockauthor=J.+Fritzenauthor=S.+S.+Carrollauthor=C.+Burleinauthor=J.+M.+DiMuzioauthor=A.+Gatesauthor=D.+J.+Grahamauthor=Q.+Huangauthor=S.+McClainauthor=C.+McHaleauthor=M.+W.+Stahlhutauthor=S.+Blackauthor=R.+Chaseauthor=A.+Sorianoauthor=C.+M.+Fandozziauthor=A.+Taylorauthor=N.+Trainorauthor=D.+B.+Olsenauthor=P.+J.+Colemanauthor=S.+W.+Ludmererauthor=J.+A.+McCauley&title=P2-quinazolinones+and+bis-macrocycles+as+new+templates+for+next-generation+hepatitis+C+virus+NS3%2F4a+protease+inhibitors%3A+discovery+of+MK-2748+and+MK-6325&doi=10.1002%2Fcmdc.201402558"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">P2-Quinazolinones and Bis-Macrocycles as New Templates for Next-Generation Hepatitis C Virus NS3/4a Protease Inhibitors: Discovery of MK-2748 and MK-6325</span></div><div class="casAuthors">Rudd, Michael T.; Butcher, John W.; Nguyen, Kevin T.; McIntyre, Charles J.; Romano, Joseph J.; Gilbert, Kevin F.; Bush, Kimberly J.; Liverton, Nigel J.; Holloway, M. Katharine; Harper, Steven; Ferrara, Marco; DiFilippo, Marcello; Summa, Vincenzo; Swestock, John; Fritzen, Jeff; Carroll, Steven S.; Burlein, Christine; DiMuzio, Jillian M.; Gates, Adam; Graham, Donald J.; Huang, Qian; McClain, Stephanie; McHale, Carolyn; Stahlhut, Mark W.; Black, Stuart; Chase, Robert; Soriano, Aileen; Fandozzi, Christine M.; Taylor, Anne; Trainor, Nicole; Olsen, David B.; Coleman, Paul J.; Ludmerer, Steven W.; McCauley, John A.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">727-735</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">With the goal of identifying inhibitors of hepatitis C virus (HCV) NS3/4a protease that are potent against a wide range of genotypes and clin. relevant mutant viruses, several subseries of macrocycles were investigated based on observations made during the discovery of MK-5172.  Quinazolinone-contg. macrocycles were identified as promising leads, and optimization for superior cross-genotype and mutant enzyme potency as well as rat liver and plasma concns. following oral dosing, led to the development of MK-2748 I.  Addnl. investigation of a series of bis-macrocycles contg. a fused 18- and 15-membered ring system were also optimized for the same properties, leading to the discovery of MK-6325 II.  Both compds. display the broad genotype and mutant potency necessary for clin. development as next-generation HCV NS3/4a protease inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4cK2wuPGi1rVg90H21EOLACvtfcHk0lgqd7BwiYB3RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvVShurc%253D&md5=65834635e5b209b0674ec60fe905e2a9</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201402558&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201402558%26sid%3Dliteratum%253Aachs%26aulast%3DRudd%26aufirst%3DM.%2BT.%26aulast%3DButcher%26aufirst%3DJ.%2BW.%26aulast%3DNguyen%26aufirst%3DK.%2BT.%26aulast%3DMcIntyre%26aufirst%3DC.%2BJ.%26aulast%3DRomano%26aufirst%3DJ.%2BJ.%26aulast%3DGilbert%26aufirst%3DK.%2BF.%26aulast%3DBush%26aufirst%3DK.%2BJ.%26aulast%3DLiverton%26aufirst%3DN.%2BJ.%26aulast%3DHolloway%26aufirst%3DM.%2BK.%26aulast%3DHarper%26aufirst%3DS.%26aulast%3DFerrara%26aufirst%3DM.%26aulast%3DDiFilippo%26aufirst%3DM.%26aulast%3DSumma%26aufirst%3DV.%26aulast%3DSwestock%26aufirst%3DJ.%26aulast%3DFritzen%26aufirst%3DJ.%26aulast%3DCarroll%26aufirst%3DS.%2BS.%26aulast%3DBurlein%26aufirst%3DC.%26aulast%3DDiMuzio%26aufirst%3DJ.%2BM.%26aulast%3DGates%26aufirst%3DA.%26aulast%3DGraham%26aufirst%3DD.%2BJ.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DMcClain%26aufirst%3DS.%26aulast%3DMcHale%26aufirst%3DC.%26aulast%3DStahlhut%26aufirst%3DM.%2BW.%26aulast%3DBlack%26aufirst%3DS.%26aulast%3DChase%26aufirst%3DR.%26aulast%3DSoriano%26aufirst%3DA.%26aulast%3DFandozzi%26aufirst%3DC.%2BM.%26aulast%3DTaylor%26aufirst%3DA.%26aulast%3DTrainor%26aufirst%3DN.%26aulast%3DOlsen%26aufirst%3DD.%2BB.%26aulast%3DColeman%26aufirst%3DP.%2BJ.%26aulast%3DLudmerer%26aufirst%3DS.%2BW.%26aulast%3DMcCauley%26aufirst%3DJ.%2BA.%26atitle%3DP2-quinazolinones%2520and%2520bis-macrocycles%2520as%2520new%2520templates%2520for%2520next-generation%2520hepatitis%2520C%2520virus%2520NS3%252F4a%2520protease%2520inhibitors%253A%2520discovery%2520of%2520MK-2748%2520and%2520MK-6325%26jtitle%3DChemMedChem%26date%3D2015%26volume%3D10%26spage%3D727%26epage%3D735%26doi%3D10.1002%2Fcmdc.201402558" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Vendeville, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilsson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Kock, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, T. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antonov, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Classon, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayesa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ivanov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johansson, P. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahnberg, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eneroth, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wikstrom, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vrang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edlund, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindstrom, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van de Vreken, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGowan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tahri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenz, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delouvroy, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Dooren, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kindermans, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Surleraux, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wigerinck, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenquist, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samuelsson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raboisson, P.</span><span> </span><span class="NLM_article-title">Discovery of novel, potent and bioavailable proline-urea based macrocyclic HCV NS3/4A protease inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">6189</span><span class="NLM_x">–</span> <span class="NLM_lpage">6193</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2008.10.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1016%2Fj.bmcl.2008.10.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=18954982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlOhtr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=6189-6193&author=S.+Vendevilleauthor=M.+Nilssonauthor=H.+de+Kockauthor=T.+I.+Linauthor=D.+Antonovauthor=B.+Classonauthor=S.+Ayesaauthor=V.+Ivanovauthor=P.+O.+Johanssonauthor=P.+Kahnbergauthor=A.+Enerothauthor=K.+Wikstromauthor=L.+Vrangauthor=M.+Edlundauthor=S.+Lindstromauthor=W.+Van+de+Vrekenauthor=D.+McGowanauthor=A.+Tahriauthor=L.+Huauthor=O.+Lenzauthor=F.+Delouvroyauthor=M.+Van+Doorenauthor=N.+Kindermansauthor=D.+Surlerauxauthor=P.+Wigerinckauthor=A.+Rosenquistauthor=B.+Samuelssonauthor=K.+Simmenauthor=P.+Raboisson&title=Discovery+of+novel%2C+potent+and+bioavailable+proline-urea+based+macrocyclic+HCV+NS3%2F4A+protease+inhibitors&doi=10.1016%2Fj.bmcl.2008.10.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel, potent and bioavailable proline-urea based macrocyclic HCV NS3/4A protease inhibitors</span></div><div class="casAuthors">Vendeville, Sandrine; Nilsson, Magnus; de Kock, Herman; Lin, Tse-I.; Antonov, Dmitry; Classon, Bjorn; Ayesa, Susana; Ivanov, Vladimir; Johansson, Per-Ola; Kahnberg, Pia; Eneroth, Anders; Wikstrom, Kristina; Vrang, Lotta; Edlund, Michael; Lindstrom, Stefan; Van de Vreken, Wim; McGowan, David; Tahri, Abdellah; Hu, Lili; Lenz, Oliver; Delouvroy, Frederic; Van Dooren, Marleen; Kindermans, Natalie; Surleraux, Dominique; Wigerinck, Piet; Rosenquist, Asa; Samuelsson, Bertil; Simmen, Kenneth; Raboisson, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6189-6193</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A novel series of P3-truncated macrocyclic HCV NS3/4A protease inhibitors contg. a P2 proline-urea or carbamate scaffold was synthesized.  Very potent inhibitors were obtained through the optimization of the macrocycle size, urea and proline substitution, and bioisosteric replacement of the P1 carboxylic acid moiety.  Variation of the lipophilicity by introduction of small lipophilic substituents resulted in improved PK profiles, ultimately leading to an extremely potent compd. (K i = 0.1 nM, EC50 = 4.5 nM) and selective (CC50 (Huh-7 cells) > 50 μM) inhibitor, displaying an excellent PK profile in rats characterized by an oral bioavailability of 54% and a high liver exposure after oral administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrHVnDgsM9Q7Vg90H21EOLACvtfcHk0ljQIgNuDnB0jQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlOhtr7E&md5=320cbbf4d9afdd7bdce3584326e15914</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.10.004%26sid%3Dliteratum%253Aachs%26aulast%3DVendeville%26aufirst%3DS.%26aulast%3DNilsson%26aufirst%3DM.%26aulast%3Dde%2BKock%26aufirst%3DH.%26aulast%3DLin%26aufirst%3DT.%2BI.%26aulast%3DAntonov%26aufirst%3DD.%26aulast%3DClasson%26aufirst%3DB.%26aulast%3DAyesa%26aufirst%3DS.%26aulast%3DIvanov%26aufirst%3DV.%26aulast%3DJohansson%26aufirst%3DP.%2BO.%26aulast%3DKahnberg%26aufirst%3DP.%26aulast%3DEneroth%26aufirst%3DA.%26aulast%3DWikstrom%26aufirst%3DK.%26aulast%3DVrang%26aufirst%3DL.%26aulast%3DEdlund%26aufirst%3DM.%26aulast%3DLindstrom%26aufirst%3DS.%26aulast%3DVan%2Bde%2BVreken%26aufirst%3DW.%26aulast%3DMcGowan%26aufirst%3DD.%26aulast%3DTahri%26aufirst%3DA.%26aulast%3DHu%26aufirst%3DL.%26aulast%3DLenz%26aufirst%3DO.%26aulast%3DDelouvroy%26aufirst%3DF.%26aulast%3DVan%2BDooren%26aufirst%3DM.%26aulast%3DKindermans%26aufirst%3DN.%26aulast%3DSurleraux%26aufirst%3DD.%26aulast%3DWigerinck%26aufirst%3DP.%26aulast%3DRosenquist%26aufirst%3DA.%26aulast%3DSamuelsson%26aufirst%3DB.%26aulast%3DSimmen%26aufirst%3DK.%26aulast%3DRaboisson%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520novel%252C%2520potent%2520and%2520bioavailable%2520proline-urea%2520based%2520macrocyclic%2520HCV%2520NS3%252F4A%2520protease%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D6189%26epage%3D6193%26doi%3D10.1016%2Fj.bmcl.2008.10.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Moreau, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Meara, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bordeleau, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garneau, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godbout, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorys, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leblanc, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villemure, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Llinàs-Brunet, M.</span><span> </span><span class="NLM_article-title">Discovery of hepatitis C virus NS3–4A protease inhibitors with improved barrier to resistance and favorable liver distribution</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1770</span><span class="NLM_x">–</span> <span class="NLM_lpage">1776</span><span class="refDoi"> DOI: 10.1021/jm400121t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400121t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktFKns7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1770-1776&author=B.+Moreauauthor=J.+A.+O%E2%80%99Mearaauthor=J.+Bordeleauauthor=M.+Garneauauthor=C.+Godboutauthor=V.+Gorysauthor=M.+Leblancauthor=E.+Villemureauthor=P.+W.+Whiteauthor=M.+Llin%C3%A0s-Brunet&title=Discovery+of+hepatitis+C+virus+NS3%E2%80%934A+protease+inhibitors+with+improved+barrier+to+resistance+and+favorable+liver+distribution&doi=10.1021%2Fjm400121t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Hepatitis C Virus NS3-4A Protease Inhibitors with Improved Barrier to Resistance and Favorable Liver Distribution</span></div><div class="casAuthors">Moreau, Benoit; O'Meara, Jeff A.; Bordeleau, Josee; Garneau, Michel; Godbout, Cedrickx; Gorys, Vida; Leblanc, Melissa; Villemure, Elisia; White, Peter W.; Llinas-Brunet, Montse</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1770-1776</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Given the emergence of resistance obsd. for the current clin.-stage hepatitis C virus (HCV) NS3 protease inhibitors, there is a need for new inhibitors with a higher barrier to resistance.  We recently reported our rational approach to the discovery of macrocyclic acylsulfonamides as HCV protease inhibitors addressing potency against clin. relevant resistant variants.  Using X-ray crystallog. of HCV protease variant/inhibitor complexes, we shed light on the complex structural mechanisms by which the D168V and R155K residue mutations confer resistance to NS3 protease inhibitors.  Here, we disclose SAR investigation and ADME/PK optimization leading to the identification of inhibitors with significantly improved potency against the key resistant variants and with increased liver partitioning.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3kmCmZS4AGbVg90H21EOLACvtfcHk0lhTjtFZCYq03w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktFKns7g%253D&md5=2b059cd96fad0a9dbc575c1005876146</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fjm400121t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400121t%26sid%3Dliteratum%253Aachs%26aulast%3DMoreau%26aufirst%3DB.%26aulast%3DO%25E2%2580%2599Meara%26aufirst%3DJ.%2BA.%26aulast%3DBordeleau%26aufirst%3DJ.%26aulast%3DGarneau%26aufirst%3DM.%26aulast%3DGodbout%26aufirst%3DC.%26aulast%3DGorys%26aufirst%3DV.%26aulast%3DLeblanc%26aufirst%3DM.%26aulast%3DVillemure%26aufirst%3DE.%26aulast%3DWhite%26aufirst%3DP.%2BW.%26aulast%3DLlin%25C3%25A0s-Brunet%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520hepatitis%2520C%2520virus%2520NS3%25E2%2580%25934A%2520protease%2520inhibitors%2520with%2520improved%2520barrier%2520to%2520resistance%2520and%2520favorable%2520liver%2520distribution%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1770%26epage%3D1776%26doi%3D10.1021%2Fjm400121t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Gillis, E. P.; Bowsher, M. S.; McPhee, F.; Jenkins, S.; Wang, Y.-K.; Scola, P. M.; Meanwell, N. A.</span><span> </span><span class="NLM_article-title">2nd Generation HCV Protease Inhibitors: Part 2, Optimization of P2*</span>. In 250th ACS National Meeting & Exposition, Boston, MA, United States, August 16–20, 2015; <span class="NLM_publisher-name">American Chemical Society</span>: <span class="NLM_publisher-loc">Washington, DC</span>,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span> <span class="NLM_fpage">MEDI-240</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&pages=MEDI-240&author=E.+P.+Gillis&author=M.+S.+Bowsher&author=F.+McPhee&author=S.+Jenkins&author=Y.-K.+Wang&author=P.+M.+Scola&author=N.+A.+Meanwell&title=2nd+Generation+HCV+Protease+Inhibitors%3A+Part+2%2C+Optimization+of+P2*"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DGillis%26aufirst%3DE.%2BP.%26atitle%3D2nd%2520Generation%2520HCV%2520Protease%2520Inhibitors%253A%2520Part%25202%252C%2520Optimization%2520of%2520P2%252A%26jtitle%3D250th%2520ACS%2520National%2520Meeting%2520%2526%2520Exposition%252C%2520Boston%252C%2520MA%252C%2520United%2520States%252C%2520August%252016%25E2%2580%259320%252C%25202015%26pub%3DAmerican%2520Chemical%2520Society%26date%3D2015%26spage%3DMEDI-240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Meanwell, N. A.</span><span> </span><span class="NLM_article-title">Synopsis of some recent tactical application of bioisosteres in drug design</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">2529</span><span class="NLM_x">–</span> <span class="NLM_lpage">2591</span><span class="refDoi"> DOI: 10.1021/jm1013693</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1013693" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsVCnu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2529-2591&author=N.+A.+Meanwell&title=Synopsis+of+some+recent+tactical+application+of+bioisosteres+in+drug+design&doi=10.1021%2Fjm1013693"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design</span></div><div class="casAuthors">Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2529-2591</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The established utility of bioisosteres is broad in nature, extending to improving potency, enhancing selectivity, altering phys. properties, reducing or redirecting metab., eliminating or modifying toxicophores, and acquiring novel intellectual property.  In this Perspective, some contemporary themes exploring the role of isosteres in drug design are sampled, with an emphasis placed on tactical applications designed to solve the kinds of problems that impinge on compd. optimization and the long-term success of drug candidates.  Interesting concepts that may have been poorly effective in the context examd. are captured, since the ideas may have merit in alternative circumstances.  A comprehensive cataloging of bioisosteres is beyond the scope of what will be provided, although a synopsis of relevant isosteres of a particular functionality is summarized in a succinct fashion in several sections.  Isosterism has also found productive application in the design and optimization of organocatalysts, and there are several examples in which functional mimicry established initially in a medicinal chem. setting has been adopted by this community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ9z_aPcU4ubVg90H21EOLACvtfcHk0lhTjtFZCYq03w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsVCnu7o%253D&md5=0637ab60c379bef535f3f709b26f3582</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fjm1013693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1013693%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DSynopsis%2520of%2520some%2520recent%2520tactical%2520application%2520of%2520bioisosteres%2520in%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2529%26epage%3D2591%26doi%3D10.1021%2Fjm1013693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Or, Y. S.; Moore, J. D.; Liu, D.; Sun, Y.; Gai, Y.; Tang, D.; Niu, D.; Xu, G.; Wang, Z.</span><span> </span><span class="NLM_article-title">Quinoxalinyl Macrocyclic Hepatitis C Virus Serine Protease Inhibitors</span>. PCT Int. Appl. WO 2008/002924, January 03,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=Y.+S.+Or&author=J.+D.+Moore&author=D.+Liu&author=Y.+Sun&author=Y.+Gai&author=D.+Tang&author=D.+Niu&author=G.+Xu&author=Z.+Wang&title=Quinoxalinyl+Macrocyclic+Hepatitis+C+Virus+Serine+Protease+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DOr%26aufirst%3DY.%2BS.%26atitle%3DQuinoxalinyl%2520Macrocyclic%2520Hepatitis%2520C%2520Virus%2520Serine%2520Protease%2520Inhibitors%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Sun, L.-Q.; Mull, E.; Gillis, E. P.; Bowsher, M. S.; Zhao, Q.; Renduchintala, V. K.; Sarkunam, K.; Nagalakshmi, P.; Babu, P. V. K. S.; Scola, P. M.</span><span> </span><span class="NLM_article-title">Hepatitis C Virus Inhibitors</span>. PCT Int. Appl. WO 2014/062196, April 24,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=L.-Q.+Sun&author=E.+Mull&author=E.+P.+Gillis&author=M.+S.+Bowsher&author=Q.+Zhao&author=V.+K.+Renduchintala&author=K.+Sarkunam&author=P.+Nagalakshmi&author=P.+V.+K.+S.+Babu&author=P.+M.+Scola&title=Hepatitis+C+Virus+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.-Q.%26atitle%3DHepatitis%2520C%2520Virus%2520Inhibitors%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Sarkar, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sommer, S. S.</span><span> </span><span class="NLM_article-title">The “megaprimer” method of site-directed mutagenesis</span> <span class="citation_source-journal">Biotechniques</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">404</span><span class="NLM_x">–</span> <span class="NLM_lpage">407</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=2340178" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADyaK3cXls1Krs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1990&pages=404-407&author=G.+Sarkarauthor=S.+S.+Sommer&title=The+%E2%80%9Cmegaprimer%E2%80%9D+method+of+site-directed+mutagenesis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">The "megaprimer" method of site-directed mutagenesis</span></div><div class="casAuthors">Sarkar, Gobinda; Sommer, Steve S.</div><div class="citationInfo"><span class="NLM_cas:title">BioTechniques</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">404-7</span>CODEN:
                <span class="NLM_cas:coden">BTNQDO</span>;
        ISSN:<span class="NLM_cas:issn">0736-6205</span>.
    </div><div class="casAbstract">A simple and efficient method of mutagenesis termed the megaprimer method is described.  The method utilizes 3 oligonucleotide primers to perform 2 rounds of polymerase chain reaction.  In the method, the product of the first polymerase chain reaction is used as one of the polymerase chain reaction primers (i.e. a megaprimer) for the second polymerase chain reaction.  When a phage promoter and a translational initiation signal are attached to the appropriate oligonucleotide primer, the mutant protein can be generated without any in vivo manipulations.  The method was used to generate 2 mutations in the catalytic domain of the human factor IX gene.  The substitution of megaprimers for oligonucleotide primers may have utility in other polymerase chain reaction-based methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3Gw-l10oiErVg90H21EOLACvtfcHk0lhcphrJ9k1emg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXls1Krs7g%253D&md5=8c790e0b8050396e1befc4368d579fda</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSarkar%26aufirst%3DG.%26aulast%3DSommer%26aufirst%3DS.%2BS.%26atitle%3DThe%2520%25E2%2580%259Cmegaprimer%25E2%2580%259D%2520method%2520of%2520site-directed%2520mutagenesis%26jtitle%3DBiotechniques%26date%3D1990%26volume%3D8%26spage%3D404%26epage%3D407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Otwinowski, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minor, W.</span><span> </span><span class="NLM_article-title">Processing of X-ray diffraction data collected in oscillation mode</span> <span class="citation_source-journal">Methods Enzymol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">276</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">–</span> <span class="NLM_lpage">326</span><span class="refDoi"> DOI: 10.1016/S0076-6879(97)76066-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1016%2FS0076-6879%2897%2976066-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=27754618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADyaK2sXivFehsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=1997&pages=307-326&author=Z.+Otwinowskiauthor=W.+Minor&title=Processing+of+X-ray+diffraction+data+collected+in+oscillation+mode&doi=10.1016%2FS0076-6879%2897%2976066-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Processing of x-ray diffraction data collected in oscillation mode</span></div><div class="casAuthors">Otwinowski, Zbyszek; Minor, Wladek</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Enzymology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">Macromolecular Crystallography, Part A</span>),
    <span class="NLM_cas:pages">307-326</span>CODEN:
                <span class="NLM_cas:coden">MENZAU</span>;
        ISSN:<span class="NLM_cas:issn">0076-6879</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">Macromol. crystallog. is an iterative process.  Rarely do the first crystals provide all the necessary data to solve the biol. problem being studied.  Each step benefits from experience learned in previous steps.  To monitor the progress, the HKL package provides 2 tools: (1) statistics, both weighted (χ2) and unweighted (R-merge), are provided, and the Bayesian reasoning and multicomponent error model facilitates obtaining the proper error ests. and (2) visualization of the process plays a double role by helping the operator to confirm that the process of data redn., including the resulting statistics, is correct, and allowing one to evaluate problems for which there are no good statistical criteria.  Visualization also provides confidence that the point of diminishing returns in data collection and redn. has been reached.  At that point, the effort should be directed to solving the structure.  The methods presented here have been applied to solve a large variety of problems, from inorg. mols. with 5 Å unit cell to rotavirus of 700 Å diam. crystd. in 700 × 1000 × 1400 Å cell.  Overall quality of the method was tested by many researchers by successful application of the programs to MAD structure detns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA3fvBOHqhhrVg90H21EOLACvtfcHk0lhcphrJ9k1emg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXivFehsbw%253D&md5=c9536971d4e32cc35352c40fb9368131</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2FS0076-6879%2897%2976066-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0076-6879%252897%252976066-X%26sid%3Dliteratum%253Aachs%26aulast%3DOtwinowski%26aufirst%3DZ.%26aulast%3DMinor%26aufirst%3DW.%26atitle%3DProcessing%2520of%2520X-ray%2520diffraction%2520data%2520collected%2520in%2520oscillation%2520mode%26jtitle%3DMethods%2520Enzymol.%26date%3D1997%26volume%3D276%26spage%3D307%26epage%3D326%26doi%3D10.1016%2FS0076-6879%2897%2976066-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">McCoy, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosse-Kunstleve, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winn, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storoni, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, R. J.</span><span> </span><span class="NLM_article-title">Phaser crystallographic software</span> <span class="citation_source-journal">J. Appl. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">658</span><span class="NLM_x">–</span> <span class="NLM_lpage">674</span><span class="refDoi"> DOI: 10.1107/S0021889807021206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1107%2FS0021889807021206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=19461840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2007&pages=658-674&author=A.+J.+McCoyauthor=R.+W.+Grosse-Kunstleveauthor=P.+D.+Adamsauthor=M.+D.+Winnauthor=L.+C.+Storoniauthor=R.+J.+Read&title=Phaser+crystallographic+software&doi=10.1107%2FS0021889807021206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Phaser crystallographic software</span></div><div class="casAuthors">McCoy, Airlie J.; Grosse-Kunstleve, Ralf W.; Adams, Paul D.; Winn, Martyn D.; Storoni, Laurent C.; Read, Randy J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">658-674</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Phaser is a program for phasing macromol. crystal structures by both mol. replacement and exptl. phasing methods.  The novel phasing algorithms implemented in Phaser have been developed using max. likelihood and multivariate statistics.  For mol. replacement, the new algorithms have proved to be significantly better than traditional methods in discriminating correct solns. from noise, and for single-wavelength anomalous dispersion exptl. phasing, the new algorithms, which account for correlations between F+ and F-, give better phases (lower mean phase error with respect to the phases given by the refined structure) than those that use mean F and anomalous differences ΔF.  One of the design concepts of Phaser was that it be capable of a high degree of automation.  To this end, Phaser (written in C++) can be called directly from Python, although it can also be called using traditional CCP4 keyword-style input.  Phaser is a platform for future development of improved phasing methods and their release, including source code, to the crystallog. community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPeVyjN_FMGbVg90H21EOLACvtfcHk0litPs61WIzbGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D&md5=c63b722ae97e0a74e6a5a079d388f09f</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1107%2FS0021889807021206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889807021206%26sid%3Dliteratum%253Aachs%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DWinn%26aufirst%3DM.%2BD.%26aulast%3DStoroni%26aufirst%3DL.%2BC.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26atitle%3DPhaser%2520crystallographic%2520software%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D2007%26volume%3D40%26spage%3D658%26epage%3D674%26doi%3D10.1107%2FS0021889807021206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Emsley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowtan, K.</span><span> </span><span class="NLM_article-title">Coot: model-building tools for molecular graphics</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">2126</span><span class="NLM_x">–</span> <span class="NLM_lpage">2132</span><span class="refDoi"> DOI: 10.1107/S0907444904019158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1107%2FS0907444904019158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=15572765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=2126-2132&author=P.+Emsleyauthor=K.+Cowtan&title=Coot%3A+model-building+tools+for+molecular+graphics&doi=10.1107%2FS0907444904019158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Coot: model-building tools for molecular graphics</span></div><div class="casAuthors">Emsley, Paul; Cowtan, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">D60</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">2126-2132</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">CCP4mg is a project that aims to provide a general-purpose tool for structural biologists, providing tools for x-ray structure soln., structure comparison and anal., and publication-quality graphics.  The map-fitting tools are available as a stand-alone package, distributed as 'Coot'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMisM42468k7Vg90H21EOLACvtfcHk0litPs61WIzbGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P&md5=1be390f3bb6fd584468499ad0921161e</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1107%2FS0907444904019158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444904019158%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DCoot%253A%2520model-building%2520tools%2520for%2520molecular%2520graphics%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2004%26volume%3D60%26spage%3D2126%26epage%3D2132%26doi%3D10.1107%2FS0907444904019158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Adams, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Afonine, P. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunkoczi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, I. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Echols, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Headd, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hung, L.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapral, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosse-Kunstleve, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCoy, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moriarty, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oeffner, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terwilliger, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwart, P. H.</span><span> </span><span class="NLM_article-title">PHENIX: a comprehensive Python-based system for macromolecular structure solution</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">213</span><span class="NLM_x">–</span> <span class="NLM_lpage">221</span><span class="refDoi"> DOI: 10.1107/S0907444909052925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1107%2FS0907444909052925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=20124702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=213-221&author=P.+D.+Adamsauthor=P.+V.+Afonineauthor=G.+Bunkocziauthor=V.+B.+Chenauthor=I.+W.+Davisauthor=N.+Echolsauthor=J.+J.+Headdauthor=L.-W.+Hungauthor=G.+J.+Kapralauthor=R.+W.+Grosse-Kunstleveauthor=A.+J.+McCoyauthor=N.+W.+Moriartyauthor=R.+Oeffnerauthor=R.+J.+Readauthor=D.+C.+Richardsonauthor=J.+S.+Richardsonauthor=T.+C.+Terwilligerauthor=P.+H.+Zwart&title=PHENIX%3A+a+comprehensive+Python-based+system+for+macromolecular+structure+solution&doi=10.1107%2FS0907444909052925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">PHENIX: a comprehensive Python-based system for macromolecular structure solution</span></div><div class="casAuthors">Adams, Paul D.; Afonine, Pavel V.; Bunkoczi, Gabor; Chen, Vincent B.; Davis, Ian W.; Echols, Nathaniel; Headd, Jeffrey J.; Hung, Li Wei; Kapral, Gary J.; Grosse-Kunstleve, Ralf W.; McCoy, Airlie J.; Moriarty, Nigel W.; Oeffner, Robert; Read, Randy J.; Richardson, David C.; Richardson, Jane S.; Terwilliger, Thomas C.; Zwart, Peter H.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">213-221</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A review.  Macromol. X-ray crystallog. is routinely applied to understand biol. processes at a mol. level.  However, significant time and effort are still required to solve and complete many of these structures because of the need for manual interpretation of complex numerical data using many software packages and the repeated use of interactive three-dimensional graphics.  PHENIX has been developed to provide a comprehensive system for macromol. crystallog. structure soln. with an emphasis on the automation of all procedures.  This has relied on the development of algorithms that minimize or eliminate subjective input, the development of algorithms that automate procedures that are traditionally performed by hand and, finally, the development of a framework that allows a tight integration between the algorithms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm_HgKRpa-ObVg90H21EOLACvtfcHk0ljg5jQL6X5INA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisbc%253D&md5=67b439ff4bd61c659cae37ca4209b7bc</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1107%2FS0907444909052925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909052925%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DAfonine%26aufirst%3DP.%2BV.%26aulast%3DBunkoczi%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DV.%2BB.%26aulast%3DDavis%26aufirst%3DI.%2BW.%26aulast%3DEchols%26aufirst%3DN.%26aulast%3DHeadd%26aufirst%3DJ.%2BJ.%26aulast%3DHung%26aufirst%3DL.-W.%26aulast%3DKapral%26aufirst%3DG.%2BJ.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DMoriarty%26aufirst%3DN.%2BW.%26aulast%3DOeffner%26aufirst%3DR.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26aulast%3DRichardson%26aufirst%3DD.%2BC.%26aulast%3DRichardson%26aufirst%3DJ.%2BS.%26aulast%3DTerwilliger%26aufirst%3DT.%2BC.%26aulast%3DZwart%26aufirst%3DP.%2BH.%26atitle%3DPHENIX%253A%2520a%2520comprehensive%2520Python-based%2520system%2520for%2520macromolecular%2520structure%2520solution%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D213%26epage%3D221%26doi%3D10.1107%2FS0907444909052925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Davis, I. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leaver-Fay, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Block, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapral, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, L. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arendall, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snoeyink, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, D. C.</span><span> </span><span class="NLM_article-title">MolProbity: all-atom contacts and structure validation for proteins and nucleic acids</span> <span class="citation_source-journal">Nucleic Acids Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">W375</span><span class="NLM_x">–</span> <span class="NLM_lpage">W383</span><span class="refDoi"> DOI: 10.1093/nar/gkm216</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1093%2Fnar%2Fgkm216" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=17452350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A280%3ADC%252BD2svhsVGhtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2007&pages=W375-W383&author=I.+W.+Davisauthor=A.+Leaver-Fayauthor=V.+B.+Chenauthor=J.+N.+Blockauthor=G.+J.+Kapralauthor=X.+Wangauthor=L.+W.+Murrayauthor=W.+B.+Arendallauthor=J.+Snoeyinkauthor=J.+S.+Richardsonauthor=D.+C.+Richardson&title=MolProbity%3A+all-atom+contacts+and+structure+validation+for+proteins+and+nucleic+acids&doi=10.1093%2Fnar%2Fgkm216"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">MolProbity: all-atom contacts and structure validation for proteins and nucleic acids</span></div><div class="casAuthors">Davis Ian W; Leaver-Fay Andrew; Chen Vincent B; Block Jeremy N; Kapral Gary J; Wang Xueyi; Murray Laura W; Arendall W Bryan 3rd; Snoeyink Jack; Richardson Jane S; Richardson David C</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic acids research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">Web Server issue</span>),
    <span class="NLM_cas:pages">W375-83</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">MolProbity is a general-purpose web server offering quality validation for 3D structures of proteins, nucleic acids and complexes.  It provides detailed all-atom contact analysis of any steric problems within the molecules as well as updated dihedral-angle diagnostics, and it can calculate and display the H-bond and van der Waals contacts in the interfaces between components.  An integral step in the process is the addition and full optimization of all hydrogen atoms, both polar and nonpolar.  New analysis functions have been added for RNA, for interfaces, and for NMR ensembles.  Additionally, both the web site and major component programs have been rewritten to improve speed, convenience, clarity and integration with other resources.  MolProbity results are reported in multiple forms: as overall numeric scores, as lists or charts of local problems, as downloadable PDB and graphics files, and most notably as informative, manipulable 3D kinemage graphics shown online in the KiNG viewer.  This service is available free to all users at http://molprobity.biochem.duke.edu.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRuyhuetoNS59bHMBt0mMIXfW6udTcc2ebbGjVBp2cYEbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2svhsVGhtQ%253D%253D&md5=726ca1e7e162ab2a4a05048f493731fb</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkm216&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkm216%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DI.%2BW.%26aulast%3DLeaver-Fay%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DV.%2BB.%26aulast%3DBlock%26aufirst%3DJ.%2BN.%26aulast%3DKapral%26aufirst%3DG.%2BJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DMurray%26aufirst%3DL.%2BW.%26aulast%3DArendall%26aufirst%3DW.%2BB.%26aulast%3DSnoeyink%26aufirst%3DJ.%26aulast%3DRichardson%26aufirst%3DJ.%2BS.%26aulast%3DRichardson%26aufirst%3DD.%2BC.%26atitle%3DMolProbity%253A%2520all-atom%2520contacts%2520and%2520structure%2520validation%2520for%2520proteins%2520and%2520nucleic%2520acids%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2007%26volume%3D35%26spage%3DW375%26epage%3DW383%26doi%3D10.1093%2Fnar%2Fgkm216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Brunger, A. T.</span><span> </span><span class="NLM_article-title">Free R value: a novel statistical quantity for assessing the accuracy of crystal structures</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">355</span><span class="NLM_x">, </span> <span class="NLM_fpage">472</span><span class="NLM_x">–</span> <span class="NLM_lpage">475</span><span class="refDoi"> DOI: 10.1038/355472a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1038%2F355472a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=18481394" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A280%3ADC%252BD1czhvFCquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=1992&pages=472-475&author=A.+T.+Brunger&title=Free+R+value%3A+a+novel+statistical+quantity+for+assessing+the+accuracy+of+crystal+structures&doi=10.1038%2F355472a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Free R value: a novel statistical quantity for assessing the accuracy of crystal structures</span></div><div class="casAuthors">Brunger A T</div><div class="citationInfo"><span class="NLM_cas:title">Nature</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">6359</span>),
    <span class="NLM_cas:pages">472-5</span>
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">The determination of macromolecular structure by crystallography involves fitting atomic models to the observed diffraction data.  The traditional measure of the quality of this fit, and presumably the accuracy of the model, is the R value.  Despite stereochemical restraints, it is possible to overfit or 'misfit' the diffraction data: an incorrect model can be refined to fairly good R values as several recent examples have shown.  Here I propose a reliable and unbiased indicator of the accuracy of such models.  By analogy with the cross-validation method of testing statistical models I define a statistical quantity (R(free) (T) that measures the agreement between observed and computed structure factor amplitudes for a 'test' set of reflections that is omitted in the modelling and refinement process.  As examples show, there is a high correlation between R(free) (T) and the accuracy of the atomic model phases.  This is useful because experimental phase information is usually inaccurate, incomplete or unavailable.  I expect that R(free) (T) will provide a measure of the information content of recently proposed models of thermal motion and disorder, time-averaging and bulk solvent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQY_IzgfwBLm_h3YQQtAhNufW6udTcc2eZkXtvrNA3AX7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1czhvFCquw%253D%253D&md5=ddeaa021753f1208b405e03c1428078f</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2F355472a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F355472a0%26sid%3Dliteratum%253Aachs%26aulast%3DBrunger%26aufirst%3DA.%2BT.%26atitle%3DFree%2520R%2520value%253A%2520a%2520novel%2520statistical%2520quantity%2520for%2520assessing%2520the%2520accuracy%2520of%2520crystal%2520structures%26jtitle%3DNature%26date%3D1992%26volume%3D355%26spage%3D472%26epage%3D475%26doi%3D10.1038%2F355472a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span>PyMOL: The PyMOL Molecular Graphics System, <span class="NLM_edition">version 1.8</span>; <span class="NLM_publisher-name">Schrödinger, LLC</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=PyMOL%3A+The+PyMOL+Molecular+Graphics+System%2C+version+1.8%3B+Schr%C3%B6dinger%2C+LLC%3A+New+York%2C+2017."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DPyMOL%253A%2520The%2520PyMOL%2520Molecular%2520Graphics%2520System%26pub%3DSchr%25C3%25B6dinger%252C%2520LLC%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span>MacroModel, Schrödinger Release 2017-1; <span class="NLM_publisher-name">Schrödinger, LLC</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=MacroModel%2C+Schr%C3%B6dinger+Release+2017-1%3B+Schr%C3%B6dinger%2C+LLC%3A+New+York%2C+2017."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DMacroModel%252C%2520Schr%25C3%25B6dinger%2520Release%25202017-1%26pub%3DSchr%25C3%25B6dinger%252C%2520LLC%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 21 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Ashley N. Matthew, Florian Leidner, Gordon J. Lockbaum, Mina Henes, Jacqueto Zephyr, Shurong Hou, Desaboini Nageswara Rao, Jennifer Timm, Linah N. Rusere, Debra A. Ragland, Janet L. Paulsen, Kristina Prachanronarong, Djade I. Soumana, Ellen A. Nalivaika, Nese Kurt Yilmaz, Akbar Ali, <span class="NLM_string-name hlFld-ContribAuthor">Celia A. Schiffer</span>. </span><span class="cited-content_cbyCitation_article-title">Drug Design Strategies to Avoid Resistance in Direct-Acting Antivirals and Beyond. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2021,</strong> <em>121 </em>
                                    (6)
                                     , 3238-3270. <a href="https://doi.org/10.1021/acs.chemrev.0c00648" title="DOI URL">https://doi.org/10.1021/acs.chemrev.0c00648</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.0c00648&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.0c00648%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DDrug%252BDesign%252BStrategies%252Bto%252BAvoid%252BResistance%252Bin%252BDirect-Acting%252BAntivirals%252Band%252BBeyond%26aulast%3DMatthew%26aufirst%3DAshley%2BN.%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D22062020%26date%3D07012021%26volume%3D121%26issue%3D6%26spage%3D3238%26epage%3D3270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Li-Qiang Sun, Eric Mull, Stanley D’Andrea, Barbara Zheng, Sheldon Hiebert, Eric Gillis, Michael Bowsher, Sarkunam Kandhasamy, Venkata Rao Baratam, Sunitha Puttaswamy, Nagalakshmi Pulicharla, Sureshbabu Vishwakrishnan, Subba Reddy, Ravi Trivedi, Sarmistha Sinha, Sankar Sivaprasad, Abhijith Rao, Salil Desai, Kaushik Ghosh, Rushith Anumula, Amit Kumar, Ramkumar Rajamani, Ying-Kai Wang, Hua Fang, Arvind Mathur, Richard Rampulla, Tatyana A. Zvyaga, Kathy Mosure, Susan Jenkins, Paul Falk, Debarati M. Tagore, Chaoqun Chen, Kishore Rendunchintala, James Loy, Nicholas A. Meanwell, Fiona McPhee, <span class="NLM_string-name hlFld-ContribAuthor">Paul M. Scola</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of BMS-986144, a Third-Generation, Pan-Genotype NS3/4A Protease Inhibitor for the Treatment of Hepatitis C Virus Infection. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (23)
                                     , 14740-14760. <a href="https://doi.org/10.1021/acs.jmedchem.0c01296" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01296</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01296&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01296%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BBMS-986144%25252C%252Ba%252BThird-Generation%25252C%252BPan-Genotype%252BNS3%25252F4A%252BProtease%252BInhibitor%252Bfor%252Bthe%252BTreatment%252Bof%252BHepatitis%252BC%252BVirus%252BInfection%26aulast%3DSun%26aufirst%3DLi-Qiang%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D24072020%26date%3D23112020%26volume%3D63%26issue%3D23%26spage%3D14740%26epage%3D14760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Heng Song, Ran Cheng, Qiao-Qiao Min, <span class="NLM_string-name hlFld-ContribAuthor">Xingang Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Decarboxylative and Deaminative Alkylation of Difluoroenoxysilanes via Photoredox Catalysis: A General Method for Site-Selective Synthesis of Difluoroalkylated Alkanes. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2020,</strong> <em>22 </em>
                                    (19)
                                     , 7747-7751. <a href="https://doi.org/10.1021/acs.orglett.0c02997" title="DOI URL">https://doi.org/10.1021/acs.orglett.0c02997</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.0c02997&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.0c02997%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DDecarboxylative%252Band%252BDeaminative%252BAlkylation%252Bof%252BDifluoroenoxysilanes%252Bvia%252BPhotoredox%252BCatalysis%25253A%252BA%252BGeneral%252BMethod%252Bfor%252BSite-Selective%252BSynthesis%252Bof%252BDifluoroalkylated%252BAlkanes%26aulast%3DSong%26aufirst%3DHeng%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D08092020%26date%3D18092020%26volume%3D22%26issue%3D19%26spage%3D7747%26epage%3D7751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Lun An, Fei-Fei Tong, Shu Zhang, <span class="NLM_string-name hlFld-ContribAuthor">Xingang Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Stereoselective Functionalization of Racemic Cyclopropylzinc Reagents via Enantiodivergent Relay Coupling. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2020,</strong> <em>142 </em>
                                    (27)
                                     , 11884-11892. <a href="https://doi.org/10.1021/jacs.0c04462" title="DOI URL">https://doi.org/10.1021/jacs.0c04462</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.0c04462&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.0c04462%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DStereoselective%252BFunctionalization%252Bof%252BRacemic%252BCyclopropylzinc%252BReagents%252Bvia%252BEnantiodivergent%252BRelay%252BCoupling%26aulast%3DAn%26aufirst%3DLun%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D23042020%26date%3D26062020%26date%3D12062020%26volume%3D142%26issue%3D27%26spage%3D11884%26epage%3D11892" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">James S. Scott, Jason Breed, Rodrigo J. Carbajo, Paul R. Davey, Ryan Greenwood, Hoan K. Huynh, Teresa Klinowska, Christopher J. Morrow, Thomas A. Moss, Radoslaw Polanski, J. Willem M. Nissink, Jeffrey Varnes, <span class="NLM_string-name hlFld-ContribAuthor">Bin Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Building Bridges in a Series of Estrogen Receptor Degraders: An Application of Metathesis in Medicinal Chemistry. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>10 </em>
                                    (10)
                                     , 1492-1497. <a href="https://doi.org/10.1021/acsmedchemlett.9b00370" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00370</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00370&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00370%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DBuilding%252BBridges%252Bin%252Ba%252BSeries%252Bof%252BEstrogen%252BReceptor%252BDegraders%25253A%252BAn%252BApplication%252Bof%252BMetathesis%252Bin%252BMedicinal%252BChemistry%26aulast%3DScott%26aufirst%3DJames%2BS.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D08082019%26date%3D23092019%26date%3D25092019%26date%3D23092019%26volume%3D10%26issue%3D10%26spage%3D1492%26epage%3D1497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Linah
N. Rusere, Ashley N. Matthew, Gordon J. Lockbaum, Muhammad Jahangir, Alicia Newton, Christos J. Petropoulos, Wei Huang, Nese Kurt Yilmaz, Celia A. Schiffer, <span class="NLM_string-name hlFld-ContribAuthor">Akbar Ali</span>. </span><span class="cited-content_cbyCitation_article-title">Quinoxaline-Based Linear HCV NS3/4A Protease Inhibitors Exhibit Potent Activity against Drug Resistant Variants. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>9 </em>
                                    (7)
                                     , 691-696. <a href="https://doi.org/10.1021/acsmedchemlett.8b00150" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.8b00150</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.8b00150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.8b00150%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DQuinoxaline-Based%252BLinear%252BHCV%252BNS3%25252F4A%252BProtease%252BInhibitors%252BExhibit%252BPotent%252BActivity%252Bagainst%252BDrug%252BResistant%252BVariants%26aulast%3DRusere%26aufirst%3DLinah%2BN.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D29032018%26date%3D17052018%26date%3D22052018%26date%3D17052018%26volume%3D9%26issue%3D7%26spage%3D691%26epage%3D696" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yue  Ma</span>, <span class="hlFld-ContribAuthor ">Estrella  Frutos-Beltrán</span>, <span class="hlFld-ContribAuthor ">Dongwei  Kang</span>, <span class="hlFld-ContribAuthor ">Christophe  Pannecouque</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>, <span class="hlFld-ContribAuthor ">Luis  Menéndez-Arias</span>, <span class="hlFld-ContribAuthor ">Xinyong  Liu</span>, <span class="hlFld-ContribAuthor ">Peng  Zhan</span>. </span><span class="cited-content_cbyCitation_article-title">Medicinal chemistry strategies for discovering antivirals effective against drug-resistant viruses. </span><span class="cited-content_cbyCitation_journal-name">Chemical Society Reviews</span><span> <strong>2021,</strong> <em>50 </em>
                                    (7)
                                     , 4514-4540. <a href="https://doi.org/10.1039/D0CS01084G" title="DOI URL">https://doi.org/10.1039/D0CS01084G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0CS01084G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0CS01084G%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Society%2520Reviews%26atitle%3DMedicinal%252Bchemistry%252Bstrategies%252Bfor%252Bdiscovering%252Bantivirals%252Beffective%252Bagainst%252Bdrug-resistant%252Bviruses%26aulast%3DMa%26aufirst%3DYue%26date%3D2021%26date%3D2021%26volume%3D50%26issue%3D7%26spage%3D4514%26epage%3D4540" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Thitiya  Boonma</span>, <span class="hlFld-ContribAuthor ">Bodee  Nutho</span>, <span class="hlFld-ContribAuthor ">Nitchakan  Darai</span>, <span class="hlFld-ContribAuthor ">Thanyada  Rungrotmongkol</span>, <span class="hlFld-ContribAuthor ">Nadtanet  Nunthaboot</span>. </span><span class="cited-content_cbyCitation_article-title">Exploring of paritaprevir and glecaprevir resistance due to A156T mutation of HCV NS3/4A protease: molecular dynamics simulation study. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Structure and Dynamics</span><span> <strong>2021,</strong> <em>11 </em>, 1-12. <a href="https://doi.org/10.1080/07391102.2020.1869587" title="DOI URL">https://doi.org/10.1080/07391102.2020.1869587</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/07391102.2020.1869587&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F07391102.2020.1869587%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Structure%2520and%2520Dynamics%26atitle%3DExploring%252Bof%252Bparitaprevir%252Band%252Bglecaprevir%252Bresistance%252Bdue%252Bto%252BA156T%252Bmutation%252Bof%252BHCV%252BNS3%25252F4A%252Bprotease%25253A%252Bmolecular%252Bdynamics%252Bsimulation%252Bstudy%26aulast%3DBoonma%26aufirst%3DThitiya%26date%3D2021%26date%3D2021%26volume%3D11%26spage%3D1%26epage%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jintong  Du</span>, <span class="hlFld-ContribAuthor ">Jing  Guo</span>, <span class="hlFld-ContribAuthor ">Dongwei  Kang</span>, <span class="hlFld-ContribAuthor ">Zhihong  Li</span>, <span class="hlFld-ContribAuthor ">Guan  Wang</span>, <span class="hlFld-ContribAuthor ">Jianbing  Wu</span>, <span class="hlFld-ContribAuthor ">Zhen  Zhang</span>, <span class="hlFld-ContribAuthor ">Hao  Fang</span>, <span class="hlFld-ContribAuthor ">Xuben  Hou</span>, <span class="hlFld-ContribAuthor ">Zhangjian  Huang</span>, <span class="hlFld-ContribAuthor ">Guobo  Li</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Xinyong  Liu</span>, <span class="hlFld-ContribAuthor ">Liang  Ouyang</span>, <span class="hlFld-ContribAuthor ">Li  Rao</span>, <span class="hlFld-ContribAuthor ">Peng  Zhan</span>, <span class="hlFld-ContribAuthor ">Xiaojin  Zhang</span>, <span class="hlFld-ContribAuthor ">Yihua  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">New techniques and strategies in drug discovery. </span><span class="cited-content_cbyCitation_journal-name">Chinese Chemical Letters</span><span> <strong>2020,</strong> <em>31 </em>
                                    (7)
                                     , 1695-1708. <a href="https://doi.org/10.1016/j.cclet.2020.03.028" title="DOI URL">https://doi.org/10.1016/j.cclet.2020.03.028</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cclet.2020.03.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cclet.2020.03.028%26sid%3Dliteratum%253Aachs%26jtitle%3DChinese%2520Chemical%2520Letters%26atitle%3DNew%252Btechniques%252Band%252Bstrategies%252Bin%252Bdrug%252Bdiscovery%26aulast%3DDu%26aufirst%3DJintong%26date%3D2020%26volume%3D31%26issue%3D7%26spage%3D1695%26epage%3D1708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marc  Montana</span>, <span class="hlFld-ContribAuthor ">Vincent  Montero</span>, <span class="hlFld-ContribAuthor ">Omar  Khoumeri</span>, <span class="hlFld-ContribAuthor ">Patrice  Vanelle</span>. </span><span class="cited-content_cbyCitation_article-title">Quinoxaline Derivatives as Antiviral Agents: A Systematic Review. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (12)
                                     , 2784. <a href="https://doi.org/10.3390/molecules25122784" title="DOI URL">https://doi.org/10.3390/molecules25122784</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25122784&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25122784%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DQuinoxaline%252BDerivatives%252Bas%252BAntiviral%252BAgents%25253A%252BA%252BSystematic%252BReview%26aulast%3DMontana%26aufirst%3DMarc%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D12%26spage%3D2784" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ashley N.  Matthew</span>, <span class="hlFld-ContribAuthor ">Jacqueto  Zephyr</span>, <span class="hlFld-ContribAuthor ">Desaboini  Nageswara Rao</span>, <span class="hlFld-ContribAuthor ">Mina  Henes</span>, <span class="hlFld-ContribAuthor ">Wasih  Kamran</span>, <span class="hlFld-ContribAuthor ">Klajdi  Kosovrasti</span>, <span class="hlFld-ContribAuthor ">Adam K.  Hedger</span>, <span class="hlFld-ContribAuthor ">Gordon J.  Lockbaum</span>, <span class="hlFld-ContribAuthor ">Jennifer  Timm</span>, <span class="hlFld-ContribAuthor ">Akbar  Ali</span>, <span class="hlFld-ContribAuthor ">Nese  Kurt Yilmaz</span>, <span class="hlFld-ContribAuthor ">Celia A.  Schiffer</span>, . </span><span class="cited-content_cbyCitation_article-title">Avoiding Drug Resistance by Substrate Envelope-Guided Design: Toward Potent and Robust HCV NS3/4A Protease Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">mBio</span><span> <strong>2020,</strong> <em>11 </em>
                                    (2)
                                     <a href="https://doi.org/10.1128/mBio.00172-20" title="DOI URL">https://doi.org/10.1128/mBio.00172-20</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1128/mBio.00172-20&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1128%2FmBio.00172-20%26sid%3Dliteratum%253Aachs%26jtitle%3DmBio%26atitle%3DAvoiding%252BDrug%252BResistance%252Bby%252BSubstrate%252BEnvelope-Guided%252BDesign%25253A%252BToward%252BPotent%252Band%252BRobust%252BHCV%252BNS3%25252F4A%252BProtease%252BInhibitors%26aulast%3DMatthew%26aufirst%3DAshley%2BN.%26date%3D2020%26volume%3D11%26issue%3D2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Thitiya  Boonma</span>, <span class="hlFld-ContribAuthor ">Bodee  Nutho</span>, <span class="hlFld-ContribAuthor ">Thanyada  Rungrotmongkol</span>, <span class="hlFld-ContribAuthor ">Nadtanet  Nunthaboot</span>. </span><span class="cited-content_cbyCitation_article-title">Understanding of the drug resistance mechanism of hepatitis C virus NS3/4A to paritaprevir due to D168N/Y mutations: A molecular dynamics simulation perspective. </span><span class="cited-content_cbyCitation_journal-name">Computational Biology and Chemistry</span><span> <strong>2019,</strong> <em>83 </em>, 107154. <a href="https://doi.org/10.1016/j.compbiolchem.2019.107154" title="DOI URL">https://doi.org/10.1016/j.compbiolchem.2019.107154</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.compbiolchem.2019.107154&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.compbiolchem.2019.107154%26sid%3Dliteratum%253Aachs%26jtitle%3DComputational%2520Biology%2520and%2520Chemistry%26atitle%3DUnderstanding%252Bof%252Bthe%252Bdrug%252Bresistance%252Bmechanism%252Bof%252Bhepatitis%252BC%252Bvirus%252BNS3%25252F4A%252Bto%252Bparitaprevir%252Bdue%252Bto%252BD168N%25252FY%252Bmutations%25253A%252BA%252Bmolecular%252Bdynamics%252Bsimulation%252Bperspective%26aulast%3DBoonma%26aufirst%3DThitiya%26date%3D2019%26volume%3D83%26spage%3D107154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Junwei  Zhou</span>, <span class="hlFld-ContribAuthor ">Liurong  Fang</span>, <span class="hlFld-ContribAuthor ">Zhixiang  Yang</span>, <span class="hlFld-ContribAuthor ">Shangen  Xu</span>, <span class="hlFld-ContribAuthor ">Mengting  Lv</span>, <span class="hlFld-ContribAuthor ">Zheng  Sun</span>, <span class="hlFld-ContribAuthor ">Jiyao  Chen</span>, <span class="hlFld-ContribAuthor ">Dang  Wang</span>, <span class="hlFld-ContribAuthor ">Jun  Gao</span>, <span class="hlFld-ContribAuthor ">Shaobo  Xiao</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of novel proteolytically inactive mutations in coronavirus 3C-like protease using a combined approach. </span><span class="cited-content_cbyCitation_journal-name">The FASEB Journal</span><span> <strong>2019,</strong> <em>33 </em>
                                    (12)
                                     , 14575-14587. <a href="https://doi.org/10.1096/fj.201901624RR" title="DOI URL">https://doi.org/10.1096/fj.201901624RR</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1096/fj.201901624RR&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1096%2Ffj.201901624RR%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520FASEB%2520Journal%26atitle%3DIdentification%252Bof%252Bnovel%252Bproteolytically%252Binactive%252Bmutations%252Bin%252Bcoronavirus%252B3C-like%252Bprotease%252Busing%252Ba%252Bcombined%252Bapproach%26aulast%3DZhou%26aufirst%3DJunwei%26date%3D2019%26volume%3D33%26issue%3D12%26spage%3D14575%26epage%3D14587" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ayşegül  Özen</span>, <span class="hlFld-ContribAuthor ">Kristina  Prachanronarong</span>, <span class="hlFld-ContribAuthor ">Ashley N.  Matthew</span>, <span class="hlFld-ContribAuthor ">Djade I.  Soumana</span>, <span class="hlFld-ContribAuthor ">Celia A.  Schiffer</span>. </span><span class="cited-content_cbyCitation_article-title">Resistance outside the substrate envelope: hepatitis C NS3/4A protease inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Critical Reviews in Biochemistry and Molecular Biology</span><span> <strong>2019,</strong> <em>54 </em>
                                    (1)
                                     , 11-26. <a href="https://doi.org/10.1080/10409238.2019.1568962" title="DOI URL">https://doi.org/10.1080/10409238.2019.1568962</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/10409238.2019.1568962&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F10409238.2019.1568962%26sid%3Dliteratum%253Aachs%26jtitle%3DCritical%2520Reviews%2520in%2520Biochemistry%2520and%2520Molecular%2520Biology%26atitle%3DResistance%252Boutside%252Bthe%252Bsubstrate%252Benvelope%25253A%252Bhepatitis%252BC%252BNS3%25252F4A%252Bprotease%252Binhibitors%26aulast%3D%25C3%2596zen%26aufirst%3DAy%25C5%259Feg%25C3%25BCl%26date%3D2019%26date%3D2019%26volume%3D54%26issue%3D1%26spage%3D11%26epage%3D26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ahmed A.  Ezat</span>, <span class="hlFld-ContribAuthor ">Wael M.  Elshemey</span>. </span><span class="cited-content_cbyCitation_article-title">A comparative study of the efficiency of HCV NS3/4A protease drugs against different HCV genotypes using in silico approaches. </span><span class="cited-content_cbyCitation_journal-name">Life Sciences</span><span> <strong>2019,</strong> <em>217 </em>, 176-184. <a href="https://doi.org/10.1016/j.lfs.2018.12.004" title="DOI URL">https://doi.org/10.1016/j.lfs.2018.12.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.lfs.2018.12.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.lfs.2018.12.004%26sid%3Dliteratum%253Aachs%26jtitle%3DLife%2520Sciences%26atitle%3DA%252Bcomparative%252Bstudy%252Bof%252Bthe%252Befficiency%252Bof%252BHCV%252BNS3%25252F4A%252Bprotease%252Bdrugs%252Bagainst%252Bdifferent%252BHCV%252Bgenotypes%252Busing%252Bin%252Bsilico%252Bapproaches%26aulast%3DEzat%26aufirst%3DAhmed%2BA.%26date%3D2019%26volume%3D217%26spage%3D176%26epage%3D184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xu  He</span>, <span class="hlFld-ContribAuthor ">Xing  Gao</span>, <span class="hlFld-ContribAuthor ">Xingang  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Nickel-Catalyzed Difluoroalkylation of (Hetero)aryl Bromides with Unactivated 1-Bromo-1,1-difluoroalkanes. </span><span class="cited-content_cbyCitation_journal-name">Chinese Journal of Chemistry</span><span> <strong>2018,</strong> <em>36 </em>
                                    (11)
                                     , 1059-1062. <a href="https://doi.org/10.1002/cjoc.201800276" title="DOI URL">https://doi.org/10.1002/cjoc.201800276</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cjoc.201800276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcjoc.201800276%26sid%3Dliteratum%253Aachs%26jtitle%3DChinese%2520Journal%2520of%2520Chemistry%26atitle%3DNickel-Catalyzed%252BDifluoroalkylation%252Bof%252B%252528Hetero%252529aryl%252BBromides%252Bwith%252BUnactivated%252B1-Bromo-1%25252C1-difluoroalkanes%26aulast%3DHe%26aufirst%3DXu%26date%3D2018%26date%3D2018%26volume%3D36%26issue%3D11%26spage%3D1059%26epage%3D1062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ashley N.  Matthew</span>, <span class="hlFld-ContribAuthor ">Florian  Leidner</span>, <span class="hlFld-ContribAuthor ">Alicia  Newton</span>, <span class="hlFld-ContribAuthor ">Christos J.  Petropoulos</span>, <span class="hlFld-ContribAuthor ">Wei  Huang</span>, <span class="hlFld-ContribAuthor ">Akbar  Ali</span>, <span class="hlFld-ContribAuthor ">Nese  KurtYilmaz</span>, <span class="hlFld-ContribAuthor ">Celia A.  Schiffer</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular Mechanism of Resistance in a Clinically Significant Double-Mutant Variant of HCV NS3/4A Protease. </span><span class="cited-content_cbyCitation_journal-name">Structure</span><span> <strong>2018,</strong> <em>26 </em>
                                    (10)
                                     , 1360-1372.e5. <a href="https://doi.org/10.1016/j.str.2018.07.004" title="DOI URL">https://doi.org/10.1016/j.str.2018.07.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.str.2018.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.str.2018.07.004%26sid%3Dliteratum%253Aachs%26jtitle%3DStructure%26atitle%3DMolecular%252BMechanism%252Bof%252BResistance%252Bin%252Ba%252BClinically%252BSignificant%252BDouble-Mutant%252BVariant%252Bof%252BHCV%252BNS3%25252F4A%252BProtease%26aulast%3DMatthew%26aufirst%3DAshley%2BN.%26date%3D2018%26volume%3D26%26issue%3D10%26spage%3D1360%26epage%3D1372.e5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lun  An</span>, <span class="hlFld-ContribAuthor ">Yu-Lan  Xiao</span>, <span class="hlFld-ContribAuthor ">Shu  Zhang</span>, <span class="hlFld-ContribAuthor ">Xingang  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Bulky Diamine Ligand Promotes Cross-Coupling of Difluoroalkyl Bromides by Iron Catalysis. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2018,</strong> <em>130 </em>
                                    (23)
                                     , 7037-7041. <a href="https://doi.org/10.1002/ange.201802713" title="DOI URL">https://doi.org/10.1002/ange.201802713</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.201802713&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.201802713%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DBulky%252BDiamine%252BLigand%252BPromotes%252BCross-Coupling%252Bof%252BDifluoroalkyl%252BBromides%252Bby%252BIron%252BCatalysis%26aulast%3DAn%26aufirst%3DLun%26date%3D2018%26date%3D2018%26volume%3D130%26issue%3D23%26spage%3D7037%26epage%3D7041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lun  An</span>, <span class="hlFld-ContribAuthor ">Yu-Lan  Xiao</span>, <span class="hlFld-ContribAuthor ">Shu  Zhang</span>, <span class="hlFld-ContribAuthor ">Xingang  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Bulky Diamine Ligand Promotes Cross-Coupling of Difluoroalkyl Bromides by Iron Catalysis. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2018,</strong> <em>57 </em>
                                    (23)
                                     , 6921-6925. <a href="https://doi.org/10.1002/anie.201802713" title="DOI URL">https://doi.org/10.1002/anie.201802713</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.201802713&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.201802713%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DBulky%252BDiamine%252BLigand%252BPromotes%252BCross-Coupling%252Bof%252BDifluoroalkyl%252BBromides%252Bby%252BIron%252BCatalysis%26aulast%3DAn%26aufirst%3DLun%26date%3D2018%26date%3D2018%26volume%3D57%26issue%3D23%26spage%3D6921%26epage%3D6925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alan  Talevi</span>. </span><span class="cited-content_cbyCitation_article-title">Drug repositioning: current approaches and their implications in the precision medicine era. </span><span class="cited-content_cbyCitation_journal-name">Expert Review of Precision Medicine and Drug Development</span><span> <strong>2018,</strong> <em>3 </em>
                                    (1)
                                     , 49-61. <a href="https://doi.org/10.1080/23808993.2018.1424535" title="DOI URL">https://doi.org/10.1080/23808993.2018.1424535</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/23808993.2018.1424535&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F23808993.2018.1424535%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Review%2520of%2520Precision%2520Medicine%2520and%2520Drug%2520Development%26atitle%3DDrug%252Brepositioning%25253A%252Bcurrent%252Bapproaches%252Band%252Btheir%252Bimplications%252Bin%252Bthe%252Bprecision%252Bmedicine%252Bera%26aulast%3DTalevi%26aufirst%3DAlan%26date%3D2018%26date%3D2018%26volume%3D3%26issue%3D1%26spage%3D49%26epage%3D61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Motoki  Ito</span>, <span class="hlFld-ContribAuthor ">Tomoya  Nakagawa</span>, <span class="hlFld-ContribAuthor ">Kazuhiro  Higuchi</span>, <span class="hlFld-ContribAuthor ">Shigeo  Sugiyama</span>. </span><span class="cited-content_cbyCitation_article-title">Dirhodium(
              ii
              )-catalyzed
              ortho
              C–H amination of sterically congested
              N
              ,
              N
              -dialkylanilines. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2018,</strong> <em>16 </em>
                                    (38)
                                     , 6876-6881. <a href="https://doi.org/10.1039/C8OB01974F" title="DOI URL">https://doi.org/10.1039/C8OB01974F</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8OB01974F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8OB01974F%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DDirhodium%252528%252Bii%252B%252529-catalyzed%252Bortho%252BC%2525E2%252580%252593H%252Bamination%252Bof%252Bsterically%252Bcongested%252BN%252B%25252C%252BN%252B-dialkylanilines%26aulast%3DIto%26aufirst%3DMotoki%26date%3D2018%26date%3D2018%26volume%3D16%26issue%3D38%26spage%3D6876%26epage%3D6881" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/medium/jm-2017-004268_0011.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/large/jm-2017-004268_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00426&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/medium/jm-2017-004268_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/large/jm-2017-004268_0001.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of HCV NS3/4A protease inhibitors. Simeprevir, paritaprevir, and grazoprevir are approved by the FDA; voxilaprevir and glecaprevir are in clinical development.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/large/jm-2017-004268_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00426&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/medium/jm-2017-004268_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/large/jm-2017-004268_0002.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Chemical structures and binding modes of grazoprevir (<b>1</b>) and analogue <b>2</b>. (a) Compound <b>2</b> was designed by replacing the P2–P4 macrocycle in <b>1</b> with a P1–P3 macrocycle. (b) Binding conformation of <b>1</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3SUD">3SUD</a>) and <b>2</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EPN">5EPN</a>) in the active site of wild-type NS3/4A protease. Compound <b>2</b> maintains the unique binding mode of <b>1</b> whereby the P2 quinoxaline makes strong interactions with the catalytic residues, avoiding contacts with known drug resistance residues. The catalytic triad is highlighted in yellow, and drug resistance residues Arg155, Ala156, and Asp168 are shown in blue, red, and green, respectively. The canonical nomenclature for drug moiety positioning is indicated using grazoprevir.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/large/jm-2017-004268_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00426&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/medium/jm-2017-004268_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/large/jm-2017-004268_0007.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of HCV NS3/4A Protease Inhibitors<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/large/jm-2017-004268_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00426&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Cs<sub>2</sub>CO<sub>3</sub>, NMP, 55 °C, 6 h; (b) 4 N HCl in dioxane, CH<sub>2</sub>Cl<sub>2</sub>, RT, 3 h; (c) HATU, DIEA, DMF, RT, 4 h; (d) LiOH·H<sub>2</sub>O, THF, H<sub>2</sub>O, RT, 24 h; (e) HATU, DIEA, DMF, RT, 2 h; (f) Zhan 1B catalyst, 1,2-DCE, 70 °C, 6 h; (g) 4 N HCl, dioxane, RT, 3 h; (h) <i>N</i>-(cyclopentyloxycarbonyloxy)-succinimide, DIEA, CH<sub>3</sub>CN, RT, 36 h.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/medium/jm-2017-004268_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/large/jm-2017-004268_0008.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Alternate Synthesis of HCV NS3/4A Protease Inhibitors<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/large/jm-2017-004268_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00426&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) HATU, DIEA, DMF, RT, 2 h; (b) Zhan 1B catalyst, 1,2-DCE, 70 °C, 5 h; (c) LiOH·H<sub>2</sub>O, THF, MeOH, H<sub>2</sub>O, RT, 24 h; (d) CDI, THF, DBU, reflux, 1.5 h, RT, 36 h.</p></p></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/medium/jm-2017-004268_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/large/jm-2017-004268_0003.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (a) X-ray crystal structure of WT1a HCV NS3/4A protease in complex with inhibitor <b>19b</b> and (b) superposition of WT-<b>2</b> and WT-<b>19a</b> complexes. The protease active site is shown as a surface with inhibitor <b>19b</b> shown in orange and <b>2</b> shown in blue. The catalytic triad is highlighted in yellow, and drug resistance residues Arg155, Ala156, and Asp168 are shown as sticks.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/large/jm-2017-004268_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00426&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/medium/jm-2017-004268_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/large/jm-2017-004268_0004.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Comparison of lead compound <b>2</b> with analogues (a) <b>18d</b> and (b) <b>18e</b> modeled in the active site of WT HCV NS3/4A protease. Compound <b>2</b> is shown in salmon, and modified inhibitors are in green. The catalytic triad is highlighted in yellow, and drug resistance residues Arg155, Ala156, and Asp168 are in sticks.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/large/jm-2017-004268_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00426&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/medium/jm-2017-004268_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/large/jm-2017-004268_0005.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (a) X-ray crystal structure of WT1a HCV NS3/4A protease in complex with inhibitor <b>18f</b> and (b) superposition of WT-<b>2</b> and WT-<b>18f</b> complexes. The protease active site is shown as a surface with inhibitor <b>18f</b> shown in orange and <b>2</b> shown in blue. The catalytic triad is highlighted in yellow, and drug resistance residues Arg155, Ala156, and Asp168 are shown as sticks.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/large/jm-2017-004268_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00426&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/medium/jm-2017-004268_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/large/jm-2017-004268_0006.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Resistance profiles of protease inhibitors in enzyme inhibition and antiviral assays for PIs with (a) <i>tert</i>-butyl and (b) cyclopentyl P4 capping groups. Enzyme inhibitory (blue bars) and antiviral (orange bars) activities against the D168A variant were normalized with respect to the wild-type NS3/4A protease domain or wild-type HCV replicon. *Indicates value higher than 1000.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00426/20170707/images/large/jm-2017-004268_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00426&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i43">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32776" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32776" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 58 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span>Hepatitis C Fact Sheet; <span class="NLM_publisher-name">World Health Organization (WHO)</span>: <span class="NLM_publisher-loc">Geneva</span>, Updated July<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">; </span><a href="http://www.who.int/mediacentre/factsheets/fs164/en/" class="extLink">http://www.who.int/mediacentre/factsheets/fs164/en/</a> (accessed February 6, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Hepatitis+C+Fact+Sheet%3B+World+Health+Organization+%28WHO%29%3A+Geneva%2C+Updated+July+2016%3B+http%3A%2F%2Fwww.who.int%2Fmediacentre%2Ffactsheets%2Ffs164%2Fen%2F+%28accessed+February+6%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DHepatitis%2520C%2520Fact%2520Sheet%26pub%3DWorld%2520Health%2520Organization%2520%2528WHO%2529%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Hajarizadeh, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grebely, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dore, G. J.</span><span> </span><span class="NLM_article-title">Epidemiology and natural history of HCV infection</span> <span class="citation_source-journal">Nat. Rev. Gastroenterol. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">553</span><span class="NLM_x">–</span> <span class="NLM_lpage">562</span><span class="refDoi"> DOI: 10.1038/nrgastro.2013.107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1038%2Fnrgastro.2013.107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=23817321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVWru77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=553-562&author=B.+Hajarizadehauthor=J.+Grebelyauthor=G.+J.+Dore&title=Epidemiology+and+natural+history+of+HCV+infection&doi=10.1038%2Fnrgastro.2013.107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Epidemiology and natural history of HCV infection</span></div><div class="casAuthors">Hajarizadeh, Behzad; Grebely, Jason; Dore, Gregory J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Gastroenterology & Hepatology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">553-562</span>CODEN:
                <span class="NLM_cas:coden">NRGHA9</span>;
        ISSN:<span class="NLM_cas:issn">1759-5045</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Worldwide, an estd. 130-170 million people have HCV infection.  HCV prevalence is highest in Egypt at >10% of the general population and China has the most people with HCV (29.8 million).  Differences in past HCV incidence and current HCV prevalence, together with the generally protracted nature of HCV disease progression, has led to considerable diversity in the burden of advanced liver disease in different countries.  Countries with a high incidence of HCV or peak incidence in the recent past will have further escalations in HCV-related cirrhosis and hepatocellular carcinoma (HCC) over the next two decades.  Acute HCV infection is difficult to detect because of the generally asymptomatic nature of the disease and the marginalization of at-risk populations.  Around 25% of patients with acute HCV infection undergo spontaneous clearance, with increased rates among those with favorable IL28B genotypes, acute symptoms and in women.  The remaining 75% of patients progress to chronic HCV infection and are subsequently at risk of progression to hepatic fibrosis, cirrhosis and HCC.  Chronic hepatitis C generally progresses slowly in the initial two decades, but can be accelerated during this time as a result of advancing age and co-factors such as heavy alc. intake and HIV co-infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAGJrt4DO4BLVg90H21EOLACvtfcHk0lhJ9fXDXilUug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVWru77F&md5=1542a3394c3bd84018527b88232950d4</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrgastro.2013.107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrgastro.2013.107%26sid%3Dliteratum%253Aachs%26aulast%3DHajarizadeh%26aufirst%3DB.%26aulast%3DGrebely%26aufirst%3DJ.%26aulast%3DDore%26aufirst%3DG.%2BJ.%26atitle%3DEpidemiology%2520and%2520natural%2520history%2520of%2520HCV%2520infection%26jtitle%3DNat.%2520Rev.%2520Gastroenterol.%2520Hepatol.%26date%3D2013%26volume%3D10%26spage%3D553%26epage%3D562%26doi%3D10.1038%2Fnrgastro.2013.107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Razavi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waked, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarrazin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myers, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Idilman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calinas, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogel, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendes Correa, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hezode, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lazaro, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akarca, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aleman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balik, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bihl, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bilodeau, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blasco, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandao Mello, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruggmann, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calleja, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheinquer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clausen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coelho, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cramp, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dore, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doss, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duberg, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Sayed, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ergor, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esmat, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falconer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felix, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferraz, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferreira, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frankova, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Samaniego, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerstoft, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giria, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goncales, F. L.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gower, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gschwantler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guimaraes Pessoa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hindman, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Husa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaberg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaita, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kautz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaymakoglu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krajden, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krarup, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laleman, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavanchy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marinho, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marotta, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mauss, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Negro, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nemecek, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ormeci, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ovrehus, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasini, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peltekian, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramji, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reis, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenberg, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roudot-Thoraval, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryder, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarmento-Castro, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Semela, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiha, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sievert, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sperl, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Starkel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stauber, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urbanek, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Damme, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Thiel, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Vlierberghe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandijck, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wedemeyer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weis, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiegand, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yosry, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zekry, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornberg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullhaupt, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estes, C.</span><span> </span><span class="NLM_article-title">The present and future disease burden of hepatitis C virus (HCV) infection with today’s treatment paradigm</span> <span class="citation_source-journal">J. Viral. Hepat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">34</span><span class="NLM_x">–</span> <span class="NLM_lpage">59</span><span class="refDoi"> DOI: 10.1111/jvh.12248</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1111%2Fjvh.12248" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=24713005" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A280%3ADC%252BC2cnhvFeltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=34-59&author=H.+Razaviauthor=I.+Wakedauthor=C.+Sarrazinauthor=R.+P.+Myersauthor=R.+Idilmanauthor=F.+Calinasauthor=W.+Vogelauthor=M.+C.+Mendes+Correaauthor=C.+Hezodeauthor=P.+Lazaroauthor=U.+Akarcaauthor=S.+Alemanauthor=I.+Balikauthor=T.+Bergauthor=F.+Bihlauthor=M.+Bilodeauauthor=A.+J.+Blascoauthor=C.+E.+Brandao+Melloauthor=P.+Bruggmannauthor=M.+Butiauthor=J.+L.+Callejaauthor=H.+Cheinquerauthor=P.+B.+Christensenauthor=M.+Clausenauthor=H.+S.+Coelhoauthor=M.+E.+Crampauthor=G.+J.+Doreauthor=W.+Dossauthor=A.+S.+Dubergauthor=M.+H.+El-Sayedauthor=G.+Ergorauthor=G.+Esmatauthor=K.+Falconerauthor=J.+Felixauthor=M.+L.+Ferrazauthor=P.+R.+Ferreiraauthor=S.+Frankovaauthor=J.+Garcia-Samaniegoauthor=J.+Gerstoftauthor=J.+A.+Giriaauthor=F.+L.+Goncalesauthor=E.+Gowerauthor=M.+Gschwantlerauthor=M.+Guimaraes+Pessoaauthor=S.+J.+Hindmanauthor=H.+Hoferauthor=P.+Husaauthor=M.+Kabergauthor=K.+D.+Kaitaauthor=A.+Kautzauthor=S.+Kaymakogluauthor=M.+Krajdenauthor=H.+Krarupauthor=W.+Lalemanauthor=D.+Lavanchyauthor=R.+T.+Marinhoauthor=P.+Marottaauthor=S.+Maussauthor=C.+Morenoauthor=K.+Murphyauthor=F.+Negroauthor=V.+Nemecekauthor=N.+Ormeciauthor=A.+L.+Ovrehusauthor=J.+Parkesauthor=K.+Pasiniauthor=K.+M.+Peltekianauthor=A.+Ramjiauthor=N.+Reisauthor=S.+K.+Robertsauthor=W.+M.+Rosenbergauthor=F.+Roudot-Thoravalauthor=S.+D.+Ryderauthor=R.+Sarmento-Castroauthor=D.+Semelaauthor=M.+Shermanauthor=G.+E.+Shihaauthor=W.+Sievertauthor=J.+Sperlauthor=P.+Starkelauthor=R.+E.+Stauberauthor=A.+J.+Thompsonauthor=P.+Urbanekauthor=P.+Van+Dammeauthor=I.+van+Thielauthor=H.+Van+Vlierbergheauthor=D.+Vandijckauthor=H.+Wedemeyerauthor=N.+Weisauthor=J.+Wiegandauthor=A.+Yosryauthor=A.+Zekryauthor=M.+Cornbergauthor=B.+Mullhauptauthor=C.+Estes&title=The+present+and+future+disease+burden+of+hepatitis+C+virus+%28HCV%29+infection+with+today%E2%80%99s+treatment+paradigm&doi=10.1111%2Fjvh.12248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm</span></div><div class="casAuthors">Razavi H; Waked I; Sarrazin C; Myers R P; Idilman R; Calinas F; Vogel W; Mendes Correa M C; Hezode C; Lazaro P; Akarca U; Aleman S; Balik I; Berg T; Bihl F; Bilodeau M; Blasco A J; Brandao Mello C E; Bruggmann P; Buti M; Calleja J L; Cheinquer H; Christensen P B; Clausen M; Coelho H S M; Cramp M E; Dore G J; Doss W; Duberg A S; El-Sayed M H; Ergor G; Esmat G; Falconer K; Felix J; Ferraz M L G; Ferreira P R; Frankova S; Garcia-Samaniego J; Gerstoft J; Giria J A; Goncales F L Jr; Gower E; Gschwantler M; Guimaraes Pessoa M; Hindman S J; Hofer H; Husa P; Kaberg M; Kaita K D E; Kautz A; Kaymakoglu S; Krajden M; Krarup H; Laleman W; Lavanchy D; Marinho R T; Marotta P; Mauss S; Moreno C; Murphy K; Negro F; Nemecek V; Ormeci N; Ovrehus A L H; Parkes J; Pasini K; Peltekian K M; Ramji A; Reis N; Roberts S K; Rosenberg W M; Roudot-Thoraval F; Ryder S D; Sarmento-Castro R; Semela D; Sherman M; Shiha G E; Sievert W; Sperl J; Starkel P; Stauber R E; Thompson A J; Urbanek P; Van Damme P; van Thiel I; Van Vlierberghe H; Vandijck D; Wedemeyer H; Weis N; Wiegand J; Yosry A; Zekry A; Cornberg M; Mullhaupt B; Estes C</div><div class="citationInfo"><span class="NLM_cas:title">Journal of viral hepatitis</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">21 Suppl 1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">34-59</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The disease burden of hepatitis C virus (HCV) is expected to increase as the infected population ages.  A modelling approach was used to estimate the total number of viremic infections, diagnosed, treated and new infections in 2013.  In addition, the model was used to estimate the change in the total number of HCV infections, the disease progression and mortality in 2013-2030.  Finally, expert panel consensus was used to capture current treatment practices in each country.  Using today's treatment paradigm, the total number of HCV infections is projected to decline or remain flat in all countries studied.  However, in the same time period, the number of individuals with late-stage liver disease is projected to increase.  This study concluded that the current treatment rate and efficacy are not sufficient to manage the disease burden of HCV.  Thus, alternative strategies are required to keep the number of HCV individuals with advanced liver disease and liver-related deaths from increasing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSSybyU3yDU0YhLSh9fo81bfW6udTcc2eYZZzgNxEvEW7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cnhvFeltw%253D%253D&md5=73a208b1f3b0e52c06578d5b36676102</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1111%2Fjvh.12248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjvh.12248%26sid%3Dliteratum%253Aachs%26aulast%3DRazavi%26aufirst%3DH.%26aulast%3DWaked%26aufirst%3DI.%26aulast%3DSarrazin%26aufirst%3DC.%26aulast%3DMyers%26aufirst%3DR.%2BP.%26aulast%3DIdilman%26aufirst%3DR.%26aulast%3DCalinas%26aufirst%3DF.%26aulast%3DVogel%26aufirst%3DW.%26aulast%3DMendes%2BCorrea%26aufirst%3DM.%2BC.%26aulast%3DHezode%26aufirst%3DC.%26aulast%3DLazaro%26aufirst%3DP.%26aulast%3DAkarca%26aufirst%3DU.%26aulast%3DAleman%26aufirst%3DS.%26aulast%3DBalik%26aufirst%3DI.%26aulast%3DBerg%26aufirst%3DT.%26aulast%3DBihl%26aufirst%3DF.%26aulast%3DBilodeau%26aufirst%3DM.%26aulast%3DBlasco%26aufirst%3DA.%2BJ.%26aulast%3DBrandao%2BMello%26aufirst%3DC.%2BE.%26aulast%3DBruggmann%26aufirst%3DP.%26aulast%3DButi%26aufirst%3DM.%26aulast%3DCalleja%26aufirst%3DJ.%2BL.%26aulast%3DCheinquer%26aufirst%3DH.%26aulast%3DChristensen%26aufirst%3DP.%2BB.%26aulast%3DClausen%26aufirst%3DM.%26aulast%3DCoelho%26aufirst%3DH.%2BS.%26aulast%3DCramp%26aufirst%3DM.%2BE.%26aulast%3DDore%26aufirst%3DG.%2BJ.%26aulast%3DDoss%26aufirst%3DW.%26aulast%3DDuberg%26aufirst%3DA.%2BS.%26aulast%3DEl-Sayed%26aufirst%3DM.%2BH.%26aulast%3DErgor%26aufirst%3DG.%26aulast%3DEsmat%26aufirst%3DG.%26aulast%3DFalconer%26aufirst%3DK.%26aulast%3DFelix%26aufirst%3DJ.%26aulast%3DFerraz%26aufirst%3DM.%2BL.%26aulast%3DFerreira%26aufirst%3DP.%2BR.%26aulast%3DFrankova%26aufirst%3DS.%26aulast%3DGarcia-Samaniego%26aufirst%3DJ.%26aulast%3DGerstoft%26aufirst%3DJ.%26aulast%3DGiria%26aufirst%3DJ.%2BA.%26aulast%3DGoncales%26aufirst%3DF.%2BL.%26aulast%3DGower%26aufirst%3DE.%26aulast%3DGschwantler%26aufirst%3DM.%26aulast%3DGuimaraes%2BPessoa%26aufirst%3DM.%26aulast%3DHindman%26aufirst%3DS.%2BJ.%26aulast%3DHofer%26aufirst%3DH.%26aulast%3DHusa%26aufirst%3DP.%26aulast%3DKaberg%26aufirst%3DM.%26aulast%3DKaita%26aufirst%3DK.%2BD.%26aulast%3DKautz%26aufirst%3DA.%26aulast%3DKaymakoglu%26aufirst%3DS.%26aulast%3DKrajden%26aufirst%3DM.%26aulast%3DKrarup%26aufirst%3DH.%26aulast%3DLaleman%26aufirst%3DW.%26aulast%3DLavanchy%26aufirst%3DD.%26aulast%3DMarinho%26aufirst%3DR.%2BT.%26aulast%3DMarotta%26aufirst%3DP.%26aulast%3DMauss%26aufirst%3DS.%26aulast%3DMoreno%26aufirst%3DC.%26aulast%3DMurphy%26aufirst%3DK.%26aulast%3DNegro%26aufirst%3DF.%26aulast%3DNemecek%26aufirst%3DV.%26aulast%3DOrmeci%26aufirst%3DN.%26aulast%3DOvrehus%26aufirst%3DA.%2BL.%26aulast%3DParkes%26aufirst%3DJ.%26aulast%3DPasini%26aufirst%3DK.%26aulast%3DPeltekian%26aufirst%3DK.%2BM.%26aulast%3DRamji%26aufirst%3DA.%26aulast%3DReis%26aufirst%3DN.%26aulast%3DRoberts%26aufirst%3DS.%2BK.%26aulast%3DRosenberg%26aufirst%3DW.%2BM.%26aulast%3DRoudot-Thoraval%26aufirst%3DF.%26aulast%3DRyder%26aufirst%3DS.%2BD.%26aulast%3DSarmento-Castro%26aufirst%3DR.%26aulast%3DSemela%26aufirst%3DD.%26aulast%3DSherman%26aufirst%3DM.%26aulast%3DShiha%26aufirst%3DG.%2BE.%26aulast%3DSievert%26aufirst%3DW.%26aulast%3DSperl%26aufirst%3DJ.%26aulast%3DStarkel%26aufirst%3DP.%26aulast%3DStauber%26aufirst%3DR.%2BE.%26aulast%3DThompson%26aufirst%3DA.%2BJ.%26aulast%3DUrbanek%26aufirst%3DP.%26aulast%3DVan%2BDamme%26aufirst%3DP.%26aulast%3Dvan%2BThiel%26aufirst%3DI.%26aulast%3DVan%2BVlierberghe%26aufirst%3DH.%26aulast%3DVandijck%26aufirst%3DD.%26aulast%3DWedemeyer%26aufirst%3DH.%26aulast%3DWeis%26aufirst%3DN.%26aulast%3DWiegand%26aufirst%3DJ.%26aulast%3DYosry%26aufirst%3DA.%26aulast%3DZekry%26aufirst%3DA.%26aulast%3DCornberg%26aufirst%3DM.%26aulast%3DMullhaupt%26aufirst%3DB.%26aulast%3DEstes%26aufirst%3DC.%26atitle%3DThe%2520present%2520and%2520future%2520disease%2520burden%2520of%2520hepatitis%2520C%2520virus%2520%2528HCV%2529%2520infection%2520with%2520today%25E2%2580%2599s%2520treatment%2520paradigm%26jtitle%3DJ.%2520Viral.%2520Hepat.%26date%3D2014%26volume%3D21%26spage%3D34%26epage%3D59%26doi%3D10.1111%2Fjvh.12248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Gower, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blach, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Razavi-Shearer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Razavi, H.</span><span> </span><span class="NLM_article-title">Global epidemiology and genotype distribution of the hepatitis C virus infection</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">S45</span><span class="NLM_x">–</span> <span class="NLM_lpage">S57</span><span class="refDoi"> DOI: 10.1016/j.jhep.2014.07.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1016%2Fj.jhep.2014.07.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=25086286" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2014&pages=S45-S57&author=E.+Gowerauthor=C.+Estesauthor=S.+Blachauthor=K.+Razavi-Shearerauthor=H.+Razavi&title=Global+epidemiology+and+genotype+distribution+of+the+hepatitis+C+virus+infection&doi=10.1016%2Fj.jhep.2014.07.027"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2014.07.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2014.07.027%26sid%3Dliteratum%253Aachs%26aulast%3DGower%26aufirst%3DE.%26aulast%3DEstes%26aufirst%3DC.%26aulast%3DBlach%26aufirst%3DS.%26aulast%3DRazavi-Shearer%26aufirst%3DK.%26aulast%3DRazavi%26aufirst%3DH.%26atitle%3DGlobal%2520epidemiology%2520and%2520genotype%2520distribution%2520of%2520the%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DJ.%2520Hepatol.%26date%3D2014%26volume%3D61%26spage%3DS45%26epage%3DS57%26doi%3D10.1016%2Fj.jhep.2014.07.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Messina, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humphreys, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaxman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooke, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pybus, O. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnes, E.</span><span> </span><span class="NLM_article-title">Global distribution and prevalence of hepatitis C virus genotypes</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">77</span><span class="NLM_x">–</span> <span class="NLM_lpage">87</span><span class="refDoi"> DOI: 10.1002/hep.27259</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1002%2Fhep.27259" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=25069599" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A280%3ADC%252BC2cbms1CgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2015&pages=77-87&author=J.+P.+Messinaauthor=I.+Humphreysauthor=A.+Flaxmanauthor=A.+Brownauthor=G.+S.+Cookeauthor=O.+G.+Pybusauthor=E.+Barnes&title=Global+distribution+and+prevalence+of+hepatitis+C+virus+genotypes&doi=10.1002%2Fhep.27259"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Global distribution and prevalence of hepatitis C virus genotypes</span></div><div class="casAuthors">Messina Jane P; Humphreys Isla; Flaxman Abraham; Brown Anthony; Cooke Graham S; Pybus Oliver G; Barnes Eleanor</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Baltimore, Md.)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">77-87</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">UNLABELLED:  Hepatitis C virus (HCV) exhibits high genetic diversity, characterized by regional variations in genotype prevalence.  This poses a challenge to the improved development of vaccines and pan-genotypic treatments, which require the consideration of global trends in HCV genotype prevalence.  Here we provide the first comprehensive survey of these trends.  To approximate national HCV genotype prevalence, studies published between 1989 and 2013 reporting HCV genotypes are reviewed and combined with overall HCV prevalence estimates from the Global Burden of Disease (GBD) project.  We also generate regional and global genotype prevalence estimates, inferring data for countries lacking genotype information.  We include 1,217 studies in our analysis, representing 117 countries and 90% of the global population.  We calculate that HCV genotype 1 is the most prevalent worldwide, comprising 83.4 million cases (46.2% of all HCV cases), approximately one-third of which are in East Asia.  Genotype 3 is the next most prevalent globally (54.3 million, 30.1%); genotypes 2, 4, and 6 are responsible for a total 22.8% of all cases; genotype 5 comprises the remaining <1%.  While genotypes 1 and 3 dominate in most countries irrespective of economic status, the largest proportions of genotypes 4 and 5 are in lower-income countries.  CONCLUSION:  Although genotype 1 is most common worldwide, nongenotype 1 HCV cases--which are less well served by advances in vaccine and drug development--still comprise over half of all HCV cases.  Relative genotype proportions are needed to inform healthcare models, which must be geographically tailored to specific countries or regions in order to improve access to new treatments.  Genotype surveillance data are needed from many countries to improve estimates of unmet need.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR2Xg9XEOxbiuQ4Pl9hzjQhfW6udTcc2ebgPydzEfDwjbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbms1CgtA%253D%253D&md5=4ad9cc1d6592acffdc485d0baccfe939</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1002%2Fhep.27259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.27259%26sid%3Dliteratum%253Aachs%26aulast%3DMessina%26aufirst%3DJ.%2BP.%26aulast%3DHumphreys%26aufirst%3DI.%26aulast%3DFlaxman%26aufirst%3DA.%26aulast%3DBrown%26aufirst%3DA.%26aulast%3DCooke%26aufirst%3DG.%2BS.%26aulast%3DPybus%26aufirst%3DO.%2BG.%26aulast%3DBarnes%26aufirst%3DE.%26atitle%3DGlobal%2520distribution%2520and%2520prevalence%2520of%2520hepatitis%2520C%2520virus%2520genotypes%26jtitle%3DHepatology%26date%3D2015%26volume%3D61%26spage%3D77%26epage%3D87%26doi%3D10.1002%2Fhep.27259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span>Guidelines for the Screening, Care and Treatment of Persons with Chronic Hepatitis C Infection; <span class="NLM_publisher-name">World Health Organization</span>: <span class="NLM_publisher-loc">Geneva</span>, updated version, April 2016; <a href="http://www.who.int/hepatitis/publications/hepatitis-c-guidelines-2016/en/" class="extLink">http://www.who.int/hepatitis/publications/hepatitis-c-guidelines-2016/en/</a> (Accessed February 6, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Guidelines+for+the+Screening%2C+Care+and+Treatment+of+Persons+with+Chronic+Hepatitis+C+Infection%3B+World+Health+Organization%3A+Geneva%2C+updated+version%2C+April+2016%3B+http%3A%2F%2Fwww.who.int%2Fhepatitis%2Fpublications%2Fhepatitis-c-guidelines-2016%2Fen%2F+%28Accessed+February+6%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DGuidelines%2520for%2520the%2520Screening%252C%2520Care%2520and%2520Treatment%2520of%2520Persons%2520with%2520Chronic%2520Hepatitis%2520C%2520Infection%26pub%3DWorld%2520Health%2520Organization" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Asselah, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyer, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saadoun, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinot-Peignoux, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcellin, P.</span><span> </span><span class="NLM_article-title">Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives</span> <span class="citation_source-journal">Liver Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">47</span><span class="NLM_x">–</span> <span class="NLM_lpage">57</span><span class="refDoi"> DOI: 10.1111/liv.13027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1111%2Fliv.13027" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2016&pages=47-57&author=T.+Asselahauthor=N.+Boyerauthor=D.+Saadounauthor=M.+Martinot-Peignouxauthor=P.+Marcellin&title=Direct-acting+antivirals+for+the+treatment+of+hepatitis+C+virus+infection%3A+optimizing+current+IFN-free+treatment+and+future+perspectives&doi=10.1111%2Fliv.13027"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1111%2Fliv.13027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fliv.13027%26sid%3Dliteratum%253Aachs%26aulast%3DAsselah%26aufirst%3DT.%26aulast%3DBoyer%26aufirst%3DN.%26aulast%3DSaadoun%26aufirst%3DD.%26aulast%3DMartinot-Peignoux%26aufirst%3DM.%26aulast%3DMarcellin%26aufirst%3DP.%26atitle%3DDirect-acting%2520antivirals%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%2520virus%2520infection%253A%2520optimizing%2520current%2520IFN-free%2520treatment%2520and%2520future%2520perspectives%26jtitle%3DLiver%2520Int.%26date%3D2016%26volume%3D36%26spage%3D47%26epage%3D57%26doi%3D10.1111%2Fliv.13027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Afdhal, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeuzem, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chojkier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gitlin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puoti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero-Gomez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarski, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agarwal, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buggisch, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foster, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bräu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanian, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Symonds, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHutchison, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muir, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mangia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcellin, P.</span><span> </span><span class="NLM_article-title">Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">1889</span><span class="NLM_x">–</span> <span class="NLM_lpage">1898</span><span class="refDoi"> DOI: 10.1056/NEJMoa1402454</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1056%2FNEJMoa1402454" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=24725239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGksbnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=1889-1898&author=N.+Afdhalauthor=S.+Zeuzemauthor=P.+Kwoauthor=M.+Chojkierauthor=N.+Gitlinauthor=M.+Puotiauthor=M.+Romero-Gomezauthor=J.-P.+Zarskiauthor=K.+Agarwalauthor=P.+Buggischauthor=G.+R.+Fosterauthor=N.+Br%C3%A4uauthor=M.+Butiauthor=I.+M.+Jacobsonauthor=G.+M.+Subramanianauthor=X.+Dingauthor=H.+Moauthor=J.+C.+Yangauthor=P.+S.+Pangauthor=W.+T.+Symondsauthor=J.+G.+McHutchisonauthor=A.+J.+Muirauthor=A.+Mangiaauthor=P.+Marcellin&title=Ledipasvir+and+sofosbuvir+for+untreated+HCV+genotype+1+infection&doi=10.1056%2FNEJMoa1402454"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection</span></div><div class="casAuthors">Afdhal, Nezam; Zeuzem, Stefan; Kwo, Paul; Chojkier, Mario; Gitlin, Norman; Puoti, Massimo; Romero-Gomez, Manuel; Zarski, Jean-Pierre; Agarwal, Kosh; Buggisch, Peter; Foster, Graham R.; Brau, Norbert; Buti, Maria; Jacobson, Ira M.; Subramanian, G. Mani; Ding, Xiao; Mo, Hongmei; Yang, Jenny C.; Pang, Phillip S.; Symonds, William T.; McHutchison, John G.; Muir, Andrew J.; Mangia, Alessandra; Marcellin, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1889-1898, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: In phase 2 studies, treatment with the all-oral combination of the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor ledipasvir resulted in high rates of sustained virol. response among previously untreated patients with hepatitis C virus (HCV) genotype 1 infection.  Methods: We conducted a phase 3, open-label study involving previously untreated patients with chronic HCV genotype 1 infection.  Patients were randomly assigned in a 1:1:1:1 ratio to receive ledipasvir and sofosbuvir in a fixed-dose combination tablet once daily for 12 wk, ledipasvir-sofosbuvir plus ribavirin for 12 wk, ledipasvir- sofosbuvir for 24 wk, or ledipasvir-sofosbuvir plus ribavirin for 24 wk.  The primary end point was a sustained virol. response at 12 wk after the end of therapy.  Results: Of the 865 patients who underwent randomization and were treated, 16% had cirrhosis, 12% were black, and 67% had HCV genotype 1a infection.  The rates of sustained virol. response were 99% (95% confidence interval [CI], 96 to 100) in the group that received 12 wk of ledipasvir-sofosbuvir; 97% (95% CI, 94 to 99) in the group that received 12 wk of ledipasvir-sofosbuvir plus ribavirin; 98% (95% CI, 95 to 99) in the group that received 24 wk of ledipasvir-sofosbuvir; and 99% (95% CI, 97 to 100) in the group that received 24 wk of ledipasvir-sofosbuvir plus ribavirin.  No patient in either 12-wk group discontinued ledipasvir-sofosbuvir owing to an adverse event.  The most common adverse events were fatigue, headache, insomnia, and nausea.  Conculsions: Once-daily ledipasvir-sofosbuvir with or without ribavirin for 12 or 24 wk was highly effective in previously untreated patients with HCV genotype 1 infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroadkxw2jRR7Vg90H21EOLACvtfcHk0ljjYHKCd8vkBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGksbnM&md5=e433fd7d493c1c0f9dfef37c1527388f</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1402454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1402454%26sid%3Dliteratum%253Aachs%26aulast%3DAfdhal%26aufirst%3DN.%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DKwo%26aufirst%3DP.%26aulast%3DChojkier%26aufirst%3DM.%26aulast%3DGitlin%26aufirst%3DN.%26aulast%3DPuoti%26aufirst%3DM.%26aulast%3DRomero-Gomez%26aufirst%3DM.%26aulast%3DZarski%26aufirst%3DJ.-P.%26aulast%3DAgarwal%26aufirst%3DK.%26aulast%3DBuggisch%26aufirst%3DP.%26aulast%3DFoster%26aufirst%3DG.%2BR.%26aulast%3DBr%25C3%25A4u%26aufirst%3DN.%26aulast%3DButi%26aufirst%3DM.%26aulast%3DJacobson%26aufirst%3DI.%2BM.%26aulast%3DSubramanian%26aufirst%3DG.%2BM.%26aulast%3DDing%26aufirst%3DX.%26aulast%3DMo%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26aulast%3DPang%26aufirst%3DP.%2BS.%26aulast%3DSymonds%26aufirst%3DW.%2BT.%26aulast%3DMcHutchison%26aufirst%3DJ.%2BG.%26aulast%3DMuir%26aufirst%3DA.%2BJ.%26aulast%3DMangia%26aufirst%3DA.%26aulast%3DMarcellin%26aufirst%3DP.%26atitle%3DLedipasvir%2520and%2520sofosbuvir%2520for%2520untreated%2520HCV%2520genotype%25201%2520infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26spage%3D1889%26epage%3D1898%26doi%3D10.1056%2FNEJMoa1402454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Ferenci, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernstein, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lalezari, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marinho, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nyberg, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Younes, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Enayati, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baruch, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhandari, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caruntu, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sepe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chulanov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janczewska, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizzardini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gervain, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Planas, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassanein, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Podsadecki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, K. R.</span><span> </span><span class="NLM_article-title">ABT-450/r–ombitasvir and dasabuvir with or without ribavirin for HCV</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">1983</span><span class="NLM_x">–</span> <span class="NLM_lpage">1992</span><span class="refDoi"> DOI: 10.1056/NEJMoa1402338</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1056%2FNEJMoa1402338" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=24795200" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGksbnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=1983-1992&author=P.+Ferenciauthor=D.+Bernsteinauthor=J.+Lalezariauthor=D.+Cohenauthor=Y.+Luoauthor=C.+Cooperauthor=E.+Tamauthor=R.+T.+Marinhoauthor=N.+Tsaiauthor=A.+Nybergauthor=T.+D.+Boxauthor=Z.+Younesauthor=P.+Enayatiauthor=S.+Greenauthor=Y.+Baruchauthor=B.+R.+Bhandariauthor=F.+A.+Caruntuauthor=T.+Sepeauthor=V.+Chulanovauthor=E.+Janczewskaauthor=G.+Rizzardiniauthor=J.+Gervainauthor=R.+Planasauthor=C.+Morenoauthor=T.+Hassaneinauthor=W.+Xieauthor=M.+Kingauthor=T.+Podsadeckiauthor=K.+R.+Reddy&title=ABT-450%2Fr%E2%80%93ombitasvir+and+dasabuvir+with+or+without+ribavirin+for+HCV&doi=10.1056%2FNEJMoa1402338"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">ABT-450/r-mbitasvir and dasabuvir with or without ribavirin for HCV</span></div><div class="casAuthors">Ferenci, Peter; Bernstein, David; Lalezari, Jacob; Cohen, Daniel; Luo, Yan; Cooper, Curtis; Tam, Edward; Marinho, Rui T.; Tsai, Naoky; Nyberg, Anders; Box, Terry D.; Younes, Ziad; Enayati, Pedram; Green, Sinikka; Baruch, Yaacov; Bhandari, Bal Raj; Caruntu, Florin Alexandru; Sepe, Thomas; Chulanov, Vladimir; Janczewska, Ewa; Rizzardini, Giuliano; Gervain, Judit; Planas, Ramon; Moreno, Christophe; Hassanein, Tarek; Xie, Wangang; King, Martin; Podsadecki, Thomas; Reddy, K. Rajender</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">1983-1992, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: The interferon-free regimen of ABT-450 with ritonavir (ABT-450/r), ombitasvir, and dasabuvir with or without ribavirin has shown efficacy in inducing a sustained virol. response in a phase 2 study involving patients with hepatitis C virus (HCV) genotype 1 infection.  We conducted two phase 3 trials to examine the efficacy and safety of this regimen in previously untreated patients with HCV genotype 1 infection and no cirrhosis.  Methods: We randomly assigned 419 patients with HCV genotype 1b infection (PEARL-III study) and 305 patients with genotype 1a infection (PEARL-IV study) to 12 wk of ABT-450/r-ombitasvir (at a once-daily dose of 150 mg of ABT-450, 100 mg of ritonavir, and 25 mg of ombitasvir), dasabuvir (250 mg twice daily), and ribavirin administered according to body wt. or to matching placebo for ribavirin.  The primary efficacy end point was a sustained virol. response (an HCV RNA level of <25 IU per mL) 12 wk after the end of treatment.  Results: The study regimen resulted in high rates of sustained virol. response among patients with HCV genotype 1b infection (99.5% with ribavirin and 99.0% without ribavirin) and among those with genotype 1a infection (97.0% and 90.2%, resp.).  Of patients with genotype 1b infection, 1 had virol. failure, and 2 did not have data available at post-treatment week 12.  Among patients with genotype 1a infection, the rate of virol. failure was higher in the ribavirin-free group than in the ribavirin group (7.8% vs. 2.0%).  In both studies, decreases in the Hb level were significantly more common in patients receiving ribavirin.  Two patients (0.3%) discontinued the study drugs owing to adverse events.  The most common adverse events were fatigue, headache, and nausea.  Conclusions: Twelve weeks of treatment with ABT-450/r-ombitasvir and dasabuvir without ribavirin was assocd. with high rates of sustained virol. response among previously untreated patients with HCV genotype 1 infection.  Rates of virol. failure were higher without ribavirin than with ribavirin among patients with genotype 1a infection but not among those with genotype 1b infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGru0b7jyqCe37Vg90H21EOLACvtfcHk0lii9dkvBMVL-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGksbnN&md5=b08a13aba3156a82bdcdd71203269b28</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1402338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1402338%26sid%3Dliteratum%253Aachs%26aulast%3DFerenci%26aufirst%3DP.%26aulast%3DBernstein%26aufirst%3DD.%26aulast%3DLalezari%26aufirst%3DJ.%26aulast%3DCohen%26aufirst%3DD.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DCooper%26aufirst%3DC.%26aulast%3DTam%26aufirst%3DE.%26aulast%3DMarinho%26aufirst%3DR.%2BT.%26aulast%3DTsai%26aufirst%3DN.%26aulast%3DNyberg%26aufirst%3DA.%26aulast%3DBox%26aufirst%3DT.%2BD.%26aulast%3DYounes%26aufirst%3DZ.%26aulast%3DEnayati%26aufirst%3DP.%26aulast%3DGreen%26aufirst%3DS.%26aulast%3DBaruch%26aufirst%3DY.%26aulast%3DBhandari%26aufirst%3DB.%2BR.%26aulast%3DCaruntu%26aufirst%3DF.%2BA.%26aulast%3DSepe%26aufirst%3DT.%26aulast%3DChulanov%26aufirst%3DV.%26aulast%3DJanczewska%26aufirst%3DE.%26aulast%3DRizzardini%26aufirst%3DG.%26aulast%3DGervain%26aufirst%3DJ.%26aulast%3DPlanas%26aufirst%3DR.%26aulast%3DMoreno%26aufirst%3DC.%26aulast%3DHassanein%26aufirst%3DT.%26aulast%3DXie%26aufirst%3DW.%26aulast%3DKing%26aufirst%3DM.%26aulast%3DPodsadecki%26aufirst%3DT.%26aulast%3DReddy%26aufirst%3DK.%2BR.%26atitle%3DABT-450%252Fr%25E2%2580%2593ombitasvir%2520and%2520dasabuvir%2520with%2520or%2520without%2520ribavirin%2520for%2520HCV%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26spage%3D1983%26epage%3D1992%26doi%3D10.1056%2FNEJMoa1402338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Lawitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gane, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearlman, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghesquiere, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guyader, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alric, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bronowicki, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lester, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sievert, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghalib, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balart, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sund, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lagging, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutko, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaughnessy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howe, A. Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wahl, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barr, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, B.</span><span> </span><span class="NLM_article-title">Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">385</span><span class="NLM_x">, </span> <span class="NLM_fpage">1075</span><span class="NLM_x">–</span> <span class="NLM_lpage">1086</span><span class="refDoi"> DOI: 10.1016/S0140-6736(14)61795-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1016%2FS0140-6736%2814%2961795-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=25467591" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFSgtr3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=385&publication_year=2015&pages=1075-1086&author=E.+Lawitzauthor=E.+Ganeauthor=B.+Pearlmanauthor=E.+Tamauthor=W.+Ghesquiereauthor=D.+Guyaderauthor=L.+Alricauthor=J.-P.+Bronowickiauthor=L.+Lesterauthor=W.+Sievertauthor=R.+Ghalibauthor=L.+Balartauthor=F.+Sundauthor=M.+Laggingauthor=F.+Dutkoauthor=M.+Shaughnessyauthor=P.+Hwangauthor=A.+Y.+M.+Howeauthor=J.+Wahlauthor=M.+Robertsonauthor=E.+Barrauthor=B.+Haber&title=Efficacy+and+safety+of+12+weeks+versus+18+weeks+of+treatment+with+grazoprevir+%28MK-5172%29+and+elbasvir+%28MK-8742%29+with+or+without+ribavirin+for+hepatitis+C+virus+genotype+1+infection+in+previously+untreated+patients+with+cirrhosis+and+patients+with+previous+null+response+with+or+without+cirrhosis+%28C-WORTHY%29%3A+a+randomised%2C+open-label+phase+2+trial&doi=10.1016%2FS0140-6736%2814%2961795-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial</span></div><div class="casAuthors">Lawitz, Eric; Gane, Edward; Pearlman, Brian; Tam, Edward; Ghesquiere, Wayne; Guyader, Dominique; Alric, Laurent; Bronowicki, Jean-Pierre; Lester, Laura; Sievert, William; Ghalib, Reem; Balart, Luis; Sund, Fredrik; Lagging, Martin; Dutko, Frank; Shaughnessy, Melissa; Hwang, Peggy; Howe, Anita Y. M.; Wahl, Janice; Robertson, Michael; Barr, Eliav; Haber, Barbara</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">385</span>
        (<span class="NLM_cas:issue">9973</span>),
    <span class="NLM_cas:pages">1075-1086</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">There is a high medical need for an interferon-free, all-oral, short-duration therapy for hepatitis C virus (HCV) that is highly effective across diverse patient populations, including patients with cirrhosis or previous null response to pegylated interferon (peginterferon) plus ribavirin (PR-null responders).  We aimed to assess the efficacy, safety, and effective treatment duration of grazoprevir (an HCV NS3/4A protease inhibitor) combined with elbasvir (an HCV NS5A inhibitor) with or without ribavirin in patients with HCV genotype 1 infection with baseline characteristics of poor response.  The C-WORTHY trial is a randomised, open-label phase 2 trial of grazoprevir plus elbasvir with or without ribavirin; here we report findings for two cohorts of previously untreated patients with cirrhosis (cohort 1) and those with previous PR-null response with or without cirrhosis (cohort 2) enrolled in part B of the study.  Eligible patients were adults aged 18 years or older with chronic HCV genotype 1 infection and HCV RNA concns. of 10 000 IU/mL or higher in peripheral blood.  We randomly assigned patients to receive grazoprevir (100 mg daily) and elbasvir (50 mg daily) with or without ribavirin for 12 or 18 wk.  Randomisation was done centrally with an interactive voice response system; patients and study investigators were masked to treatment duration up to week 12 but not to treatment allocation.  The primary endpoint was the proportion of patients achieving HCV RNA less than 25 IU/mL at 12 wk after end of treatment (SVR12), assessed by COBAS TaqMan version 2.0.  This study is registered with ClinicalTrials.gov, no. NCT01717326.  We describe findings for 253 patients enrolled in cohort 1 (n=123) or cohort 2 (n=130).  In cohort 1, we randomly assigned 60 patients to the 12-wk regimen (31 with ribavirin and 29 with no ribavirin) and 63 to the 18-wk regimen (32 with ribavirin and 31 with no ribavirin); in cohort 2, we randomly assigned 65 patients to the 12-wk regimen (32 with ribavirin and 33 with no ribavirin) and 65 to the 18-wk regimen 33 with ribavirin and 32 with no ribavirin. High SVR12 rates were achieved irresp. of the use of ribavirin or extension of the treatment duration from 12 to 18 wk; SVR12 rates ranged from 90% (95% CI 74-98; 28/31; cohort 1, 12 wk, ribavirin-contg.) to 100% (95% CI 89-100; 33/33; cohort 2, 18 wk, ribavirin-contg.).  Among patients treated for 12 wk with grazoprevir plus elbasvir without ribavirin, 97% (95% CI 82-100, 28/29) of patients in cohort 1 and 91% (76-98, 30/33) of patients in cohort 2 achieved SVR12.  Adverse events reported in more than 10% of patients were fatigue (66 patients, 26% [95% CI 21-32]), headache (58 patients, 23% [95% CI 18-29]), and asthenia (35 patients, 14% [95% CI 10-19]).  Treatment with grazoprevir plus elbasvir, both with and without ribavirin and for both 12 and 18 wk' treatment duration, showed high rates of efficacy in previously untreated patients with cirrhosis and previous PR-null responders with and without cirrhosis.  These results support the phase 3 development of grazoprevir plus elbasvir.Merck & Co, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQI1vPRgvrsrVg90H21EOLACvtfcHk0lii9dkvBMVL-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFSgtr3I&md5=e10e9a1ec653df21f11c1e8c725731bf</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2814%2961795-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252814%252961795-5%26sid%3Dliteratum%253Aachs%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DGane%26aufirst%3DE.%26aulast%3DPearlman%26aufirst%3DB.%26aulast%3DTam%26aufirst%3DE.%26aulast%3DGhesquiere%26aufirst%3DW.%26aulast%3DGuyader%26aufirst%3DD.%26aulast%3DAlric%26aufirst%3DL.%26aulast%3DBronowicki%26aufirst%3DJ.-P.%26aulast%3DLester%26aufirst%3DL.%26aulast%3DSievert%26aufirst%3DW.%26aulast%3DGhalib%26aufirst%3DR.%26aulast%3DBalart%26aufirst%3DL.%26aulast%3DSund%26aufirst%3DF.%26aulast%3DLagging%26aufirst%3DM.%26aulast%3DDutko%26aufirst%3DF.%26aulast%3DShaughnessy%26aufirst%3DM.%26aulast%3DHwang%26aufirst%3DP.%26aulast%3DHowe%26aufirst%3DA.%2BY.%2BM.%26aulast%3DWahl%26aufirst%3DJ.%26aulast%3DRobertson%26aufirst%3DM.%26aulast%3DBarr%26aufirst%3DE.%26aulast%3DHaber%26aufirst%3DB.%26atitle%3DEfficacy%2520and%2520safety%2520of%252012%2520weeks%2520versus%252018%2520weeks%2520of%2520treatment%2520with%2520grazoprevir%2520%2528MK-5172%2529%2520and%2520elbasvir%2520%2528MK-8742%2529%2520with%2520or%2520without%2520ribavirin%2520for%2520hepatitis%2520C%2520virus%2520genotype%25201%2520infection%2520in%2520previously%2520untreated%2520patients%2520with%2520cirrhosis%2520and%2520patients%2520with%2520previous%2520null%2520response%2520with%2520or%2520without%2520cirrhosis%2520%2528C-WORTHY%2529%253A%2520a%2520randomised%252C%2520open-label%2520phase%25202%2520trial%26jtitle%3DLancet%26date%3D2015%26volume%3D385%26spage%3D1075%26epage%3D1086%26doi%3D10.1016%2FS0140-6736%2814%2961795-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Everson, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Towner, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyles, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nahass, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thuluvath, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etzkorn, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinestrosa, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabinovitz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNally, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brainard, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doehle, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHutchison, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, T. T.</span><span> </span><span class="NLM_article-title">Sofosbuvir with velpatasvir in treatment-naive noncirrhotic patients with genotype 1 to 6 hepatitis C virus infection: a randomized trial</span> <span class="citation_source-journal">Ann. Intern. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">163</span><span class="NLM_x">, </span> <span class="NLM_fpage">818</span><span class="NLM_x">–</span> <span class="NLM_lpage">826</span><span class="refDoi"> DOI: 10.7326/M15-1000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.7326%2FM15-1000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=26551051" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A280%3ADC%252BC28vgt1agtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2015&pages=818-826&author=G.+T.+Eversonauthor=W.+J.+Townerauthor=M.+N.+Davisauthor=D.+L.+Wylesauthor=R.+G.+Nahassauthor=P.+J.+Thuluvathauthor=K.+Etzkornauthor=F.+Hinestrosaauthor=M.+Tongauthor=M.+Rabinovitzauthor=J.+McNallyauthor=D.+M.+Brainardauthor=L.+Hanauthor=B.+Doehleauthor=J.+G.+McHutchisonauthor=T.+Morganauthor=R.+T.+Chungauthor=T.+T.+Tran&title=Sofosbuvir+with+velpatasvir+in+treatment-naive+noncirrhotic+patients+with+genotype+1+to+6+hepatitis+C+virus+infection%3A+a+randomized+trial&doi=10.7326%2FM15-1000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial</span></div><div class="casAuthors">Everson Gregory T; Towner William J; Davis Mitchell N; Wyles David L; Nahass Ronald G; Thuluvath Paul J; Etzkorn Kyle; Hinestrosa Federico; Tong Myron; Rabinovitz Mordechai; McNally John; Brainard Diana M; Han Lingling; Doehle Brian; McHutchison John G; Morgan Timothy; Chung Raymond T; Tran Tram T</div><div class="citationInfo"><span class="NLM_cas:title">Annals of internal medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">818-26</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Effective, pangenotypic treatments for hepatitis C virus (HCV) infection are needed.  OBJECTIVE:  To assess the safety and efficacy of sofosbuvir with velpatasvir in patients infected with HCV genotypes 1 to 6.  DESIGN:  Randomized, phase 2, open-label study. (ClinicalTrials.gov: NCT01858766).  SETTING:  48 U.S. sites.  PATIENTS:  377 treatment-naive noncirrhotic patients.  In part A, patients infected with HCV genotypes 1 to 6 were randomly assigned to sofosbuvir, 400 mg, with velpatasvir, 25 or 100 mg, for 12 weeks.  In part B, patients with genotype 1 or 2 HCV infection were randomly assigned to sofosbuvir, 400 mg, and velpatasvir, 25 or 100 mg, with or without ribavirin for 8 weeks.  MEASUREMENTS:  Sustained virologic response at 12 weeks (SVR12).  RESULTS:  In part A, SVR12 rates were 96% (26 of 27) with velpatasvir, 25 mg, and 100% (28 of 28) with velpatasvir, 100 mg, for genotype 1; 93% (25 of 27) in both groups for genotype 3; and 96% (22 of 23) with velpatasvir, 25 mg, and 95% (21 of 22) with velpatasvir, 100 mg, for genotypes 2, 4, 5, and 6.  In part B, for genotype 1, SVR12 rates were 87% (26 of 30) with velpatasvir, 25 mg; 83% (25 of 30) with velpatasvir, 25 mg, plus ribavirin; 90% (26 of 29) with velpatasvir, 100 mg; and 81% (25 of 31) with velpatasvir, 100 mg, plus ribavirin.  For genotype 2, SVR12 rates were 77% (20 of 26) with velpatasvir, 25 mg; 88% (22 of 25) with velpatasvir, 25 mg, plus ribavirin; 88% (23 of 26) with velpatasvir, 100 mg; and 88% (23 of 26) with velpatasvir, 100 mg, plus ribavirin.  Adverse events included fatigue (21%), headache (20%), and nausea (12%).  One patient committed suicide.  LIMITATION:  The study was open-label, no inferential statistics were planned, and sample sizes were small.  CONCLUSION:  Twelve weeks of sofosbuvir, 400 mg, and velpatasvir, 100 mg, was well-tolerated and resulted in high SVR in patients infected with HCV genotypes 1 to 6.  PRIMARY FUNDING SOURCE:  Gilead Sciences.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSe_4IC_iyrYa2q3xNe7a7QfW6udTcc2eYhnvw2plP4KLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28vgt1agtg%253D%253D&md5=d849efe4192fca8ae7921dd1e2bebfcb</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.7326%2FM15-1000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7326%252FM15-1000%26sid%3Dliteratum%253Aachs%26aulast%3DEverson%26aufirst%3DG.%2BT.%26aulast%3DTowner%26aufirst%3DW.%2BJ.%26aulast%3DDavis%26aufirst%3DM.%2BN.%26aulast%3DWyles%26aufirst%3DD.%2BL.%26aulast%3DNahass%26aufirst%3DR.%2BG.%26aulast%3DThuluvath%26aufirst%3DP.%2BJ.%26aulast%3DEtzkorn%26aufirst%3DK.%26aulast%3DHinestrosa%26aufirst%3DF.%26aulast%3DTong%26aufirst%3DM.%26aulast%3DRabinovitz%26aufirst%3DM.%26aulast%3DMcNally%26aufirst%3DJ.%26aulast%3DBrainard%26aufirst%3DD.%2BM.%26aulast%3DHan%26aufirst%3DL.%26aulast%3DDoehle%26aufirst%3DB.%26aulast%3DMcHutchison%26aufirst%3DJ.%2BG.%26aulast%3DMorgan%26aufirst%3DT.%26aulast%3DChung%26aufirst%3DR.%2BT.%26aulast%3DTran%26aufirst%3DT.%2BT.%26atitle%3DSofosbuvir%2520with%2520velpatasvir%2520in%2520treatment-naive%2520noncirrhotic%2520patients%2520with%2520genotype%25201%2520to%25206%2520hepatitis%2520C%2520virus%2520infection%253A%2520a%2520randomized%2520trial%26jtitle%3DAnn.%2520Intern.%2520Med.%26date%3D2015%26volume%3D163%26spage%3D818%26epage%3D826%26doi%3D10.7326%2FM15-1000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Pawlotsky, J. M.</span><span> </span><span class="NLM_article-title">Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">151</span><span class="NLM_x">, </span> <span class="NLM_fpage">70</span><span class="NLM_x">–</span> <span class="NLM_lpage">86</span><span class="refDoi"> DOI: 10.1053/j.gastro.2016.04.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1053%2Fj.gastro.2016.04.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=27080301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVyhs7bE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2016&pages=70-86&author=J.+M.+Pawlotsky&title=Hepatitis+C+virus+resistance+to+direct-acting+antiviral+drugs+in+interferon-free+regimens&doi=10.1053%2Fj.gastro.2016.04.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens</span></div><div class="casAuthors">Pawlotsky, Jean-Michel</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">70-86</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Treatment of hepatitis C virus (HCV) infection has progressed considerably with the approval of interferon-free, direct-acting antiviral (DAA)-based combination therapies.  Although most treated patients achieve virol. cure, HCV resistance to DAAs has an important role in the failure of interferon-free treatment regimens.  The presence of viral variants resistant to NS5A inhibitors at baseline is assocd. with lower rates of virol. cure in certain groups of patients, such as those with genotype 1a or 3 HCV, those with cirrhosis, and/or prior nonresponders to pegylated interferon-based regimens.  DAA-resistant HCV is generally dominant at virol. failure (most often relapse).  Viruses resistant to NS3-4A protease inhibitors disappear from peripheral blood in a few weeks to months, whereas NS5A inhibitor-resistant viruses persist for years.  Re-treatment options are available, but first-line treatment strategies should be optimized to efficiently prevent treatment failure due to HCV resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqN3LhkXIk5e7Vg90H21EOLACvtfcHk0lgh8Dm7R-PFbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVyhs7bE&md5=b536a77a661808be47d80a62175b24f5</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2016.04.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2016.04.003%26sid%3Dliteratum%253Aachs%26aulast%3DPawlotsky%26aufirst%3DJ.%2BM.%26atitle%3DHepatitis%2520C%2520virus%2520resistance%2520to%2520direct-acting%2520antiviral%2520drugs%2520in%2520interferon-free%2520regimens%26jtitle%3DGastroenterology%26date%3D2016%26volume%3D151%26spage%3D70%26epage%3D86%26doi%3D10.1053%2Fj.gastro.2016.04.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Meanwell, N. A.</span><span> </span><span class="NLM_article-title">2015 Philip S. Portoghese Medicinal Chemistry Lectureship. Curing hepatitis C virus infection with direct-acting antiviral agents: the arc of a medicinal chemistry triumph</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">7311</span><span class="NLM_x">–</span> <span class="NLM_lpage">7351</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00915</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00915" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht12itr%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7311-7351&author=N.+A.+Meanwell&title=2015+Philip+S.+Portoghese+Medicinal+Chemistry+Lectureship.+Curing+hepatitis+C+virus+infection+with+direct-acting+antiviral+agents%3A+the+arc+of+a+medicinal+chemistry+triumph&doi=10.1021%2Facs.jmedchem.6b00915"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">2015 Philip S. Portoghese Medicinal Chemistry Lectureship. Curing Hepatitis C Virus Infection with Direct-Acting Antiviral Agents: The Arc of a Medicinal Chemistry Triumph</span></div><div class="casAuthors">Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7311-7351</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The development of direct-acting antiviral agents that can cure a chronic hepatitis C virus (HCV) infection after 8-12 wk of daily, well-tolerated therapy has revolutionized the treatment of this insidious disease.  In this article, three of Bristol-Myers Squibb's HCV programs are summarized, each of which produced a clin. candidate: the NS3 protease inhibitor asunaprevir (64), marketed as Sunvepra, the NS5A replication complex inhibitor daclatasvir (117), marketed as Daklinza, and the allosteric NS5B polymerase inhibitor beclabuvir (142), which is in late stage clin. studies.  A clin. study with 64 and 117 established for the first time that a chronic HCV infection could be cured by treatment with direct-acting antiviral agents alone in the absence of interferon.  The development of small mol. HCV therapeutics, designed by medicinal chemists, has been hailed as "the arc of a medical triumph" but may equally well be described as "the arc of a medicinal chem. triumph".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-IMg2ReRMArVg90H21EOLACvtfcHk0ljoOkC5jH6xqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht12itr%252FO&md5=c8232aba85caf67bf38494bc5ddeb508</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00915%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3D2015%2520Philip%2520S.%2520Portoghese%2520Medicinal%2520Chemistry%2520Lectureship.%2520Curing%2520hepatitis%2520C%2520virus%2520infection%2520with%2520direct-acting%2520antiviral%2520agents%253A%2520the%2520arc%2520of%2520a%2520medicinal%2520chemistry%2520triumph%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7311%26epage%3D7351%26doi%3D10.1021%2Facs.jmedchem.6b00915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">McCauley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudd, M. T.</span><span> </span><span class="NLM_article-title">Hepatitis C virus NS3/4a protease inhibitors</span> <span class="citation_source-journal">Curr. Opin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">84</span><span class="NLM_x">–</span> <span class="NLM_lpage">92</span><span class="refDoi"> DOI: 10.1016/j.coph.2016.07.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1016%2Fj.coph.2016.07.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=27544488" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1ygurrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=84-92&author=J.+A.+McCauleyauthor=M.+T.+Rudd&title=Hepatitis+C+virus+NS3%2F4a+protease+inhibitors&doi=10.1016%2Fj.coph.2016.07.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis C virus NS3/4a protease inhibitors</span></div><div class="casAuthors">McCauley, John A.; Rudd, Michael T.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">84-92</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) infection is a major health issue around the world and HCV NS3/4a protease inhibitors have been the focus of intensive research for the past 20 years.  From the first identification of substrate-derived peptide inhibitors to the complex, macrocyclic compds., including paritaprevir and grazoprevir, that are currently available, the field has used structure-based design to confront the issues of potency, resistance and pharmacokinetics.  Numerous breakthrough structures from a multitude of companies have led to compds. that are now key components of combination therapies with cure rates of >90%.  Herein, we detail the compds. that have advanced to clin. trials including their design and their impact on the NS3/4a protease field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoecX2r0UguZLVg90H21EOLACvtfcHk0ljoOkC5jH6xqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1ygurrJ&md5=1d7d626d8c10ab9d619e8caa14a3f9a5</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2016.07.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2016.07.015%26sid%3Dliteratum%253Aachs%26aulast%3DMcCauley%26aufirst%3DJ.%2BA.%26aulast%3DRudd%26aufirst%3DM.%2BT.%26atitle%3DHepatitis%2520C%2520virus%2520NS3%252F4a%2520protease%2520inhibitors%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2016%26volume%3D30%26spage%3D84%26epage%3D92%26doi%3D10.1016%2Fj.coph.2016.07.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Kwong, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kauffman, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurter, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mueller, P.</span><span> </span><span class="NLM_article-title">Discovery and development of telaprevir: an NS3–4A protease inhibitor for treating genotype 1 chronic hepatitis C virus</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">993</span><span class="NLM_x">–</span> <span class="NLM_lpage">1003</span><span class="refDoi"> DOI: 10.1038/nbt.2020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1038%2Fnbt.2020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=22068541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVCntLvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=993-1003&author=A.+D.+Kwongauthor=R.+S.+Kauffmanauthor=P.+Hurterauthor=P.+Mueller&title=Discovery+and+development+of+telaprevir%3A+an+NS3%E2%80%934A+protease+inhibitor+for+treating+genotype+1+chronic+hepatitis+C+virus&doi=10.1038%2Fnbt.2020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus</span></div><div class="casAuthors">Kwong, Ann D.; Kauffman, Robert S.; Hurter, Patricia; Mueller, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">993-1003</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Infection with hepatitis C virus (HCV) is a major medical problem with over 170 million people infected worldwide.  Substantial morbidity and mortality are assocd. with hepatic manifestations (cirrhosis and hepatocellular carcinoma), which develop with increasing frequency in people infected with HCV for more than 20 years.  Less well known is the burden of HCV disease assocd. with extrahepatic manifestations (diabetes, B-cell proliferative disorders, depression, cognitive disorders, arthritis and Sjoegren's syndrome).  For patients infected with genotype 1 HCV, treatment with polyethylene glycol decorated interferon (peginterferon) α and ribavirin (PR) is assocd. with a low (40-50%) success rate, substantial treatment-limiting side effects and a long (48-wk) duration of treatment.  In the past 15 years, major scientific advances have enabled the development of new classes of HCV therapy, the direct-acting antiviral agents, also known as specifically targeted antiviral therapy for hepatitis C (STAT-C).  In combination with PR, the HCV NS3-4A protease inhibitor telaprevir has recently been approved for treatment of genotype 1 chronic HCV in the United States, Canada, European Union and Japan.  Compared with PR, telaprevir combination therapy offers significantly improved viral cure rates and the possibility of shortened treatment duration for diverse patient populations.  Developers of innovative drugs have to blaze a new path with few validated sign posts to guide the way.  Indeed, telaprevir's development was once put on hold because of its performance in a std. IC50 assay.  Data from new hypotheses and novel expts. were required to justify further investment and reduce risk that the drug might fail in the clinic.  In addn., the poor drug-like properties of telaprevir were a formidable hurdle, which the manufg. and formulation teams had to overcome to make the drug.  Finally, novel clin. trial designs were developed to improve efficacy and shorten treatment in parallel instead of sequentially.  Lessons learned from the development of telaprevir suggest that makers of innovative medicines cannot rely solely on traditional drug discovery metrics, but must develop innovative, scientifically guided pathways for success.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodUEHshXTAvbVg90H21EOLACvtfcHk0lg6L9Tw5VUUxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVCntLvJ&md5=952966419a2e72107550d0a63c337ae4</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2020%26sid%3Dliteratum%253Aachs%26aulast%3DKwong%26aufirst%3DA.%2BD.%26aulast%3DKauffman%26aufirst%3DR.%2BS.%26aulast%3DHurter%26aufirst%3DP.%26aulast%3DMueller%26aufirst%3DP.%26atitle%3DDiscovery%2520and%2520development%2520of%2520telaprevir%253A%2520an%2520NS3%25E2%2580%25934A%2520protease%2520inhibitor%2520for%2520treating%2520genotype%25201%2520chronic%2520hepatitis%2520C%2520virus%26jtitle%3DNat.%2520Biotechnol.%26date%3D2011%26volume%3D29%26spage%3D993%26epage%3D1003%26doi%3D10.1038%2Fnbt.2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Venkatraman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bogen, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arasappan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jao, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovey, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendrata, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parekh, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinto, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Popov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pike, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santhanam, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vibulbhan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butkiewicz, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chase, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agrawal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingravallo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pichardo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baroudy, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malcolm, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prongay, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madison, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broske, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, K.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brisson, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prelusky, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korfmacher, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bogdanowich-Knipp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavlovsky, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saksena, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ganguly, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piwinski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girijavallabhan, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Njoroge, F. G.</span><span> </span><span class="NLM_article-title">Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">6074</span><span class="NLM_x">–</span> <span class="NLM_lpage">6086</span><span class="refDoi"> DOI: 10.1021/jm060325b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060325b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BD28XptlOlsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6074-6086&author=S.+Venkatramanauthor=S.+L.+Bogenauthor=A.+Arasappanauthor=F.+Bennettauthor=K.+Chenauthor=E.+Jaoauthor=Y.-T.+Liuauthor=R.+Loveyauthor=S.+Hendrataauthor=Y.+Huangauthor=W.+Panauthor=T.+Parekhauthor=P.+Pintoauthor=V.+Popovauthor=R.+Pikeauthor=S.+Ruanauthor=B.+Santhanamauthor=B.+Vibulbhanauthor=W.+Wuauthor=W.+Yangauthor=J.+Kongauthor=X.+Liangauthor=J.+Wongauthor=R.+Liuauthor=N.+Butkiewiczauthor=R.+Chaseauthor=A.+Hartauthor=S.+Agrawalauthor=P.+Ingravalloauthor=J.+Pichardoauthor=R.+Kongauthor=B.+Baroudyauthor=B.+Malcolmauthor=Z.+Guoauthor=A.+Prongayauthor=V.+Madisonauthor=L.+Broskeauthor=X.+Cuiauthor=K.-C.+Chengauthor=Y.+Hsiehauthor=J.-M.+Brissonauthor=D.+Preluskyauthor=W.+Korfmacherauthor=R.+Whiteauthor=S.+Bogdanowich-Knippauthor=A.+Pavlovskyauthor=P.+Bradleyauthor=A.+K.+Saksenaauthor=A.+Gangulyauthor=J.+Piwinskiauthor=V.+Girijavallabhanauthor=F.+G.+Njoroge&title=Discovery+of+%281R%2C5S%29-N-%5B3-amino-1-%28cyclobutylmethyl%29-2%2C3-dioxopropyl%5D-+3-%5B2%28S%29-%5B%5B%5B%281%2C1-dimethylethyl%29amino%5Dcarbonyl%5Damino%5D-3%2C3-dimethyl-1-oxobutyl%5D-+6%2C6-dimethyl-3-azabicyclo%5B3.1.0%5Dhexan-2%28S%29-carboxamide+%28SCH+503034%29%2C+a+selective%2C+potent%2C+orally+bioavailable+hepatitis+C+virus+NS3+protease+inhibitor%3A+a+potential+therapeutic+agent+for+the+treatment+of+hepatitis+C+infection&doi=10.1021%2Fjm060325b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (1R,5S)-N-[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a Selective, Potent, Orally Bioavailable Hepatitis C Virus NS3 Protease Inhibitor: A Potential Therapeutic Agent for the Treatment of Hepatitis C Infection</span></div><div class="casAuthors">Venkatraman, Srikanth; Bogen, Stephane L.; Arasappan, Ashok; Bennett, Frank; Chen, Kevin; Jao, Edwin; Liu, Yi-Tsung; Lovey, Raymond; Hendrata, Siska; Huang, Yuhua; Pan, Weidong; Parekh, Tejal; Pinto, Patrick; Popov, Veljko; Pike, Russel; Ruan, Sumei; Santhanam, Bama; Vibulbhan, Bancha; Wu, Wanli; Yang, Weiying; Kong, Jianshe; Liang, Xiang; Wong, Jesse; Liu, Rong; Butkiewicz, Nancy; Chase, Robert; Hart, Andrea; Agrawal, Sony; Ingravallo, Paul; Pichardo, John; Kong, Rong; Baroudy, Bahige; Malcolm, Bruce; Guo, Zhuyan; Prongay, Andrew; Madison, Vincent; Broske, Lisa; Cui, Xiaoming; Cheng, Kuo-Chi; Hsieh, Tony Y.; Brisson, Jean-Marc; Prelusky, Danial; Korfmacher, Walter; White, Ronald; Bogdanowich-Knipp, Susan; Pavlovsky, Anastasia; Bradley, Prudence; Saksena, Anil K.; Ganguly, Ashit; Piwinski, John; Girijavallabhan, Viyyoor; Njoroge, F. George</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6074-6086</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) infection is the major cause of chronic liver disease, leading to cirrhosis and hepatocellular carcinoma, which affects more than 170 million people worldwide.  Currently the only therapeutic regimens are s.c. interferon-α or polyethylene glycol (PEG)-interferon-α alone or in combination with oral ribavirin.  Although combination therapy is reasonably successful with the majority of genotypes, its efficacy against the predominant genotype (genotype 1) is moderate at best, with only about 40% of the patients showing sustained virol. response.  Herein, the SAR leading to the discovery of SCH 503034 (I), a novel, potent, selective, orally bioavailable NS3 protease inhibitor that has been advanced to clin. trials in human beings for the treatment of hepatitis C viral infections is described.  X-ray structure of I complexed with the NS3 protease and biol. data are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjAR2KjtnJV7Vg90H21EOLACvtfcHk0lg6L9Tw5VUUxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptlOlsLg%253D&md5=e48b2e2d3eb19f7f28aaa76f96d03414</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm060325b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060325b%26sid%3Dliteratum%253Aachs%26aulast%3DVenkatraman%26aufirst%3DS.%26aulast%3DBogen%26aufirst%3DS.%2BL.%26aulast%3DArasappan%26aufirst%3DA.%26aulast%3DBennett%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DJao%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DY.-T.%26aulast%3DLovey%26aufirst%3DR.%26aulast%3DHendrata%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DPan%26aufirst%3DW.%26aulast%3DParekh%26aufirst%3DT.%26aulast%3DPinto%26aufirst%3DP.%26aulast%3DPopov%26aufirst%3DV.%26aulast%3DPike%26aufirst%3DR.%26aulast%3DRuan%26aufirst%3DS.%26aulast%3DSanthanam%26aufirst%3DB.%26aulast%3DVibulbhan%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DKong%26aufirst%3DJ.%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DWong%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DButkiewicz%26aufirst%3DN.%26aulast%3DChase%26aufirst%3DR.%26aulast%3DHart%26aufirst%3DA.%26aulast%3DAgrawal%26aufirst%3DS.%26aulast%3DIngravallo%26aufirst%3DP.%26aulast%3DPichardo%26aufirst%3DJ.%26aulast%3DKong%26aufirst%3DR.%26aulast%3DBaroudy%26aufirst%3DB.%26aulast%3DMalcolm%26aufirst%3DB.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DProngay%26aufirst%3DA.%26aulast%3DMadison%26aufirst%3DV.%26aulast%3DBroske%26aufirst%3DL.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DCheng%26aufirst%3DK.-C.%26aulast%3DHsieh%26aufirst%3DY.%26aulast%3DBrisson%26aufirst%3DJ.-M.%26aulast%3DPrelusky%26aufirst%3DD.%26aulast%3DKorfmacher%26aufirst%3DW.%26aulast%3DWhite%26aufirst%3DR.%26aulast%3DBogdanowich-Knipp%26aufirst%3DS.%26aulast%3DPavlovsky%26aufirst%3DA.%26aulast%3DBradley%26aufirst%3DP.%26aulast%3DSaksena%26aufirst%3DA.%2BK.%26aulast%3DGanguly%26aufirst%3DA.%26aulast%3DPiwinski%26aufirst%3DJ.%26aulast%3DGirijavallabhan%26aufirst%3DV.%26aulast%3DNjoroge%26aufirst%3DF.%2BG.%26atitle%3DDiscovery%2520of%2520%25281R%252C5S%2529-N-%255B3-amino-1-%2528cyclobutylmethyl%2529-2%252C3-dioxopropyl%255D-%25203-%255B2%2528S%2529-%255B%255B%255B%25281%252C1-dimethylethyl%2529amino%255Dcarbonyl%255Damino%255D-3%252C3-dimethyl-1-oxobutyl%255D-%25206%252C6-dimethyl-3-azabicyclo%255B3.1.0%255Dhexan-2%2528S%2529-carboxamide%2520%2528SCH%2520503034%2529%252C%2520a%2520selective%252C%2520potent%252C%2520orally%2520bioavailable%2520hepatitis%2520C%2520virus%2520NS3%2520protease%2520inhibitor%253A%2520a%2520potential%2520therapeutic%2520agent%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%2520infection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6074%26epage%3D6086%26doi%3D10.1021%2Fjm060325b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Zeuzem, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreone, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pol, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diago, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Focaccia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Younossi, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foster, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horban, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferenci, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nevens, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullhaupt, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pockros, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terg, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shouval, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Hoek, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiland, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Heeswijk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Meyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boogaerts, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Picchio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beumont, M.</span><span> </span><span class="NLM_article-title">Telaprevir for retreatment of HCV infection</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">2417</span><span class="NLM_x">–</span> <span class="NLM_lpage">2428</span><span class="refDoi"> DOI: 10.1056/NEJMoa1013086</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1056%2FNEJMoa1013086" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=21696308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotVCrsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=2417-2428&author=S.+Zeuzemauthor=P.+Andreoneauthor=S.+Polauthor=E.+Lawitzauthor=M.+Diagoauthor=S.+Robertsauthor=R.+Focacciaauthor=Z.+Younossiauthor=G.+R.+Fosterauthor=A.+Horbanauthor=P.+Ferenciauthor=F.+Nevensauthor=B.+Mullhauptauthor=P.+Pockrosauthor=R.+Tergauthor=D.+Shouvalauthor=B.+van+Hoekauthor=O.+Weilandauthor=R.+Van+Heeswijkauthor=S.+De+Meyerauthor=D.+Luoauthor=G.+Boogaertsauthor=R.+Poloauthor=G.+Picchioauthor=M.+Beumont&title=Telaprevir+for+retreatment+of+HCV+infection&doi=10.1056%2FNEJMoa1013086"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Telaprevir for retreatment of HCV infection</span></div><div class="casAuthors">Zeuzem, Stefan; Andreone, Pietro; Pol, Stanislas; Lawitz, Eric; Diago, Moises; Roberts, Stuart; Focaccia, Roberto; Younossi, Zobair; Foster, Graham R.; Horban, Andrzej; Ferenci, Peter; Nevens, Frederik; Mullhaupt, Beat; Pockros, Paul; Terg, Ruben; Shouval, Daniel; van Hoek, Bart; Weiland, Ola; Van Heeswijk, Rolf; De Meyer, Sandra; Luo, Don; Boogaerts, Griet; Polo, Ramon; Picchio, Gaston; Beumont, Maria</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2417-2428</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Up to 60% of patients with hepatitis C virus (HCV) genotype 1 infection do not have a sustained virol. response to therapy with peginterferon alfa plus ribavirin.  METHODS: In this randomized, phase 3 trial, we evaluated the addn. of telaprevir to peginterferon alfa-2a plus ribavirin in patients with HCV genotype 1 infection who had no response or a partial response to previous therapy or who had a relapse after an initial response.  A total of 663 patients were assigned to one of three groups: the T12PR48 group, which received telaprevir for 12 wk and peginterferon plus ribavirin for a total of 48 wk; the lead-in T12PR48 group, which received 4 wk of peginterferon plus ribavirin followed by 12 wk of telaprevir and peginterferon plus ribavirin for a total of 48 wk; and the control group (PR48), which received peginterferon plus ribavirin for 48 wk.  The primary end point was the rate of sustained virol. response, which was defined as undetectable HCV RNA 24 wk after the last planned dose of a study drug.  RESULTS: Rates of sustained virol. response were significantly higher in the two telaprevir groups than in the control group among patients who had a previous relapse (83% in the T12PR48 group, 88% in the lead-in T12PR48 group, and 24% in the PR48 group), a partial response (59%, 54%, and 15%, resp.), and no response (29%, 33%, and 5%, resp.) (P < 0.001 for all comparisons).  Grade 3 adverse events (mainly anemia, neutropenia, and leukopenia) were more frequent in the telaprevir groups than in the control group (37% vs. 22%).  CONCLUSIONS: Telaprevir combined with peginterferon plus ribavirin significantly improved rates of sustained virol. response in patients with previously treated HCV infection, regardless of whether there was a lead-in phase. (Funded by Tibotec and Vertex Pharmaceuticals; REALIZE ClinicalTrials.gov no., NCT00703118.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzx61JZTi22bVg90H21EOLACvtfcHk0lg63Srjkt24cA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotVCrsrg%253D&md5=de254ca59467daf5259a3dff8d2d831a</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1013086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1013086%26sid%3Dliteratum%253Aachs%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DAndreone%26aufirst%3DP.%26aulast%3DPol%26aufirst%3DS.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DDiago%26aufirst%3DM.%26aulast%3DRoberts%26aufirst%3DS.%26aulast%3DFocaccia%26aufirst%3DR.%26aulast%3DYounossi%26aufirst%3DZ.%26aulast%3DFoster%26aufirst%3DG.%2BR.%26aulast%3DHorban%26aufirst%3DA.%26aulast%3DFerenci%26aufirst%3DP.%26aulast%3DNevens%26aufirst%3DF.%26aulast%3DMullhaupt%26aufirst%3DB.%26aulast%3DPockros%26aufirst%3DP.%26aulast%3DTerg%26aufirst%3DR.%26aulast%3DShouval%26aufirst%3DD.%26aulast%3Dvan%2BHoek%26aufirst%3DB.%26aulast%3DWeiland%26aufirst%3DO.%26aulast%3DVan%2BHeeswijk%26aufirst%3DR.%26aulast%3DDe%2BMeyer%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DD.%26aulast%3DBoogaerts%26aufirst%3DG.%26aulast%3DPolo%26aufirst%3DR.%26aulast%3DPicchio%26aufirst%3DG.%26aulast%3DBeumont%26aufirst%3DM.%26atitle%3DTelaprevir%2520for%2520retreatment%2520of%2520HCV%2520infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D2417%26epage%3D2428%26doi%3D10.1056%2FNEJMoa1013086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Poordad, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCone, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bacon, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruno, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manns, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sulkowski, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodman, Z. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boparai, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiNubile, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sniukiene, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brass, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albrecht, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bronowicki, J.-P.</span><span> </span><span class="NLM_article-title">Boceprevir for untreated chronic HCV genotype 1 infection</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">1195</span><span class="NLM_x">–</span> <span class="NLM_lpage">1206</span><span class="refDoi"> DOI: 10.1056/NEJMoa1010494</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1056%2FNEJMoa1010494" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=21449783" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkt1Chtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=1195-1206&author=F.+Poordadauthor=J.+McConeauthor=B.+R.+Baconauthor=S.+Brunoauthor=M.+P.+Mannsauthor=M.+S.+Sulkowskiauthor=I.+M.+Jacobsonauthor=K.+R.+Reddyauthor=Z.+D.+Goodmanauthor=N.+Boparaiauthor=M.+J.+DiNubileauthor=V.+Sniukieneauthor=C.+A.+Brassauthor=J.+K.+Albrechtauthor=J.-P.+Bronowicki&title=Boceprevir+for+untreated+chronic+HCV+genotype+1+infection&doi=10.1056%2FNEJMoa1010494"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Boceprevir for untreated chronic HCV genotype 1 infection</span></div><div class="casAuthors">Poordad, Fred; McCone, Jonathan, Jr.; Bacon, Bruce; Bruno, Savino; Manns, Michael P.; Sulkowski, Mark S.; Jacobson, Ira M.; Rajender Reddy, K.; Goodman, Zachary D.; Boparai, Navdeep; DiNubile, Mark J.; Sniukiene, Vilma; Brass, Clifford A.; Albrecht, Janice K.; Bronowicki, Jean-Pierre</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1195-1206</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Peginterferon-ribavirin therapy is the current std. of care for chronic infection with hepatitis C virus (HCV).  The rate of sustained virol. response has been below 50% in cases of HCV genotype 1 infection.  Boceprevir, a potent oral HCV-protease inhibitor, has been evaluated as an addnl. treatment in phase 1 and phase 2 studies.  We conducted a double-blind study in which previously untreated adults with HCV genotype 1 infection were randomly assigned to one of three groups.  In all three groups, peginterferon alfa-2b and ribavirin were administered for 4 wk (the lead- in period).  Subsequently, group 1 (the control group) received placebo plus peginterferon-ribavirin for 44 wk; group 2 received boceprevir plus peginterferon-ribavirin for 24 wk, and those with a detectable HCV RNA level between weeks 8 and 24 received placebo plus peginterferon-ribavirin for an addnl. 20 wk; and group 3 received boceprevir plus peginterferon-ribavirin for 44 wk.  Non-black patients and black patients were enrolled and analyzed sep.  A total of 938 non-black and 159 black patients were treated.  In the non-black cohort, a sustained virol. response was achieved in 125 of the 311 patients (40%) in group 1, in 211 of the 316 patients (67%) in group 2 (P < 0.001), and in 213 of the 311 patients (68%) in group 3 (P < 0.001).  In the black cohort, a sustained virol. response was achieved in 12 of the 52 patients (23%) in group 1, in 22 of the 52 patients (42%) in group 2 (P = 0.04), and in 29 of the 55 patients (53%) in group 3 (P = 0.004).  In group 2, a total of 44% of patients received peginterferon-ribavirin for 28 wk.  Anemia led to dose redns. in 13% of controls and 21% of boceprevir recipients, with discontinuations in 1% and 2%, resp.  The addn. of boceprevir to std. therapy with peginterferon-ribavirin, as compared with std. therapy alone, significantly increased the rates of sustained virol. response in previously untreated adults with chronic HCV genotype 1 infection.  The rates were similar with 24 wk and 44 wk of boceprevir.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCdL0rY0lmGrVg90H21EOLACvtfcHk0lgYtvTDfrQg1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkt1Chtrc%253D&md5=47ea838a941fdf7f9a27350a403e794e</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1010494&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1010494%26sid%3Dliteratum%253Aachs%26aulast%3DPoordad%26aufirst%3DF.%26aulast%3DMcCone%26aufirst%3DJ.%26aulast%3DBacon%26aufirst%3DB.%2BR.%26aulast%3DBruno%26aufirst%3DS.%26aulast%3DManns%26aufirst%3DM.%2BP.%26aulast%3DSulkowski%26aufirst%3DM.%2BS.%26aulast%3DJacobson%26aufirst%3DI.%2BM.%26aulast%3DReddy%26aufirst%3DK.%2BR.%26aulast%3DGoodman%26aufirst%3DZ.%2BD.%26aulast%3DBoparai%26aufirst%3DN.%26aulast%3DDiNubile%26aufirst%3DM.%2BJ.%26aulast%3DSniukiene%26aufirst%3DV.%26aulast%3DBrass%26aufirst%3DC.%2BA.%26aulast%3DAlbrecht%26aufirst%3DJ.%2BK.%26aulast%3DBronowicki%26aufirst%3DJ.-P.%26atitle%3DBoceprevir%2520for%2520untreated%2520chronic%2520HCV%2520genotype%25201%2520infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D1195%26epage%3D1206%26doi%3D10.1056%2FNEJMoa1010494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Rosenquist, Å.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samuelsson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johansson, P.-O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenz, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raboisson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vendeville, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Kock, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilsson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horvath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalmeijer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de la Rosa, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beumont-Mauviel, M.</span><span> </span><span class="NLM_article-title">Discovery and development of simeprevir (TMC435), a HCV NS3/4A protease inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1673</span><span class="NLM_x">–</span> <span class="NLM_lpage">1693</span><span class="refDoi"> DOI: 10.1021/jm401507s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401507s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpslekuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1673-1693&author=%C3%85.+Rosenquistauthor=B.+Samuelssonauthor=P.-O.+Johanssonauthor=M.+D.+Cummingsauthor=O.+Lenzauthor=P.+Raboissonauthor=K.+Simmenauthor=S.+Vendevilleauthor=H.+de+Kockauthor=M.+Nilssonauthor=A.+Horvathauthor=R.+Kalmeijerauthor=G.+de+la+Rosaauthor=M.+Beumont-Mauviel&title=Discovery+and+development+of+simeprevir+%28TMC435%29%2C+a+HCV+NS3%2F4A+protease+inhibitor&doi=10.1021%2Fjm401507s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Simeprevir (TMC435), a HCV NS3/4A Protease Inhibitor</span></div><div class="casAuthors">Rosenquist, Aasa; Samuelsson, Bertil; Johansson, Per-Ola; Cummings, Maxwell D.; Lenz, Oliver; Raboisson, Pierre; Simmen, Kenny; Vendeville, Sandrine; de Kock, Herman; Nilsson, Magnus; Horvath, Andras; Kalmeijer, Ronald; de la Rosa, Guy; Beumont-Mauviel, Maria</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1673-1693</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Hepatitis C virus is a blood-borne infection and the leading cause of chronic liver disease (including cirrhosis and cancer) and liver transplantation.  Since the identification of HCV in 1989, there has been an extensive effort to identify and improve treatment options.  An important milestone was reached in 2011 with the approval of the first-generation HCV NS3/4A protease inhibitors.  However, new therapies are needed to improve cure rates, shorten treatment duration, and improve tolerability.  Here we summarize the extensive medicinal chem. effort to develop novel P2 cyclopentane macrocyclic inhibitors guided by HCV NS3 protease assays, the cellular replicon system, structure-based design, and a panel of DMPK assays.  The selection of compd. 29 (simeprevir, TMC435) as clin. candidate was based on its excellent biol., PK, and safety pharmacol. profile.  Compd. 29 has recently been approved for treatment of chronic HCV infection in combination with pegylated interferon-α and ribavirin in Japan, Canada, and USA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryCRg3NRRjzrVg90H21EOLACvtfcHk0lgYtvTDfrQg1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpslekuw%253D%253D&md5=fd9c1df095e47a111d9680af4c40ccc6</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm401507s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401507s%26sid%3Dliteratum%253Aachs%26aulast%3DRosenquist%26aufirst%3D%25C3%2585.%26aulast%3DSamuelsson%26aufirst%3DB.%26aulast%3DJohansson%26aufirst%3DP.-O.%26aulast%3DCummings%26aufirst%3DM.%2BD.%26aulast%3DLenz%26aufirst%3DO.%26aulast%3DRaboisson%26aufirst%3DP.%26aulast%3DSimmen%26aufirst%3DK.%26aulast%3DVendeville%26aufirst%3DS.%26aulast%3Dde%2BKock%26aufirst%3DH.%26aulast%3DNilsson%26aufirst%3DM.%26aulast%3DHorvath%26aufirst%3DA.%26aulast%3DKalmeijer%26aufirst%3DR.%26aulast%3Dde%2Bla%2BRosa%26aufirst%3DG.%26aulast%3DBeumont-Mauviel%26aufirst%3DM.%26atitle%3DDiscovery%2520and%2520development%2520of%2520simeprevir%2520%2528TMC435%2529%252C%2520a%2520HCV%2520NS3%252F4A%2520protease%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1673%26epage%3D1693%26doi%3D10.1021%2Fjm401507s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Pilot-Matias, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tripathi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaultier, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dekhtyar, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reisch, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopkins, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pithawalla, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middleton, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDaniel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Or, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menon, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kempf, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, C.</span><span> </span><span class="NLM_article-title">In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">988</span><span class="NLM_x">–</span> <span class="NLM_lpage">997</span><span class="refDoi"> DOI: 10.1128/AAC.04227-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1128%2FAAC.04227-14" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=988-997&author=T.+Pilot-Matiasauthor=R.+Tripathiauthor=D.+Cohenauthor=I.+Gaultierauthor=T.+Dekhtyarauthor=L.+Luauthor=T.+Reischauthor=M.+Irvinauthor=T.+Hopkinsauthor=R.+Pithawallaauthor=T.+Middletonauthor=T.+Ngauthor=K.+McDanielauthor=Y.+S.+Orauthor=R.+Menonauthor=D.+Kempfauthor=A.+Mollaauthor=C.+Collins&title=In+vitro+and+in+vivo+antiviral+activity+and+resistance+profile+of+the+hepatitis+C+virus+NS3%2F4A+protease+inhibitor+ABT-450&doi=10.1128%2FAAC.04227-14"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1128%2FAAC.04227-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.04227-14%26sid%3Dliteratum%253Aachs%26aulast%3DPilot-Matias%26aufirst%3DT.%26aulast%3DTripathi%26aufirst%3DR.%26aulast%3DCohen%26aufirst%3DD.%26aulast%3DGaultier%26aufirst%3DI.%26aulast%3DDekhtyar%26aufirst%3DT.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DReisch%26aufirst%3DT.%26aulast%3DIrvin%26aufirst%3DM.%26aulast%3DHopkins%26aufirst%3DT.%26aulast%3DPithawalla%26aufirst%3DR.%26aulast%3DMiddleton%26aufirst%3DT.%26aulast%3DNg%26aufirst%3DT.%26aulast%3DMcDaniel%26aufirst%3DK.%26aulast%3DOr%26aufirst%3DY.%2BS.%26aulast%3DMenon%26aufirst%3DR.%26aulast%3DKempf%26aufirst%3DD.%26aulast%3DMolla%26aufirst%3DA.%26aulast%3DCollins%26aufirst%3DC.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520antiviral%2520activity%2520and%2520resistance%2520profile%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS3%252F4A%2520protease%2520inhibitor%2520ABT-450%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26spage%3D988%26epage%3D997%26doi%3D10.1128%2FAAC.04227-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Harper, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCauley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudd, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiFilippo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crescenzi, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrocchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holloway, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butcher, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romano, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bush, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nizi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludmerer, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burlein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMuzio, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHale, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahlhut, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monteagudo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cianetti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giuliano, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pucci, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trainor, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fandozzi, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vacca, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Summa, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liverton, N. J.</span><span> </span><span class="NLM_article-title">Discovery of MK-5172, a macrocyclic hepatitis C virus NS3/4a protease inhibitor</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">332</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span><span class="refDoi"> DOI: 10.1021/ml300017p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300017p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtFyjurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=332-336&author=S.+Harperauthor=J.+A.+McCauleyauthor=M.+T.+Ruddauthor=M.+Ferraraauthor=M.+DiFilippoauthor=B.+Crescenziauthor=U.+Kochauthor=A.+Petrocchiauthor=M.+K.+Hollowayauthor=J.+W.+Butcherauthor=J.+J.+Romanoauthor=K.+J.+Bushauthor=K.+F.+Gilbertauthor=C.+J.+McIntyreauthor=K.+T.+Nguyenauthor=E.+Niziauthor=S.+S.+Carrollauthor=S.+W.+Ludmererauthor=C.+Burleinauthor=J.+M.+DiMuzioauthor=D.+J.+Grahamauthor=C.+M.+McHaleauthor=M.+W.+Stahlhutauthor=D.+B.+Olsenauthor=E.+Monteagudoauthor=S.+Cianettiauthor=C.+Giulianoauthor=V.+Pucciauthor=N.+Trainorauthor=C.+M.+Fandozziauthor=M.+Rowleyauthor=P.+J.+Colemanauthor=J.+P.+Vaccaauthor=V.+Summaauthor=N.+J.+Liverton&title=Discovery+of+MK-5172%2C+a+macrocyclic+hepatitis+C+virus+NS3%2F4a+protease+inhibitor&doi=10.1021%2Fml300017p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor</span></div><div class="casAuthors">Harper, Steven; McCauley, John A.; Rudd, Michael T.; Ferrara, Marco; DiFilippo, Marcello; Crescenzi, Benedetta; Koch, Uwe; Petrocchi, Alessia; Holloway, M. Katharine; Butcher, John W.; Romano, Joseph J.; Bush, Kimberly J.; Gilbert, Kevin F.; McIntyre, Charles J.; Nguyen, Kevin T.; Nizi, Emanuela; Carroll, Steven S.; Ludmerer, Steven W.; Burlein, Christine; DiMuzio, Jillian M.; Graham, Donald J.; McHale, Carolyn M.; Stahlhut, Mark W.; Olsen, David B.; Monteagudo, Edith; Cianetti, Simona; Giuliano, Claudio; Pucci, Vincenzo; Trainor, Nicole; Fandozzi, Christine M.; Rowley, Michael; Coleman, Paul J.; Vacca, Joseph P.; Summa, Vincenzo; Liverton, Nigel J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">332-336</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new class of HCV NS3/4a protease inhibitors contg. a P2 to P4 macrocyclic constraint was designed using a mol. modeling-derived strategy.  Building on the profile of previous clin. compds. and exploring the P2 and linker regions of the series allowed for optimization of broad genotype and mutant enzyme potency, cellular activity, and rat liver exposure following oral dosing.  These studies led to the identification of clin. candidate 15 (MK-5172), which is active against genotype 1-3 NS3/4a and clin. relevant mutant enzymes and has good plasma exposure and excellent liver exposure in multiple species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAzCaAN9VqJrVg90H21EOLACvtfcHk0lilcKIDaJ4p8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtFyjurg%253D&md5=efc04ad0ad47aef13b367fc38d6bbf63</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fml300017p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300017p%26sid%3Dliteratum%253Aachs%26aulast%3DHarper%26aufirst%3DS.%26aulast%3DMcCauley%26aufirst%3DJ.%2BA.%26aulast%3DRudd%26aufirst%3DM.%2BT.%26aulast%3DFerrara%26aufirst%3DM.%26aulast%3DDiFilippo%26aufirst%3DM.%26aulast%3DCrescenzi%26aufirst%3DB.%26aulast%3DKoch%26aufirst%3DU.%26aulast%3DPetrocchi%26aufirst%3DA.%26aulast%3DHolloway%26aufirst%3DM.%2BK.%26aulast%3DButcher%26aufirst%3DJ.%2BW.%26aulast%3DRomano%26aufirst%3DJ.%2BJ.%26aulast%3DBush%26aufirst%3DK.%2BJ.%26aulast%3DGilbert%26aufirst%3DK.%2BF.%26aulast%3DMcIntyre%26aufirst%3DC.%2BJ.%26aulast%3DNguyen%26aufirst%3DK.%2BT.%26aulast%3DNizi%26aufirst%3DE.%26aulast%3DCarroll%26aufirst%3DS.%2BS.%26aulast%3DLudmerer%26aufirst%3DS.%2BW.%26aulast%3DBurlein%26aufirst%3DC.%26aulast%3DDiMuzio%26aufirst%3DJ.%2BM.%26aulast%3DGraham%26aufirst%3DD.%2BJ.%26aulast%3DMcHale%26aufirst%3DC.%2BM.%26aulast%3DStahlhut%26aufirst%3DM.%2BW.%26aulast%3DOlsen%26aufirst%3DD.%2BB.%26aulast%3DMonteagudo%26aufirst%3DE.%26aulast%3DCianetti%26aufirst%3DS.%26aulast%3DGiuliano%26aufirst%3DC.%26aulast%3DPucci%26aufirst%3DV.%26aulast%3DTrainor%26aufirst%3DN.%26aulast%3DFandozzi%26aufirst%3DC.%2BM.%26aulast%3DRowley%26aufirst%3DM.%26aulast%3DColeman%26aufirst%3DP.%2BJ.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26aulast%3DSumma%26aufirst%3DV.%26aulast%3DLiverton%26aufirst%3DN.%2BJ.%26atitle%3DDiscovery%2520of%2520MK-5172%252C%2520a%2520macrocyclic%2520hepatitis%2520C%2520virus%2520NS3%252F4a%2520protease%2520inhibitor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D332%26epage%3D336%26doi%3D10.1021%2Fml300017p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Scola, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, A. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venables, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sit, S.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cocuzza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bilder, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Andrea, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewawasam, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friborg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falk, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levine, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheaffer, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barry, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, Y.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schartman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donoso, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosure, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinz, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zvyaga, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Good, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajamani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kish, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tredup, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klei, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mueller, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grasela, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levesque, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warner, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span> </span><span class="NLM_article-title">The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1730</span><span class="NLM_x">–</span> <span class="NLM_lpage">1752</span><span class="refDoi"> DOI: 10.1021/jm500297k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500297k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtVeqsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1730-1752&author=P.+M.+Scolaauthor=L.-Q.+Sunauthor=A.+X.+Wangauthor=J.+Chenauthor=N.+Sinauthor=B.+L.+Venablesauthor=S.-Y.+Sitauthor=Y.+Chenauthor=A.+Cocuzzaauthor=D.+M.+Bilderauthor=S.+V.+D%E2%80%99Andreaauthor=B.+Zhengauthor=P.+Hewawasamauthor=Y.+Tuauthor=J.+Friborgauthor=P.+Falkauthor=D.+Hernandezauthor=S.+Levineauthor=C.+Chenauthor=F.+Yuauthor=A.+K.+Sheafferauthor=G.+Zhaiauthor=D.+Barryauthor=J.+O.+Knipeauthor=Y.-H.+Hanauthor=R.+Schartmanauthor=M.+Donosoauthor=K.+Mosureauthor=M.+W.+Sinzauthor=T.+Zvyagaauthor=A.+C.+Goodauthor=R.+Rajamaniauthor=K.+Kishauthor=J.+Tredupauthor=H.+E.+Kleiauthor=Q.+Gaoauthor=L.+Muellerauthor=R.+J.+Colonnoauthor=D.+M.+Graselaauthor=S.+P.+Adamsauthor=J.+Loyauthor=P.+C.+Levesqueauthor=H.+Sunauthor=H.+Shiauthor=L.+Sunauthor=W.+Warnerauthor=D.+Liauthor=J.+Zhuauthor=N.+A.+Meanwellauthor=F.+McPhee&title=The+discovery+of+asunaprevir+%28BMS-650032%29%2C+an+orally+efficacious+NS3+protease+inhibitor+for+the+treatment+of+hepatitis+C+virus+infection&doi=10.1021%2Fjm500297k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The Discovery of Asunaprevir (BMS-650032), An Orally Efficacious NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection</span></div><div class="casAuthors">Scola, Paul M.; Sun, Li-Qiang; Wang, Alan Xiangdong; Chen, Jie; Sin, Ny; Venables, Brian L.; Sit, Sing-Yuen; Chen, Yan; Cocuzza, Anthony; Bilder, Donna M.; D'Andrea, Stanley V.; Zheng, Barbara; Hewawasam, Piyasena; Tu, Yong; Friborg, Jacques; Falk, Paul; Hernandez, Dennis; Levine, Steven; Chen, Chaoqun; Yu, Fei; Sheaffer, Amy K.; Zhai, Guangzhi; Barry, Diana; Knipe, Jay O.; Han, Yong-Hae; Schartman, Richard; Donoso, Maria; Mosure, Kathy; Sinz, Michael W.; Zvyaga, Tatyana; Good, Andrew C.; Rajamani, Ramkumar; Kish, Kevin; Tredup, Jeffrey; Klei, Herbert E.; Gao, Qi; Mueller, Luciano; Colonno, Richard J.; Grasela, Dennis M.; Adams, Stephen P.; Loy, James; Levesque, Paul C.; Sun, Huabin; Shi, Hong; Sun, Lucy; Warner, William; Li, Danshi; Zhu, Jialong; Meanwell, Nicholas A.; McPhee, Fiona</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1730-1752</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of asunaprevir (BMS-650032) is described.  This tripeptidic acylsulfonamide inhibitor of the NS3/4A enzyme is currently in phase III clin. trials for the treatment of hepatitis C virus infection.  The discovery of Asunaprevir was enabled by employing an isolated rabbit heart model to screen for the cardiovascular (CV) liabilities (changes to HR and SNRT) that were responsible for the discontinuation of an earlier lead from this chem. series, BMS-605339, from clin. trials.  The structure-activity relationships (SARs) developed with respect to CV effects established that small structural changes to the P2* subsite of the mol. had a significant impact on the CV profile of a given compd.  The antiviral activity, preclin. PK profile, and toxicol. studies in rat and dog supported clin. development of BMS-650032.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCzMFiXs8YO7Vg90H21EOLACvtfcHk0lh-w-4KyehUtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtVeqsLc%253D&md5=e8015d3874b80be645a9b80b5bd05865</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm500297k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500297k%26sid%3Dliteratum%253Aachs%26aulast%3DScola%26aufirst%3DP.%2BM.%26aulast%3DSun%26aufirst%3DL.-Q.%26aulast%3DWang%26aufirst%3DA.%2BX.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DSin%26aufirst%3DN.%26aulast%3DVenables%26aufirst%3DB.%2BL.%26aulast%3DSit%26aufirst%3DS.-Y.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DCocuzza%26aufirst%3DA.%26aulast%3DBilder%26aufirst%3DD.%2BM.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DS.%2BV.%26aulast%3DZheng%26aufirst%3DB.%26aulast%3DHewawasam%26aufirst%3DP.%26aulast%3DTu%26aufirst%3DY.%26aulast%3DFriborg%26aufirst%3DJ.%26aulast%3DFalk%26aufirst%3DP.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DLevine%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DF.%26aulast%3DSheaffer%26aufirst%3DA.%2BK.%26aulast%3DZhai%26aufirst%3DG.%26aulast%3DBarry%26aufirst%3DD.%26aulast%3DKnipe%26aufirst%3DJ.%2BO.%26aulast%3DHan%26aufirst%3DY.-H.%26aulast%3DSchartman%26aufirst%3DR.%26aulast%3DDonoso%26aufirst%3DM.%26aulast%3DMosure%26aufirst%3DK.%26aulast%3DSinz%26aufirst%3DM.%2BW.%26aulast%3DZvyaga%26aufirst%3DT.%26aulast%3DGood%26aufirst%3DA.%2BC.%26aulast%3DRajamani%26aufirst%3DR.%26aulast%3DKish%26aufirst%3DK.%26aulast%3DTredup%26aufirst%3DJ.%26aulast%3DKlei%26aufirst%3DH.%2BE.%26aulast%3DGao%26aufirst%3DQ.%26aulast%3DMueller%26aufirst%3DL.%26aulast%3DColonno%26aufirst%3DR.%2BJ.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26aulast%3DAdams%26aufirst%3DS.%2BP.%26aulast%3DLoy%26aufirst%3DJ.%26aulast%3DLevesque%26aufirst%3DP.%2BC.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DWarner%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DMcPhee%26aufirst%3DF.%26atitle%3DThe%2520discovery%2520of%2520asunaprevir%2520%2528BMS-650032%2529%252C%2520an%2520orally%2520efficacious%2520NS3%2520protease%2520inhibitor%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1730%26epage%3D1752%26doi%3D10.1021%2Fjm500297k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">McCauley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudd, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romano, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butcher, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bush, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holloway, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swestock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMuzio, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludmerer, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahlhut, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fandozzi, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trainor, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vacca, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liverton, N. J.</span><span> </span><span class="NLM_article-title">Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2443</span><span class="NLM_x">–</span> <span class="NLM_lpage">2463</span><span class="refDoi"> DOI: 10.1021/jm9015526</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9015526" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitV2gsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2443-2463&author=J.+A.+McCauleyauthor=C.+J.+McIntyreauthor=M.+T.+Ruddauthor=K.+T.+Nguyenauthor=J.+J.+Romanoauthor=J.+W.+Butcherauthor=K.+F.+Gilbertauthor=K.+J.+Bushauthor=M.+K.+Hollowayauthor=J.+Swestockauthor=B.+L.+Wanauthor=S.+S.+Carrollauthor=J.+M.+DiMuzioauthor=D.+J.+Grahamauthor=S.+W.+Ludmererauthor=S.+S.+Maoauthor=M.+W.+Stahlhutauthor=C.+M.+Fandozziauthor=N.+Trainorauthor=D.+B.+Olsenauthor=J.+P.+Vaccaauthor=N.+J.+Liverton&title=Discovery+of+vaniprevir+%28MK-7009%29%2C+a+macrocyclic+hepatitis+C+virus+NS3%2F4a+protease+inhibitor&doi=10.1021%2Fjm9015526"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Vaniprevir (MK-7009), a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor</span></div><div class="casAuthors">McCauley, John A.; McIntyre, Charles J.; Rudd, Michael T.; Nguyen, Kevin T.; Romano, Joseph J.; Butcher, John W.; Gilbert, Kevin F.; Bush, Kimberly J.; Holloway, M. Katharine; Swestock, John; Wan, Bang-Lin; Carroll, Steven S.; DiMuzio, Jillian M.; Graham, Donald J.; Ludmerer, Steven W.; Mao, Shi-Shan; Stahlhut, Mark W.; Fandozzi, Christine M.; Trainor, Nicole; Olsen, David B.; Vacca, Joseph P.; Liverton, Nigel J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2443-2463</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new class of HCV NS3/4a protease inhibitors which contain a P2 to P4 macrocyclic constraint was designed using a mol.-modeling derived strategy.  Exploration of the P2 heterocyclic region, the P2 to P4 linker, and the P1 side chain of this class of compds. via a modular synthetic strategy allowed for the optimization of enzyme potency, cellular activity, and rat liver exposure following oral dosing.  These studies led to the identification of clin. candidate vaniprevir, MK-7009, which is active against both the genotype 1 and genotype 2 NS3/4a protease enzymes and has good plasma exposure and excellent liver exposure in multiple species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_2CVs9I1H_7Vg90H21EOLACvtfcHk0ljO7NJoxSp8cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitV2gsr8%253D&md5=dc820c588d5482f6913091a87eaf9af1</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm9015526&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9015526%26sid%3Dliteratum%253Aachs%26aulast%3DMcCauley%26aufirst%3DJ.%2BA.%26aulast%3DMcIntyre%26aufirst%3DC.%2BJ.%26aulast%3DRudd%26aufirst%3DM.%2BT.%26aulast%3DNguyen%26aufirst%3DK.%2BT.%26aulast%3DRomano%26aufirst%3DJ.%2BJ.%26aulast%3DButcher%26aufirst%3DJ.%2BW.%26aulast%3DGilbert%26aufirst%3DK.%2BF.%26aulast%3DBush%26aufirst%3DK.%2BJ.%26aulast%3DHolloway%26aufirst%3DM.%2BK.%26aulast%3DSwestock%26aufirst%3DJ.%26aulast%3DWan%26aufirst%3DB.%2BL.%26aulast%3DCarroll%26aufirst%3DS.%2BS.%26aulast%3DDiMuzio%26aufirst%3DJ.%2BM.%26aulast%3DGraham%26aufirst%3DD.%2BJ.%26aulast%3DLudmerer%26aufirst%3DS.%2BW.%26aulast%3DMao%26aufirst%3DS.%2BS.%26aulast%3DStahlhut%26aufirst%3DM.%2BW.%26aulast%3DFandozzi%26aufirst%3DC.%2BM.%26aulast%3DTrainor%26aufirst%3DN.%26aulast%3DOlsen%26aufirst%3DD.%2BB.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26aulast%3DLiverton%26aufirst%3DN.%2BJ.%26atitle%3DDiscovery%2520of%2520vaniprevir%2520%2528MK-7009%2529%252C%2520a%2520macrocyclic%2520hepatitis%2520C%2520virus%2520NS3%252F4a%2520protease%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2443%26epage%3D2463%26doi%3D10.1021%2Fjm9015526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Lawitz, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Riordan, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asatryan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freilich, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overcash, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, T. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kort, J.</span><span> </span><span class="NLM_article-title">Potent antiviral activities of the direct-acting antivirals ABT-493 and ABT-530 with three-day monotherapy for hepatitis C virus genotype 1 infection</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">1546</span><span class="NLM_x">–</span> <span class="NLM_lpage">1555</span><span class="refDoi"> DOI: 10.1128/AAC.02264-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1128%2FAAC.02264-15" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2016&pages=1546-1555&author=E.+J.+Lawitzauthor=W.+D.+O%E2%80%99Riordanauthor=A.+Asatryanauthor=B.+L.+Freilichauthor=T.+D.+Boxauthor=J.+S.+Overcashauthor=S.+Lovellauthor=T.+I.+Ngauthor=W.+Liuauthor=A.+Campbellauthor=C.+W.+Linauthor=B.+Yaoauthor=J.+Kort&title=Potent+antiviral+activities+of+the+direct-acting+antivirals+ABT-493+and+ABT-530+with+three-day+monotherapy+for+hepatitis+C+virus+genotype+1+infection&doi=10.1128%2FAAC.02264-15"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1128%2FAAC.02264-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.02264-15%26sid%3Dliteratum%253Aachs%26aulast%3DLawitz%26aufirst%3DE.%2BJ.%26aulast%3DO%25E2%2580%2599Riordan%26aufirst%3DW.%2BD.%26aulast%3DAsatryan%26aufirst%3DA.%26aulast%3DFreilich%26aufirst%3DB.%2BL.%26aulast%3DBox%26aufirst%3DT.%2BD.%26aulast%3DOvercash%26aufirst%3DJ.%2BS.%26aulast%3DLovell%26aufirst%3DS.%26aulast%3DNg%26aufirst%3DT.%2BI.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DCampbell%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DC.%2BW.%26aulast%3DYao%26aufirst%3DB.%26aulast%3DKort%26aufirst%3DJ.%26atitle%3DPotent%2520antiviral%2520activities%2520of%2520the%2520direct-acting%2520antivirals%2520ABT-493%2520and%2520ABT-530%2520with%2520three-day%2520monotherapy%2520for%2520hepatitis%2520C%2520virus%2520genotype%25201%2520infection%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2016%26volume%3D60%26spage%3D1546%26epage%3D1555%26doi%3D10.1128%2FAAC.02264-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Rodriguez-Torres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glass, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freilich, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Bisceglie, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirby, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dvory-Sobol, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">An, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stamm, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brainard, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krefetz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marbury, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E.</span><span> </span><span class="NLM_article-title">GS-9857 in patients with chronic hepatitis C virus genotype 1–4 infection: a randomized, double-blind, dose-ranging phase 1 study</span> <span class="citation_source-journal">J. Viral. Hepat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">614</span><span class="NLM_x">–</span> <span class="NLM_lpage">622</span><span class="refDoi"> DOI: 10.1111/jvh.12527</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1111%2Fjvh.12527" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=26957110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFOkurbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2016&pages=614-622&author=M.+Rodriguez-Torresauthor=S.+Glassauthor=J.+Hillauthor=B.+Freilichauthor=D.+Hassmanauthor=A.+M.+Di+Bisceglieauthor=J.+G.+Taylorauthor=B.+J.+Kirbyauthor=H.+Dvory-Sobolauthor=J.+C.+Yangauthor=D.+Anauthor=L.+M.+Stammauthor=D.+M.+Brainardauthor=S.+Kimauthor=D.+Krefetzauthor=W.+Smithauthor=T.+Marburyauthor=E.+Lawitz&title=GS-9857+in+patients+with+chronic+hepatitis+C+virus+genotype+1%E2%80%934+infection%3A+a+randomized%2C+double-blind%2C+dose-ranging+phase+1+study&doi=10.1111%2Fjvh.12527"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 study</span></div><div class="casAuthors">Rodriguez-Torres, M.; Glass, S.; Hill, J.; Freilich, B.; Hassman, D.; Di Bisceglie, A. M.; Taylor, J. G.; Kirby, B. J.; Dvory-Sobol, H.; Yang, J. C.; An, D.; Stamm, L. M.; Brainard, D. M.; Kim, S.; Krefetz, D.; Smith, W.; Marbury, T.; Lawitz, E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Viral Hepatitis</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">614-622</span>CODEN:
                <span class="NLM_cas:coden">JVHEER</span>;
        ISSN:<span class="NLM_cas:issn">1365-2893</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Summary : GS-9857, an inhibitor of the hepatitis C virus (HCV) nonstructural protein (NS) 3/4A, demonstrates potent activity against HCV genotypes 1-6 and improved coverage against commonly encountered NS3 resistance-assocd. variants (RAVs).  In this study, the safety, tolerability, antiviral activity and pharmacokinetics (PK) of GS-9857 were evaluated in patients with chronic HCV genotype 1-4 infection.  Patients with genotype 1-4 infection received placebo or once-daily GS-9857 at doses ranging from 50 to 300 mg for 3 days under fasting conditions.  GS-9857 was well tolerated; all reported adverse events (AEs) were mild or moderate in severity.  Diarrhoea and headache were the most commonly reported AEs.  Grade 3 or 4 lab. abnormalities were obsd. in 17% of patients receiving GS-9857; there were no Grade 3 or 4 abnormalities in alanine aminotransferase, aspartate aminotransferase or alk. phosphatase levels.  GS-9857 demonstrated potent antiviral activity in patients with chronic HCV infection, achieving mean and median max. redns. in HCV RNA of ≥3 log10 IU/mL following administration of a 100-mg dose in patients with HCV genotype 1a, 1b, 2, 3 or 4 infection.  The antiviral activity of GS-9857 was unaffected by the presence of pretreatment NS3 RAVs.  In patients with genotype 1-4 infection, GS-9857 exhibited linear PK and was assocd. with a median half-life of 29-42 h, supporting once-daily dosing.  Thus, the tolerability, efficacy and pharmacokinetic profile of GS-9857 support its further evaluation for treatment of patients with chronic HCV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8oJDwl-bOdbVg90H21EOLACvtfcHk0liy2h8J0mUqSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFOkurbK&md5=257769b545cb4289b8f9fc5298454f91</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1111%2Fjvh.12527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjvh.12527%26sid%3Dliteratum%253Aachs%26aulast%3DRodriguez-Torres%26aufirst%3DM.%26aulast%3DGlass%26aufirst%3DS.%26aulast%3DHill%26aufirst%3DJ.%26aulast%3DFreilich%26aufirst%3DB.%26aulast%3DHassman%26aufirst%3DD.%26aulast%3DDi%2BBisceglie%26aufirst%3DA.%2BM.%26aulast%3DTaylor%26aufirst%3DJ.%2BG.%26aulast%3DKirby%26aufirst%3DB.%2BJ.%26aulast%3DDvory-Sobol%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26aulast%3DAn%26aufirst%3DD.%26aulast%3DStamm%26aufirst%3DL.%2BM.%26aulast%3DBrainard%26aufirst%3DD.%2BM.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DKrefetz%26aufirst%3DD.%26aulast%3DSmith%26aufirst%3DW.%26aulast%3DMarbury%26aufirst%3DT.%26aulast%3DLawitz%26aufirst%3DE.%26atitle%3DGS-9857%2520in%2520patients%2520with%2520chronic%2520hepatitis%2520C%2520virus%2520genotype%25201%25E2%2580%25934%2520infection%253A%2520a%2520randomized%252C%2520double-blind%252C%2520dose-ranging%2520phase%25201%2520study%26jtitle%3DJ.%2520Viral.%2520Hepat.%26date%3D2016%26volume%3D23%26spage%3D614%26epage%3D622%26doi%3D10.1111%2Fjvh.12527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Tsantrizos, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonneau, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goudreau, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukolj, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaPlante, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Llinas-Brunet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nar, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamarre, D.</span><span> </span><span class="NLM_article-title">Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">1356</span><span class="NLM_x">–</span> <span class="NLM_lpage">1360</span><span class="refDoi"> DOI: 10.1002/anie.200390347</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1002%2Fanie.200390347" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjtlygsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2003&pages=1356-1360&author=Y.+S.+Tsantrizosauthor=G.+Bolgerauthor=P.+Bonneauauthor=D.+R.+Cameronauthor=N.+Goudreauauthor=G.+Kukoljauthor=S.+R.+LaPlanteauthor=M.+Llinas-Brunetauthor=H.+Narauthor=D.+Lamarre&title=Macrocyclic+inhibitors+of+the+NS3+protease+as+potential+therapeutic+agents+of+hepatitis+C+virus+infection&doi=10.1002%2Fanie.200390347"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection</span></div><div class="casAuthors">Tsantrizos, Youla S.; Bolger, Gordon; Bonneau, Pierre; Cameron, Dale R.; Goudreau, Nathalie; Kukolj, George; LaPlante, Steven R.; Llinas-Brunet, Montse; Nar, Herbert; Lamarre, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1356-1360</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A novel class of selective inhibitors of the hepatitis C virus NS3 protease, an enzyme which is essential for viral replication in vivo, was developed.  The inhibitors are based on the structure-activity relationship between a substrate-based peptidomimetic ligand and the HCV NS3 serine protease.  The designed HCV inhibitor and its satd. analogs are the first inhibitors of the NS3 protease which inhibit HCV RNA replication in the cell-based replicon assay.  In addn., they are orally absorbed and stable to metabolic breakdown.  Thus, these compds. show many of the desirable properties of a druglike archetype and could lead t a clin. useful antiviral agent for the treatment of hepatitis C viral infections in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCij3shP5tmLVg90H21EOLACvtfcHk0liy2h8J0mUqSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjtlygsrc%253D&md5=e0a3c98ee0096bfc3d058bf0b92b81c3</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1002%2Fanie.200390347&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200390347%26sid%3Dliteratum%253Aachs%26aulast%3DTsantrizos%26aufirst%3DY.%2BS.%26aulast%3DBolger%26aufirst%3DG.%26aulast%3DBonneau%26aufirst%3DP.%26aulast%3DCameron%26aufirst%3DD.%2BR.%26aulast%3DGoudreau%26aufirst%3DN.%26aulast%3DKukolj%26aufirst%3DG.%26aulast%3DLaPlante%26aufirst%3DS.%2BR.%26aulast%3DLlinas-Brunet%26aufirst%3DM.%26aulast%3DNar%26aufirst%3DH.%26aulast%3DLamarre%26aufirst%3DD.%26atitle%3DMacrocyclic%2520inhibitors%2520of%2520the%2520NS3%2520protease%2520as%2520potential%2520therapeutic%2520agents%2520of%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2003%26volume%3D42%26spage%3D1356%26epage%3D1360%26doi%3D10.1002%2Fanie.200390347" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">LaPlante, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nar, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemke, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakalian, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aubry, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawai, S. H.</span><span> </span><span class="NLM_article-title">Ligand bioactive conformation plays a critical role in the design of drugs that target the hepatitis C virus NS3 protease</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1777</span><span class="NLM_x">–</span> <span class="NLM_lpage">1789</span><span class="refDoi"> DOI: 10.1021/jm401338c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401338c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1Cktb7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1777-1789&author=S.+R.+LaPlanteauthor=H.+Narauthor=C.+T.+Lemkeauthor=A.+Jakalianauthor=N.+Aubryauthor=S.+H.+Kawai&title=Ligand+bioactive+conformation+plays+a+critical+role+in+the+design+of+drugs+that+target+the+hepatitis+C+virus+NS3+protease&doi=10.1021%2Fjm401338c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand Bioactive Conformation Plays a Critical Role in the Design of Drugs That Target the Hepatitis C Virus NS3 Protease</span></div><div class="casAuthors">LaPlante, Steven R.; Nar, Herbert; Lemke, Christopher T.; Jakalian, Araz; Aubry, Norman; Kawai, Stephen H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1777-1789</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A ligand-focused strategy employed NMR, X-ray, modeling, and medicinal chem. to expose the crit. role that bioactive conformation played in the design of a variety of drugs that target the HCV protease.  The bioactive conformation (bound states) were detd. for key inhibitors identified along our drug discovery pathway from the hit to clin. compds.  All adopt similar bioactive conformations for the common core derived from the hit peptide DDIVPC.  A carefully designed SAR anal., based on the advanced inhibitor 1 in which the P1 to P3 side chains and the N-terminal Boc were sequentially truncated, revealed a correlation between affinity and the relative predominance of the bioactive conformation in the free state.  Interestingly, synergistic conformation effects on potency were also noted.  Comparisons with clin. and recently marketed drugs from the pharmaceutical industry showed that all have the same core and similar bioactive conformations.  This suggested that the variety of appendages discovered for these compds. also properly satisfy the bioactive conformation requirements and allowed for a large variety of HCV protease drug candidates to be designed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFi-4R4F9wwbVg90H21EOLACvtfcHk0lh7jFFfZXzAJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1Cktb7P&md5=2ccb36504903255ba012223529318a69</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm401338c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401338c%26sid%3Dliteratum%253Aachs%26aulast%3DLaPlante%26aufirst%3DS.%2BR.%26aulast%3DNar%26aufirst%3DH.%26aulast%3DLemke%26aufirst%3DC.%2BT.%26aulast%3DJakalian%26aufirst%3DA.%26aulast%3DAubry%26aufirst%3DN.%26aulast%3DKawai%26aufirst%3DS.%2BH.%26atitle%3DLigand%2520bioactive%2520conformation%2520plays%2520a%2520critical%2520role%2520in%2520the%2520design%2520of%2520drugs%2520that%2520target%2520the%2520hepatitis%2520C%2520virus%2520NS3%2520protease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1777%26epage%3D1789%26doi%3D10.1021%2Fjm401338c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Lontok, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrington, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howe, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kieffer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lennerstrand, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenz, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pilot-Matias, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V.</span><span> </span><span class="NLM_article-title">Hepatitis C virus drug resistance-associated substitutions: state of the art summary</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">1623</span><span class="NLM_x">–</span> <span class="NLM_lpage">1632</span><span class="refDoi"> DOI: 10.1002/hep.27934</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1002%2Fhep.27934" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=26095927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A280%3ADC%252BC2MblsFaluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2015&pages=1623-1632&author=E.+Lontokauthor=P.+Harringtonauthor=A.+Howeauthor=T.+Kiefferauthor=J.+Lennerstrandauthor=O.+Lenzauthor=F.+McPheeauthor=H.+Moauthor=N.+Parkinauthor=T.+Pilot-Matiasauthor=V.+Miller&title=Hepatitis+C+virus+drug+resistance-associated+substitutions%3A+state+of+the+art+summary&doi=10.1002%2Fhep.27934"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis C virus drug resistance-associated substitutions: State of the art summary</span></div><div class="casAuthors">Lontok Erik; Miller Veronica; Harrington Patrick; Howe Anita; Kieffer Tara; Lennerstrand Johan; Lenz Oliver; McPhee Fiona; Mo Hongmei; Parkin Neil; Pilot-Matias Tami</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Baltimore, Md.)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1623-32</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">UNLABELLED:  Hepatitis C virus (HCV) drug development has resulted in treatment regimens composed of interferon-free, all-oral combinations of direct-acting antivirals.  While the new regimens are potent and highly efficacious, the full clinical impact of HCV drug resistance, its implications for retreatment, and the potential role of baseline resistance testing remain critical research and clinical questions.  In this report, we discuss the viral proteins targeted by HCV direct-acting antivirals and summarize clinically relevant resistance data for compounds that have been approved or are currently in phase 3 clinical trials.  CONCLUSION:  This report provides a comprehensive, systematic review of all resistance information available from sponsors' trials as a tool to inform the HCV drug development field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSWdgOjMha0H1WTCLT8lX9SfW6udTcc2eZePToCuLjhmbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MblsFaluw%253D%253D&md5=7d87bedfe7e1e825117a9f9a325da452</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fhep.27934&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.27934%26sid%3Dliteratum%253Aachs%26aulast%3DLontok%26aufirst%3DE.%26aulast%3DHarrington%26aufirst%3DP.%26aulast%3DHowe%26aufirst%3DA.%26aulast%3DKieffer%26aufirst%3DT.%26aulast%3DLennerstrand%26aufirst%3DJ.%26aulast%3DLenz%26aufirst%3DO.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DMo%26aufirst%3DH.%26aulast%3DParkin%26aufirst%3DN.%26aulast%3DPilot-Matias%26aufirst%3DT.%26aulast%3DMiller%26aufirst%3DV.%26atitle%3DHepatitis%2520C%2520virus%2520drug%2520resistance-associated%2520substitutions%253A%2520state%2520of%2520the%2520art%2520summary%26jtitle%3DHepatology%26date%3D2015%26volume%3D62%26spage%3D1623%26epage%3D1632%26doi%3D10.1002%2Fhep.27934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Kieffer, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, S.</span><span> </span><span class="NLM_article-title">Resistance to hepatitis C virus protease inhibitors</span> <span class="citation_source-journal">Curr. Opin. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">16</span><span class="NLM_x">–</span> <span class="NLM_lpage">21</span><span class="refDoi"> DOI: 10.1016/j.coviro.2014.04.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1016%2Fj.coviro.2014.04.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=24852142" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslGjsbbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2014&pages=16-21&author=T.+L.+Kiefferauthor=S.+George&title=Resistance+to+hepatitis+C+virus+protease+inhibitors&doi=10.1016%2Fj.coviro.2014.04.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Resistance to hepatitis C virus protease inhibitors</span></div><div class="casAuthors">Kieffer, Tara L.; George, Shelley</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Virology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">16-21</span>CODEN:
                <span class="NLM_cas:coden">COVUAF</span>;
        ISSN:<span class="NLM_cas:issn">1879-6257</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">Significant scientific advances have enabled the development of new classes of antivirals for the treatment of HCV.  Protease inhibitors were the first approved, achieving substantially higher response rates, with shorter treatment durations, in the majority of genotype 1 infected patients.  However, in patients who fail treatment, drug resistant variants frequently emerge.  The pattern of resistant variants obsd. is a result of the specific inhibitor, viral subtype, and level of drug selective pressure.  Data suggest the replacement of these variants over time; however, retreatment of these patients is an area of needed investigation.  As multiple drug classes progress in development, combinations of agents improve treatment success, increase the genetic barrier to resistance, and provide shorter treatment durations for diverse patient populations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5RruOLoAqxLVg90H21EOLACvtfcHk0lgqSpT1wFXHig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslGjsbbF&md5=6603e69f789b515ec49c0eaee2ada46e</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.coviro.2014.04.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coviro.2014.04.008%26sid%3Dliteratum%253Aachs%26aulast%3DKieffer%26aufirst%3DT.%2BL.%26aulast%3DGeorge%26aufirst%3DS.%26atitle%3DResistance%2520to%2520hepatitis%2520C%2520virus%2520protease%2520inhibitors%26jtitle%3DCurr.%2520Opin.%2520Virol.%26date%3D2014%26volume%3D8%26spage%3D16%26epage%3D21%26doi%3D10.1016%2Fj.coviro.2014.04.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Chan, K.; Yu, M.; Peng, B.; Corsa, A.; Worth, A.; Gong, R.; Xu, S.; Chen, X.; Appleby, T. C.; Taylor, J.; Delaney, W. E.; Cheng, G.</span><span> </span><span class="NLM_article-title">In vitro efficacy and resistance profiling of protease inhibitors against a novel HCV genotype 3a replicon</span>. In International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies, Toronto, ON, Canada, 2013;<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=K.+Chan&author=M.+Yu&author=B.+Peng&author=A.+Corsa&author=A.+Worth&author=R.+Gong&author=S.+Xu&author=X.+Chen&author=T.+C.+Appleby&author=J.+Taylor&author=W.+E.+Delaney&author=G.+Cheng&title=In+vitro+efficacy+and+resistance+profiling+of+protease+inhibitors+against+a+novel+HCV+genotype+3a+replicon"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DK.%26atitle%3DIn%2520vitro%2520efficacy%2520and%2520resistance%2520profiling%2520of%2520protease%2520inhibitors%2520against%2520a%2520novel%2520HCV%2520genotype%25203a%2520replicon%26jtitle%3DInternational%2520Workshop%2520on%2520HIV%2520%2526%2520Hepatitis%2520Virus%2520Drug%2520Resistance%2520and%2520Curative%2520Strategies%252C%2520Toronto%252C%2520ON%252C%2520Canada%252C%25202013%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Romano, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Royer, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiffer, C. A.</span><span> </span><span class="NLM_article-title">Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">20986</span><span class="NLM_x">–</span> <span class="NLM_lpage">20991</span><span class="refDoi"> DOI: 10.1073/pnas.1006370107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1073%2Fpnas.1006370107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=21084633" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFyrsbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=20986-20991&author=K.+P.+Romanoauthor=A.+Aliauthor=W.+E.+Royerauthor=C.+A.+Schiffer&title=Drug+resistance+against+HCV+NS3%2F4A+inhibitors+is+defined+by+the+balance+of+substrate+recognition+versus+inhibitor+binding&doi=10.1073%2Fpnas.1006370107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Drug resistance against: HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding</span></div><div class="casAuthors">Romano, Keith P.; Ali, Akbar; Royer, William E.; Schiffer, Celia A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">20986-20991, S20986/1-S20986/5</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Hepatitis C virus infects an estd. 180 million people worldwide, prompting enormous efforts to develop inhibitors targeting the essential NS3/4A protease.  Resistance against the most promising protease inhibitors, telaprevir, boceprevir, and ITMN-191, has emerged in clin. trials.  In this study, crystal structures of the NS3/4A protease domain reveal that viral substrates bind to the protease active site in a conserved manner defining a consensus vol., or substrate envelope.  Mutations that confer the most severe resistance in the clinic occur where the inhibitors protrude from the substrate envelope, as these changes selectively weaken inhibitor binding without compromising the binding of substrates.  These findings suggest a general model for predicting the susceptibility of protease inhibitors to resistance: drugs designed to fit within the substrate envelope will be less susceptible to resistance, as mutations affecting inhibitor binding would simultaneously interfere with the recognition of viral substrates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6Sz81F04YRrVg90H21EOLACvtfcHk0lgqSpT1wFXHig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFyrsbbM&md5=db72884b6a45110805bcdf70fbaea6a4</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1006370107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1006370107%26sid%3Dliteratum%253Aachs%26aulast%3DRomano%26aufirst%3DK.%2BP.%26aulast%3DAli%26aufirst%3DA.%26aulast%3DRoyer%26aufirst%3DW.%2BE.%26aulast%3DSchiffer%26aufirst%3DC.%2BA.%26atitle%3DDrug%2520resistance%2520against%2520HCV%2520NS3%252F4A%2520inhibitors%2520is%2520defined%2520by%2520the%2520balance%2520of%2520substrate%2520recognition%2520versus%2520inhibitor%2520binding%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26spage%3D20986%26epage%3D20991%26doi%3D10.1073%2Fpnas.1006370107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Romano, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aydin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soumana, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Özen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deveau, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silver, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petropoulos, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiffer, C. A.</span><span> </span><span class="NLM_article-title">The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors</span> <span class="citation_source-journal">PLoS Pathog.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">e1002832</span><span class="refDoi"> DOI: 10.1371/journal.ppat.1002832</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1371%2Fjournal.ppat.1002832" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=22910833" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFeisrbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=e1002832&author=K.+P.+Romanoauthor=A.+Aliauthor=C.+Aydinauthor=D.+Soumanaauthor=A.+%C3%96zenauthor=L.+M.+Deveauauthor=C.+Silverauthor=H.+Caoauthor=A.+Newtonauthor=C.+J.+Petropoulosauthor=W.+Huangauthor=C.+A.+Schiffer&title=The+molecular+basis+of+drug+resistance+against+hepatitis+C+virus+NS3%2F4A+protease+inhibitors&doi=10.1371%2Fjournal.ppat.1002832"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors</span></div><div class="casAuthors">Romano, Keith P.; Ali, Akbar; Aydin, Cihan; Soumana, Djade; Ozen, Aysegul; Deveau, Laura M.; Silver, Casey; Cao, Hong; Newton, Alicia; Petropoulos, Christos J.; Huang, Wei; Schiffer, Celia A.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Pathogens</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">e1002832</span>CODEN:
                <span class="NLM_cas:coden">PPLACN</span>;
        ISSN:<span class="NLM_cas:issn">1553-7374</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) infects over 170 million people worldwide and is the leading cause of chronic liver diseases, including cirrhosis, liver failure and liver cancer.  Available antiviral therapies cause severe side effects and are effective only for a subset of patients, though treatment outcomes have recently been improved by the combination therapy now including boceprevir and telaprevir, which inhibit the viral NS3/4A protease.  Despite extensive efforts to develop more potent next-generation protease inhibitors, however, the long-term efficacy of this drug class is challenged by the rapid emergence of resistance.  Single-site mutations at protease residues R155, A156 and D168 confer resistance to nearly all inhibitors in clin. development.  Thus, developing the next-generation of drugs that retain activity against a broader spectrum of resistant viral variants requires a comprehensive understanding of the mol. basis of drug resistance.  In this study, 16 high-resoln. crystal structures of four representative protease inhibitors - telaprevir, danoprevir, vaniprevir and MK-5172 - in complex with the wild-type protease and three major drug-resistant variants R155K, A156T and D168A, reveal unique mol. underpinnings of resistance to each drug.  The drugs exhibit differential susceptibilities to these protease variants in both enzymic and antiviral assays.  Telaprevir, danoprevir and vaniprevir interact directly with sites that confer resistance upon mutation, while MK-5172 interacts in a unique conformation with the catalytic triad.  This novel mode of MK-5172 binding explains its retained potency against two multi-drug-resistant variants, R155K and D168A.  These findings define the mol. basis of HCV N3/4A protease inhibitor resistance and provide potential strategies for designing robust therapies against this rapidly evolving virus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprECYOGWNgj7Vg90H21EOLACvtfcHk0lhlRAsVrk8RdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFeisrbK&md5=15ca5b9d370793cd3fa814755ddf99c6</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1002832&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1002832%26sid%3Dliteratum%253Aachs%26aulast%3DRomano%26aufirst%3DK.%2BP.%26aulast%3DAli%26aufirst%3DA.%26aulast%3DAydin%26aufirst%3DC.%26aulast%3DSoumana%26aufirst%3DD.%26aulast%3D%25C3%2596zen%26aufirst%3DA.%26aulast%3DDeveau%26aufirst%3DL.%2BM.%26aulast%3DSilver%26aufirst%3DC.%26aulast%3DCao%26aufirst%3DH.%26aulast%3DNewton%26aufirst%3DA.%26aulast%3DPetropoulos%26aufirst%3DC.%2BJ.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DSchiffer%26aufirst%3DC.%2BA.%26atitle%3DThe%2520molecular%2520basis%2520of%2520drug%2520resistance%2520against%2520hepatitis%2520C%2520virus%2520NS3%252F4A%2520protease%2520inhibitors%26jtitle%3DPLoS%2520Pathog.%26date%3D2012%26volume%3D8%26spage%3De1002832%26doi%3D10.1371%2Fjournal.ppat.1002832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Soumana, D. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiffer, C. A.</span><span> </span><span class="NLM_article-title">Structural analysis of asunaprevir resistance in HCV NS3/4A protease</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">2485</span><span class="NLM_x">–</span> <span class="NLM_lpage">2490</span><span class="refDoi"> DOI: 10.1021/cb5006118</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb5006118" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFygtb%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=2485-2490&author=D.+I.+Soumanaauthor=A.+Aliauthor=C.+A.+Schiffer&title=Structural+analysis+of+asunaprevir+resistance+in+HCV+NS3%2F4A+protease&doi=10.1021%2Fcb5006118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Analysis of Asunaprevir Resistance in HCV NS3/4A Protease</span></div><div class="casAuthors">Soumana, Djade I.; Ali, Akbar; Schiffer, Celia A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2485-2490</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Asunaprevir (ASV), an isoquinoline-based competitive inhibitor targeting the hepatitis C virus (HCV) NS3/4A protease, is very potent in vivo.  However, the potency is significantly compromised by the drug resistance mutations R155K and D168A.  In this study three crystal structures of ASV and an analog were detd. to analyze the structural basis of drug resistance susceptibility.  These structures revealed that ASV makes extensive contacts with Arg155 outside the substrate envelope.  Arg155 in turn is stabilized by Asp168, and thus when either residue is mutated, the enzyme's interaction with ASV's P2* isoquinoline is disrupted.  Adding a P1-P3 macrocycle to ASV enhances the inhibitor's resistance barrier, likely due to poising the inhibitor to its bound conformation.  Macrocyclic inhibitors with P2* extension moieties avoiding interaction with the protease S2 residues including Arg155 must be chosen for future design of more robust protease inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIGE9O_qeabbVg90H21EOLACvtfcHk0lhlRAsVrk8RdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFygtb%252FM&md5=ee215d143e48b8305d1272c4e9192def</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fcb5006118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb5006118%26sid%3Dliteratum%253Aachs%26aulast%3DSoumana%26aufirst%3DD.%2BI.%26aulast%3DAli%26aufirst%3DA.%26aulast%3DSchiffer%26aufirst%3DC.%2BA.%26atitle%3DStructural%2520analysis%2520of%2520asunaprevir%2520resistance%2520in%2520HCV%2520NS3%252F4A%2520protease%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D2485%26epage%3D2490%26doi%3D10.1021%2Fcb5006118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Soumana, D. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurt Yilmaz, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prachanronarong, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiffer, C. A.</span><span> </span><span class="NLM_article-title">Molecular and dynamic mechanism underlying drug resistance in genotype 3 hepatitis C NS3/4A protease</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">138</span><span class="NLM_x">, </span> <span class="NLM_fpage">11850</span><span class="NLM_x">–</span> <span class="NLM_lpage">11859</span><span class="refDoi"> DOI: 10.1021/jacs.6b06454</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.6b06454" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlamt7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2016&pages=11850-11859&author=D.+I.+Soumanaauthor=N.+Kurt+Yilmazauthor=A.+Aliauthor=K.+L.+Prachanronarongauthor=C.+A.+Schiffer&title=Molecular+and+dynamic+mechanism+underlying+drug+resistance+in+genotype+3+hepatitis+C+NS3%2F4A+protease&doi=10.1021%2Fjacs.6b06454"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular and Dynamic Mechanism Underlying Drug Resistance in Genotype 3 Hepatitis C NS3/4A Protease</span></div><div class="casAuthors">Soumana, Djade I.; Kurt Yilmaz, Nese; Ali, Akbar; Prachanronarong, Kristina L.; Schiffer, Celia A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">11850-11859</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV), affecting an estd. 150 million people worldwide, is the leading cause of viral hepatitis, cirrhosis and hepatocellular carcinoma.  HCV is genetically diverse with six genotypes (GTs) and multiple subtypes of different global distribution and prevalence.  Recent development of direct-acting antivirals against HCV including NS3/4A protease inhibitors (PIs) has greatly improved treatment outcomes for GT-1.  However, all current PIs exhibit significantly lower potency against GT-3.  Lack of structural data on GT-3 protease has limited the ability to understand PI failure in GT-3.  In this study the mol. basis for reduced potency of current inhibitors to GT-3 NS3/4A protease is elucidated with structure detn., mol. dynamics simulations and inhibition assays.  A chimeric GT-1a3a NS3/4A protease amenable to crystn. was engineered to fully recapitulate decreased sensitivity of GT-3 protease to PIs.  High-resoln. crystal structures of this GT-1a3a bound to 3 PIs, asunaprevir, danoprevir and vaniprevir, had only subtle differences relative to GT-1 despite orders of magnitude loss in affinity.  In contrast, hydrogen-bonding interactions within and with the protease active site, and dynamic fluctuations of the PIs were drastically altered.  The correlation between loss of intermol. dynamics and inhibitor potency suggest a drug resistance mechanism where polymorphisms (or mutations) at the drug target confer resistance through altering the intermol. dynamics of the protein-inhibitor complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_Ljasdqx_-7Vg90H21EOLACvtfcHk0li21S81pWZN2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlamt7vE&md5=318231c49ad4eff7ec424112c1d56273</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjacs.6b06454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.6b06454%26sid%3Dliteratum%253Aachs%26aulast%3DSoumana%26aufirst%3DD.%2BI.%26aulast%3DKurt%2BYilmaz%26aufirst%3DN.%26aulast%3DAli%26aufirst%3DA.%26aulast%3DPrachanronarong%26aufirst%3DK.%2BL.%26aulast%3DSchiffer%26aufirst%3DC.%2BA.%26atitle%3DMolecular%2520and%2520dynamic%2520mechanism%2520underlying%2520drug%2520resistance%2520in%2520genotype%25203%2520hepatitis%2520C%2520NS3%252F4A%2520protease%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2016%26volume%3D138%26spage%3D11850%26epage%3D11859%26doi%3D10.1021%2Fjacs.6b06454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">O’Meara, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemke, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godbout, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukolj, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lagacé, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreau, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thibeault, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Llinàs-Brunet, M.</span><span> </span><span class="NLM_article-title">Molecular mechanism by which a potent hepatitis C virus NS3-NS4A protease inhibitor overcomes emergence of resistance</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">288</span><span class="NLM_x">, </span> <span class="NLM_fpage">5673</span><span class="NLM_x">–</span> <span class="NLM_lpage">5681</span><span class="refDoi"> DOI: 10.1074/jbc.M112.439455</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1074%2Fjbc.M112.439455" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=23271737" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtVGhu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=5673-5681&author=J.+A.+O%E2%80%99Mearaauthor=C.+T.+Lemkeauthor=C.+Godboutauthor=G.+Kukoljauthor=L.+Lagac%C3%A9author=B.+Moreauauthor=D.+Thibeaultauthor=P.+W.+Whiteauthor=M.+Llin%C3%A0s-Brunet&title=Molecular+mechanism+by+which+a+potent+hepatitis+C+virus+NS3-NS4A+protease+inhibitor+overcomes+emergence+of+resistance&doi=10.1074%2Fjbc.M112.439455"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Mechanism by Which a Potent Hepatitis C Virus NS3-NS4A Protease Inhibitor Overcomes Emergence of Resistance</span></div><div class="casAuthors">O'Meara, Jeff A.; Lemke, Christopher T.; Godbout, Cedrickx; Kukolj, George; Lagace, Lisette; Moreau, Benoit; Thibeault, Diane; White, Peter W.; Llinas-Brunet, Montse</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">5673-5681</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Although optimizing the resistance profile of an inhibitor can be challenging, it is potentially important for improving the long term effectiveness of antiviral therapy.  This work describes our rational approach toward the identification of a macrocyclic acylsulfonamide that is a potent inhibitor of the NS3-NS4A proteases of all hepatitis C virus genotypes and of a panel of genotype 1-resistant variants.  The enhanced potency of this compd. vs. variants D168V and R155K facilitated x-ray detn. of the inhibitor-variant complexes.  In turn, these structural studies revealed a complex mol. basis of resistance and rationalized how such compds. are able to circumvent these mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUYkmfd-pz4rVg90H21EOLACvtfcHk0li21S81pWZN2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtVGhu7k%253D&md5=f595fad59b9278f76873eab3bd29897c</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M112.439455&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M112.439455%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Meara%26aufirst%3DJ.%2BA.%26aulast%3DLemke%26aufirst%3DC.%2BT.%26aulast%3DGodbout%26aufirst%3DC.%26aulast%3DKukolj%26aufirst%3DG.%26aulast%3DLagac%25C3%25A9%26aufirst%3DL.%26aulast%3DMoreau%26aufirst%3DB.%26aulast%3DThibeault%26aufirst%3DD.%26aulast%3DWhite%26aufirst%3DP.%2BW.%26aulast%3DLlin%25C3%25A0s-Brunet%26aufirst%3DM.%26atitle%3DMolecular%2520mechanism%2520by%2520which%2520a%2520potent%2520hepatitis%2520C%2520virus%2520NS3-NS4A%2520protease%2520inhibitor%2520overcomes%2520emergence%2520of%2520resistance%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26spage%3D5673%26epage%3D5681%26doi%3D10.1074%2Fjbc.M112.439455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Ali, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aydin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gildemeister, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romano, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Özen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soumana, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petropoulos, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiffer, C. A.</span><span> </span><span class="NLM_article-title">Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3/4A protease inhibitors to drug resistance</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1469</span><span class="NLM_x">–</span> <span class="NLM_lpage">1478</span><span class="refDoi"> DOI: 10.1021/cb400100g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb400100g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtVWksr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=1469-1478&author=A.+Aliauthor=C.+Aydinauthor=R.+Gildemeisterauthor=K.+P.+Romanoauthor=H.+Caoauthor=A.+%C3%96zenauthor=D.+Soumanaauthor=A.+Newtonauthor=C.+J.+Petropoulosauthor=W.+Huangauthor=C.+A.+Schiffer&title=Evaluating+the+role+of+macrocycles+in+the+susceptibility+of+hepatitis+C+virus+NS3%2F4A+protease+inhibitors+to+drug+resistance&doi=10.1021%2Fcb400100g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluating the Role of Macrocycles in the Susceptibility of Hepatitis C Virus NS3/4A Protease Inhibitors to Drug Resistance</span></div><div class="casAuthors">Ali, Akbar; Aydin, Cihan; Gildemeister, Reinhold; Romano, Keith P.; Cao, Hong; Ozen, Aysegul; Soumana, Djade; Newton, Alicia; Petropoulos, Christos J.; Huang, Wei; Schiffer, Celia A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1469-1478</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The hepatitis C virus (HCV) infects an estd. 150 million people worldwide and is the major cause of viral hepatitis, cirrhosis, and liver cancer.  The available antiviral therapies, which include PEGylated interferon, ribavirin, and one of the HCV NS3/4A protease inhibitors telaprevir or boceprevir, are ineffective for some patients and cause severe side effects.  More potent NS3/4A protease inhibitors are in clin. development, but the long-term effectiveness of these drugs is challenged by the development of drug resistance.  Here, the authors investigated the role of macrocycles in the susceptibility of NS3/4A protease inhibitors to drug resistance in asunaprevir, danoprevir, vaniprevir, and MK-5172, with similar core structures but varied P2 moieties and macrocyclizations.  Linear and macrocyclic analogs of these drugs were designed, synthesized, and tested against wild-type and drug-resistant variants R155K, V36M/R155K, A156T, and D168A in enzymic and antiviral assays.  Macrocyclic inhibitors were generally more potent, but the location of the macrocycle was crit. for retaining activity against drug-resistant variants: the P1-P3 macrocyclic inhibitors were less susceptible to drug resistance than the linear and P2-P4 macrocyclic analogs.  In addn., the heterocyclic moiety at P2 largely detd. the inhibitor resistance profile, susceptibility to drug resistance, and the extent of modulation by the helicase domain.  Our findings suggest that to design robust inhibitors that retain potency to drug-resistant NS3/4A protease variants, inhibitors should combine P1-P3 macrocycles with flexible P2 moieties that optimally contact with the invariable catalytic triad of this enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSMqHEQz0LDLVg90H21EOLACvtfcHk0li21S81pWZN2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtVWksr0%253D&md5=141011162bbb591eb06990071fca3d84</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fcb400100g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb400100g%26sid%3Dliteratum%253Aachs%26aulast%3DAli%26aufirst%3DA.%26aulast%3DAydin%26aufirst%3DC.%26aulast%3DGildemeister%26aufirst%3DR.%26aulast%3DRomano%26aufirst%3DK.%2BP.%26aulast%3DCao%26aufirst%3DH.%26aulast%3D%25C3%2596zen%26aufirst%3DA.%26aulast%3DSoumana%26aufirst%3DD.%26aulast%3DNewton%26aufirst%3DA.%26aulast%3DPetropoulos%26aufirst%3DC.%2BJ.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DSchiffer%26aufirst%3DC.%2BA.%26atitle%3DEvaluating%2520the%2520role%2520of%2520macrocycles%2520in%2520the%2520susceptibility%2520of%2520hepatitis%2520C%2520virus%2520NS3%252F4A%2520protease%2520inhibitors%2520to%2520drug%2520resistance%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2013%26volume%3D8%26spage%3D1469%26epage%3D1478%26doi%3D10.1021%2Fcb400100g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Summa, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludmerer, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCauley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fandozzi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burlein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Claudio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMuzio, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Filippo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gates, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harper, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hazuda, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHale, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monteagudo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pucci, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudd, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soriano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahlhut, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vacca, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liverton, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, S. S.</span><span> </span><span class="NLM_article-title">MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">4161</span><span class="NLM_x">–</span> <span class="NLM_lpage">4167</span><span class="refDoi"> DOI: 10.1128/AAC.00324-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1128%2FAAC.00324-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=22615282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFajs7zF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=4161-4167&author=V.+Summaauthor=S.+W.+Ludmererauthor=J.+A.+McCauleyauthor=C.+Fandozziauthor=C.+Burleinauthor=G.+Claudioauthor=P.+J.+Colemanauthor=J.+M.+DiMuzioauthor=M.+Ferraraauthor=M.+Di+Filippoauthor=A.+T.+Gatesauthor=D.+J.+Grahamauthor=S.+Harperauthor=D.+J.+Hazudaauthor=C.+McHaleauthor=E.+Monteagudoauthor=V.+Pucciauthor=M.+Rowleyauthor=M.+T.+Ruddauthor=A.+Sorianoauthor=M.+W.+Stahlhutauthor=J.+P.+Vaccaauthor=D.+B.+Olsenauthor=N.+J.+Livertonauthor=S.+S.+Carroll&title=MK-5172%2C+a+selective+inhibitor+of+hepatitis+C+virus+NS3%2F4a+protease+with+broad+activity+across+genotypes+and+resistant+variants&doi=10.1128%2FAAC.00324-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants</span></div><div class="casAuthors">Summa, Vincenzo; Ludmerer, Steven W.; McCauley, John A.; Fandozzi, Christine; Burlein, Christine; Claudio, Giuliano; Coleman, Paul J.; DiMuzio, Jillian M.; Ferrara, Marco; Di Filippo, Marcello; Gates, Adam T.; Graham, Donald J.; Harper, Steven; Hazuda, Daria J.; McHale, Carolyn; Monteagudo, Edith; Pucci, Vincenzo; Rowley, Michael; Rudd, Michael T.; Soriano, Aileen; Stahlhut, Mark W.; Vacca, Joseph P.; Olsen, David B.; Liverton, Nigel J.; Carroll, Steven S.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4161-4167</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">HCV NS3/4a protease inhibitors are proven therapeutic agents against chronic hepatitis C virus infection, with boceprevir and telaprevir having recently received regulatory approval as add-on therapy to pegylated interferon/ribavirin for patients harboring genotype 1 infections.  Overcoming antiviral resistance, broad genotype coverage, and a convenient dosing regimen are important attributes for future agents to be used in combinations without interferon.  In this communication, we report the preclin. profile of MK-5172, a novel P2-P4 quinoxaline macrocyclic NS3/4a protease inhibitor currently in clin. development.  The compd. demonstrates subnanomolar activity against a broad enzyme panel encompassing major hepatitis C virus (HCV) genotypes as well as variants resistant to earlier protease inhibitors.  In replicon selections, MK-5172 exerted high selective pressure, which yielded few resistant colonies.  In both rat and dog, MK-5172 demonstrates good plasma and liver exposures, with 24-h liver levels suggestive of once-daily dosing.  When administered to HCV-infected chimpanzees harboring chronic gt1a or gt1b infections, MK-5172 suppressed viral load between 4 to 5 logs at a dose of 1 mg/kg of body wt. twice daily (b.i.d.) for 7 days.  Based on its preclin. profile, MK-5172 is anticipated to be broadly active against multiple HCV genotypes and clin. important resistance variants and highly suited for incorporation into newer all-oral regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomXxLJMTmWqrVg90H21EOLACvtfcHk0liAm9BxUf4FLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFajs7zF&md5=8874f9279917137113e429cda31c1bba</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1128%2FAAC.00324-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00324-12%26sid%3Dliteratum%253Aachs%26aulast%3DSumma%26aufirst%3DV.%26aulast%3DLudmerer%26aufirst%3DS.%2BW.%26aulast%3DMcCauley%26aufirst%3DJ.%2BA.%26aulast%3DFandozzi%26aufirst%3DC.%26aulast%3DBurlein%26aufirst%3DC.%26aulast%3DClaudio%26aufirst%3DG.%26aulast%3DColeman%26aufirst%3DP.%2BJ.%26aulast%3DDiMuzio%26aufirst%3DJ.%2BM.%26aulast%3DFerrara%26aufirst%3DM.%26aulast%3DDi%2BFilippo%26aufirst%3DM.%26aulast%3DGates%26aufirst%3DA.%2BT.%26aulast%3DGraham%26aufirst%3DD.%2BJ.%26aulast%3DHarper%26aufirst%3DS.%26aulast%3DHazuda%26aufirst%3DD.%2BJ.%26aulast%3DMcHale%26aufirst%3DC.%26aulast%3DMonteagudo%26aufirst%3DE.%26aulast%3DPucci%26aufirst%3DV.%26aulast%3DRowley%26aufirst%3DM.%26aulast%3DRudd%26aufirst%3DM.%2BT.%26aulast%3DSoriano%26aufirst%3DA.%26aulast%3DStahlhut%26aufirst%3DM.%2BW.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26aulast%3DOlsen%26aufirst%3DD.%2BB.%26aulast%3DLiverton%26aufirst%3DN.%2BJ.%26aulast%3DCarroll%26aufirst%3DS.%2BS.%26atitle%3DMK-5172%252C%2520a%2520selective%2520inhibitor%2520of%2520hepatitis%2520C%2520virus%2520NS3%252F4a%2520protease%2520with%2520broad%2520activity%2520across%2520genotypes%2520and%2520resistant%2520variants%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D4161%26epage%3D4167%26doi%3D10.1128%2FAAC.00324-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Soumana, D. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurt Yilmaz, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prachanronarong, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aydin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiffer, C. A.</span><span> </span><span class="NLM_article-title">Structural and thermodynamic effects of macrocyclization in HCV NS3/4A inhibitor MK-5172</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">900</span><span class="NLM_x">–</span> <span class="NLM_lpage">909</span><span class="refDoi"> DOI: 10.1021/acschembio.5b00647</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.5b00647" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVGitb3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=900-909&author=D.+I.+Soumanaauthor=N.+Kurt+Yilmazauthor=K.+L.+Prachanronarongauthor=C.+Aydinauthor=A.+Aliauthor=C.+A.+Schiffer&title=Structural+and+thermodynamic+effects+of+macrocyclization+in+HCV+NS3%2F4A+inhibitor+MK-5172&doi=10.1021%2Facschembio.5b00647"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Thermodynamic Effects of Macrocyclization in HCV NS3/4A Inhibitor MK-5172</span></div><div class="casAuthors">Soumana, Djade I.; Kurt Yilmaz, Nese; Prachanronarong, Kristina L.; Aydin, Cihan; Ali, Akbar; Schiffer, Celia A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">900-909</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Recent advances in direct-acting antivirals against Hepatitis C Virus (HCV) have led to the development of potent inhibitors, including MK-5172, that target the viral NS3/4A protease with relatively low susceptibility to resistance.  MK-5172 has a P2-P4 macrocycle and a unique binding mode among current protease inhibitors where the P2 quinoxaline packs against the catalytic residues H57 and D81.  However, the effect of macrocyclization on this binding mode is not clear, as is the relation between macrocyclization, thermodn. stabilization, and susceptibility to the resistance mutation A156T.  We have detd. high-resoln. crystal structures of linear and P1-P3 macrocyclic analogs of MK-5172 bound to WT and A156T protease and compared these structures, their mol. dynamics, and exptl. binding thermodn. to the parent compd.  We find that the "unique" binding mode of MK-5172 is conserved even when the P2-P4 macrocycle is removed or replaced with a P1-P3 macrocycle.  While beneficial to decreasing the entropic penalty assocd. with binding, the constraint exerted by the P2-P4 macrocycle prevents efficient rearrangement to accommodate the A156T mutation, a deficit alleviated in the linear and P1-P3 analogs.  Design of macrocyclic inhibitors against NS3/4A needs to achieve the best balance between exerting optimal conformational constraint for enhancing potency, fitting within the substrate envelope and allowing adaptability to be robust against resistance mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVaszg0NfWS7Vg90H21EOLACvtfcHk0lgnyShFz3BqyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVGitb3F&md5=4f3cadfdedbb5af22d0ef55c088d3687</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Facschembio.5b00647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.5b00647%26sid%3Dliteratum%253Aachs%26aulast%3DSoumana%26aufirst%3DD.%2BI.%26aulast%3DKurt%2BYilmaz%26aufirst%3DN.%26aulast%3DPrachanronarong%26aufirst%3DK.%2BL.%26aulast%3DAydin%26aufirst%3DC.%26aulast%3DAli%26aufirst%3DA.%26aulast%3DSchiffer%26aufirst%3DC.%2BA.%26atitle%3DStructural%2520and%2520thermodynamic%2520effects%2520of%2520macrocyclization%2520in%2520HCV%2520NS3%252F4A%2520inhibitor%2520MK-5172%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2016%26volume%3D11%26spage%3D900%26epage%3D909%26doi%3D10.1021%2Facschembio.5b00647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">King, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prabu-Jeyabalan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nalivaika, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiffer, C. A.</span><span> </span><span class="NLM_article-title">Combating susceptibility to drug resistance: lessons from HIV-1 protease</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1333</span><span class="NLM_x">–</span> <span class="NLM_lpage">1338</span><span class="refDoi"> DOI: 10.1016/j.chembiol.2004.08.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1016%2Fj.chembiol.2004.08.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=15489160" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BD2cXos1Ciu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2004&pages=1333-1338&author=N.+M.+Kingauthor=M.+Prabu-Jeyabalanauthor=E.+A.+Nalivaikaauthor=C.+A.+Schiffer&title=Combating+susceptibility+to+drug+resistance%3A+lessons+from+HIV-1+protease&doi=10.1016%2Fj.chembiol.2004.08.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Combating Susceptibility to Drug Resistance Lessons from HIV-1 Protease</span></div><div class="casAuthors">King, Nancy M.; Prabu-Jeyabalan, Moses; Nalivaika, Ellen A.; Schiffer, Celia A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1333-1338</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Drug resistance is a major obstacle in modern medicine.  However, resistance is rarely considered in drug development and may inadvertently be facilitated, as many designed inhibitors contact residues that can mutate to confer resistance, without significantly impairing function.  Contemporary drug design often ignores the detailed at. basis for function and primarily focuses on disrupting the target's activity, which is necessary but not sufficient for developing a robust drug.  In this study, we examine the impact of drug-resistant mutations in HIV-1 protease on substrate recognition and demonstrate that most primary active site mutations do not extensively contact substrates, but are crit. to inhibitor binding.  We propose a general, structure-based strategy to reduce the probability of drug resistance by designing inhibitors that interact only with those residues that are essential for function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbsk2AyTcCmbVg90H21EOLACvtfcHk0lgnyShFz3BqyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXos1Ciu78%253D&md5=701599b15cf9ecc2c026ad4eac650a90</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2004.08.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2004.08.010%26sid%3Dliteratum%253Aachs%26aulast%3DKing%26aufirst%3DN.%2BM.%26aulast%3DPrabu-Jeyabalan%26aufirst%3DM.%26aulast%3DNalivaika%26aufirst%3DE.%2BA.%26aulast%3DSchiffer%26aufirst%3DC.%2BA.%26atitle%3DCombating%2520susceptibility%2520to%2520drug%2520resistance%253A%2520lessons%2520from%2520HIV-1%2520protease%26jtitle%3DChem.%2520Biol.%26date%3D2004%26volume%3D11%26spage%3D1333%26epage%3D1338%26doi%3D10.1016%2Fj.chembiol.2004.08.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Özen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherman, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiffer, C. A.</span><span> </span><span class="NLM_article-title">Improving the resistance profile of hepatitis C NS3/4A inhibitors: dynamic substrate envelope guided design</span> <span class="citation_source-journal">J. Chem. Theory Comput.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">5693</span><span class="NLM_x">–</span> <span class="NLM_lpage">5705</span><span class="refDoi"> DOI: 10.1021/ct400603p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ct400603p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1amt7%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=5693-5705&author=A.+%C3%96zenauthor=W.+Shermanauthor=C.+A.+Schiffer&title=Improving+the+resistance+profile+of+hepatitis+C+NS3%2F4A+inhibitors%3A+dynamic+substrate+envelope+guided+design&doi=10.1021%2Fct400603p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Improving the Resistance Profile of Hepatitis C NS3/4A Inhibitors: Dynamic Substrate Envelope Guided Design</span></div><div class="casAuthors">Ozen, Aysegul; Sherman, Woody; Schiffer, Celia A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Theory and Computation</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5693-5705</span>CODEN:
                <span class="NLM_cas:coden">JCTCCE</span>;
        ISSN:<span class="NLM_cas:issn">1549-9618</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Drug resistance is a principal concern in the treatment of quickly evolving diseases.  The viral protease NS3/4A is a primary drug target for the hepatitis C virus (HCV) and is known to evolve resistance mutations in response to drug therapy.  At the mol. level, drug resistance reflects a subtle change in the balance of mol. recognition by NS3/4A; the drug resistant protease variants are no longer effectively inhibited by the competitive active site inhibitors but can still process the natural substrates with enough efficiency for viral survival.  In previous works, the authors have developed the "substrate envelope" hypothesis, which posits that inhibitors should be less susceptible to drug resistance if they better mimic the natural substrate mol. recognition features.  The authors perform mol. dynamics simulations on four native substrates bound to NS3/4A and discover a clearly conserved dynamic substrate envelope.  The authors show that the most severe drug resistance mutations in NS3/4A occur at residues that are outside the substrate envelope.  Comparative anal. of three NS3/4A inhibitors reveals structural and dynamic characteristics of inhibitors that could lead to resistance.  The authors also suggest inhibitor modifications to improve resistance profiles based on the dynamic substrate envelope.  This study provides a general framework for guiding the development of novel inhibitors that will be more robust against resistance by mimicking the static and dynamic binding characteristics of natural substrates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk2uHtoexId7Vg90H21EOLACvtfcHk0lgnyShFz3BqyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1amt7%252FF&md5=91c75667e5fc91c1c07d59c71e995283</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fct400603p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fct400603p%26sid%3Dliteratum%253Aachs%26aulast%3D%25C3%2596zen%26aufirst%3DA.%26aulast%3DSherman%26aufirst%3DW.%26aulast%3DSchiffer%26aufirst%3DC.%2BA.%26atitle%3DImproving%2520the%2520resistance%2520profile%2520of%2520hepatitis%2520C%2520NS3%252F4A%2520inhibitors%253A%2520dynamic%2520substrate%2520envelope%2520guided%2520design%26jtitle%3DJ.%2520Chem.%2520Theory%2520Comput.%26date%3D2013%26volume%3D9%26spage%3D5693%26epage%3D5705%26doi%3D10.1021%2Fct400603p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Kurt Yilmaz, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swanstrom, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiffer, C. A.</span><span> </span><span class="NLM_article-title">Improving viral protease inhibitors to counter drug resistance</span> <span class="citation_source-journal">Trends Microbiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">547</span><span class="NLM_x">–</span> <span class="NLM_lpage">557</span><span class="refDoi"> DOI: 10.1016/j.tim.2016.03.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1016%2Fj.tim.2016.03.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=27090931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC28XlslCjtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=547-557&author=N.+Kurt+Yilmazauthor=R.+Swanstromauthor=C.+A.+Schiffer&title=Improving+viral+protease+inhibitors+to+counter+drug+resistance&doi=10.1016%2Fj.tim.2016.03.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Improving Viral Protease Inhibitors to Counter Drug Resistance</span></div><div class="casAuthors">Kurt Yilmaz, Nese; Swanstrom, Ronald; Schiffer, Celia A.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Microbiology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">547-557</span>CODEN:
                <span class="NLM_cas:coden">TRMIEA</span>;
        ISSN:<span class="NLM_cas:issn">0966-842X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Drug resistance is a major problem in health care, undermining therapy outcomes and necessitating novel approaches to drug design.  Extensive studies on resistance to viral protease inhibitors, particularly those of HIV-1 and hepatitis C virus (HCV) protease, revealed a plethora of information on the structural and mol. mechanisms underlying resistance.  These insights led to several strategies to improve viral protease inhibitors to counter resistance, such as exploiting the essential biol. function and leveraging evolutionary constraints.  Incorporation of these strategies into structure-based drug design can minimize vulnerability to resistance, not only for viral proteases but for other quickly evolving drug targets as well, toward designing inhibitors one step ahead of evolution to counter resistance with more intelligent and rational design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrl6bKzn4Yf4rVg90H21EOLACvtfcHk0lg6ntO1R_9-GA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlslCjtL4%253D&md5=a14170ffc3d71a9770e3d1f7a3146d6c</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.tim.2016.03.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tim.2016.03.010%26sid%3Dliteratum%253Aachs%26aulast%3DKurt%2BYilmaz%26aufirst%3DN.%26aulast%3DSwanstrom%26aufirst%3DR.%26aulast%3DSchiffer%26aufirst%3DC.%2BA.%26atitle%3DImproving%2520viral%2520protease%2520inhibitors%2520to%2520counter%2520drug%2520resistance%26jtitle%3DTrends%2520Microbiol.%26date%3D2016%26volume%3D24%26spage%3D547%26epage%3D557%26doi%3D10.1016%2Fj.tim.2016.03.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Wang, X. A.; Sun, L.-Q.; Sit, S.-Y.; Sin, N.; Scola, P. M.; Hewawasam, P.; Good, A. C.; Chen, Y.; Campbell, J. A.</span><span> </span><span class="NLM_article-title">Hepatitis C Virus Inhibitors</span>. US Patent 6995174,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=X.+A.+Wang&author=L.-Q.+Sun&author=S.-Y.+Sit&author=N.+Sin&author=P.+M.+Scola&author=P.+Hewawasam&author=A.+C.+Good&author=Y.+Chen&author=J.+A.+Campbell&title=Hepatitis+C+Virus+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%2BA.%26atitle%3DHepatitis%2520C%2520Virus%2520Inhibitors%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Rudd, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butcher, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romano, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bush, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liverton, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holloway, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harper, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiFilippo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Summa, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swestock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritzen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burlein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMuzio, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gates, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McClain, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHale, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahlhut, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chase, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soriano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fandozzi, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trainor, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludmerer, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCauley, J. A.</span><span> </span><span class="NLM_article-title">P2-quinazolinones and bis-macrocycles as new templates for next-generation hepatitis C virus NS3/4a protease inhibitors: discovery of MK-2748 and MK-6325</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">727</span><span class="NLM_x">–</span> <span class="NLM_lpage">735</span><span class="refDoi"> DOI: 10.1002/cmdc.201402558</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1002%2Fcmdc.201402558" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=25759009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvVShurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=727-735&author=M.+T.+Ruddauthor=J.+W.+Butcherauthor=K.+T.+Nguyenauthor=C.+J.+McIntyreauthor=J.+J.+Romanoauthor=K.+F.+Gilbertauthor=K.+J.+Bushauthor=N.+J.+Livertonauthor=M.+K.+Hollowayauthor=S.+Harperauthor=M.+Ferraraauthor=M.+DiFilippoauthor=V.+Summaauthor=J.+Swestockauthor=J.+Fritzenauthor=S.+S.+Carrollauthor=C.+Burleinauthor=J.+M.+DiMuzioauthor=A.+Gatesauthor=D.+J.+Grahamauthor=Q.+Huangauthor=S.+McClainauthor=C.+McHaleauthor=M.+W.+Stahlhutauthor=S.+Blackauthor=R.+Chaseauthor=A.+Sorianoauthor=C.+M.+Fandozziauthor=A.+Taylorauthor=N.+Trainorauthor=D.+B.+Olsenauthor=P.+J.+Colemanauthor=S.+W.+Ludmererauthor=J.+A.+McCauley&title=P2-quinazolinones+and+bis-macrocycles+as+new+templates+for+next-generation+hepatitis+C+virus+NS3%2F4a+protease+inhibitors%3A+discovery+of+MK-2748+and+MK-6325&doi=10.1002%2Fcmdc.201402558"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">P2-Quinazolinones and Bis-Macrocycles as New Templates for Next-Generation Hepatitis C Virus NS3/4a Protease Inhibitors: Discovery of MK-2748 and MK-6325</span></div><div class="casAuthors">Rudd, Michael T.; Butcher, John W.; Nguyen, Kevin T.; McIntyre, Charles J.; Romano, Joseph J.; Gilbert, Kevin F.; Bush, Kimberly J.; Liverton, Nigel J.; Holloway, M. Katharine; Harper, Steven; Ferrara, Marco; DiFilippo, Marcello; Summa, Vincenzo; Swestock, John; Fritzen, Jeff; Carroll, Steven S.; Burlein, Christine; DiMuzio, Jillian M.; Gates, Adam; Graham, Donald J.; Huang, Qian; McClain, Stephanie; McHale, Carolyn; Stahlhut, Mark W.; Black, Stuart; Chase, Robert; Soriano, Aileen; Fandozzi, Christine M.; Taylor, Anne; Trainor, Nicole; Olsen, David B.; Coleman, Paul J.; Ludmerer, Steven W.; McCauley, John A.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">727-735</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">With the goal of identifying inhibitors of hepatitis C virus (HCV) NS3/4a protease that are potent against a wide range of genotypes and clin. relevant mutant viruses, several subseries of macrocycles were investigated based on observations made during the discovery of MK-5172.  Quinazolinone-contg. macrocycles were identified as promising leads, and optimization for superior cross-genotype and mutant enzyme potency as well as rat liver and plasma concns. following oral dosing, led to the development of MK-2748 I.  Addnl. investigation of a series of bis-macrocycles contg. a fused 18- and 15-membered ring system were also optimized for the same properties, leading to the discovery of MK-6325 II.  Both compds. display the broad genotype and mutant potency necessary for clin. development as next-generation HCV NS3/4a protease inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4cK2wuPGi1rVg90H21EOLACvtfcHk0lg6ntO1R_9-GA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvVShurc%253D&md5=65834635e5b209b0674ec60fe905e2a9</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201402558&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201402558%26sid%3Dliteratum%253Aachs%26aulast%3DRudd%26aufirst%3DM.%2BT.%26aulast%3DButcher%26aufirst%3DJ.%2BW.%26aulast%3DNguyen%26aufirst%3DK.%2BT.%26aulast%3DMcIntyre%26aufirst%3DC.%2BJ.%26aulast%3DRomano%26aufirst%3DJ.%2BJ.%26aulast%3DGilbert%26aufirst%3DK.%2BF.%26aulast%3DBush%26aufirst%3DK.%2BJ.%26aulast%3DLiverton%26aufirst%3DN.%2BJ.%26aulast%3DHolloway%26aufirst%3DM.%2BK.%26aulast%3DHarper%26aufirst%3DS.%26aulast%3DFerrara%26aufirst%3DM.%26aulast%3DDiFilippo%26aufirst%3DM.%26aulast%3DSumma%26aufirst%3DV.%26aulast%3DSwestock%26aufirst%3DJ.%26aulast%3DFritzen%26aufirst%3DJ.%26aulast%3DCarroll%26aufirst%3DS.%2BS.%26aulast%3DBurlein%26aufirst%3DC.%26aulast%3DDiMuzio%26aufirst%3DJ.%2BM.%26aulast%3DGates%26aufirst%3DA.%26aulast%3DGraham%26aufirst%3DD.%2BJ.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DMcClain%26aufirst%3DS.%26aulast%3DMcHale%26aufirst%3DC.%26aulast%3DStahlhut%26aufirst%3DM.%2BW.%26aulast%3DBlack%26aufirst%3DS.%26aulast%3DChase%26aufirst%3DR.%26aulast%3DSoriano%26aufirst%3DA.%26aulast%3DFandozzi%26aufirst%3DC.%2BM.%26aulast%3DTaylor%26aufirst%3DA.%26aulast%3DTrainor%26aufirst%3DN.%26aulast%3DOlsen%26aufirst%3DD.%2BB.%26aulast%3DColeman%26aufirst%3DP.%2BJ.%26aulast%3DLudmerer%26aufirst%3DS.%2BW.%26aulast%3DMcCauley%26aufirst%3DJ.%2BA.%26atitle%3DP2-quinazolinones%2520and%2520bis-macrocycles%2520as%2520new%2520templates%2520for%2520next-generation%2520hepatitis%2520C%2520virus%2520NS3%252F4a%2520protease%2520inhibitors%253A%2520discovery%2520of%2520MK-2748%2520and%2520MK-6325%26jtitle%3DChemMedChem%26date%3D2015%26volume%3D10%26spage%3D727%26epage%3D735%26doi%3D10.1002%2Fcmdc.201402558" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Vendeville, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilsson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Kock, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, T. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antonov, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Classon, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayesa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ivanov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johansson, P. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahnberg, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eneroth, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wikstrom, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vrang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edlund, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindstrom, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van de Vreken, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGowan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tahri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenz, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delouvroy, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Dooren, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kindermans, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Surleraux, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wigerinck, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenquist, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samuelsson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raboisson, P.</span><span> </span><span class="NLM_article-title">Discovery of novel, potent and bioavailable proline-urea based macrocyclic HCV NS3/4A protease inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">6189</span><span class="NLM_x">–</span> <span class="NLM_lpage">6193</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2008.10.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1016%2Fj.bmcl.2008.10.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=18954982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlOhtr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=6189-6193&author=S.+Vendevilleauthor=M.+Nilssonauthor=H.+de+Kockauthor=T.+I.+Linauthor=D.+Antonovauthor=B.+Classonauthor=S.+Ayesaauthor=V.+Ivanovauthor=P.+O.+Johanssonauthor=P.+Kahnbergauthor=A.+Enerothauthor=K.+Wikstromauthor=L.+Vrangauthor=M.+Edlundauthor=S.+Lindstromauthor=W.+Van+de+Vrekenauthor=D.+McGowanauthor=A.+Tahriauthor=L.+Huauthor=O.+Lenzauthor=F.+Delouvroyauthor=M.+Van+Doorenauthor=N.+Kindermansauthor=D.+Surlerauxauthor=P.+Wigerinckauthor=A.+Rosenquistauthor=B.+Samuelssonauthor=K.+Simmenauthor=P.+Raboisson&title=Discovery+of+novel%2C+potent+and+bioavailable+proline-urea+based+macrocyclic+HCV+NS3%2F4A+protease+inhibitors&doi=10.1016%2Fj.bmcl.2008.10.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel, potent and bioavailable proline-urea based macrocyclic HCV NS3/4A protease inhibitors</span></div><div class="casAuthors">Vendeville, Sandrine; Nilsson, Magnus; de Kock, Herman; Lin, Tse-I.; Antonov, Dmitry; Classon, Bjorn; Ayesa, Susana; Ivanov, Vladimir; Johansson, Per-Ola; Kahnberg, Pia; Eneroth, Anders; Wikstrom, Kristina; Vrang, Lotta; Edlund, Michael; Lindstrom, Stefan; Van de Vreken, Wim; McGowan, David; Tahri, Abdellah; Hu, Lili; Lenz, Oliver; Delouvroy, Frederic; Van Dooren, Marleen; Kindermans, Natalie; Surleraux, Dominique; Wigerinck, Piet; Rosenquist, Asa; Samuelsson, Bertil; Simmen, Kenneth; Raboisson, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6189-6193</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A novel series of P3-truncated macrocyclic HCV NS3/4A protease inhibitors contg. a P2 proline-urea or carbamate scaffold was synthesized.  Very potent inhibitors were obtained through the optimization of the macrocycle size, urea and proline substitution, and bioisosteric replacement of the P1 carboxylic acid moiety.  Variation of the lipophilicity by introduction of small lipophilic substituents resulted in improved PK profiles, ultimately leading to an extremely potent compd. (K i = 0.1 nM, EC50 = 4.5 nM) and selective (CC50 (Huh-7 cells) > 50 μM) inhibitor, displaying an excellent PK profile in rats characterized by an oral bioavailability of 54% and a high liver exposure after oral administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrHVnDgsM9Q7Vg90H21EOLACvtfcHk0lhvw4FpPPY6zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlOhtr7E&md5=320cbbf4d9afdd7bdce3584326e15914</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.10.004%26sid%3Dliteratum%253Aachs%26aulast%3DVendeville%26aufirst%3DS.%26aulast%3DNilsson%26aufirst%3DM.%26aulast%3Dde%2BKock%26aufirst%3DH.%26aulast%3DLin%26aufirst%3DT.%2BI.%26aulast%3DAntonov%26aufirst%3DD.%26aulast%3DClasson%26aufirst%3DB.%26aulast%3DAyesa%26aufirst%3DS.%26aulast%3DIvanov%26aufirst%3DV.%26aulast%3DJohansson%26aufirst%3DP.%2BO.%26aulast%3DKahnberg%26aufirst%3DP.%26aulast%3DEneroth%26aufirst%3DA.%26aulast%3DWikstrom%26aufirst%3DK.%26aulast%3DVrang%26aufirst%3DL.%26aulast%3DEdlund%26aufirst%3DM.%26aulast%3DLindstrom%26aufirst%3DS.%26aulast%3DVan%2Bde%2BVreken%26aufirst%3DW.%26aulast%3DMcGowan%26aufirst%3DD.%26aulast%3DTahri%26aufirst%3DA.%26aulast%3DHu%26aufirst%3DL.%26aulast%3DLenz%26aufirst%3DO.%26aulast%3DDelouvroy%26aufirst%3DF.%26aulast%3DVan%2BDooren%26aufirst%3DM.%26aulast%3DKindermans%26aufirst%3DN.%26aulast%3DSurleraux%26aufirst%3DD.%26aulast%3DWigerinck%26aufirst%3DP.%26aulast%3DRosenquist%26aufirst%3DA.%26aulast%3DSamuelsson%26aufirst%3DB.%26aulast%3DSimmen%26aufirst%3DK.%26aulast%3DRaboisson%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520novel%252C%2520potent%2520and%2520bioavailable%2520proline-urea%2520based%2520macrocyclic%2520HCV%2520NS3%252F4A%2520protease%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D6189%26epage%3D6193%26doi%3D10.1016%2Fj.bmcl.2008.10.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Moreau, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Meara, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bordeleau, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garneau, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godbout, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorys, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leblanc, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villemure, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Llinàs-Brunet, M.</span><span> </span><span class="NLM_article-title">Discovery of hepatitis C virus NS3–4A protease inhibitors with improved barrier to resistance and favorable liver distribution</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1770</span><span class="NLM_x">–</span> <span class="NLM_lpage">1776</span><span class="refDoi"> DOI: 10.1021/jm400121t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400121t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktFKns7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1770-1776&author=B.+Moreauauthor=J.+A.+O%E2%80%99Mearaauthor=J.+Bordeleauauthor=M.+Garneauauthor=C.+Godboutauthor=V.+Gorysauthor=M.+Leblancauthor=E.+Villemureauthor=P.+W.+Whiteauthor=M.+Llin%C3%A0s-Brunet&title=Discovery+of+hepatitis+C+virus+NS3%E2%80%934A+protease+inhibitors+with+improved+barrier+to+resistance+and+favorable+liver+distribution&doi=10.1021%2Fjm400121t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Hepatitis C Virus NS3-4A Protease Inhibitors with Improved Barrier to Resistance and Favorable Liver Distribution</span></div><div class="casAuthors">Moreau, Benoit; O'Meara, Jeff A.; Bordeleau, Josee; Garneau, Michel; Godbout, Cedrickx; Gorys, Vida; Leblanc, Melissa; Villemure, Elisia; White, Peter W.; Llinas-Brunet, Montse</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1770-1776</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Given the emergence of resistance obsd. for the current clin.-stage hepatitis C virus (HCV) NS3 protease inhibitors, there is a need for new inhibitors with a higher barrier to resistance.  We recently reported our rational approach to the discovery of macrocyclic acylsulfonamides as HCV protease inhibitors addressing potency against clin. relevant resistant variants.  Using X-ray crystallog. of HCV protease variant/inhibitor complexes, we shed light on the complex structural mechanisms by which the D168V and R155K residue mutations confer resistance to NS3 protease inhibitors.  Here, we disclose SAR investigation and ADME/PK optimization leading to the identification of inhibitors with significantly improved potency against the key resistant variants and with increased liver partitioning.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3kmCmZS4AGbVg90H21EOLACvtfcHk0lhiVklvOOAgRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktFKns7g%253D&md5=2b059cd96fad0a9dbc575c1005876146</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fjm400121t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400121t%26sid%3Dliteratum%253Aachs%26aulast%3DMoreau%26aufirst%3DB.%26aulast%3DO%25E2%2580%2599Meara%26aufirst%3DJ.%2BA.%26aulast%3DBordeleau%26aufirst%3DJ.%26aulast%3DGarneau%26aufirst%3DM.%26aulast%3DGodbout%26aufirst%3DC.%26aulast%3DGorys%26aufirst%3DV.%26aulast%3DLeblanc%26aufirst%3DM.%26aulast%3DVillemure%26aufirst%3DE.%26aulast%3DWhite%26aufirst%3DP.%2BW.%26aulast%3DLlin%25C3%25A0s-Brunet%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520hepatitis%2520C%2520virus%2520NS3%25E2%2580%25934A%2520protease%2520inhibitors%2520with%2520improved%2520barrier%2520to%2520resistance%2520and%2520favorable%2520liver%2520distribution%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1770%26epage%3D1776%26doi%3D10.1021%2Fjm400121t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Gillis, E. P.; Bowsher, M. S.; McPhee, F.; Jenkins, S.; Wang, Y.-K.; Scola, P. M.; Meanwell, N. A.</span><span> </span><span class="NLM_article-title">2nd Generation HCV Protease Inhibitors: Part 2, Optimization of P2*</span>. In 250th ACS National Meeting & Exposition, Boston, MA, United States, August 16–20, 2015; <span class="NLM_publisher-name">American Chemical Society</span>: <span class="NLM_publisher-loc">Washington, DC</span>,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span> <span class="NLM_fpage">MEDI-240</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&pages=MEDI-240&author=E.+P.+Gillis&author=M.+S.+Bowsher&author=F.+McPhee&author=S.+Jenkins&author=Y.-K.+Wang&author=P.+M.+Scola&author=N.+A.+Meanwell&title=2nd+Generation+HCV+Protease+Inhibitors%3A+Part+2%2C+Optimization+of+P2*"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DGillis%26aufirst%3DE.%2BP.%26atitle%3D2nd%2520Generation%2520HCV%2520Protease%2520Inhibitors%253A%2520Part%25202%252C%2520Optimization%2520of%2520P2%252A%26jtitle%3D250th%2520ACS%2520National%2520Meeting%2520%2526%2520Exposition%252C%2520Boston%252C%2520MA%252C%2520United%2520States%252C%2520August%252016%25E2%2580%259320%252C%25202015%26pub%3DAmerican%2520Chemical%2520Society%26date%3D2015%26spage%3DMEDI-240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Meanwell, N. A.</span><span> </span><span class="NLM_article-title">Synopsis of some recent tactical application of bioisosteres in drug design</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">2529</span><span class="NLM_x">–</span> <span class="NLM_lpage">2591</span><span class="refDoi"> DOI: 10.1021/jm1013693</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1013693" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsVCnu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2529-2591&author=N.+A.+Meanwell&title=Synopsis+of+some+recent+tactical+application+of+bioisosteres+in+drug+design&doi=10.1021%2Fjm1013693"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design</span></div><div class="casAuthors">Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2529-2591</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The established utility of bioisosteres is broad in nature, extending to improving potency, enhancing selectivity, altering phys. properties, reducing or redirecting metab., eliminating or modifying toxicophores, and acquiring novel intellectual property.  In this Perspective, some contemporary themes exploring the role of isosteres in drug design are sampled, with an emphasis placed on tactical applications designed to solve the kinds of problems that impinge on compd. optimization and the long-term success of drug candidates.  Interesting concepts that may have been poorly effective in the context examd. are captured, since the ideas may have merit in alternative circumstances.  A comprehensive cataloging of bioisosteres is beyond the scope of what will be provided, although a synopsis of relevant isosteres of a particular functionality is summarized in a succinct fashion in several sections.  Isosterism has also found productive application in the design and optimization of organocatalysts, and there are several examples in which functional mimicry established initially in a medicinal chem. setting has been adopted by this community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ9z_aPcU4ubVg90H21EOLACvtfcHk0lhiVklvOOAgRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsVCnu7o%253D&md5=0637ab60c379bef535f3f709b26f3582</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fjm1013693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1013693%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DSynopsis%2520of%2520some%2520recent%2520tactical%2520application%2520of%2520bioisosteres%2520in%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2529%26epage%3D2591%26doi%3D10.1021%2Fjm1013693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Or, Y. S.; Moore, J. D.; Liu, D.; Sun, Y.; Gai, Y.; Tang, D.; Niu, D.; Xu, G.; Wang, Z.</span><span> </span><span class="NLM_article-title">Quinoxalinyl Macrocyclic Hepatitis C Virus Serine Protease Inhibitors</span>. PCT Int. Appl. WO 2008/002924, January 03,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=Y.+S.+Or&author=J.+D.+Moore&author=D.+Liu&author=Y.+Sun&author=Y.+Gai&author=D.+Tang&author=D.+Niu&author=G.+Xu&author=Z.+Wang&title=Quinoxalinyl+Macrocyclic+Hepatitis+C+Virus+Serine+Protease+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DOr%26aufirst%3DY.%2BS.%26atitle%3DQuinoxalinyl%2520Macrocyclic%2520Hepatitis%2520C%2520Virus%2520Serine%2520Protease%2520Inhibitors%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Sun, L.-Q.; Mull, E.; Gillis, E. P.; Bowsher, M. S.; Zhao, Q.; Renduchintala, V. K.; Sarkunam, K.; Nagalakshmi, P.; Babu, P. V. K. S.; Scola, P. M.</span><span> </span><span class="NLM_article-title">Hepatitis C Virus Inhibitors</span>. PCT Int. Appl. WO 2014/062196, April 24,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=L.-Q.+Sun&author=E.+Mull&author=E.+P.+Gillis&author=M.+S.+Bowsher&author=Q.+Zhao&author=V.+K.+Renduchintala&author=K.+Sarkunam&author=P.+Nagalakshmi&author=P.+V.+K.+S.+Babu&author=P.+M.+Scola&title=Hepatitis+C+Virus+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.-Q.%26atitle%3DHepatitis%2520C%2520Virus%2520Inhibitors%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Sarkar, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sommer, S. S.</span><span> </span><span class="NLM_article-title">The “megaprimer” method of site-directed mutagenesis</span> <span class="citation_source-journal">Biotechniques</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">404</span><span class="NLM_x">–</span> <span class="NLM_lpage">407</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=2340178" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADyaK3cXls1Krs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1990&pages=404-407&author=G.+Sarkarauthor=S.+S.+Sommer&title=The+%E2%80%9Cmegaprimer%E2%80%9D+method+of+site-directed+mutagenesis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">The "megaprimer" method of site-directed mutagenesis</span></div><div class="casAuthors">Sarkar, Gobinda; Sommer, Steve S.</div><div class="citationInfo"><span class="NLM_cas:title">BioTechniques</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">404-7</span>CODEN:
                <span class="NLM_cas:coden">BTNQDO</span>;
        ISSN:<span class="NLM_cas:issn">0736-6205</span>.
    </div><div class="casAbstract">A simple and efficient method of mutagenesis termed the megaprimer method is described.  The method utilizes 3 oligonucleotide primers to perform 2 rounds of polymerase chain reaction.  In the method, the product of the first polymerase chain reaction is used as one of the polymerase chain reaction primers (i.e. a megaprimer) for the second polymerase chain reaction.  When a phage promoter and a translational initiation signal are attached to the appropriate oligonucleotide primer, the mutant protein can be generated without any in vivo manipulations.  The method was used to generate 2 mutations in the catalytic domain of the human factor IX gene.  The substitution of megaprimers for oligonucleotide primers may have utility in other polymerase chain reaction-based methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3Gw-l10oiErVg90H21EOLACvtfcHk0lijgDiLsfKp-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXls1Krs7g%253D&md5=8c790e0b8050396e1befc4368d579fda</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSarkar%26aufirst%3DG.%26aulast%3DSommer%26aufirst%3DS.%2BS.%26atitle%3DThe%2520%25E2%2580%259Cmegaprimer%25E2%2580%259D%2520method%2520of%2520site-directed%2520mutagenesis%26jtitle%3DBiotechniques%26date%3D1990%26volume%3D8%26spage%3D404%26epage%3D407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Otwinowski, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minor, W.</span><span> </span><span class="NLM_article-title">Processing of X-ray diffraction data collected in oscillation mode</span> <span class="citation_source-journal">Methods Enzymol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">276</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">–</span> <span class="NLM_lpage">326</span><span class="refDoi"> DOI: 10.1016/S0076-6879(97)76066-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1016%2FS0076-6879%2897%2976066-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=27754618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADyaK2sXivFehsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=1997&pages=307-326&author=Z.+Otwinowskiauthor=W.+Minor&title=Processing+of+X-ray+diffraction+data+collected+in+oscillation+mode&doi=10.1016%2FS0076-6879%2897%2976066-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Processing of x-ray diffraction data collected in oscillation mode</span></div><div class="casAuthors">Otwinowski, Zbyszek; Minor, Wladek</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Enzymology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">Macromolecular Crystallography, Part A</span>),
    <span class="NLM_cas:pages">307-326</span>CODEN:
                <span class="NLM_cas:coden">MENZAU</span>;
        ISSN:<span class="NLM_cas:issn">0076-6879</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">Macromol. crystallog. is an iterative process.  Rarely do the first crystals provide all the necessary data to solve the biol. problem being studied.  Each step benefits from experience learned in previous steps.  To monitor the progress, the HKL package provides 2 tools: (1) statistics, both weighted (χ2) and unweighted (R-merge), are provided, and the Bayesian reasoning and multicomponent error model facilitates obtaining the proper error ests. and (2) visualization of the process plays a double role by helping the operator to confirm that the process of data redn., including the resulting statistics, is correct, and allowing one to evaluate problems for which there are no good statistical criteria.  Visualization also provides confidence that the point of diminishing returns in data collection and redn. has been reached.  At that point, the effort should be directed to solving the structure.  The methods presented here have been applied to solve a large variety of problems, from inorg. mols. with 5 Å unit cell to rotavirus of 700 Å diam. crystd. in 700 × 1000 × 1400 Å cell.  Overall quality of the method was tested by many researchers by successful application of the programs to MAD structure detns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA3fvBOHqhhrVg90H21EOLACvtfcHk0lijgDiLsfKp-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXivFehsbw%253D&md5=c9536971d4e32cc35352c40fb9368131</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2FS0076-6879%2897%2976066-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0076-6879%252897%252976066-X%26sid%3Dliteratum%253Aachs%26aulast%3DOtwinowski%26aufirst%3DZ.%26aulast%3DMinor%26aufirst%3DW.%26atitle%3DProcessing%2520of%2520X-ray%2520diffraction%2520data%2520collected%2520in%2520oscillation%2520mode%26jtitle%3DMethods%2520Enzymol.%26date%3D1997%26volume%3D276%26spage%3D307%26epage%3D326%26doi%3D10.1016%2FS0076-6879%2897%2976066-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">McCoy, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosse-Kunstleve, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winn, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storoni, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, R. J.</span><span> </span><span class="NLM_article-title">Phaser crystallographic software</span> <span class="citation_source-journal">J. Appl. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">658</span><span class="NLM_x">–</span> <span class="NLM_lpage">674</span><span class="refDoi"> DOI: 10.1107/S0021889807021206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1107%2FS0021889807021206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=19461840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2007&pages=658-674&author=A.+J.+McCoyauthor=R.+W.+Grosse-Kunstleveauthor=P.+D.+Adamsauthor=M.+D.+Winnauthor=L.+C.+Storoniauthor=R.+J.+Read&title=Phaser+crystallographic+software&doi=10.1107%2FS0021889807021206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Phaser crystallographic software</span></div><div class="casAuthors">McCoy, Airlie J.; Grosse-Kunstleve, Ralf W.; Adams, Paul D.; Winn, Martyn D.; Storoni, Laurent C.; Read, Randy J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">658-674</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Phaser is a program for phasing macromol. crystal structures by both mol. replacement and exptl. phasing methods.  The novel phasing algorithms implemented in Phaser have been developed using max. likelihood and multivariate statistics.  For mol. replacement, the new algorithms have proved to be significantly better than traditional methods in discriminating correct solns. from noise, and for single-wavelength anomalous dispersion exptl. phasing, the new algorithms, which account for correlations between F+ and F-, give better phases (lower mean phase error with respect to the phases given by the refined structure) than those that use mean F and anomalous differences ΔF.  One of the design concepts of Phaser was that it be capable of a high degree of automation.  To this end, Phaser (written in C++) can be called directly from Python, although it can also be called using traditional CCP4 keyword-style input.  Phaser is a platform for future development of improved phasing methods and their release, including source code, to the crystallog. community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPeVyjN_FMGbVg90H21EOLACvtfcHk0lhYSgDJnb6iaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D&md5=c63b722ae97e0a74e6a5a079d388f09f</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1107%2FS0021889807021206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889807021206%26sid%3Dliteratum%253Aachs%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DWinn%26aufirst%3DM.%2BD.%26aulast%3DStoroni%26aufirst%3DL.%2BC.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26atitle%3DPhaser%2520crystallographic%2520software%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D2007%26volume%3D40%26spage%3D658%26epage%3D674%26doi%3D10.1107%2FS0021889807021206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Emsley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowtan, K.</span><span> </span><span class="NLM_article-title">Coot: model-building tools for molecular graphics</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">2126</span><span class="NLM_x">–</span> <span class="NLM_lpage">2132</span><span class="refDoi"> DOI: 10.1107/S0907444904019158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1107%2FS0907444904019158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=15572765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=2126-2132&author=P.+Emsleyauthor=K.+Cowtan&title=Coot%3A+model-building+tools+for+molecular+graphics&doi=10.1107%2FS0907444904019158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Coot: model-building tools for molecular graphics</span></div><div class="casAuthors">Emsley, Paul; Cowtan, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">D60</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">2126-2132</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">CCP4mg is a project that aims to provide a general-purpose tool for structural biologists, providing tools for x-ray structure soln., structure comparison and anal., and publication-quality graphics.  The map-fitting tools are available as a stand-alone package, distributed as 'Coot'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMisM42468k7Vg90H21EOLACvtfcHk0lhYSgDJnb6iaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P&md5=1be390f3bb6fd584468499ad0921161e</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1107%2FS0907444904019158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444904019158%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DCoot%253A%2520model-building%2520tools%2520for%2520molecular%2520graphics%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2004%26volume%3D60%26spage%3D2126%26epage%3D2132%26doi%3D10.1107%2FS0907444904019158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Adams, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Afonine, P. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunkoczi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, I. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Echols, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Headd, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hung, L.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapral, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosse-Kunstleve, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCoy, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moriarty, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oeffner, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terwilliger, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwart, P. H.</span><span> </span><span class="NLM_article-title">PHENIX: a comprehensive Python-based system for macromolecular structure solution</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">213</span><span class="NLM_x">–</span> <span class="NLM_lpage">221</span><span class="refDoi"> DOI: 10.1107/S0907444909052925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1107%2FS0907444909052925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=20124702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=213-221&author=P.+D.+Adamsauthor=P.+V.+Afonineauthor=G.+Bunkocziauthor=V.+B.+Chenauthor=I.+W.+Davisauthor=N.+Echolsauthor=J.+J.+Headdauthor=L.-W.+Hungauthor=G.+J.+Kapralauthor=R.+W.+Grosse-Kunstleveauthor=A.+J.+McCoyauthor=N.+W.+Moriartyauthor=R.+Oeffnerauthor=R.+J.+Readauthor=D.+C.+Richardsonauthor=J.+S.+Richardsonauthor=T.+C.+Terwilligerauthor=P.+H.+Zwart&title=PHENIX%3A+a+comprehensive+Python-based+system+for+macromolecular+structure+solution&doi=10.1107%2FS0907444909052925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">PHENIX: a comprehensive Python-based system for macromolecular structure solution</span></div><div class="casAuthors">Adams, Paul D.; Afonine, Pavel V.; Bunkoczi, Gabor; Chen, Vincent B.; Davis, Ian W.; Echols, Nathaniel; Headd, Jeffrey J.; Hung, Li Wei; Kapral, Gary J.; Grosse-Kunstleve, Ralf W.; McCoy, Airlie J.; Moriarty, Nigel W.; Oeffner, Robert; Read, Randy J.; Richardson, David C.; Richardson, Jane S.; Terwilliger, Thomas C.; Zwart, Peter H.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">213-221</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A review.  Macromol. X-ray crystallog. is routinely applied to understand biol. processes at a mol. level.  However, significant time and effort are still required to solve and complete many of these structures because of the need for manual interpretation of complex numerical data using many software packages and the repeated use of interactive three-dimensional graphics.  PHENIX has been developed to provide a comprehensive system for macromol. crystallog. structure soln. with an emphasis on the automation of all procedures.  This has relied on the development of algorithms that minimize or eliminate subjective input, the development of algorithms that automate procedures that are traditionally performed by hand and, finally, the development of a framework that allows a tight integration between the algorithms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm_HgKRpa-ObVg90H21EOLACvtfcHk0lhYSgDJnb6iaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisbc%253D&md5=67b439ff4bd61c659cae37ca4209b7bc</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1107%2FS0907444909052925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909052925%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DAfonine%26aufirst%3DP.%2BV.%26aulast%3DBunkoczi%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DV.%2BB.%26aulast%3DDavis%26aufirst%3DI.%2BW.%26aulast%3DEchols%26aufirst%3DN.%26aulast%3DHeadd%26aufirst%3DJ.%2BJ.%26aulast%3DHung%26aufirst%3DL.-W.%26aulast%3DKapral%26aufirst%3DG.%2BJ.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DMoriarty%26aufirst%3DN.%2BW.%26aulast%3DOeffner%26aufirst%3DR.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26aulast%3DRichardson%26aufirst%3DD.%2BC.%26aulast%3DRichardson%26aufirst%3DJ.%2BS.%26aulast%3DTerwilliger%26aufirst%3DT.%2BC.%26aulast%3DZwart%26aufirst%3DP.%2BH.%26atitle%3DPHENIX%253A%2520a%2520comprehensive%2520Python-based%2520system%2520for%2520macromolecular%2520structure%2520solution%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D213%26epage%3D221%26doi%3D10.1107%2FS0907444909052925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Davis, I. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leaver-Fay, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Block, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapral, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, L. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arendall, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snoeyink, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, D. C.</span><span> </span><span class="NLM_article-title">MolProbity: all-atom contacts and structure validation for proteins and nucleic acids</span> <span class="citation_source-journal">Nucleic Acids Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">W375</span><span class="NLM_x">–</span> <span class="NLM_lpage">W383</span><span class="refDoi"> DOI: 10.1093/nar/gkm216</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1093%2Fnar%2Fgkm216" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=17452350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A280%3ADC%252BD2svhsVGhtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2007&pages=W375-W383&author=I.+W.+Davisauthor=A.+Leaver-Fayauthor=V.+B.+Chenauthor=J.+N.+Blockauthor=G.+J.+Kapralauthor=X.+Wangauthor=L.+W.+Murrayauthor=W.+B.+Arendallauthor=J.+Snoeyinkauthor=J.+S.+Richardsonauthor=D.+C.+Richardson&title=MolProbity%3A+all-atom+contacts+and+structure+validation+for+proteins+and+nucleic+acids&doi=10.1093%2Fnar%2Fgkm216"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">MolProbity: all-atom contacts and structure validation for proteins and nucleic acids</span></div><div class="casAuthors">Davis Ian W; Leaver-Fay Andrew; Chen Vincent B; Block Jeremy N; Kapral Gary J; Wang Xueyi; Murray Laura W; Arendall W Bryan 3rd; Snoeyink Jack; Richardson Jane S; Richardson David C</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic acids research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">Web Server issue</span>),
    <span class="NLM_cas:pages">W375-83</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">MolProbity is a general-purpose web server offering quality validation for 3D structures of proteins, nucleic acids and complexes.  It provides detailed all-atom contact analysis of any steric problems within the molecules as well as updated dihedral-angle diagnostics, and it can calculate and display the H-bond and van der Waals contacts in the interfaces between components.  An integral step in the process is the addition and full optimization of all hydrogen atoms, both polar and nonpolar.  New analysis functions have been added for RNA, for interfaces, and for NMR ensembles.  Additionally, both the web site and major component programs have been rewritten to improve speed, convenience, clarity and integration with other resources.  MolProbity results are reported in multiple forms: as overall numeric scores, as lists or charts of local problems, as downloadable PDB and graphics files, and most notably as informative, manipulable 3D kinemage graphics shown online in the KiNG viewer.  This service is available free to all users at http://molprobity.biochem.duke.edu.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRuyhuetoNS59bHMBt0mMIXfW6udTcc2eZUwKyfuuHbFbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2svhsVGhtQ%253D%253D&md5=726ca1e7e162ab2a4a05048f493731fb</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkm216&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkm216%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DI.%2BW.%26aulast%3DLeaver-Fay%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DV.%2BB.%26aulast%3DBlock%26aufirst%3DJ.%2BN.%26aulast%3DKapral%26aufirst%3DG.%2BJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DMurray%26aufirst%3DL.%2BW.%26aulast%3DArendall%26aufirst%3DW.%2BB.%26aulast%3DSnoeyink%26aufirst%3DJ.%26aulast%3DRichardson%26aufirst%3DJ.%2BS.%26aulast%3DRichardson%26aufirst%3DD.%2BC.%26atitle%3DMolProbity%253A%2520all-atom%2520contacts%2520and%2520structure%2520validation%2520for%2520proteins%2520and%2520nucleic%2520acids%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2007%26volume%3D35%26spage%3DW375%26epage%3DW383%26doi%3D10.1093%2Fnar%2Fgkm216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Brunger, A. T.</span><span> </span><span class="NLM_article-title">Free R value: a novel statistical quantity for assessing the accuracy of crystal structures</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">355</span><span class="NLM_x">, </span> <span class="NLM_fpage">472</span><span class="NLM_x">–</span> <span class="NLM_lpage">475</span><span class="refDoi"> DOI: 10.1038/355472a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=10.1038%2F355472a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=18481394" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;key=1%3ACAS%3A280%3ADC%252BD1czhvFCquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=1992&pages=472-475&author=A.+T.+Brunger&title=Free+R+value%3A+a+novel+statistical+quantity+for+assessing+the+accuracy+of+crystal+structures&doi=10.1038%2F355472a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Free R value: a novel statistical quantity for assessing the accuracy of crystal structures</span></div><div class="casAuthors">Brunger A T</div><div class="citationInfo"><span class="NLM_cas:title">Nature</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">6359</span>),
    <span class="NLM_cas:pages">472-5</span>
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">The determination of macromolecular structure by crystallography involves fitting atomic models to the observed diffraction data.  The traditional measure of the quality of this fit, and presumably the accuracy of the model, is the R value.  Despite stereochemical restraints, it is possible to overfit or 'misfit' the diffraction data: an incorrect model can be refined to fairly good R values as several recent examples have shown.  Here I propose a reliable and unbiased indicator of the accuracy of such models.  By analogy with the cross-validation method of testing statistical models I define a statistical quantity (R(free) (T) that measures the agreement between observed and computed structure factor amplitudes for a 'test' set of reflections that is omitted in the modelling and refinement process.  As examples show, there is a high correlation between R(free) (T) and the accuracy of the atomic model phases.  This is useful because experimental phase information is usually inaccurate, incomplete or unavailable.  I expect that R(free) (T) will provide a measure of the information content of recently proposed models of thermal motion and disorder, time-averaging and bulk solvent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQY_IzgfwBLm_h3YQQtAhNufW6udTcc2eZUwKyfuuHbFbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1czhvFCquw%253D%253D&md5=ddeaa021753f1208b405e03c1428078f</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2F355472a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F355472a0%26sid%3Dliteratum%253Aachs%26aulast%3DBrunger%26aufirst%3DA.%2BT.%26atitle%3DFree%2520R%2520value%253A%2520a%2520novel%2520statistical%2520quantity%2520for%2520assessing%2520the%2520accuracy%2520of%2520crystal%2520structures%26jtitle%3DNature%26date%3D1992%26volume%3D355%26spage%3D472%26epage%3D475%26doi%3D10.1038%2F355472a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span>PyMOL: The PyMOL Molecular Graphics System, <span class="NLM_edition">version 1.8</span>; <span class="NLM_publisher-name">Schrödinger, LLC</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=PyMOL%3A+The+PyMOL+Molecular+Graphics+System%2C+version+1.8%3B+Schr%C3%B6dinger%2C+LLC%3A+New+York%2C+2017."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DPyMOL%253A%2520The%2520PyMOL%2520Molecular%2520Graphics%2520System%26pub%3DSchr%25C3%25B6dinger%252C%2520LLC%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span>MacroModel, Schrödinger Release 2017-1; <span class="NLM_publisher-name">Schrödinger, LLC</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=MacroModel%2C+Schr%C3%B6dinger+Release+2017-1%3B+Schr%C3%B6dinger%2C+LLC%3A+New+York%2C+2017."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DMacroModel%252C%2520Schr%25C3%25B6dinger%2520Release%25202017-1%26pub%3DSchr%25C3%25B6dinger%252C%2520LLC%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3SUD" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3SUD','PDB','3SUD'); return false;">PDB: 3SUD</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EPN" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EPN','PDB','5EPN'); return false;">PDB: 5EPN</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5VOJ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5VOJ','PDB','5VOJ'); return false;">PDB: 5VOJ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EPY" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EPY','PDB','5EPY'); return false;">PDB: 5EPY</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5VP9" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5VP9','PDB','5VP9'); return false;">PDB: 5VP9</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i36"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00426">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_48204"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b00426">10.1021/acs.jmedchem.7b00426</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Enzyme inhibitory and antiviral activity data with fold-change relative to wild-type; X-ray data collection and crystallographic refinement statistics; synthesis of intermediates and final compounds; protein expression, purification and <i>K</i><sub>m</sub> experiments (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00426/suppl_file/jm7b00426_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00426/suppl_file/jm7b00426_si_002.csv">CSV</a>)</p></li><li><p class="inline">Compound <b>18d</b> model (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00426/suppl_file/jm7b00426_si_003.pdb">PDB</a>)</p></li><li><p class="inline">Compound <b>18e</b> model (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00426/suppl_file/jm7b00426_si_004.pdb">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00426/suppl_file/jm7b00426_si_001.pdf">jm7b00426_si_001.pdf (718.44 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00426/suppl_file/jm7b00426_si_002.csv">jm7b00426_si_002.csv (4.74 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00426/suppl_file/jm7b00426_si_003.pdb">jm7b00426_si_003.pdb (286.3 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00426/suppl_file/jm7b00426_si_004.pdb">jm7b00426_si_004.pdb (286.9 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">The PDB accession codes for inhibitors <b>18f</b>- and <b>19b</b>-bound WT NS3/4A protease X-ray structures are <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5VP9">5VP9</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5VOJ">5VOJ</a>. Authors will release the atomic coordinates and experimental data upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b00426&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-13%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b00426" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b00426" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                7MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67998fabebf521be","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
